<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:83.2pt;left:52.3pt;line-height:12.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:12.5pt">Review</span></p>
<p style="top:97.5pt;left:52.3pt;line-height:20.4pt"><span style="font-family:AdvTT96740c24,serif;font-size:20.4pt">Opioid-Sparing Effect of Cannabinoids: A Systematic Review</span></p>
<p style="top:121.4pt;left:52.3pt;line-height:20.4pt"><span style="font-family:AdvTT96740c24,serif;font-size:20.4pt">and Meta-Analysis</span></p>
<p style="top:180.9pt;left:72.3pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Suzanne Nielsen</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">*</span></sup><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">,1,2</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Pamela Sabioni</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">3</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Jose M Trigo</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">3</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Mark A Ware</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">4</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Brigid D Betz-Stablein</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">5</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">,</span></p>
<p style="top:192.3pt;left:72.3pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Bridin Murnion</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">6,7</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Nicholas Lintzeris</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">2,6</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Kok Eng Khor</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">8</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Michael Farrell</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">1</span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">, Andrew Smith</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">9</span></sup><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt"> </span></sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">and Bernard Le Foll</span><sup><span style="font-family:AdvTTdd0b0455.B,serif;font-size:6.7pt">3</span></sup></p>
<p style="top:205.3pt;left:72.3pt;line-height:6.3pt"><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">1</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">The National Drug and Alcohol Research Centre, The University of New South Wales, Sydney, NSW, Australia;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> 2</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Drug and Alcohol Services, South</span></p>
<p style="top:218.6pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Eastern Sydney Local Health District, Surry Hills, NSW, Australia;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> </span><sup><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">3</span></sup><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Translational Addiction Research Laboratory, Campbell Family Mental Health</span></p>
<p style="top:230.1pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> </span><sup><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">4</span></sup><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Departments of Anaesthesia and Family Medicine, McGill</span></p>
<p style="top:241.5pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">University, Montreal, QC, Canada;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> </span><sup><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">5</span></sup><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW, Australia;</span></p>
<p style="top:251.1pt;left:72.3pt;line-height:6.3pt"><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">6</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Discipline of Addiction Medicine, University of Sydney, Sydney, NSW, Australia;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> 7</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Pain Management Centre, Royal Prince Alfred Hospital,</span></p>
<p style="top:264.4pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Camperdown, NSW, Australia;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> </span><sup><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">8</span></sup><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Department of Pain Management, Prince of Wales Hospital, Randwick, NSW, Australia;</span><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt"> </span><sup><span style="font-family:AdvOT503af387.I,serif;font-size:6.3pt">9</span></sup><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Pain and Addiction</span></p>
<p style="top:275.9pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Medicine, Centre for Addiction and Mental Health, Toronto, ON, Canada</span></p>
<p style="top:314.5pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Cannabinoids, when co-administered with opioids, may enable reduced opioid doses without loss of analgesic efficacy (ie, an opioid-</span></p>
<p style="top:326.0pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">sparing effect). The aim of this study was to conduct a systematic review to determine the opioid-sparing potential of cannabinoids. Eligible</span></p>
<p style="top:337.4pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">studies included pre-clinical and clinical studies for which the outcome was either analgesia or opioid dose requirements. Clinical studies</span></p>
<p style="top:348.9pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">included controlled studies and case series. We searched Scopus, Cochrane Database of Systematic Reviews, Medline, and Embase.</span></p>
<p style="top:360.3pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Nineteen pre-clinical and nine clinical studies met the search criteria. Seventeen of the 19 pre-clinical studies provided evidence of</span></p>
<p style="top:371.8pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">synergistic effects from opioid and cannabinoid co-administration. Our meta-analysis of pre-clinical studies indicated that the median</span></p>
<p style="top:383.2pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">effective dose (ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.3pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">) of morphine administered in combination with delta-9-tetrahydrocannabinol (delta-9-THC) is 3.6 times lower</span></p>
<p style="top:394.7pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">(95% confidence interval (CI) 1.95, 6.76;</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt"> n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:9.0pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> 6) than the ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.3pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> of morphine alone. In addition, the ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.3pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> for codeine administered in</span></p>
<p style="top:406.2pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">combination with delta-9-THC was 9.5 times lower (95% CI 1.6, 57.5,</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt"> n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:9.0pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> 2) than the ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.3pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> of codeine alone. One case series (</span><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:9.0pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> 3)</span></p>
<p style="top:417.6pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">provided very-low-quality evidence of a reduction in opioid requirements with cannabinoid co-administration. Larger controlled clinical</span></p>
<p style="top:429.1pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">studies showed some clinical benefits of cannabinoids; however, opioid dose changes were rarely reported and mixed findings were</span></p>
<p style="top:440.5pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">observed for analgesia. In summary, pre-clinical studies provide robust evidence of the opioid-sparing effect of cannabinoids, whereas one</span></p>
<p style="top:452.0pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">of the nine clinical studies identified provided very-low-quality evidence of such an effect. Prospective high-quality-controlled clinical trials</span></p>
<p style="top:463.4pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">are required to determine the opioid-sparing effect of cannabinoids.</span></p>
<p style="top:474.9pt;left:72.3pt;line-height:9.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:9.0pt">Neuropsychopharmacology</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> (2017)</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.0pt"> 42,</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt"> 1752</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1765; doi:10.1038/npp.2017.51; published online 5 April 2017</span></p>
<p style="top:161.7pt;left:50.8pt;line-height:9.0pt"><span style="font-family:AdvP4C4E46,serif;font-size:9.0pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></p>
<p style="top:518.0pt;left:52.3pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">INTRODUCTION</span></p>
<p style="top:535.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Chronic pain is associated with enormous personal, social,</span></p>
<p style="top:547.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and economic burden and is the largest contributor to years</span></p>
<p style="top:559.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">lived with disability globally (Rice</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015). Despite this,</span></p>
<p style="top:571.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">existing medications provide only modest relief. Opioids in</span></p>
<p style="top:583.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">particular have considerable side effects, including constipa-</span></p>
<p style="top:595.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tion, impaired sleep, and respiratory depression (Chou</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:607.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2015). The last two decades have seen an increase in the</span></p>
<p style="top:619.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">prescription of opioids, which has been associated with an</span></p>
<p style="top:631.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">increase in opioid use disorders and opioid-related mortality</span></p>
<p style="top:642.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(Chou</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015; Volkow and McLellan, 2016; Zedler</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:654.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2014). This has been termed as an</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt"> &#x2018;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid crisis</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2019;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, and has</span></p>
<p style="top:518.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">caused regulators, health professionals, and the public to</span></p>
<p style="top:529.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">begin seeking means to reduce problems associated with</span></p>
<p style="top:540.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">high-dose opioid use. Consequently, there is a need for</span></p>
<p style="top:551.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">evidence-based strategies for reducing reliance on high-dose</span></p>
<p style="top:562.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioids without compromising pain management.</span></p>
<p style="top:573.2pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Using combinations of medications to harness comple-</span></p>
<p style="top:584.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">mentary but distinct mechanisms of action can maximize the</span></p>
<p style="top:595.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesic response, enabling the use of a lower dose of each</span></p>
<p style="top:606.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">medication and resulting in an improved side effect profile.</span></p>
<p style="top:617.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">One promising area for medication combinations is the use</span></p>
<p style="top:628.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of opioid-sparing medications. Opioid-sparing medications,</span></p>
<p style="top:639.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when co-administered with opioids, enable a reduced opioid</span></p>
<p style="top:650.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dose</span></p>
<p style="top:650.0pt;left:345.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">without</span></p>
<p style="top:650.0pt;left:385.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">loss</span></p>
<p style="top:650.0pt;left:409.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of</span></p>
<p style="top:650.0pt;left:426.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesic</span></p>
<p style="top:650.0pt;left:471.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">efficacy.</span></p>
<p style="top:650.0pt;left:513.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Cannabinoid</span></p>
<p style="top:661.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">medications are increasingly being studied for their analge-</span></p>
<p style="top:672.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sic- and opioid-sparing potential. The endocannabinoid</span></p>
<p style="top:682.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">system represents an ideal target because it is a key</span></p>
<p style="top:693.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">endogenous system in modulating pain-processing pathways</span></p>
<p style="top:704.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(Woodhams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015).</span></p>
<p style="top:715.8pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The endocannabinoid system is composed of the canna-</span></p>
<p style="top:726.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">binoid CB1 and CB2 receptors, the endocannabinoid ligands</span></p>
<p style="top:677.8pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">*Correspondence: Dr S Nielsen, The National Drug and Alcohol</span></p>
<p style="top:687.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Research Centre, The University of New South Wales, Sydney, NSW</span></p>
<p style="top:697.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">2052, Australia, Tel: +61 2 89361017, Fax: +61 2 9385 0222,</span></p>
<p style="top:707.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">E-mail: suzanne.nielsen@unsw.edu.au</span></p>
<p style="top:717.6pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Received 11 July 2016; revised 31 January 2017; accepted 7 March</span></p>
<p style="top:727.6pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">2017; accepted article preview online 22 March 2017</span></p>
<p style="top:24.2pt;left:139.7pt;line-height:7.1pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.1pt">Neuropsychopharmacology (2017) 42,</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.1pt"> 1752</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.1pt">1765</span></p>
<p style="top:34.2pt;left:64.6pt;line-height:7.1pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.1pt">&#xa9;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.7pt"> 2017 American College of Neuropsychopharmacology.</span></p>
<p style="top:34.5pt;left:216.7pt;line-height:6.7pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.7pt">All rights reserved 0893-133X/17</span></p>
<p style="top:48.4pt;left:182.0pt;line-height:7.1pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.1pt">www.neuropsychopharmacology.org</span></p>


<p style="top:58.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">anandamide and 2-arachidonoylglycerol, and their synthesis</span></p>
<p style="top:69.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and degradation system (Pertwee, 2006). CB1 and CB2</span></p>
<p style="top:80.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">receptors are differentially expressed on the central nervous</span></p>
<p style="top:91.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">system (Cencioni</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2010; Herkenham</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1991) and</span></p>
<p style="top:102.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">play important roles in pain processes. Both cannabinoid</span></p>
<p style="top:113.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">receptors and endocannabinoids are present in the primary</span></p>
<p style="top:124.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">afferent pain circuits to the brain (Manzanares</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999;</span></p>
<p style="top:135.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Woodhams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015). Cannabinoid and opioid receptors</span></p>
<p style="top:146.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">have similar signal transduction systems (Cichewicz, 2004;</span></p>
<p style="top:156.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Howlett</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2002; Vigano</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2005) and are expressed in</span></p>
<p style="top:167.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">several brain regions involved in antinociception, including</span></p>
<p style="top:178.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the periaqueductal gray, raphe nuclei, and central-medial</span></p>
<p style="top:189.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">thalamic nuclei (Cichewicz, 2004). In addition, mu-opioid</span></p>
<p style="top:200.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">receptors and CB1 receptors co-localize in the spinal cord at</span></p>
<p style="top:211.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the first synaptic contact for peripheral nociceptive afferent</span></p>
<p style="top:222.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">neurons (Hohmann</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999; Salio</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2001).</span></p>
<p style="top:233.6pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">It has previously been observed that CB2 receptors</span></p>
<p style="top:244.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">indirectly stimulate opioid receptors located in primary</span></p>
<p style="top:255.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">afferent pathways (Ibrahim</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2005). Therefore, in</span></p>
<p style="top:266.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">addition to their direct analgesic effects, cannabinoids may</span></p>
<p style="top:277.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">work synergistically to enhance opioid analgesia. The</span></p>
<p style="top:288.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">behavioral, anatomical, and biochemical similarities between</span></p>
<p style="top:299.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid and cannabinoid receptor systems and their endo-</span></p>
<p style="top:310.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">genous ligands are well documented. For example, activation</span></p>
<p style="top:321.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of either cannabinoid or opioid receptors produces compar-</span></p>
<p style="top:332.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">able neurobehavioral and physiological effects, including</span></p>
<p style="top:343.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">antinociception (Manzanares</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999). This is highlighted</span></p>
<p style="top:354.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">by both CB1 and CB2 agonists being able to induce</span></p>
<p style="top:365.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">antinociception</span></p>
<p style="top:365.1pt;left:100.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">by</span></p>
<p style="top:365.1pt;left:119.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">increasing</span></p>
<p style="top:365.1pt;left:169.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid</span></p>
<p style="top:365.1pt;left:204.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">precursors</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2019;</span></p>
<p style="top:365.1pt;left:258.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">gene</span></p>
<p style="top:376.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">expression or via release of endogenous opioids (Houser</span></p>
<p style="top:387.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2000; Ibrahim</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2005; Valverde</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2001). Further,</span></p>
<p style="top:398.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">pharmacological modulation of the opioid system can</span></p>
<p style="top:409.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">modify the effects of delta-9-tetrahydrocannabinol (delta-9-</span></p>
<p style="top:420.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC)</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a partial agonist at the CB1 and CB2 receptor</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">on</span></p>
<p style="top:430.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">nociception (Mason</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999; Pugh</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1997; Smith</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:441.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1994) and</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> vice versa</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">. Finally, cannabinoid antagonists have</span></p>
<p style="top:452.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">been shown to reverse the antinociception induced by</span></p>
<p style="top:463.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">morphine (da Fonseca Pacheco</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008). Collectively,</span></p>
<p style="top:474.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">this strongly supports shared mechanisms between both</span></p>
<p style="top:485.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">systems in regard to analgesia.</span></p>
<p style="top:496.7pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Animal models have identified a role for CB1 receptor</span></p>
<p style="top:507.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">activation in reducing neuropathic, visceral, and inflamma-</span></p>
<p style="top:518.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tory pain (Pertwee, 2008; Walker</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999). Several pre-</span></p>
<p style="top:529.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical studies have demonstrated that systemic administra-</span></p>
<p style="top:540.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tion of cannabinoid receptor ligands produces analgesia in</span></p>
<p style="top:551.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">acute and chronic pain models (Walker and Huang, 2002).</span></p>
<p style="top:562.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">In addition, the role of CB2 receptors has been explored in</span></p>
<p style="top:573.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">pre-clinical studies, suggesting that these receptors may</span></p>
<p style="top:584.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">mediate effects in inflammatory pain states (Ibrahim</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:595.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2006; Quartilho</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2003), and reduce inflammation and</span></p>
<p style="top:606.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">neuropathic pain (Gui</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015).</span></p>
<p style="top:617.2pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Further to these pre-clinical findings, clinical studies</span></p>
<p style="top:628.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">indicate that cannabinoid administration may reduce pain</span></p>
<p style="top:639.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and improve other symptoms such as sleep disturbances</span></p>
<p style="top:650.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">associated with chronic pain (Ware</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2010a; Ware</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:661.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2010b). This effect could be mediated by delta-9-THC, which</span></p>
<p style="top:672.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">is the main psychoactive ingredient present in cannabis</span></p>
<p style="top:683.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(Cichewicz, 2004; Jensen</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015). Despite the growing</span></p>
<p style="top:693.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">body of relevant literature, to date no systematic review has</span></p>
<p style="top:704.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">focused on the opioid-sparing effects of cannabinoids. To</span></p>
<p style="top:715.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">address this gap, we conducted a systematic review of pre-</span></p>
<p style="top:726.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical and clinical studies to examine the strength of</span></p>
<p style="top:58.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">existing evidence demonstrating the opioid-sparing effect of</span></p>
<p style="top:69.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoids in the context of analgesia.</span></p>
<p style="top:97.8pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">MATERIALS AND METHODS</span></p>
<p style="top:114.7pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Search</span></p>
<p style="top:132.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">We conducted a systematic search of the literature in</span></p>
<p style="top:142.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">accordance with recommendations by the Preferred Report-</span></p>
<p style="top:153.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ing</span></p>
<p style="top:153.9pt;left:315.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Items</span></p>
<p style="top:153.9pt;left:346.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">for</span></p>
<p style="top:153.9pt;left:366.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Systematic</span></p>
<p style="top:153.9pt;left:418.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Reviews</span></p>
<p style="top:153.9pt;left:459.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and</span></p>
<p style="top:153.9pt;left:482.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Meta-Analyses</span></p>
<p style="top:164.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(PRISMA) (Moher</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2009). The search aimed to identify</span></p>
<p style="top:175.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical and pre-clinical studies using the following electronic</span></p>
<p style="top:186.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">databases: Scopus, Cochrane Database of Systematic Re-</span></p>
<p style="top:197.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">views, Medline, and Embase. Search terms are listed and a</span></p>
<p style="top:208.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sample</span></p>
<p style="top:208.7pt;left:331.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">search</span></p>
<p style="top:208.7pt;left:366.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">strategy</span></p>
<p style="top:208.7pt;left:406.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">is</span></p>
<p style="top:208.7pt;left:421.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reported</span></p>
<p style="top:208.7pt;left:464.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">in</span></p>
<p style="top:208.7pt;left:481.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Supplementary</span></p>
<p style="top:219.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Appendix 1. No date limits were included. Searches were</span></p>
<p style="top:230.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">run on 29 October 2015. In addition, reference lists from</span></p>
<p style="top:241.6pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">identified studies and review articles were searched to find</span></p>
<p style="top:252.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">additional studies not identified by the main search.</span></p>
<p style="top:263.5pt;left:303.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Eligible studies included:</span></p>
<p style="top:280.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> Human or animal studies.</span></p>
<p style="top:291.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> Outcomes of either pain/analgesia or opioid requirements/</span></p>
<p style="top:302.4pt;left:304.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid-sparing effects from concurrently administered</span></p>
<p style="top:313.3pt;left:304.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioids and cannabinoids.</span></p>
<p style="top:324.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> Controlled clinical studies and case series.</span></p>
<p style="top:346.2pt;left:303.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Titles were screened by two authors (SN and PS). Where</span></p>
<p style="top:357.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">inconsistencies were identified, the authors were able to</span></p>
<p style="top:368.1pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reach consensus on each occasion.</span></p>
<p style="top:393.6pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Data Extraction and Outcomes</span></p>
<p style="top:411.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Data extraction forms were developed and circulated to the</span></p>
<p style="top:421.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">author group before piloting and refining. All data were</span></p>
<p style="top:432.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">extracted by one of the authors (SN, PS, or JMT) and</span></p>
<p style="top:443.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">checked by a second author (SN, PS, or JMT). These same</span></p>
<p style="top:454.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">authors reviewed and resolved any inconsistencies, with</span></p>
<p style="top:465.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">input from the authorship group as required. When required</span></p>
<p style="top:476.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">data were missing, attempts were made to contact authors of</span></p>
<p style="top:487.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">published reports to collect additional information.</span></p>
<p style="top:513.2pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Outcome Measures</span></p>
<p style="top:530.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">For pre-clinical studies, the primary outcome was the dose of</span></p>
<p style="top:541.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid required to give an equivalent antinociceptive effect in</span></p>
<p style="top:552.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the presence and absence of cannabinoids. For clinical</span></p>
<p style="top:563.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies, the primary outcome was evidence of the opioid-</span></p>
<p style="top:574.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sparing effect of cannabinoids. Data were extracted on opioid</span></p>
<p style="top:585.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dose and/or analgesic outcome where cannabinoids were</span></p>
<p style="top:596.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">co-administered. Secondary outcome measures examined</span></p>
<p style="top:607.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">included analgesia, sleep, and quality of life.</span></p>
<p style="top:632.7pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Analysis</span></p>
<p style="top:649.7pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.5pt">Pre-clinical studies</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">.</span></p>
<p style="top:650.1pt;left:387.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Data were extracted and a narrative</span></p>
<p style="top:661.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">review was conducted. Ten studies were identified as</span></p>
<p style="top:672.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sufficiently similar in design and outcome measures to be</span></p>
<p style="top:682.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">eligible for meta-analysis. Of these, six reported sufficient</span></p>
<p style="top:693.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">data to enable meta-analysis; that is, the dose of opioid</span></p>
<p style="top:704.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">required to produce comparable analgesia in the presence</span></p>
<p style="top:715.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and absence of cannabinoids, the variance of the observed</span></p>
<p style="top:726.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dose, and the sample size. Authors of the other studies were</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1753</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:422.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">contacted in an attempt to include additional studies in the</span></p>
<p style="top:433.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">meta-analysis; however, no additional data were identified to</span></p>
<p style="top:444.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">enable the inclusion of any additional studies.</span></p>
<p style="top:455.3pt;left:62.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">To prepare the data for the meta-analysis, the effective</span></p>
<p style="top:466.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dose (ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">) and either confidence limits or SE were</span></p>
<p style="top:477.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">extracted from the relevant literature. ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> is calculated on</span></p>
<p style="top:488.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> scale. Therefore, to meet the assumption of</span></p>
<p style="top:499.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">normality, the log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt"> </span><sup><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt">c</span></sup></p>
<p style="top:499.2pt;left:143.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> must be used in the meta-</span></p>
<p style="top:510.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analysis. The log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> of the confidence limits must also be</span></p>
<p style="top:521.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">determined to calculate the SD of the log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt"> </span><sup><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt">c</span></sup></p>
<p style="top:521.1pt;left:232.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">:</span></p>
<p style="top:552.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">SD log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt"> </span><sup><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt">c</span></sup></p>
<p style="top:552.0pt;left:91.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span></p>
<p style="top:541.0pt;left:64.5pt;line-height:10.0pt"><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt">&#xfffd;</span></p>
<p style="top:541.0pt;left:111.9pt;line-height:10.0pt"><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt">&#xfffd;</span></p>
<p style="top:552.0pt;left:120.5pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xbc;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> </span><sup><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">log</span></sup><sup><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span></sup><sup><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">UL</span></sup><sup><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span></sup><sup><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> log</span></sup><sup><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span></sup><sup><span style="font-family:AdvP4C4E46,serif;font-size:10.0pt"> c</span></sup></p>
<p style="top:545.2pt;left:198.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span></p>
<p style="top:558.8pt;left:166.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1</span><span style="font-family:AdvP4C4E51,serif;font-size:10.0pt">:</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">96</span></p>
<p style="top:552.0pt;left:220.1pt;line-height:10.0pt"><span style="font-family:AdvP4C4E51,serif;font-size:10.0pt">;</span></p>
<p style="top:573.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">where UL is the upper confidence limit.</span></p>
<p style="top:584.3pt;left:62.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">When only SE was reported, the confidence limits were</span></p>
<p style="top:595.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">calculated using the method of Litchfield and Wilcoxon</span></p>
<p style="top:606.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(1949) and the above procedure was repeated to calculate</span></p>
<p style="top:617.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the SD. This method also allowed for the inclusion of studies</span></p>
<p style="top:628.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that did not report exact sample sizes for all treatment</span></p>
<p style="top:639.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">groups, as sample size was not required for the calculation</span></p>
<p style="top:650.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of SD.</span></p>
<p style="top:661.0pt;left:62.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Data for the meta-analysis were analyzed using Review</span></p>
<p style="top:672.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Manager 5.1 (Cochrane Collaboration, Oxford, UK). When</span></p>
<p style="top:682.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">calculating the continuous outcome of an equally effective</span></p>
<p style="top:693.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid dose (eg, the log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> for morphine when adminis-</span></p>
<p style="top:704.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tered alone</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> vs</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> when administered with a cannabinoid), the</span></p>
<p style="top:715.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">inverse variance statistical method and random effects model</span></p>
<p style="top:726.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">were used to compensate for study heterogeneity.</span></p>
<p style="top:422.4pt;left:328.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">No statistical difference was found in outcomes between</span></p>
<p style="top:433.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the studies that used different species or nociceptive assays.</span></p>
<p style="top:444.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Therefore, the mean difference of log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt"> 10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> of and the</span></p>
<p style="top:455.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">corresponding 95% confidence intervals (CI) were calcu-</span></p>
<p style="top:466.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">lated. Due to the nature of log calculations, the mean</span></p>
<p style="top:477.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">difference</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when back-transformed to the original units</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span></p>
<p style="top:488.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">represents the response ratio. For easier interpretation, we</span></p>
<p style="top:499.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">present the reciprocal of the response rate.</span></p>
<p style="top:522.9pt;left:318.3pt;line-height:10.5pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.5pt">Assessment of bias in pre-clinical studies</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">.</span></p>
<p style="top:523.3pt;left:508.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">A funnel plot</span></p>
<p style="top:534.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">was produced to examine publication bias and small study</span></p>
<p style="top:545.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effects in the pre-clinical studies included in the meta-</span></p>
<p style="top:556.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analysis.</span></p>
<p style="top:579.9pt;left:318.3pt;line-height:10.5pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.5pt">Clinical studies</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">.</span></p>
<p style="top:580.3pt;left:396.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The nine clinical studies identified were</span></p>
<p style="top:591.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">heterogeneous in design and outcomes, and therefore</span></p>
<p style="top:602.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">not suitable for meta-analysis. Thus, a narrative synthesis</span></p>
<p style="top:613.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">was conducted instead, with all studies scored for quality</span></p>
<p style="top:624.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">using the Grading of Recommendations Assessment, Devel-</span></p>
<p style="top:635.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opment and Evaluation (GRADE) criteria (Guyatt</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:646.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2008).</span></p>
<p style="top:676.6pt;left:318.3pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">RESULTS</span></p>
<p style="top:693.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The initial searches identified 3019 records after duplicates</span></p>
<p style="top:704.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">were removed, with 19 pre-clinical and nine clinical studies</span></p>
<p style="top:715.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">identified for inclusion in the final review (see Figure 1 for</span></p>
<p style="top:726.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the PRISMA diagram).</span></p>
<img style="position:absolute;transform:matrix(.43216218,0,-0,.4361841,179.054,-190.55194)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEoAAAO8CAIAAABhkbW/AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAWOElEQVR4nO2bC1viShOE+f8/8ux6wZW7iFxc4dmvQoWmmQB69jtr
Km7NU2JIJrHf6Z6eSJrebrf71c0Gy7fbbXMnG9/2Ym8+5/X152bzCq3Xm+VqtXh5
Cb0sly0KxsAkCL+rzfUGpv58e8v2Z4edwcM5wJjPn6Gn+XwynY3G4+GoEjZaFA2A
PbOnp+nsCa+wcLFYAJucTWf2CmJ0wgm4BHkGw9Hj4+Dhx2P/4YeIYMyPR7TBYDAM
YHACEuFWzLVefg8vw2+TyRRn3vcfmpc+u/MzwWDA7d09hA28pYAKSDgThEAovUcH
Vn4D23SG3nf3fSpGS0GMI7Dd4Gc/0HilcHQ8mcCHmJCZsMJDyFbzDTE5mZINp5MN
b6G4eosKvDzuQYhtBCqjFIQnmTP7DV2JxyHB3EOg8kJ0Y4SEiEiIDZg6rCbiBH6K
HFPhYUY+Py9wDF1jbGL6YoPMUATD54t/nTONzgw8jjtMpbXwE72H1xoPPg08slGR
M/k3crh/snLapGF54pGZO+FCTL/tvlV4mHhYQYBHGI5E9OaYxUVbTC05JiOgOIdo
MLYxrRClcBhmHFQtDLgVYFLhCHEw8JonbvMPtDXTckahV8NgLhvYxgrBu5kKD3MR
xByPvMTFfGt9KX9XYSQMBieCkXdqB7zBMHx9li1Gq0W/XVEkHk5F3LKd4u29F9bH
CREMreuKGXGIGwhO3MEgOCs8pJeMx04Ph9VTMDILZ9Il2Y0MzhoPP1j0gNc/RHDh
vW4JNof36ltq43VGxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOe
rIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU8
48nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9W
xjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7x
ZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvj
GU9WxjOerIz3JfFwAEiX8DK5sq55L/CI+qW8l10UeJ0jhNnve4/bXXTgRbzm3Gvi
KdBej6l/kVo08d6FP8HbbrdX5l5fL1vCnmxS0wGDwfCI9/PtbT5/Bh6p2Cm7TgQv
jPnxWIlWNQOVeE/zeY2HX8SLsSHe7d09uuJC8HWQt466N2hAkwjDCRViakE8ggvz
rrfZvFZ4gyE9VniPo9U6VcZrei8vY9jAUeAhKo94IA6PnXW6lDj9YtBJRd3c3gFv
sTjg1cE5GIINxyJ5FsPTOlKQxDShAJPxvt/cVngvL0iZNR5Yh6Mx0YkX8a2WQoMk
R2nshIeAB8uXq9UR72W5nExn6JczSpyZB6x1vPAStmlk/zQ4Ibhqvd7UePiF6QcH
jieTOD+8rxacdEDGIxt3Ms/DVUybFR5+QAhcLIWYgRGNeeJ2Aq9a8YajyWSKtEnX
VXhY+/AGeWa1WoMbndg1kESmX16Qw1F54tFvCMOIzBqPDQ7FYSafglBHObWQDemQ
BgMY9jOpAKfGg9+Ihw24FfOSV2n+U9sucCzIIOHoRyjxVga5A67jvVi0Co+4JGaa
mc6eyMlI0EmexIPHmN6RLEAFa+EY5P9gA8gJXrynG+FiZBoQcnmprjMYQtjDjbbE
+UZ3jcZjkMFOLOKYb9lPR+/BXYHHLIp+GAZkGpyGGxoIYwPFRiuiJRD+G4BoDBqc
BjYY3PRT/f9e3hXb20PDaSFepV3Bhizu3KaWcep1r8l9lrn1tju05s6zHXq71D7b
2D/QSry8S5mz8M8Hzzri5dgVJIyhz0a+649ewdY8U6pFqjtr7Rk8faTcikwenNHh
It5/HEx/pgVhLFrXfdg7C63c3vVw7ty7dJWv0YzX5Wa8LjfjdbkZr8vNeF1uxuty
M16Xm/G63Hrd+lf937av7r22DfizzXhdbl8Tb5cfocSuS58WXtr/me33bCjx4rP7
4inhZvMqosKw65+y94ItNnCJ5Wq1OLT5/Hk6e4Ke5nO8tC4+eY4n4TAVgs1FDUTp
PTbWDeC0yWQ6nkyg4WjMCjo+uW9XdQ3BcASNxmOWRVTVA4vFarWmMy/iYe96vcHw
4DRcqyic6x++CdBi1UfUpEZl2L76Y8R6pCA8g8fKMjid9R7kiaq71otaiuJUFu9E
eSY8yQoQEpZzD2w4ADb0Y+Ujz2Qw8NJFCfrn4zUJw4es39nnh2dMrhPvhd8KtmpY
9lHeT/X0UQb7yWpyRqyytgh2gpAVgSfeY0EujqFTFH3WxUjDEV77qaQrF4Z+pmL+
0zAmBU4iziBaC8GHsUJWeFHM2U818DyfEy8K52LAWlSUGYc9gcqSLDgwntomvOEo
agmZhfupODeyaFuKv352TmZPYIrFI/gKr6qlnkzBk72fCx7z1cn5+bqU2GL/w6Ge
FX5CdqEDz3zBrSgvL7JW66nlLGEuOoVv+CWbhHeooo7e940vYGrW54bfIjuwLLf+
kg2CE2nz0pdLRUpxryjKcgMP3sOd2sVvX8YcvWt8f+96kLSI95BW/AjOhHcanP0L
33ETxCusKvHwE3iRJIvi/nyX0DrMJR/SVN6Q/H1fyzdeB2Q848nKeMaTlfGMJyvj
GU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iy
Mp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGM
JyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZ
z3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaT
lfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeH8JHhRv80aLKmyAwRB30viL
eDgQPNwWxDvrrg/gDYYdxQuDY+ND3stv9fEy58W51wnvwYwcjWEY92Pnj8fHp/m8
xttut83UEnjYRm8dPNpDkxhiGRKCzTg6nz/XeD/f3vAm4/UPaZNd4evWqUKwB2kC
ykbm0adLjnj4BVfyhIx3e3cfeAp+O+INR028iFiYfYK32bwCD2dF78iw+TQRRXAW
CSK88v3mFocWiwWiEmmlwgMr8eixvsY0u0IYqSXPPeJ9+36DjSMenMh1D8dubu+I
l0dI8NasCZbxYPbLcomUWeGBcvHyMhqP+/vAveXcfBxwyjEApAizSRFlsVDDQ3DV
arWu8fALb7AOxo0L+WTxcoKIKM1zajyZYMbVePhBfMKb09lTJJj+Pj4jOGXx+ulW
E9YiqQ5HY96y7Path+yJXxGizXSkpmxeoDLi4DewAYSuq/HYEKKTybR/mIGFx1p3
YHHL0T/EJE3lrSYCEGzr9WZ3aFVwEg/EWABxGpYOJhipyGzeUVGxmCEyYT+TCkPy
xHt5EiJKef9GT0YAFJf+TIUBsCcvYKCCtfQbM8qv1E7wuMGVEHFcZBomG260JQ56
uAtGwmOwFk7jOl6w9AKX3sQG+qE3BgPTFOdDk+kM2xAGqS3BhnpjMq2ErTnaM+xc
wtz1BmZHRjmDF4QBCV/jzOrc9QbbeG1RNIMbeZu2kY14ZXBm3Nx2So32ZIbibRGD
J3PvSg+1VtjWfJvt75091sRrnblIic121sJecXh7aFdQW2y08OO2ld7bnmv/77z5
L9ol83KHd/B+nfoQ6YiKq7SOWhiWEyZbidfc9etcoOb97bZi3N/Ha+7NsXrpaFtt
dyFBnMe7fqEr8C22jxt2De8LtC7h/UY0dQnvN5rxutyM1+VmvC4343W5Ga/LzXhd
bsbrcvu78XZXPxJut33kX9uv6b3d2Q/hL3WV+kDp+kdjRfua3ot2fEJUjMfZsfnY
B61/tl0i2e3rO15ff+bHtBfxLhG23nbpsV5hHsDW6w2LWrjnnY9xi2cMrdPSJD6a
3QDk9WfxjIDei/695sfsHJ7Vav2yXD4/L6pH888LkQZLnubz6ax60M8H6+AhJI2n
Y494+Rgbyz9wNi4xmUyHozELYKs60dY1GLKcj2URk+kMkPDkpWchvTwR0Qkex5Bg
eHgtVi23WM5ypcyFVSij8ZiFVqz9KDh72a0YBngfYwIwnlzUhkb5zOcrF+/knXiF
tfAk3AjCIhjrB2CcbGSD66OEMIplWlc2IxeUsWgKO0EI+5erFauoa7zsN1Yi5aLA
XLUcpYUtqp+Kje/2xakUIGEqfIOUAcITPOAidjFNM1sUrcaFOE4csM9XGLA3axBJ
gYegqgyrSjhj+Olk7sF1CNwok7tLta7huvgzbeWSbEDY1vyyGrCRaU4WBlYBxvds
MlvEPdNxi8VyTOP36esxXB7iGykxIRGiJ3ctWC7PfoeoiPXWs0sUdt6ffrHmIX0t
gYn0+B2id/FEdAmvWdUKvHe+4NZvVGSL6z5Vjr///b0viNc/lMvnG7Gu4GXOf4HX
urn/JV7cqXxB73V67hV4WMb/+q/lG09OxjOerIxnPFkZz3iyMp7xZGU848nKeMaT
lfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxn
PFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nK
eMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOe
rIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU8
48nKeMaTlfGMJyvjGU9WxjOerIz3BfEGwyZeJwhhIQ3OeE/zeY2Hn0vek8LLDMVO
vtJU2Pzj8fFMcOIwjrE3tzNeJtfBax46E5yLxWI4Goejz3qvdbwMQweEuAeC39Dh
BA8/L8vleDLhMbziMPoQLy7XOlWwwcIcXxB3wmxaXs494vGcin0wxGuMjYjTzuLd
3t0XeCQ4wVu8vCA42ZuH6clMqKMIzsJ7MaewXeIhtYDt+80tpyZ6kDBCVE3E4+hn
f97c3mH7Ih7p8Zbn0Pv9Q2ppl6ef1oAitXADpn77foMNrAU/396QNXv4xWWdeHhF
b+BxBgZe/httKdgiqwdz7AQC3mItqPHws1ytJpMp+sVMBRsdqIPHP10syJHzwpM4
BOORLLfbbY23Xm8QrNjL7JLzZ8ZrN39mgGCLBYxGMn/CVXAY8Kq5h1+YhZUDp7Po
zX54jTNbn3v9cytwdiZTBla4+fx5s3mF2+q7FvxCpCJecTiPhBpeEIbCn3QJ6HC/
Aldx4h3x4EPE62g8Ru+YgeHMfOfalvL4FneO9B58gwCEk+A6Rma9MLBhL9yKAaDf
ODBYKTgwFBfQVsSbkli+Y5WjM7AfUw5syCO7fSvxsAvQq9UaaQZuxAlIsv98+86l
oi2qPLJx20WPge2fbzf7pfoBBoONS3luPbJuDw0+xCoPQgwGrpXzlYL6h/RIYK5h
SCcwGI7BlCvxSLVLDWMAFwMSy/109oSB4Z14vnP9fMXU2GfHaSUYN5/DacgaMDjS
yQke9hIv7+VqEZyYkxBoIW5/vjjc4KGwDSrEGow8C1bjxeGiRzgz+BnDu1YbjEEQ
AoyhyJ1nwWo8DMBH+hXMrbQcWZH6r7deds7uggOjffCif6LlGXQFvmi9HHhXWozC
9W5/rpFwexjf3T5QQ9tG+qjxMhv75fZfxtZ/0cLu2BN4Zwl70e8SVXHF/yO+/q92
Ca8wuDirV/Rul+FKO2vYu6b2rh/Wab836J3B+71mvC4343W5Ga/LzXhdbsbrcjNe
l5vxutyM1+VmvC63vw9P85OyaLvGR+ln97N1z3vNDzzzRnH0+DlnfBhanPar7Scn
RbsOnz+or/F2e7ZLH9bzon/gqcHvtN17n5qT4oi3O33A8MFIaKWFA7eXncGnrvH2
+ISowMDJm83rer2B+IgT4smtaLt/rAdj+PgSWq5W8XAyLCd57Ok1n9yiR/XMebHg
w97Z09N01r5oxmQ649t4sA5Iwu8OqSXHYPXwuaAnG86HRuMxvwOQy5NaURQQwZ7h
aAzBNkKydCBAMk4vhy+2MRgYJ1Kx7JG1SVEgg9cWxdqxKKity8ims/n8GUHbzB3H
hQFRCjYMBguTWEECPFZ9nC3p+kzliquohebbKG2BD7eny1uNBza4GH7j9zUiFHNZ
SVsVLdmGUFFQhj0sTCqSTY8xyVorfpshIjB/RaD1WsDsuihmj2L4qmRuMGSUIgaP
eNiqCq2QSyZTVjiSLQam9UKrS3VXhAwLYz/8dJJa4LoiLMXVr8uFR6yIjiJNCn6K
6Vfh5a9pXKqRi1Lm1uOTNpCPFdGFVzDFWGwMwgqvqMN9SN/fC57WZ2BRG/7w47G5
kwZX5dTT2bES/i/4eqLxOiHjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGM
JyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZ
z3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaT
lfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxn
PFkZz3iyMp7xZGU848nKeMaTlfGMJyvjGU9WxjOerIxnPFkZz3iyMp7xZGU848nK
eMaTlfGMJyvjGU9WxjOerIxnPFkZz3iy+vvw5vPnwWDIY0TCK/Cg4mSS6+jH42O2
ihuBB7Qz3uM5xCscqIBHG+gJKuPd7/mOePDg4uVlOBrTYxX7YIhXvlWLT9gecyeU
O9zt+Y7BGXjsWuENR3jpH0JUivA6Hky9vbtHh6f5/Dj3gAck9OMxeA94dLQaXj8F
Z9hGZgh7vt/cYs8Rb7vdLhYL4t3c3jHzwIc5xFtHauLFNkwNg2H9t+83MBh4P9/e
ajymFnqPsYveTDCaeCGyEa+/j9h/vp3i4Ve1MAxHDFyGMvEYnxmv9cx5lo1TCUdh
P/HgsBpvs3nF3JtMpugdDiRhTD8FvLMxWaX5fZ7nfs4v7MR02+1bD1PwZbmczp64
9HG+8nxGM/F49Xa9F6FULW17sMiC/XSzhVUARDUe5l7lwMUiHEgenpm9p5NFIztE
Cuzvw43+BMh6vQFbve6BcLVaYynEscBT814RnKHwKlfs0Xgcq0K97qHhPe88yUPv
Z7z+4ZatLcUtWIEXizu2wYZZhlRC19XeowMRr+PJpH8IwsJ7/fT/RFsqaGkbcgk3
GJZwEiKxxEODA5lCeUfGc4qVkC5tnTDYIs8j7mA5MgjYIjLrdQ8iLny4XK3gXyQf
Xii8FzdBCopY5dDDWsYkwIAQrqvwsCvw0LCBtIOuOAGhHEtKu07LYhDBXaDCbGJA
witk+3XaekGcCQEML8PXSKeT6QyXgHCt1lVZMp1h6JEeYR7yBcCwsBVOO+JxL163
+xYHCIkzIfhTTbAK5jWpdod2klq4NjRjV7AVAMWhwv7/AXLhH9ZUme7+AAAAAElF
TkSuQmCC">
<p style="top:85.8pt;left:185.5pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Records identified through database </span></p>
<p style="top:93.9pt;left:222.8pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">searching </span></p>
<p style="top:102.7pt;left:221.4pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 3245)</span></p>
<p style="top:184.2pt;left:158.7pt;line-height:7.7pt"><span style="font-family:Times New Roman,serif;font-size:7.7pt">Screening</span></p>
<p style="top:343.7pt;left:158.7pt;line-height:7.7pt"><span style="font-family:Times New Roman,serif;font-size:7.7pt">Included</span></p>
<p style="top:265.1pt;left:158.7pt;line-height:7.7pt"><span style="font-family:Times New Roman,serif;font-size:7.7pt">Eligibility</span></p>
<p style="top:108.8pt;left:158.7pt;line-height:7.7pt"><span style="font-family:Times New Roman,serif;font-size:7.7pt">Identification</span></p>
<p style="top:85.8pt;left:325.3pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Additional records identified </span></p>
<p style="top:93.9pt;left:335.5pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">through other sources</span></p>
<p style="top:102.0pt;left:356.4pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 3)</span></p>
<p style="top:143.4pt;left:240.1pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Records after duplicates removed</span></p>
<p style="top:151.6pt;left:272.4pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 3019)</span></p>
<p style="top:195.3pt;left:246.9pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Records screened (SN+PS)</span></p>
<p style="top:203.5pt;left:270.4pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 3019)</span></p>
<p style="top:195.4pt;left:394.2pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Records excluded </span></p>
<p style="top:203.6pt;left:404.5pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 2973)</span></p>
<p style="top:244.3pt;left:245.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Full-text articles assessed for</span></p>
<p style="top:252.4pt;left:257.6pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">eligibility (SN + PS)</span></p>
<p style="top:260.6pt;left:275.3pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 46)</span></p>
<p style="top:228.4pt;left:381.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Full-text articles excluded, </span></p>
<p style="top:236.5pt;left:389.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 18; wrong study</span></p>
<p style="top:244.6pt;left:385.3pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">design, opioid doses not</span></p>
<p style="top:252.7pt;left:381.9pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">reported, cannabinoids not</span></p>
<p style="top:260.8pt;left:381.6pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">administered concurrently, </span></p>
<p style="top:268.9pt;left:390.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">no data on analgesic</span></p>
<p style="top:277.1pt;left:404.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">outcomes)</span></p>
<p style="top:296.2pt;left:243.5pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Studies included in qualitative </span></p>
<p style="top:304.3pt;left:273.3pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">synthesis </span></p>
<p style="top:312.5pt;left:274.9pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 28)</span></p>
<p style="top:342.3pt;left:241.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Studies included in quantitative </span></p>
<p style="top:350.4pt;left:246.9pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">synthesis (meta-analysis) of </span></p>
<p style="top:358.5pt;left:245.3pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">preclinical data for morphine</span></p>
<p style="top:366.7pt;left:276.6pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 6)</span></p>
<p style="top:342.3pt;left:365.7pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">Studies included in quantitative </span></p>
<p style="top:350.4pt;left:370.9pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">synthesis (meta-analysis) of </span></p>
<p style="top:358.5pt;left:371.8pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">preclinical data for codeine</span></p>
<p style="top:366.7pt;left:400.6pt;line-height:7.0pt"><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n = 2)</span></p>
<p style="top:388.7pt;left:52.3pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Figure 1</span></p>
<p style="top:388.7pt;left:93.3pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">PRISMA diagram showing study identification. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1754</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:727.2pt;left:31.2pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Table 1</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.5pt"> Summary of Evidence of Opioid-Sparing Effects from Pre-Clinical Studies</span></p>
<p style="top:554.4pt;left:50.5pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Equipotent opioid dose represented as ED</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:4.9pt">50</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">(95% CL) or</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt"> SEM, unless measured otherwise specified</span></p>
<p style="top:729.2pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Study</span></p>
<p style="top:729.2pt;left:78.2pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">reference</span></p>
<p style="top:681.3pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Pain model (species)</span></p>
<p style="top:606.8pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Opioid administered</span></p>
<p style="top:501.2pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid</span></p>
<p style="top:501.2pt;left:78.2pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">administered</span></p>
<p style="top:414.7pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid condition</span></p>
<p style="top:332.3pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Vehicle condition</span></p>
<p style="top:247.3pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Potency ratio or evidence of</span></p>
<p style="top:247.3pt;left:78.2pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">synergism</span></p>
<p style="top:146.0pt;left:70.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Other notes</span></p>
<p style="top:729.2pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Cichewicz</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:103.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1999</span></p>
<p style="top:681.3pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test</span></p>
<p style="top:681.3pt;left:103.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(male ICR mice)</span></p>
<p style="top:606.8pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine p.o.</span></p>
<p style="top:501.2pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">13.1 mg/kg (8.8, 19.5)</span></p>
<p style="top:332.3pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">28.8 mg/kg (20.2, 41)</span></p>
<p style="top:247.3pt;left:96.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 2.2</span></p>
<p style="top:606.8pt;left:114.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Codeine p.o.</span></p>
<p style="top:501.2pt;left:114.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:114.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.9 mg/kg (1.4, 24.9)</span></p>
<p style="top:332.3pt;left:114.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">139.9 mg/kg (75.2, 260.5)</span></p>
<p style="top:247.3pt;left:114.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 25.8</span></p>
<p style="top:606.8pt;left:124.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Oxymorphone p.o.</span></p>
<p style="top:501.2pt;left:124.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.8pt;left:124.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.5 mg/kg (0.3, 0.8)</span></p>
<p style="top:332.3pt;left:124.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.6 mg/kg (1.7, 3.9)</span></p>
<p style="top:247.3pt;left:124.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 5.0</span></p>
<p style="top:606.8pt;left:134.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Hydromorphone p.o.</span></p>
<p style="top:501.2pt;left:134.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.8pt;left:134.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.4 mg/kg (0.2, 0.8)</span></p>
<p style="top:332.3pt;left:134.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.6 mg/kg (3.2, 9.7)</span></p>
<p style="top:247.3pt;left:134.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 12.6</span></p>
<p style="top:606.8pt;left:145.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Methadone p.o.</span></p>
<p style="top:501.2pt;left:145.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.8pt;left:145.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.7 mg/kg (1.4, 5.2)</span></p>
<p style="top:332.3pt;left:145.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">12.0 mg/kg (8.1, 17.9)</span></p>
<p style="top:247.3pt;left:145.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 4.1</span></p>
<p style="top:606.8pt;left:155.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">LAAM p.o.</span></p>
<p style="top:501.2pt;left:155.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:155.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.6 mg/kg (1.7, 3.9)</span></p>
<p style="top:332.3pt;left:155.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">8.0 mg/kg (6.4, 10.1)</span></p>
<p style="top:247.3pt;left:155.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 2.5</span></p>
<p style="top:606.8pt;left:166.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Heroin p.o.</span></p>
<p style="top:501.2pt;left:166.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:166.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.4 mg/kg (1.7, 16.9)</span></p>
<p style="top:332.3pt;left:166.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">26.1 mg/kg (12.7, 53.4)</span></p>
<p style="top:247.3pt;left:166.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 4.1</span></p>
<p style="top:606.8pt;left:176.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Meperidine p.o.</span></p>
<p style="top:501.2pt;left:176.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.8pt;left:176.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">11.1 mg/kg (4.2, 29.4)</span></p>
<p style="top:332.3pt;left:176.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">86.2 mg/kg (52.8, 140.6)</span></p>
<p style="top:247.3pt;left:176.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 8.9</span></p>
<p style="top:606.8pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Fentanyl p.o.</span></p>
<p style="top:501.2pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.5 mg/kg (0.3, 0.8)</span></p>
<p style="top:332.3pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">6.1 mg/kg (estimated from an</span></p>
<p style="top:332.3pt;left:194.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">extrapolated curve)</span></p>
<p style="top:247.3pt;left:187.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not determined (50% MPE not</span></p>
<p style="top:247.3pt;left:194.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">seen)</span></p>
<p style="top:606.8pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Pentazocine p.o.</span></p>
<p style="top:501.2pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:414.8pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">838.6 mg/kg (estimated</span></p>
<p style="top:414.7pt;left:212.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">from an extrapolated curve)</span></p>
<p style="top:332.3pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">625.9 mg/kg (estimated from</span></p>
<p style="top:332.3pt;left:212.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">an extrapolated curve)</span></p>
<p style="top:247.3pt;left:205.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not determined (50% MPE not</span></p>
<p style="top:247.3pt;left:212.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">seen)</span></p>
<p style="top:729.2pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Cichewicz and</span></p>
<p style="top:729.2pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Welch, 2003</span></p>
<p style="top:681.3pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test</span></p>
<p style="top:681.3pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(male ICR mice)</span></p>
<p style="top:606.8pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine p.o.</span></p>
<p style="top:606.8pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Codeine p.o.</span></p>
<p style="top:501.2pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (5</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">35 mg/kg</span></p>
<p style="top:501.2pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and 1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">27 mg/kg p.o.)</span></p>
<p style="top:501.2pt;left:253.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (5</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">30 and</span></p>
<p style="top:501.2pt;left:260.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">18 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:222.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">13.6 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 1.94</span></p>
<p style="top:414.7pt;left:252.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">20.1 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 3.0</span></p>
<p style="top:332.3pt;left:222.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">24.5 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 4.8</span></p>
<p style="top:332.3pt;left:230.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">78.2 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 14.4</span></p>
<p style="top:247.3pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">For each ratio tested, experimental</span></p>
<p style="top:247.3pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">values were less than the calculated</span></p>
<p style="top:247.3pt;left:238.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">additive values (synergism)</span></p>
<p style="top:247.3pt;left:253.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">For each ratio tested, experimental</span></p>
<p style="top:247.3pt;left:260.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">values were less than the calculated</span></p>
<p style="top:247.3pt;left:267.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">additive values (synergism)</span></p>
<p style="top:146.0pt;left:223.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Fixed-ratio combinations of 9-THC</span></p>
<p style="top:146.0pt;left:230.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">with either morphine or codeine</span></p>
<p style="top:146.0pt;left:238.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">were tested for antinociceptive</span></p>
<p style="top:146.0pt;left:245.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">effects. The experimentally derived</span></p>
<p style="top:146.0pt;left:253.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> for each combination was</span></p>
<p style="top:146.0pt;left:260.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">compared with the theoretical</span></p>
<p style="top:146.0pt;left:267.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">additive ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">, using an</span></p>
<p style="top:146.0pt;left:282.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">isobolographic analysis. All the</span></p>
<p style="top:146.0pt;left:290.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">fixed-ratio combinations tested</span></p>
<p style="top:146.0pt;left:297.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">produced greater antinociception</span></p>
<p style="top:146.0pt;left:305.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(synergy) than predicted from</span></p>
<p style="top:146.0pt;left:312.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">simple additivity</span></p>
<p style="top:729.2pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Cichewicz</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:330.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2005</span></p>
<p style="top:681.3pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Pin-prick test</span></p>
<p style="top:681.3pt;left:330.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(IAF hairless guinea pigs)</span></p>
<p style="top:606.8pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Fentanyl s.c.</span></p>
<p style="top:501.2pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (50 mg/kg i.p.)</span></p>
<p style="top:414.8pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">6.8</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg (3.3, 14.2)</span></p>
<p style="top:332.3pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">50.8</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg (41.0, 63.0)</span></p>
<p style="top:247.3pt;left:323.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Greater than additive effect on</span></p>
<p style="top:247.3pt;left:330.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception. Potency ratio: 6.7</span></p>
<p style="top:247.3pt;left:338.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(1.8</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">17.0)</span></p>
<p style="top:606.8pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Buprenorphine s.c.</span></p>
<p style="top:501.2pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (50 mg/kg i.p.)</span></p>
<p style="top:414.8pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.02 mg/kg (0.01, 0.05)</span></p>
<p style="top:332.3pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.97 mg/kg (1.84, 4.81)</span></p>
<p style="top:247.3pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Greater than additive effect on</span></p>
<p style="top:247.3pt;left:356.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception. Enhanced potency</span></p>
<p style="top:247.3pt;left:363.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">in a non-parallel fashion</span></p>
<p style="top:146.0pt;left:348.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not possible to compare the</span></p>
<p style="top:146.0pt;left:356.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">change in potency produced by</span></p>
<p style="top:146.0pt;left:363.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">delta-9-THC due to the non-</span></p>
<p style="top:146.0pt;left:371.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">parallel nature of the two dose</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span></p>
<p style="top:146.0pt;left:378.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">response curves for buprenorphine</span></p>
<p style="top:606.8pt;left:389.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Fentanyl t.d.</span></p>
<p style="top:501.2pt;left:389.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (400 mg/kg t.d.)</span></p>
<p style="top:414.8pt;left:389.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2 h: 254.9</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg</span></p>
<p style="top:414.7pt;left:396.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(202.90, 320.6)</span></p>
<p style="top:414.7pt;left:403.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">4 h: 176.3</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg</span></p>
<p style="top:414.7pt;left:411.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(144.3, 215.5)</span></p>
<p style="top:332.3pt;left:389.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2 h: 928.6</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg</span></p>
<p style="top:332.3pt;left:396.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(599.5, 1438.3)</span></p>
<p style="top:332.3pt;left:403.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">4 h: 1067.0</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g/kg</span></p>
<p style="top:332.3pt;left:411.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(840.4, 1356.1)</span></p>
<p style="top:247.3pt;left:389.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio at 2 h: 3.7</span></p>
<p style="top:247.3pt;left:396.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio at 4 h: 5.8</span></p>
<p style="top:606.8pt;left:421.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Buprenorphine t.d.</span></p>
<p style="top:501.2pt;left:421.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (400 mg/kg t.d.)</span></p>
<p style="top:414.8pt;left:421.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2 h: 4.3 mg/kg (2.8, 6.8)</span></p>
<p style="top:414.7pt;left:429.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">4 h: 2.2 mg/kg (1.1, 4.6)</span></p>
<p style="top:332.3pt;left:421.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2 h: 26.1 mg/kg (17.1, 39.9)</span></p>
<p style="top:332.3pt;left:429.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">4 h: 15.6 mg/kg (10.0, 24.5)</span></p>
<p style="top:247.3pt;left:421.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio at 2 h: 8.2</span></p>
<p style="top:247.3pt;left:429.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio at 4 h: 7.2</span></p>
<p style="top:729.2pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Cox</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">, 2007</span></p>
<p style="top:681.3pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Paw pressure test (Male</span></p>
<p style="top:681.3pt;left:447.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Sprague</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Dawley rats)</span></p>
<p style="top:606.8pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.p. (normal rats)</span></p>
<p style="top:606.8pt;left:447.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.p. (arthritic rats)</span></p>
<p style="top:501.2pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC</span></p>
<p style="top:501.2pt;left:446.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.4 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 0.5 i.p.)</span></p>
<p style="top:501.2pt;left:454.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(1 : 1 ratio THC : Morphine)</span></p>
<p style="top:501.2pt;left:462.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (0.6 mg/</span></p>
<p style="top:501.2pt;left:469.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 0.55 i.p.)</span></p>
<p style="top:501.2pt;left:477.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(1 : 1 ratio THC : Morphine)</span></p>
<p style="top:414.7pt;left:439.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.4 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 0.5</span></p>
<p style="top:414.7pt;left:446.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.6 mg/kg</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 0.55</span></p>
<p style="top:332.3pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.4 mg/kg (2.2, 2.8)</span></p>
<p style="top:332.3pt;left:447.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.2 mg/kg (1.9, 2.4).</span></p>
<p style="top:247.3pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">The combination of delta-9-THC</span></p>
<p style="top:247.3pt;left:447.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and morphine showed synergism in</span></p>
<p style="top:247.3pt;left:454.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">both non-arthritic and arthritic rats</span></p>
<p style="top:146.0pt;left:439.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Results from normal rats included in</span></p>
<p style="top:146.0pt;left:447.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">the meta-analysis only</span></p>
<p style="top:729.2pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Finn</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">, 2004</span></p>
<p style="top:681.3pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Formalin-evoked</span></p>
<p style="top:681.3pt;left:495.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">nociceptive behavior</span></p>
<p style="top:681.3pt;left:502.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(adult male Lister-</span></p>
<p style="top:681.3pt;left:510.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Hooded rats)</span></p>
<p style="top:606.8pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.p.</span></p>
<p style="top:501.2pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (1 mg/kg i.p.)</span></p>
<p style="top:414.7pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not reported</span></p>
<p style="top:332.3pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not reported</span></p>
<p style="top:247.3pt;left:487.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not clearly synergistic. Potentially</span></p>
<p style="top:247.3pt;left:495.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">additive. Morphine (2 mg/kg) +</span></p>
<p style="top:247.3pt;left:502.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">delta-9-THC (1 mg/kg) had a</span></p>
<p style="top:247.3pt;left:510.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">significant effect on nociceptive</span></p>
<p style="top:247.3pt;left:517.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">behavior (compared to morphine</span></p>
<p style="top:247.3pt;left:525.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">alone but not delta-9-THC alone).</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1755</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:727.2pt;left:55.0pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Table 1</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.5pt"> Continued</span></p>
<p style="top:554.4pt;left:74.7pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Equipotent opioid dose represented as ED</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:4.9pt">50</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">(95% CL) or</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt"> SEM, unless measured otherwise specified</span></p>
<p style="top:729.2pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Study</span></p>
<p style="top:729.2pt;left:102.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">reference</span></p>
<p style="top:681.3pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Pain model (species)</span></p>
<p style="top:606.8pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Opioid administered</span></p>
<p style="top:501.2pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid</span></p>
<p style="top:501.2pt;left:102.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">administered</span></p>
<p style="top:414.7pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid condition</span></p>
<p style="top:332.4pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Vehicle condition</span></p>
<p style="top:247.3pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Potency ratio or evidence of</span></p>
<p style="top:247.3pt;left:102.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">synergism</span></p>
<p style="top:146.0pt;left:94.9pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Other notes</span></p>
<p style="top:729.2pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Katsuyama</span></p>
<p style="top:729.2pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">, 2013</span></p>
<p style="top:681.3pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Capsaicin test (Male mice</span></p>
<p style="top:681.3pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">of ddY strain)</span></p>
<p style="top:606.8pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine (1.0 mg/kg s.c. and</span></p>
<p style="top:606.8pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">100 pmol i.t.)</span></p>
<p style="top:501.2pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Beta-caryophyllene (2.25 mg</span></p>
<p style="top:501.2pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">i.pl., CB2 receptor agonist)</span></p>
<p style="top:414.7pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ID</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 1.16 mg/kg</span></p>
<p style="top:414.7pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(1.03, 1.32, systemic, s.c.)</span></p>
<p style="top:414.7pt;left:135.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and 130.1 pmol (111.9,</span></p>
<p style="top:414.7pt;left:142.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">156.4, spinal, i.t.)</span></p>
<p style="top:332.4pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ID</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 2.51 mg/kg (2.17, 2.97)</span></p>
<p style="top:332.4pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(systemic, s.c.) and</span></p>
<p style="top:332.4pt;left:135.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">193.7 pmol (165.7, 225.6,</span></p>
<p style="top:332.4pt;left:142.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">spinal, i.t.)</span></p>
<p style="top:247.3pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine + beta-caryophyllene</span></p>
<p style="top:247.3pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">decreased licking/biting response</span></p>
<p style="top:247.3pt;left:133.0pt;line-height:7.0pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt">p</span><span style="font-family:AdvEls,serif;font-size:7.0pt">o</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.05 compared to morphine +</span></p>
<p style="top:247.3pt;left:142.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">saline or beta-caryophyllene +</span></p>
<p style="top:247.3pt;left:150.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">jojoba wax.</span></p>
<p style="top:146.0pt;left:120.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Ineffective doses of beta-</span></p>
<p style="top:146.0pt;left:127.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">caryophyllene significantly</span></p>
<p style="top:146.0pt;left:135.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">enhanced morphine-induced</span></p>
<p style="top:146.0pt;left:142.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception.</span></p>
<p style="top:729.2pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Li</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">, 2008</span></p>
<p style="top:681.3pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Thermal antinociception</span></p>
<p style="top:681.3pt;left:168.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(rhesus monkeys)</span></p>
<p style="top:606.8pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:501.2pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (0.32 and</span></p>
<p style="top:501.2pt;left:168.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1.0 mg/kg s.c.)</span></p>
<p style="top:414.7pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 2.42 mg/kg</span></p>
<p style="top:332.4pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 6.36 mg/kg (3.81, 8.91)</span></p>
<p style="top:247.3pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Pre-treatment with delta-9-THC</span></p>
<p style="top:247.3pt;left:168.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">enhanced the antinociceptive</span></p>
<p style="top:247.3pt;left:175.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">effects of morphine.</span></p>
<p style="top:146.0pt;left:160.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine dose dependently</span></p>
<p style="top:146.0pt;left:168.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">increased the latency for monkeys</span></p>
<p style="top:146.0pt;left:175.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">to remove their tails from 50&#xb0;C and</span></p>
<p style="top:146.0pt;left:183.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">55&#xb0;C water.</span></p>
<p style="top:729.2pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Maguire</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2013</span></p>
<p style="top:681.3pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Warm water tail</span></p>
<p style="top:681.3pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">withdrawal (rhesus</span></p>
<p style="top:681.3pt;left:208.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">monkeys)</span></p>
<p style="top:606.8pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:501.2pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">CP 55 940 (0.01 mg/kg s.c.)</span></p>
<p style="top:501.2pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">WIN 55 212</span></p>
<p style="top:501.2pt;left:208.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.32 mg/kg s.c.)</span></p>
<p style="top:414.7pt;left:193.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Mean (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 3)</span></p>
<p style="top:414.7pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">CP 0.23 mg/kg</span></p>
<p style="top:414.7pt;left:208.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">WIN 0.24 mg/kg</span></p>
<p style="top:332.4pt;left:193.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1.26 mg/kg (mean,</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 3)</span></p>
<p style="top:247.3pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Pre-treatment with CP 55 940</span></p>
<p style="top:247.3pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">resulted in a mean leftward shift to</span></p>
<p style="top:247.3pt;left:208.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">of</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt"> &#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">6.73-fold. Pre-treatment with</span></p>
<p style="top:247.3pt;left:215.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">WIN 55 212 resulted in mean</span></p>
<p style="top:247.3pt;left:223.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">leftward shift of</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt"> &#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.5-fold.</span></p>
<p style="top:146.0pt;left:193.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Antinociception from the</span></p>
<p style="top:146.0pt;left:201.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">combination appeared to be</span></p>
<p style="top:146.0pt;left:208.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">achieved without an increase in</span></p>
<p style="top:146.0pt;left:215.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">abuse liability.</span></p>
<p style="top:729.2pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Pugh</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:241.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1996</span></p>
<p style="top:681.3pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test (mail ICR</span></p>
<p style="top:681.3pt;left:241.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">mice)</span></p>
<p style="top:606.8pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.t.</span></p>
<p style="top:501.2pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (6</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">cg/mouse</span></p>
<p style="top:501.2pt;left:241.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">i.t., inactive analgesic dose)</span></p>
<p style="top:414.7pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.01 mcg/mouse</span></p>
<p style="top:332.4pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.318 mcg/mouse (2.825,</span></p>
<p style="top:332.4pt;left:241.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.036)</span></p>
<p style="top:247.3pt;left:233.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Greater than additive effect</span></p>
<p style="top:247.3pt;left:241.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">observed, clear leftward shift of</span></p>
<p style="top:247.3pt;left:248.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">graph.</span></p>
<p style="top:729.2pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Reche</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:266.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1996</span></p>
<p style="top:681.3pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick and hot plate</span></p>
<p style="top:681.3pt;left:266.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test (Swiss albino mice)</span></p>
<p style="top:606.8pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.p.</span></p>
<p style="top:501.2pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC i.p.</span></p>
<p style="top:414.7pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">NA</span></p>
<p style="top:414.7pt;left:266.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Only one dose of morphine</span></p>
<p style="top:414.7pt;left:274.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(2 mg/kg i.p.) examined.</span></p>
<p style="top:414.7pt;left:281.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Study measured change in</span></p>
<p style="top:414.7pt;left:289.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> of delta-9-THC.</span></p>
<p style="top:332.4pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">NA</span></p>
<p style="top:247.3pt;left:259.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine pre-administration</span></p>
<p style="top:247.3pt;left:266.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">shifted the dose</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">response curve</span></p>
<p style="top:247.3pt;left:274.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">for delta-9-THC to the left (a 2.5-</span></p>
<p style="top:247.3pt;left:281.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">fold shift for the tail-flick test and a</span></p>
<p style="top:247.3pt;left:289.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">three-fold shift for the hot plate</span></p>
<p style="top:247.3pt;left:296.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test). Analgesic effect blocked by</span></p>
<p style="top:247.3pt;left:304.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">SR-141 716 (cannabinoid</span></p>
<p style="top:247.3pt;left:311.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antagonist) and naloxone.</span></p>
<p style="top:729.2pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Smith</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:329.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">1998</span></p>
<p style="top:681.3pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick and hot plate</span></p>
<p style="top:681.3pt;left:329.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test (male ICR mice)</span></p>
<p style="top:606.8pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:606.8pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine p.o.</span></p>
<p style="top:501.2pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick: delta-9-THC</span></p>
<p style="top:501.2pt;left:329.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(4 mg/kg s.c.)</span></p>
<p style="top:501.2pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick: delta-9-THC</span></p>
<p style="top:501.2pt;left:351.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(20 mg/kg p.o.)</span></p>
<p style="top:414.7pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.29 mg/kg</span></p>
<p style="top:414.7pt;left:329.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(95% CI 0.04, 1.94)</span></p>
<p style="top:414.7pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.8 mg/kg (2.0, 3.9)</span></p>
<p style="top:332.4pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.81 mg/kg (2.24, 3.53)</span></p>
<p style="top:332.4pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">31.7 mg/kg (22.4, 44.9)</span></p>
<p style="top:247.3pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 8.5</span></p>
<p style="top:247.3pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Potency ratio: 7.6</span></p>
<p style="top:146.0pt;left:322.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Multiple conditions tested different</span></p>
<p style="top:146.0pt;left:329.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">combinations of s.c and p.o</span></p>
<p style="top:146.0pt;left:337.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine. Only s.c. + s.c. and p.o. +</span></p>
<p style="top:146.0pt;left:344.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">p.o. for the tail-flick test are</span></p>
<p style="top:146.0pt;left:351.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">reported here. A paw withdrawal</span></p>
<p style="top:146.0pt;left:359.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test was also conducted to</span></p>
<p style="top:146.0pt;left:366.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">demonstrate that enhancement of</span></p>
<p style="top:146.0pt;left:374.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception was not limited to</span></p>
<p style="top:146.0pt;left:381.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">the tail.</span></p>
<p style="top:729.2pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Smith</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2007</span></p>
<p style="top:681.3pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Paw withdrawal test</span></p>
<p style="top:681.3pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(male Sprague</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Dawley</span></p>
<p style="top:681.3pt;left:407.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">rats)</span></p>
<p style="top:606.8pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:501.2pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC</span></p>
<p style="top:501.2pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.75 mg /kg i.p.)</span></p>
<p style="top:414.7pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> morphine +</span></p>
<p style="top:414.7pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">delta-9-THC (0.75 mg/kg)</span></p>
<p style="top:332.4pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> morphine alone</span></p>
<p style="top:332.4pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(100 mg/kg)</span></p>
<p style="top:247.3pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tolerance to morphine alone</span></p>
<p style="top:247.3pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">rapidly established; no loss of effect</span></p>
<p style="top:247.3pt;left:407.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">with low-dose combinations of</span></p>
<p style="top:247.3pt;left:414.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine + delta-9-THC</span></p>
<p style="top:146.0pt;left:392.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">A morphine pellet arm and delta-9-</span></p>
<p style="top:146.0pt;left:399.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">THC alone arm were not reported</span></p>
<p style="top:146.0pt;left:407.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">in this table due to difficulties in</span></p>
<p style="top:146.0pt;left:414.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">comparing doses between</span></p>
<p style="top:146.0pt;left:422.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine formulations.</span></p>
<p style="top:729.2pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tham</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2005</span></p>
<p style="top:681.3pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick and hot plate</span></p>
<p style="top:681.3pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test (Swiss male mice)</span></p>
<p style="top:606.8pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:501.2pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick: CP 55 940</span></p>
<p style="top:501.2pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">3 mg/kg s.c.)</span></p>
<p style="top:501.2pt;left:447.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Hot plate: CP 55 940</span></p>
<p style="top:501.2pt;left:455.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">3 mg/kg s.c.)</span></p>
<p style="top:414.7pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">3.31 mg/kg</span></p>
<p style="top:414.7pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">7.54 mg/kg</span></p>
<p style="top:332.4pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">11.3 mg/kg (9.6, 13.4)</span></p>
<p style="top:332.4pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">29.4 mg/kg (27.3, 31.6)</span></p>
<p style="top:247.3pt;left:432.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Analyses showed greater than</span></p>
<p style="top:247.3pt;left:440.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">additive results (synergism).</span></p>
<p style="top:729.2pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Wakley and</span></p>
<p style="top:729.2pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Craft, 2011</span></p>
<p style="top:681.3pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Paw pressure test (male</span></p>
<p style="top:681.3pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Sprague</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Dawley rats)</span></p>
<p style="top:606.8pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Methadone i.p.</span></p>
<p style="top:501.2pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC</span></p>
<p style="top:501.2pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.32</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">3.2 mg/kg i.p.)</span></p>
<p style="top:414.7pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not reported (dose</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span></p>
<p style="top:414.7pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">response curve shown)</span></p>
<p style="top:332.4pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> in naive rats, 1.27 mg/kg</span></p>
<p style="top:332.4pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(95% CI 0.91, 1.91), ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> in</span></p>
<p style="top:332.4pt;left:480.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">rats trained for discrimination,</span></p>
<p style="top:332.4pt;left:487.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">3.49 mg/kg (95% CI 2.59,</span></p>
<p style="top:332.4pt;left:495.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.31)</span></p>
<p style="top:247.3pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">In opioid and delta-9-THC naive</span></p>
<p style="top:247.3pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">rats, methadone 1.0 mg/kg</span></p>
<p style="top:247.3pt;left:480.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">significantly enhanced the</span></p>
<p style="top:247.3pt;left:487.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociceptive effect of delta-9-</span></p>
<p style="top:247.3pt;left:495.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">THC, however this was not</span></p>
<p style="top:247.3pt;left:502.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">observed in rats that were</span></p>
<p style="top:247.3pt;left:510.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">previously trained for drug</span></p>
<p style="top:247.3pt;left:517.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">discrimination tasks.</span></p>
<p style="top:146.0pt;left:465.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">The rats trained for drug</span></p>
<p style="top:146.0pt;left:473.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">discrimination tasks had received</span></p>
<p style="top:146.0pt;left:480.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">repeated administration of opioids</span></p>
<p style="top:146.0pt;left:487.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and cannabinoids over many</span></p>
<p style="top:146.0pt;left:495.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">months and may have been</span></p>
<p style="top:146.0pt;left:502.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">tolerant to drug effects at the doses</span></p>
<p style="top:146.0pt;left:510.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">administered.</span></p>
<p style="top:729.2pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Welch and</span></p>
<p style="top:729.2pt;left:535.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Stevens, 1992</span></p>
<p style="top:681.3pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick and hot plate</span></p>
<p style="top:681.3pt;left:535.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">test (mice)</span></p>
<p style="top:606.8pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine i.t.</span></p>
<p style="top:501.2pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC</span></p>
<p style="top:501.2pt;left:535.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(3.133 mcg/mouse)</span></p>
<p style="top:414.7pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.15 mcg/mouse</span></p>
<p style="top:414.7pt;left:535.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.11, 0.21)</span></p>
<p style="top:332.4pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.61 mcg/mouse (0.26, 1.44)</span></p>
<p style="top:247.3pt;left:528.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:501.2pt;left:546.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC</span></p>
<p style="top:501.2pt;left:553.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(6.25 mcg/mouse)</span></p>
<p style="top:414.7pt;left:546.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.05 mcg/mouse</span></p>
<p style="top:414.7pt;left:553.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.03, 0.08)</span></p>
<p style="top:247.3pt;left:546.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1756</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:727.2pt;left:31.5pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Table 1</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.5pt"> Continued</span></p>
<p style="top:554.4pt;left:51.1pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Equipotent opioid dose represented as ED</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:4.9pt">50</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">(95% CL) or</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt"> SEM, unless measured otherwise specified</span></p>
<p style="top:729.2pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Study</span></p>
<p style="top:729.2pt;left:78.8pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">reference</span></p>
<p style="top:681.3pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Pain model (species)</span></p>
<p style="top:606.8pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Opioid administered</span></p>
<p style="top:501.2pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid</span></p>
<p style="top:501.2pt;left:78.8pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">administered</span></p>
<p style="top:414.7pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Cannabinoid condition</span></p>
<p style="top:332.4pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Vehicle condition</span></p>
<p style="top:247.3pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Potency ratio or evidence of</span></p>
<p style="top:247.3pt;left:78.8pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">synergism</span></p>
<p style="top:146.0pt;left:71.4pt;line-height:7.0pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.0pt">Other notes</span></p>
<p style="top:501.2pt;left:96.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-8-THC</span></p>
<p style="top:501.2pt;left:104.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(25 mcg/mouse)</span></p>
<p style="top:414.7pt;left:96.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.05 mcg/mouse</span></p>
<p style="top:414.7pt;left:104.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.02, 0.10)</span></p>
<p style="top:247.3pt;left:96.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:501.2pt;left:114.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Levonantradol</span></p>
<p style="top:501.2pt;left:122.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.005 mcg/mouse)</span></p>
<p style="top:414.7pt;left:114.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.06 mcg/mouse</span></p>
<p style="top:414.7pt;left:122.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.01, 0.24)</span></p>
<p style="top:247.3pt;left:114.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:501.2pt;left:132.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">CP 55 940 (0.01 mcg/mouse)</span></p>
<p style="top:414.7pt;left:132.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.3 mcg/mouse (0.0, 0.10)</span></p>
<p style="top:247.3pt;left:132.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Additive</span></p>
<p style="top:501.2pt;left:143.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">CP 56 667 (0.5 mcg/mouse)</span></p>
<p style="top:414.7pt;left:143.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.26 mcg/mouse</span></p>
<p style="top:414.7pt;left:150.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.08, 0.82)</span></p>
<p style="top:247.3pt;left:143.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Additive</span></p>
<p style="top:501.2pt;left:161.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">11-hydroxy-delta-9-THC</span></p>
<p style="top:501.2pt;left:168.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(3 mcg/mouse)</span></p>
<p style="top:414.7pt;left:161.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.08 mcg/mouse</span></p>
<p style="top:414.7pt;left:168.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.04, 0.19)</span></p>
<p style="top:247.3pt;left:161.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:501.2pt;left:179.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Dextronantradol</span></p>
<p style="top:501.2pt;left:186.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(25 mcg/mouse)</span></p>
<p style="top:414.7pt;left:179.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.51 mcg/mouse</span></p>
<p style="top:414.7pt;left:186.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(0.36, 0.89)</span></p>
<p style="top:247.3pt;left:179.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">No</span></p>
<p style="top:729.2pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Williams</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2006</span></p>
<p style="top:681.3pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test</span></p>
<p style="top:681.3pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(mail ICR mice)</span></p>
<p style="top:606.8pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Study 1: low-dose codeine</span></p>
<p style="top:606.8pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(30 mg/kg) and morphine</span></p>
<p style="top:606.8pt;left:211.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(20 mg/kg) and fully efficacious ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:606.8pt;left:219.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">codeine (100 mg/kg) and morphine</span></p>
<p style="top:606.8pt;left:226.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(80 mg/kg). Study 2: high-dose</span></p>
<p style="top:606.8pt;left:234.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">codeine (200 mg/kg) and morphine</span></p>
<p style="top:606.8pt;left:241.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">(100 mg/kg) (all p.o.)</span></p>
<p style="top:501.2pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.,</span></p>
<p style="top:501.2pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">inactive analgesic dose)</span></p>
<p style="top:414.7pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> codeine (30 mg/kg)</span></p>
<p style="top:414.7pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> morphine (20 mg/kg)</span></p>
<p style="top:332.4pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> codeine (200 mg/kg)</span></p>
<p style="top:332.4pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> morphine (100 mg/kg)</span></p>
<p style="top:247.3pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">A low dose of morphine (20 mg/</span></p>
<p style="top:247.3pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">kg) or codeine (30 mg/kg) with a</span></p>
<p style="top:247.3pt;left:211.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">single pre-treatment of an inactive</span></p>
<p style="top:247.3pt;left:219.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">dose of delta-9-THC produced the</span></p>
<p style="top:247.3pt;left:226.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">same efficacy (ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">) as the high</span></p>
<p style="top:247.3pt;left:234.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">doses of each opioid alone. For</span></p>
<p style="top:247.3pt;left:241.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">codeine, delta-9-THC pre-</span></p>
<p style="top:247.3pt;left:249.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">treatment also increased the</span></p>
<p style="top:247.3pt;left:256.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">duration of action of the ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:4.9pt">80</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> dose</span></p>
<p style="top:247.3pt;left:264.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">of codeine.</span></p>
<p style="top:146.0pt;left:196.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Study 1: pre-treatment with delta-</span></p>
<p style="top:146.0pt;left:204.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">9-THC did not enhance the fully</span></p>
<p style="top:146.0pt;left:211.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">efficacious dose of morphine but</span></p>
<p style="top:146.0pt;left:219.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">enhanced low-dose morphine and</span></p>
<p style="top:146.0pt;left:226.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">both doses of codeine, in addition</span></p>
<p style="top:146.0pt;left:234.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">to extending the time course. Study</span></p>
<p style="top:146.0pt;left:241.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2: delta-9-THC restored analgesic</span></p>
<p style="top:146.0pt;left:249.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">efficacy after the time that the</span></p>
<p style="top:146.0pt;left:256.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">opioids had ceased being effective</span></p>
<p style="top:146.0pt;left:264.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">on their own (360 min post dose</span></p>
<p style="top:146.0pt;left:271.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">for morphine and 120 min post</span></p>
<p style="top:146.0pt;left:279.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">dose for codeine).</span></p>
<p style="top:729.2pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Williams</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2008</span></p>
<p style="top:681.3pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test (diabetic</span></p>
<p style="top:681.3pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and non-diabetic mice</span></p>
<p style="top:681.3pt;left:304.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and rats)</span></p>
<p style="top:606.8pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:606.8pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine s.c.</span></p>
<p style="top:501.2pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:501.2pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">in non-diabetic mice</span></p>
<p style="top:501.2pt;left:304.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC (20 mg/kg p.o.)</span></p>
<p style="top:501.2pt;left:312.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">in diabetic mice</span></p>
<p style="top:414.7pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2.5 mg/kg (1.8, 3.4)</span></p>
<p style="top:414.7pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">0.84 mg/kg (0.79, 0.89)</span></p>
<p style="top:332.4pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">5.6 mg/kg (4.3, 7.2)</span></p>
<p style="top:332.4pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">6.1 mg/kg (5.2, 7.1)</span></p>
<p style="top:247.3pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:247.3pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yes</span></p>
<p style="top:146.0pt;left:289.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Delta-9-THC significantly enhanced</span></p>
<p style="top:146.0pt;left:297.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine-induced antinociception</span></p>
<p style="top:146.0pt;left:304.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">in both diabetic and non-diabetic</span></p>
<p style="top:146.0pt;left:312.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">mice.</span></p>
<p style="top:729.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Wilson</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2008</span></p>
<p style="top:681.3pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Hot plate test (male</span></p>
<p style="top:681.3pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Sprague</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Dawley rats)</span></p>
<p style="top:606.8pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine microinjections</span></p>
<p style="top:606.8pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">into PAG</span></p>
<p style="top:501.2pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">HU-210 (5</span><span style="font-family:AdvOTb8f60ac3+03,serif;font-size:7.0pt"> &#x3bc;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">g)</span></p>
<p style="top:414.7pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not reported (dose</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span></p>
<p style="top:414.7pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">response curve shown)</span></p>
<p style="top:332.4pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Not reported (dose</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2013;</span></p>
<p style="top:332.4pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">response curve shown)</span></p>
<p style="top:247.3pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">No evidence of synergism.</span></p>
<p style="top:247.3pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine + HU-210 showed the</span></p>
<p style="top:247.3pt;left:337.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">greatest increase in hot plate</span></p>
<p style="top:247.3pt;left:344.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">latency (39.9 s</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 1.1 s), but was not</span></p>
<p style="top:247.3pt;left:352.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">significantly different from</span></p>
<p style="top:247.3pt;left:359.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine alone (33.1 s</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.0pt"> &#xb1;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt"> 4.0 s)</span></p>
<p style="top:146.0pt;left:322.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">HU-210 shown to prevent</span></p>
<p style="top:146.0pt;left:329.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">development of tolerance to</span></p>
<p style="top:146.0pt;left:337.4pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">morphine</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.0pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">s antinociceptive effects.</span></p>
<p style="top:146.0pt;left:344.9pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">HU-210 pre-treatment enhanced</span></p>
<p style="top:146.0pt;left:352.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">subsequent morphine</span></p>
<p style="top:146.0pt;left:359.8pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception. Co-administration</span></p>
<p style="top:146.0pt;left:367.3pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">of HU-210 into the PAG</span></p>
<p style="top:146.0pt;left:374.7pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">attenuated morphine</span></p>
<p style="top:146.0pt;left:382.2pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">antinociception. The authors</span></p>
<p style="top:146.0pt;left:389.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">suggested that opioids and</span></p>
<p style="top:146.0pt;left:397.1pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">cannabinoids may have opposing</span></p>
<p style="top:146.0pt;left:404.6pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">actions within the PAG.</span></p>
<p style="top:729.2pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Yesilyurt</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.0pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">,</span></p>
<p style="top:729.2pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">2003</span></p>
<p style="top:681.3pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Tail-flick test (adult</span></p>
<p style="top:681.3pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">female Bulb-C mice)</span></p>
<p style="top:606.8pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine topical</span></p>
<p style="top:501.2pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">WIN 55, 212-2 (20 mg/ml,</span></p>
<p style="top:501.2pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">topical, mixed CB1-CB2</span></p>
<p style="top:501.2pt;left:430.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">receptor agonist)</span></p>
<p style="top:414.7pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine (20 mg/ml) +</span></p>
<p style="top:414.7pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">WIN sustained analgesic</span></p>
<p style="top:414.7pt;left:430.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">effect of 50% analgesia</span></p>
<p style="top:414.7pt;left:437.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">over 4 h</span></p>
<p style="top:332.4pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Morphine (20 mg/ml) alone</span></p>
<p style="top:332.4pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">produced 18% analgesic</span></p>
<p style="top:332.4pt;left:430.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">effect, peak at 20 min then</span></p>
<p style="top:332.4pt;left:437.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">reduced.</span></p>
<p style="top:247.3pt;left:415.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">Antinociceptive effects were</span></p>
<p style="top:247.3pt;left:422.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">markedly potentiated (they peaked</span></p>
<p style="top:247.3pt;left:430.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">and were sustained at 30 min)</span></p>
<p style="top:247.3pt;left:437.5pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">compared to morphine response</span></p>
<p style="top:247.3pt;left:445.0pt;line-height:7.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.0pt">alone.</span></p>
<p style="top:728.4pt;left:462.7pt;line-height:8.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.0pt">Abbreviations: delta-9-THC, delta-9-tetrahydrocannabinol; ED, effective dose; ICR, imprinting control region; ID, inhibitory dose; i.p., intraperitoneal; i.t., intrathecal; MPE, maximum possible effect; PAG, periaqueductal gray</span></p>
<p style="top:728.4pt;left:472.2pt;line-height:8.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.0pt">matter; pmol, picomol; p.o., oral administration; s.c., subcutaneous; t.d, transdermal.</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1757</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:57.9pt;left:52.3pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Summary of Pre-Clinical Studies</span></p>
<p style="top:75.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Nineteen pre-clinical studies were identified in which the</span></p>
<p style="top:86.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesic effect of opioid and cannabinoid co-administration</span></p>
<p style="top:97.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">was examined (Cichewicz</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999, 2005; Cichewicz and</span></p>
<p style="top:108.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">McCarthy, 2003; Cox</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2007; Finn</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2004; Katsuyama</span></p>
<p style="top:119.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2013; Li</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008; Maguire</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2013; Pugh Jr</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:130.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1996; Reche</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1996; Smith</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1998, 2007; Tham</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:141.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2005; Wakley and Craft, 2011; Welch and Stevens, 1992;</span></p>
<p style="top:152.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Williams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006, 2008; Wilson</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008; Yesilyurt</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:163.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2003) (Table 1). Fourteen of these studies examined delta-9-</span></p>
<p style="top:174.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC, whereas one to two studies examined each of 10</span></p>
<p style="top:185.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">other cannabinoid agonists, including beta-caryophyllene,</span></p>
<p style="top:196.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">CP 55 940, CP 56 667, delta-8-THC, 11-hydroxy-delta-9-</span></p>
<p style="top:207.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC, dextronantradol, levonantradol, WIN 55, 212-2, and</span></p>
<p style="top:219.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">HU-210.</span></p>
<p style="top:219.0pt;left:95.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Seventeen</span></p>
<p style="top:219.0pt;left:144.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies</span></p>
<p style="top:219.0pt;left:181.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">examined</span></p>
<p style="top:219.0pt;left:228.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">morphine,</span></p>
<p style="top:219.0pt;left:279.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">three</span></p>
<p style="top:230.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies examined codeine, and one to two studies examined</span></p>
<p style="top:241.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">buprenorphine, fentanyl, oxycodone, morphine, hydromor-</span></p>
<p style="top:252.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">phone, methadone, LAAM, meperidine, and pentazocine.</span></p>
<p style="top:263.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Most of the studies used rodents; however, two used rhesus</span></p>
<p style="top:274.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">monkeys and one used guinea pigs. The most common</span></p>
<p style="top:285.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">antinociceptive assays were tail-flick tests (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 10) and hot</span></p>
<p style="top:296.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">plate tests (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 5), although individual studies also used other</span></p>
<p style="top:307.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">forms of mechanical, thermal, and chemical nociception.</span></p>
<p style="top:318.4pt;left:61.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Most studies (17 of the 19) demonstrated that combining a</span></p>
<p style="top:329.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoid with an opioid resulted in a synergistic effect on</span></p>
<p style="top:340.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesia compared to the analgesic effects of the individual</span></p>
<p style="top:351.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">drugs. One study examined a single dose of morphine and</span></p>
<p style="top:362.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">demonstrated that morphine could potentiate the analgesic</span></p>
<p style="top:373.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect of intrathecally administered delta-9-THC (Reche</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:384.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1996). However, this study could not demonstrate an opioid-</span></p>
<p style="top:395.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sparing effect due to the use of a single dose of opioid.</span></p>
<p style="top:406.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Another study found that 2 mg/kg morphine administered</span></p>
<p style="top:418.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">with 1 mg/kg delta-9-THC resulted in a significant effect on</span></p>
<p style="top:429.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">nociception compared to morphine alone (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">p</span><span style="font-family:AdvEls,serif;font-size:10.0pt">o</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">005), but not</span></p>
<p style="top:440.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when compared to delta-9-THC alone (Finn</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2004). In</span></p>
<p style="top:451.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">another study, a greater increase in hot plate latency was</span></p>
<p style="top:462.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">found for morphine combined with HU-210 (38.9 s</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> &#xb1;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 1.1 s)</span></p>
<p style="top:473.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">compared with HU-210 alone (33.1 s</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> &#xb1;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 4.0 s) (Wilson</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:484.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2008); however, this difference did not reach significance.</span></p>
<p style="top:495.2pt;left:61.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">One study testing multiple opioid agonists identified clear</span></p>
<p style="top:506.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">synergistic effects for delta-9-THC for most opioid drugs,</span></p>
<p style="top:517.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">with the exception of fentanyl and pentazocine (Cichewicz</span></p>
<p style="top:528.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999). The potency ratio when administered alone for</span></p>
<p style="top:539.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">those opioids found to have a synergistic effect, compared to</span></p>
<p style="top:550.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when those same opioids were co-administered with delta-9-</span></p>
<p style="top:561.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC varied between 2.2 and 25.8. Another study tested</span></p>
<p style="top:58.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">multiple cannabinoid agonists when co-administered with</span></p>
<p style="top:69.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">morphine and demonstrated a synergistic effect with delta-9-</span></p>
<p style="top:80.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC, delta-8-THC, levonantradol, and 11-hydroxy-delta-9-</span></p>
<p style="top:91.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC; additive effects with CP 55 940 and CP 56 667; and no</span></p>
<p style="top:102.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">observable potentiation of morphine effects with dextronan-</span></p>
<p style="top:113.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tradol, which is an isomer of levonantradol (Welch and</span></p>
<p style="top:124.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Stevens, 1992). In contrast to the finding of an additive effect</span></p>
<p style="top:135.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">for CP 55 940, two other studies of CP 55 940 in combina-</span></p>
<p style="top:146.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tions with morphine demonstrated a synergistic analgesic</span></p>
<p style="top:156.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect (Maguire</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2013; Tham</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2005). In addition</span></p>
<p style="top:167.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to changes in the magnitude of the analgesic effect, two</span></p>
<p style="top:178.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies showed that the duration of the analgesic effect</span></p>
<p style="top:189.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">can be extended by administrating a low-dose opioid</span></p>
<p style="top:200.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and cannabinoid in combination, compared with adminis-</span></p>
<p style="top:211.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">trating an opioid alone (Williams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006; Yesilyurt</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:222.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2003).</span></p>
<p style="top:248.4pt;left:318.3pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Meta-Analysis of Pre-Clinical Studies</span></p>
<p style="top:265.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Six studies used sufficiently similar approaches to enable a</span></p>
<p style="top:276.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">meta-analysis (Cichewicz</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999; Cichewicz and Welch,</span></p>
<p style="top:287.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2003; Cox</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2007; Smith</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1998; Welch and Stevens,</span></p>
<p style="top:298.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1992; Williams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008) (Figure 2). A further four studies</span></p>
<p style="top:309.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">were comparable in study design, but did not contain the</span></p>
<p style="top:320.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">required data (ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> or variance on estimates) to enable</span></p>
<p style="top:331.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">meta-analysis (Finn</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2004; Pugh Jr</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1996; Smith</span></p>
<p style="top:342.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2007; Williams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006). All studies included in the</span></p>
<p style="top:353.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">meta-analysis used rodents and reported comparable anti-</span></p>
<p style="top:364.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">nociceptive doses of morphine alone and morphine co-</span></p>
<p style="top:375.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">administered with delta-9-THC. Results from the meta-</span></p>
<p style="top:386.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analysis are reported in terms of mean difference.</span></p>
<p style="top:397.2pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The meta-analysis identified a significant opioid-sparing</span></p>
<p style="top:408.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect with morphine and delta-9-THC co-administration,</span></p>
<p style="top:419.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">Z</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 5.59,</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> p</span><span style="font-family:AdvEls,serif;font-size:10.0pt">o</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.001 (MD in log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt"> &#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.56 (</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.83,</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt"> &#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.29)).</span></p>
<p style="top:430.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">As there was significant heterogeneity in the data (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">I</span><sup><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">2</span></sup><sup><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> </span></sup><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt">=</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 95%),</span></p>
<p style="top:441.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a random effects model was used. When back-transformed</span></p>
<p style="top:452.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to the original units, the response ratio was 3.6 (95% CI 1.95,</span></p>
<p style="top:463.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">6.76),</span></p>
<p style="top:463.0pt;left:348.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">indicating</span></p>
<p style="top:463.0pt;left:397.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that</span></p>
<p style="top:463.0pt;left:422.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the</span></p>
<p style="top:463.0pt;left:442.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">median</span></p>
<p style="top:463.0pt;left:481.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span></p>
<p style="top:463.0pt;left:509.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of</span></p>
<p style="top:463.0pt;left:526.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">morphine</span></p>
<p style="top:473.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">was 3.6 times lower when given in combination with delta-</span></p>
<p style="top:484.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">9-THC compared to when morphine was administered</span></p>
<p style="top:495.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">alone.</span></p>
<p style="top:506.8pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Two</span></p>
<p style="top:506.8pt;left:353.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies</span></p>
<p style="top:506.8pt;left:389.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">compared</span></p>
<p style="top:506.8pt;left:438.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">doses</span></p>
<p style="top:506.8pt;left:469.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of</span></p>
<p style="top:506.8pt;left:485.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">codeine</span></p>
<p style="top:506.8pt;left:524.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">with</span></p>
<p style="top:506.8pt;left:551.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and</span></p>
<p style="top:517.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">without delta-9-THC in rodents (Cichewicz</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1999;</span></p>
<p style="top:528.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Cichewicz and Welch, 2003) (Figure 3). Both studies used</span></p>
<p style="top:539.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">male ICR mice and the tail-flick assay. Meta-analysis of these</span></p>
<p style="top:550.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">data indicated a significant opioid-sparing effect of delta-9-</span></p>
<p style="top:561.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">THC when co-administered with codeine,</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> Z</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 2.49,</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 0.01</span></p>
<img style="position:absolute;transform:matrix(.43629784,0,-0,.4364878,-320.10734,712.1708)" src="data:image/jpeg;base64,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">
<p style="top:718.4pt;left:52.3pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Figure 2</span></p>
<p style="top:718.4pt;left:92.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">Forrest plot for meta-analysis examining the opioid-sparing effect of delta-9-THC when co-administered with morphine. Note: all mean difference</span></p>
<p style="top:727.9pt;left:52.3pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">and SD values are of log</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.0pt">10</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.0pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">. THC, tetrahydrocannabinol.</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1758</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:190.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(MD in the log</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">10</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt"> &#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.98 (</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">1.76,</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt"> &#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">0.21)). Significant</span></p>
<p style="top:201.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">heterogeneity in the data (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">I</span><sup><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">2</span></sup><sup><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> </span></sup><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt">=</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 98%) necessitated the use of a</span></p>
<p style="top:212.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">random effects model. When back-transformed to the</span></p>
<p style="top:223.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">original units, the response ratio was 9.5 (95% CI 1.6,</span></p>
<p style="top:234.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">57.5), indicating that the ED</span><span style="font-family:AdvOT852e08ef,serif;font-size:7.0pt">50</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> of codeine was 9.5 times lower</span></p>
<p style="top:245.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when given in combination with delta-9-THC compared to</span></p>
<p style="top:256.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">when codeine was administered alone.</span></p>
<p style="top:267.5pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Funnel plots did not provide evidence of publication or</span></p>
<p style="top:278.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">small study bias with these pre-clinical studies (Figure 4).</span></p>
<p style="top:304.0pt;left:28.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Results from Clinical Studies</span></p>
<p style="top:321.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Nine clinical studies with 750 participants provided data</span></p>
<p style="top:332.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">relevant to the research question (Table 2); however, the</span></p>
<p style="top:343.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">heterogeneous nature of the studies precluded meta-analysis.</span></p>
<p style="top:354.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Three laboratory-based studies examined pain responses in</span></p>
<p style="top:365.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">participants concurrently being administered opioids and</span></p>
<p style="top:376.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoids. One study recruited people with mixed</span></p>
<p style="top:387.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">chronic non-cancer pain (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 24) who were prescribed</span></p>
<p style="top:398.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioids (Abrams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2011). A significant reduction in pain</span></p>
<p style="top:409.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ratings was observed for the participants in this study</span></p>
<p style="top:420.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">following co-administration of cannabinoids</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">39.6 (95% CI</span></p>
<p style="top:430.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">35.8, 43.3) at baseline</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> vs</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 29.1 (95% CI 25.4, 32.8) following</span></p>
<p style="top:441.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">co-administration (Abrams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2011). It should be noted</span></p>
<p style="top:452.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that no placebo or control condition was used in this study</span></p>
<p style="top:463.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">for comparison (Abrams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2011).</span></p>
<p style="top:474.7pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">In another two studies, healthy volunteers (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 12 and 13,</span></p>
<p style="top:485.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">respectively) participated in crossover studies, with single</span></p>
<p style="top:496.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">doses of placebo, morphine alone, dronabinol alone, and</span></p>
<p style="top:507.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dronabinol and morphine combined administered over four</span></p>
<p style="top:518.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sessions (Naef</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2003; Roberts</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006). These studies</span></p>
<p style="top:529.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">did not identify a synergistic effect on experimental pain in</span></p>
<p style="top:540.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">healthy controls, although Roberts</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2006) found that the</span></p>
<p style="top:551.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">co-administration of dronabinol and morphine resulted in a</span></p>
<p style="top:562.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reduced unpleasantness of pain compared to either drug</span></p>
<p style="top:573.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">alone. In a case series examining the effects of cannabinoid</span></p>
<p style="top:584.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">administration in patients with chronic non-cancer pain,</span></p>
<p style="top:595.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">three patients with mixed pain conditions (multiple sclerosis,</span></p>
<p style="top:606.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">HIV-related peripheral neuropathy, and lower back and leg</span></p>
<p style="top:617.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">pain) reported reductions in opioid requirements after</span></p>
<p style="top:628.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">initiation of smoked cannabis plant material (Lynch and</span></p>
<p style="top:639.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Clark, 2003).</span></p>
<p style="top:650.1pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Five controlled studies were identified. One small, non-</span></p>
<p style="top:661.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">randomized study of patients with advanced cancer pain</span></p>
<p style="top:672.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">found that 5 out of 12 patients achieved pain control</span></p>
<p style="top:683.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">after receiving a cannabis infusion, compared with 2 out of</span></p>
<p style="top:693.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">14 achieving pain control in the control group</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2014;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a non-</span></p>
<p style="top:704.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">statistically different effect (Lissoni</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2014). Two</span></p>
<p style="top:715.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">randomized</span></p>
<p style="top:715.8pt;left:87.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">controlled</span></p>
<p style="top:715.8pt;left:139.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">trials</span></p>
<p style="top:715.8pt;left:169.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">examined</span></p>
<p style="top:715.8pt;left:218.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">delta-9-THC :</span></p>
<p style="top:726.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Cannabidiol</span></p>
<p style="top:726.8pt;left:91.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(THC : CBD)</span></p>
<p style="top:726.8pt;left:158.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">combination</span></p>
<p style="top:726.8pt;left:222.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">oral</span></p>
<p style="top:726.8pt;left:251.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sprays</span></p>
<p style="top:409.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">compared to a placebo (Johnson</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2010; Portenoy</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:420.0pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2012) in patients with cancer pain who were taking opioids.</span></p>
<p style="top:430.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">These studies found improved analgesia with the THC : CBD</span></p>
<p style="top:441.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">combination compared to the placebo. Johnson</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2010)</span></p>
<p style="top:452.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">found no effect of THC : CBD on breakthrough opioid dose</span></p>
<p style="top:463.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">requirements. Portenoy</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2012) conducted a dose-</span></p>
<p style="top:474.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ranging study, using fixed dose ranges of the THC : CBD</span></p>
<p style="top:485.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">combination. In this study, a significant analgesic effect was</span></p>
<p style="top:496.7pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">only found in the lowest dose group, with poorer tolerability</span></p>
<p style="top:507.6pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">observed for higher doses.</span></p>
<p style="top:518.5pt;left:303.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Two controlled studies examined the effects of dronabinol:</span></p>
<p style="top:529.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">one in patients with mixed chronic pain (Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008)</span></p>
<p style="top:540.5pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and one in patients with prostate cancer (Seeling</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006).</span></p>
<p style="top:551.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2008) found significantly reduced pain</span></p>
<p style="top:562.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">intensity</span></p>
<p style="top:562.4pt;left:338.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">with</span></p>
<p style="top:562.4pt;left:364.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the</span></p>
<p style="top:562.4pt;left:384.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoid</span></p>
<p style="top:562.4pt;left:474.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">combination</span></p>
<p style="top:562.4pt;left:534.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">in</span></p>
<p style="top:573.4pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">double-blinded laboratory sessions compared to opioid</span></p>
<p style="top:584.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">alone. Additional improvements in sleep, energy, and social</span></p>
<p style="top:595.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">functioning were reported in a 4-week open-label phase of</span></p>
<p style="top:606.3pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the same study (Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008). In the study by Seeling</span></p>
<p style="top:617.2pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2006), perioperative use of dronabinol compared with</span></p>
<p style="top:628.1pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a placebo in patients with prostate cancer, no difference</span></p>
<p style="top:639.1pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">was found in self-administered opioid dose requirements</span></p>
<p style="top:650.1pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">between groups.</span></p>
<p style="top:676.6pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">Quality Ratings of Clinical Studies</span></p>
<p style="top:693.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The clinical studies were rated using the GRADE criteria.</span></p>
<p style="top:704.9pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">One study provided very-low-quality evidence, three studies</span></p>
<p style="top:715.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">provided</span></p>
<p style="top:715.8pt;left:340.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">low-quality</span></p>
<p style="top:715.8pt;left:396.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">evidence,</span></p>
<p style="top:715.8pt;left:443.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">two</span></p>
<p style="top:715.8pt;left:468.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies</span></p>
<p style="top:715.8pt;left:506.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">provided</span></p>
<p style="top:726.8pt;left:294.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">moderate-quality evidence, and three randomized controlled</span></p>
<img style="position:absolute;transform:matrix(.43628178,0,-0,.43646307,-351.83399,12.225403)" src="data:image/jpeg;base64,
/9j/7gAOQWRvYmUAZAAAAAAA/9sAQwACAQEBAQECAQEBAgICAgIEAwICAgIFBAQD
BAYFBgYGBQYGBgcJCAYHCQcGBggLCAkKCgoKCgYICwwLCgwJCgoK/8AACwgA7wW7
AQARAP/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMC
BAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJ
ChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3
eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS
09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/aAAgBAAAAPwD9/KKKKKKKKKKK
KKKKKKKKKKKKKKKKKK8c/bp/ax8B/sSfs1eKf2k/iIm+x8OaezxWxbAupypKR+5J
XFfnl8F/2uv+C/P7QP7Pul/tu/CbwF4D1bwr4hvzPYfDu9sRFeS6eJSgKzNJ8hAX
dnYc496+5viv/wAFC/gj+y18AvD/AMWv2x/ENr4J1TWrOEXWjRP9puUmcDKqi4Yg
E9cVs/s0/wDBQD9kz9rf4a6j8Yfgn8X7S+0XSIWOqve/uXs416tJG5BTp1OOtfBf
/BXD/g4h+GHwT/Zqn8bfsCfFTRdZ8W2fiWLTbyPUrLzIXgEiiUx/MNxAJII6da+r
PF//AAVj/ZX/AGZvgX8OfGX7V/xMSx8QeL/B9jqf9lWOntcXUrTQRyF1jU7gvzVg
/tSf8FNvhFe/8E7NX/bB/Zn/AGo/Dmh6dFd20C+Kdd0Jr4WZklVAktqJEfeS2OSM
Zp/gH/gsX+xp8P4PA3ws+N37RVtfeOPEnhqDUVvYNEeCHUleNH3xgsdmdwITJPPt
Xqn7MP8AwUj/AGO/2sofEt18E/jLBf8A/CJo0viWC9PlPYqOMsGPyiuA+GX/AAW7
/wCCbvxW+NEXwJ8F/tDI2t3OpPZWs17bmOzuLhH2NEkzEKzbuK+soWJ2iObem/8A
eAJuVsjI2+g5BzXiMP8AwUH/AGVdU/bJuv2DrP4gTt8UINL+3zeHpbRxG0GMn5/u
9K9f8T2XiWTwre2PhLVYrLVJbVxYXd9EZ4oJSCFJAIyAe2a/Fv43/wDBQj/guJ8F
/wDgpr4d/wCCZk3x2+Fh1HxFp8OoaZ4mufB7AJA5b5ZM3HzHC46jmvbfjh/wU3/b
2/Zu/wCCsv7O/wDwT38Vax4W1qx8eW5Hi68s/D7RSTuRId0RMh2j5Peus/4KXf8A
BT79o39lP/gp58C/2TvAV1odv4M8dXcS+JbjULXfO0bOFbDbhjjPauWvv+Cmv7fX
/BQT9rX4ifs6f8Ev7XwxomgfCydrbWfE3iizE6Xt4pwI4/mTaD83GT0r6n/4Jk/G
v9vr4oeCdV0r9vj4G6b4U17Rr4wRalpMoW31IDAEiJzwfqa+qaKKKKZOZBETEMt2
FZ2vaxpXhzSLzxRrF4LeysrV5rtn42xxgsT9MV+Unwr/AOCmn/BUn/gpn8SPiZr/
APwTusvBfh7wJ8M9Ul0+2ufEmm/aJNcuU/gB8xPL6EDr0zX2L+yn+1p+0B4Z/ZGu
vjV/wU5+HmlfDDW9AR11q5t9TSS3u0A+WRMAbSTnC5NXP2Uf+CsH7Cf7aHjW6+Fv
7Pfxxh1PxDap5iWWpRGKWUdf3YYjf17V51+3J/wWk/ZJ/Z98P/EX4b+CPita3fxQ
8JeHrq4stLuLRpYI7oRttV2BAHI6fSvOf+CUP/BYqL4w/wDBLP8A4br/AOChHjbR
dCSDXr3T5r2yt/KEqxyuioiFiWJC9BX0P8Cf+Cpn7HP7ZvhHxhcfs2/GuKS/8NaD
c3N7Bqlg0TWgSJnE5jcgsq4Bz3xXgX7K/wDwWw+APw+/Zff45ftf/tg6H4mtr3xZ
PpNjq2g+F3s44QshRFcmV95x/FkdK+hPhJ/wVl/YZ+MXxtsf2d/B/wAaBc+KtW09
b3SrS4sXgW7hJ4ETtw7cEkDnANZ37RP/AAWW/wCCef7MXxXl+Dfxa+Oq2mvRN5d7
BZWzTpZHOP3zrxH+Poa+jfBnjbwr8RPDOneNPBWuw6jpWowJLZ3ljch0kRhuByvt
Xl37WH/BQL9lj9irXvBvhT9oPx2dJvfHusNp3hmFLRpjc3KlAQcfdwXXk+teo+IP
F+ieFvBtz8Qdf1EJp1jZm8urpbc/8e4XdnH0rzX9lj9u79mL9tf4V33xk/Z0+JEG
teH9OuZE1G6aMxNbtGMvuVuRgD9K8jv/APguz/wTFt/CfiDxdd/tCWz2Ph7XP7H1
KMWxMhvBu/dxpnMmdjcj0pnjr/gqt8D/AIt/sSfFH9o/9jXx9a6rrngrQLmcWmpw
eXJbTJGWXfCTnbnHHevnf/gmB/wcI/CL4n/sReF/jF+3z8U9I0jxlq3iWXTLxtH0
ow26/vGWLzPmYKCBk5Nfp74N8QaT4t8M2fijQtVivrPUIFntruBgUlRuQQR2xWnR
RRRRRRRRRRRRRXlP7cPxc8XfAX9kr4h/GfwGtodY8MeENQ1KwN5ygkhgd1yMjPKj
ivyc/wCCCf8AwcL/ALTH7cfxn8ZfCv8AbEu/D0UVl4Un1bQLjS9KNsWkjKjYWLnd
wTXIf8E6/wDg4r/bj/a2/wCCsOmfss60fCsngDU9V1CK0ddIMNwttFG7CTzC/wDs
HtX6X/Ej/gt3/wAE2Phd8aH+A/jD49wprtvdG3uTDbNJa28u7GJJR8qHPrivUP2h
v27P2Zf2ZfCel+L/AIn/ABESS11iFJdHtdKgN3cXysflaONDlx9PSuB+FX/BYf8A
YQ+Mngvxp498F/F90h+H+nTX3irS9X057W9toYvvsIZMNx7CuY0//gvH/wAExtW8
J6b4+j+P23SNauxZ2l7LYPEiyE42sWPBz/Ovfvjd8aH8H/st+Kfj78NLq11EaZ4N
uNX8P3TLvinxA0kZOD8ynA/CvyO/Y0/4KVf8Fzf2wP2L/G37b/w+8efDOXS/BWt3
UL+Ex4SYXVxBD8z4k8/GcH+7XsU3/BduL4xf8E5PAX7XWl/G/wAPfCfVbzxKml+M
YtW8NPq3nSxNGJUhWOSPyydx9SM14H48/wCDlT4//E/9tmb4I/APxzpXh3wboWkJ
cTa3ffD+fUZ9YkEKuxWBJVaJWJOCSQK9A/4JE/8ABZz9uT/gqJ+1/rPw+vPHnhXw
t4R8LQi51HTn8NNLNdxIWLSfaRKFt8hfusDivt4f8Fvv+CbVz8cW/Z/Hx0xrlvqn
2F7j7A4sTc5I8v7R9wnIPetL9oj/AILD/sE/ss/HC2/Z8+M/xantfFt7Yx3cGn21
g8waJyQhQr13EEcV1Xx1/wCCln7I/wCzX8HtE+Onxo8cz6No+vuF0iCSwdryYHOD
5I+fGB6d6zPA3/BVH9iD4gfs4eIP2q/CvxcF74S8LosuuTi2ZbixDsEG6EncvJHB
rjdN/wCC6f8AwTP1bTfDuup8eAth4ruPI0bUptOeOFpAQu1pDwrZPQ816D+1X/wU
0/Y6/Y0m0zSvjp8SnhvdZtBcWFlptk11NLCVLCQRpzjA61e+BP8AwUa/Y6/aK+B9
7+0J8L/jbY3nhfSJTFq11PKIpbJxnKzxsd0Z4PDY6GuM+Av/AAWU/wCCfX7R/wAW
j8GPhl8a/O16V2S2W9s2ghuCDj9zI52uMjsTX1A6wsN1wxGJVUbu5B4q1RRRRRRR
RRRRRRRRRRRRRRRRRRRSPu2naOccZqvJPEqiOZ4wxKrKCOOR0r8Hf2jP+Dj/APbX
+AX/AAWQ1v8AZH1K38KN8OtI8aW+kzpJpnmTxwyRxHzBKH+Xl+mOtb//AAXi/wCD
jT9pr9i39qfT/gn+x5eeGZtLi0OC91K+1XSDO7NKuRGCHG0cHmv0U8Uf8FXP2aP2
Zv2d/h58S/2vviNaaN4g8aeGbW9TStKsmnnkLxq7lIkJbbnJr0f4Sft+/smfGj9n
6b9pnwD8aNLufBkLlJdQnlW3a1YdY2VjkPyPlOD2ryvwL/wW9/4J3+Ovixp3wZtP
inf6Vq+sX/2TR01/w5NZw3UvPzRzSYWRTg4I9a1fE/8AwWd/4J+eEPir4v8AhBr3
xh8vxH4Imki8QWENk0hjWMbmYY4IxmvWP2U/2vf2ef23PAg+LX7N3xBtfEOixStb
XEsS4aN8nKsucqflPX0r82fiX/wUo/4KlfGn/gsz41/4Ju/ssePfh94d0jQbaaWz
1HxH4ZN46CONpMFRMhO4Ltz2zmup/Yy/4LLftGXnxW+MH7D37edtoPg74ofDvRLj
UNI8XWlhus7i2Aysptg2SuCpxvr5u/aZ/wCDnj4j/B34B+FfCnwd+L+hfEH4ia74
kaz13xNB4OlsrDTrbfgGKNpH85x6BhWL4w/4OIv24bz9oPwR+yN8MviHocmr69c2
aX3jO5+Hc8Yj8/G1HtTLuYc/6zcAMZxX6jfGb/gqh+yv+wvpXhfwP+2Z8bbU+M9R
09Jb5vDulM0Nw5BJkMKsxjGOxJ6V0fxT/wCCr/7CXwb/AGbNE/a18afGq2HgXxDP
HDper2FuZT5kmMKyqcqeRkHkVufCz/goX+yp8ZPhNrnx08LeN5oPB2g2wm1bVtW0
yS0iwQGVleTAbII4Fcl+zR/wWK/YE/a9+Kg+DvwQ+NEMviSYFrSy1S0Nt9vC9oGc
/vPbbnrWLqX/AAXG/wCCcel+LvFHgK8+Llw+seDLiaPXbGHSJC9q0b7H+oDcZr0P
w9/wUm/Yw8Sfs0zfth6V8btIf4eW42y6s8ihhNkZQqTnfyvHWuZ/Zh/4LA/sB/te
fEeH4T/Br4zRzeJJl8yz0vVrU28tynrEHPzjkciqnx2/4LQ/8E7f2bfi/J8EPij8
dIotcjuFgvksbUz29m7EALNIh2x8nv619M+BfE/hTxt4XsvGXgjV7e+0rU7dLixu
rSUPFJGwyGUjjkGteiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
iiiiiiiiivz/AP8Ag5f+Dfjb46/8EoPHXhn4e6XNf3+k3Ntqk1pbbvMaOEOxwB14
7VR/4Jrf8FKf2LvgX/wSh+F/jj4sfGSw8PW2jaImm6hZ38v+kQ3HmspUxLk53EdB
3r40/wCCqvjLwL8T/wDguR+zb8UfiXq8d18Fdc0izmt7rUo3GnsSVYmQMMdx1FeG
eGrHxfrv7U/7e2qfsfx3Uvwz/wCEFZNNi8PR4sproPa8RYwB8okJ2+leG/tBar+y
Ld/8G+HwwTTzpX/C0LLxjt1EQR/6UEDQ+aJcjkkZ616x8RYv2ibb/gr98KUh13wj
pS6j8HNEXw3d/E+Nm0fyDpttuGfLkCtn0XtXMfGz4BzfBz/glT+1BfJ+1N4U+IUV
/wCPdJ+36N4NMxstKvPt8Jbb5kSKMfLwmVrsf2dPAnhb4hf8Fgf2O9E8caNDd2Tf
DrRJIre5QMkpWygHI6HrVCPQ/GGhft2/8FC/BPwB0+4tPL0TbaaVog2YiEql9irj
GBu6Vwnw4/Z6+Ifxp/4Js/CK68fftU/BH4d6fp/jTbocuJl8TteCXBWUR2xJbd1L
OcnrX9LOk/DTVvGH7MWnfCnVPiJd22oXvhe3tX8R6acTbhGuJ48454B5r8UfD3/B
B79tK1/4LX3uqv8AGH4iweB5fDkhX4zGC3N67FR+4+9gDtnrX7tfDvwSfAngTSvB
r+IbrVm0+zW3k1C+bMl0VH33x3OO1fi7+3QbX/iK++EMcd1EXTwVp6yo4Lgn5/kG
7I//AF1yX/Bb/wCGE/xz/wCDiT9nj4QWvxM1Lwy+r2SxDXdIwLrTiQ53Rnjk7e5x
8xriv+CgP7Gup/sv/wDBb39nTwhrX7RPiDx5Nrn2aOG88W7TJBKZdqhQuRgnFe5f
8G93irw5+w/+2d+1T+zb+1Pr9v4T8T6j48uNe05NXkEUV3YiSU+bG7deJF496/Uz
9lb9ub9mP9tUalffs9fEWDX10K8e11EojgI69xkbW5PUGvZ6KKKKR9wUlcZ964f9
ofwrq3j34D+M/B2kMPtWq+F7y2snQ/NveFlBHvkjFfkn/wAGwnxp+GH7Kfwg+O3w
A/aJ8W2nhfxB4Z8fXF/qdvrTiBzB8xEgzy+QVPGetP8A+DjD9qfwX+2v/wAEz/DH
xX/ZC+I0vinwTZeP4Y/Gd9pCSpHFEJYdqygquVBz6jFeC/GuT4O+KP8AgrH+xrb/
APBPi2025Np4Et28eN4Li2KJPIj3G4ZQvzeue9edfsfXfwCsLH9vHR/2sTY/8JvL
Z3jaA2uoTcmQK23y2IJHOK+bbyz+Ld3/AMEhf2etR8LzyDwvY/FLUU1M3aE6f9re
9cx/aAAcqAG6gjFfdXgr9nXxi/8AwUPu/jx4w/a/+Da69cfBrUTceBPho86RXVt/
Z1woEyJbpGXHJ57gV8AaxYWF9/wSN8OR3Vntim+OksbExqI1Q3DgqQPY9K/Qf/gp
T4M0b4Z/8FwP2QtN+E/hWLRp5vhXG8K6fEsfnTG2uQHwvBPGOe4r5r+Afwq+O3xW
8Zfti+BPHXxY+GHhQXOsXf8AwkVx8VA/9qwwb7jMlkfJk52ngbgMgV+33/BBr4VX
vwm/4Js+DvBmpfGe08b+SJ2i1zT3kKBC8gVf3gBwqkY+lfAP/BdH/giZ+118Zv2n
/hX8U/gR4z8cfEPStV8XSya3GUi8nwmjyQlZYfnBOeeveMV+sf7Hn7KEv7O3wDPw
U8cfF7XvHkt3aCPUL3xMqGYI0W0w4UlQoBx+FfgP+0z8cPi9/wAEHP2kf2h/2KPg
/oVx/wAI18YLcH4fCNMrZvcPIh2Z+qivLf2nf+Cd/wASf2EPiX+ynq+kxWJ1Xx3G
ur+Ib3xFEX04anM6un2pSrJja784JwK+lfD/AOz94r8F/Fb9p34ra/8Atb/C7WdW
vfhvdv4k8CfDSW4axid7eRVYboI0yvDceleQf8Kr+Gtj/wAGl1j8WtP8E2lv4gvP
i68F3qjrullCTzqCGPK9O2K/oE/4JT3l3f8A/BOn4QXd+G81/BsG/e5Y/eYdT1r6
CoooooooooooooorwD/gqikcn/BOf40pKBtPw31fcxOAo+ySZr+Wr4cp48/Y9/YY
+GH7afwhtgup+JtXv9Ev5pAdmzz5k2kjnnYK9v8A2Yv2bL/9n7/gqP8ABbwjommz
Ra3rPwLutXewVis8d3LaXpHI5JJXjmqX7Lfwy+JHxU/Zc/aS+HnxC+NPwk+H+m3P
jeVvE2ofElJRromEkvltaOsEjgAEjAZQTivrT42/tI+Kv2W/hx+yr+xT4d17wv4j
8W+J9IgRfjTr0cksGn2MkjoRGk0ZQttDYLLkZHNfK994Ht/hF/wUQ/ao8B6P8TF8
XQr8DdYNzrltGiJczFIiW8tAEbBz271teIPhF8NtL/4NZ7D4jw+HrFdZvviEsh1C
WIGVZRJGp2NjKjA6DAr9u/hNd3d9/wAEHNFmF4Z52/Z7jzOf4n/s7396/Pz/AIN7
P2iPhF8Dv+CL3xy134l+PNN09YvEOsRrbS3MYuJTJbFFCxk5JLH0r8+9U+E3jzwB
/wAEafhd4x8a6FJb2fiv44S3uhW93AMzxmeA52sOQwIz2r7O/wCCVXhTw1cf8F+v
jD4ePg7Tby1tvglDJHZz2ERit5Dp9iSwUjCnLtyOeazf+CIOg6+n7Lv7e0HwqsI5
fEcNlfQ6JJp8IW4iOy44RgAQPYHtXy5+zP8ABT4h/G//AIJYt4c+JP7SPwk8AaJY
ePWlkvPE0kqeJzdieTcu6OBnbLFsZfpivp7wf8NvD9//AMHHvwE8D/ELVrHxnFZf
Ci2a61G7g8yG7KRXhSQiRcnBwRkdcV03/BejR/jLon/BcT4Kjw5PoOm6Nd2cUWgP
4zZxoHmgICsyBXRADnovavN5vgFefDb4aftqfEq7/bA+HPi+/wBU0W3XxP4N+Hvn
f2fZXHnISIw0MaZC7fujFedftO/Df4deD/8Ag2A+CnxF0HwzFDqV58UvNn1F4h9o
xumOA3UA49a+hvhBdaBon/BwN4I1n9r1Yv8AhFbr4X2//CMXXij57EgWZOcSZTOc
ivWv+Cr+t/sXeNP+CW/x6/4dVnS31WLxZH/wsn/hDYpvKfDTfaCAQFHO77gAr43+
Hn7PPjb4vfCL9lrxBrP7Wnwb+HsGnalD/wAIzY6NJP8A23eSrK7Olzst8liN4wzE
dO9f0vaIZ5NKtLe8k8947aItdfwSNjlh39+RWlRRRRRRRRRRRRRRRRRRRRRRRRRR
QenNVZMC4Kwors7LuDDgDB5r+W79qL4Aw/Hf/grR+2frWnQpNqXg6xi13SPLXO2a
FrM5GfYHNfPnxjsPF37Vf/BP/wAZf8FAvi3bRSa3H4v0fQbGaNcI0SNKGUfgRmvr
T4pad+0dqH/BXb4W6fY+KPCWmLN8LtPj8LX/AMUI2OiQxNYR7x/q5F3Al/4a9H/Z
5S0/4Jw/sYftUfH3W/ir4G+NENx4itYYvB3haS4bTbDUzNL5kyhokURglPujovSv
mr/goPH4s8TeE/2bP2kfH/x20HWPE3ibVLee28I+ErWKKPRLYz/KgdER2cDaDu96
+rf+Ce/w88DeP/8AgtL+2gfFHhWy1NbTwlqE1us8ayqGa1lGcN34HSvff+DPq6c/
BL4+aTa7VgsvioscVuF2rCmJ+FA4rgv2etf8PeC/+DtL4par4o1+w02GXSbsia/u
liXb9lfkFiBmvJ/izqFv+1L/AMFlf2qf2kPhI51XwX4W+Bt5pmoa1Am+KS6SGBMA
9M5jfpXxRpWlaBP+xL+y5q0Hh6zS5f8AaDW3nnNpHvuE82MhWOPnTJ/i96/Sr9rv
wx4U0r/g6x+Duk6f4U060jk8M6U99bxWUawynYn8AG3I55xXh3xK8NftIXn/AAcC
fHzw1qGt+ANHudU0OdNJuPi6rHTYbBoEG61xFKocfMRgDqa8U/an/Z+g+BP/AARe
u9Lg/aN0D4jWE/xiRN3h+WZraynE37yNfNRMDt8oxX6Tf8F1/APifwp/wQN8G6X8
BdAms7ZrPRZ/EA0eDYGgNohZ5dnJXcVz1r5A+F/7OPjP4q/Ez9kH4n+Lv2tvgr4S
udIudO/4RfSfCfnJqt8qyQkpciK3HJAAO5j1NdX/AMEl/hn4M8b/ALb37c+r+OPC
1lrN5Y6LqyRTzW6OofzASwDD1yc9a+KPAFv8Q5f+CM/g64srTUJvBdn+0NdDxWbQ
EwpBiyKCUZ+7uLHpjmv3n8D+Pf8AgkFe/E34VeHfCDeC2+Nsvw8gHg4aDbGO4U/Z
I/v+QoXdnH3+a/F39kn4TfHr4ieDv2nvB/xI+M/wq8ILLrEyeLrr4oK51W3bzRta
3YwSMP4cbWFfvn/wQ3+Gtx8JP+CbXgLwPJ8XLTxxDawSG08RWTyNFPESNqqZFVsK
OBxX1zRRRRRRRRRRRRRRRRRRRRRRRRRRRRSNJGn33A4zye1AZTnDA4689KNyk4DD
PpmgMpGQwx65o3KG2FhkjIGeaNy4zkUoIPQg460ZGM5opC6BghcAnoCetLketIzK
gyzAfU0FlX7zAfU0pIHU9elFIzKvLMB9TQXQHBYfnS5HrRSblJwCMjrQXQYy45OB
z1oLKDgsAT05pcjGc0ZB6GiikZlUFmIAHUmgMp6MOOvNUNasNN1myuNI1S3iu7e7
haGazmQNHIpGCrD0NfL95/wRc/4Joah8R3+It3+y3oL6ml0LuNTbERRTZzvQHgH/
ABr1T9oj9ib9l/8Aaq+HNt8Jfjr8ItI1rQrKJU0y0mtwGswnQRHqB06VH+zr+xL+
zb+yb8NJfhF8AfhBpXh7w5cuw1GxigDC7jZSGDeuSe9eSa1/wQ2/4JbeINE1HQNT
/ZN8Ny2+rai19KDbgGOYkHcg7c16J8dv+Ce37HX7S/gDRfAHxp+Cum6zpfhuwis9
HluYMS2kMSiNY1PULtA/KqOqf8EuP2F7/wDZtvf2R1/Z60O1+HuoPBJd6DZW+xJZ
InDqx6kncAc+1SeH/wDgmh+xX4H+Knhf45eHfgVpdtr/AIG0aPTfC15BB81lboiK
FUdc4RfyrV+H3/BP39kr4U/G7xX+0Z4E+D2nWXi3xrb+T4o1FIATqCHs4xzXBaB/
wR0/4JyeEfjHF8edE/ZS8MxeIn1A3HmrZ/uYZmbc0ioTgPnnd0zX06LWKFVCWyhI
k2KGXJKY4A9BTgGaKJFCopXDJ1G3609WVGCwuoAQ4jB9+teQ+LP2Ev2YPiJ+0lo/
7Xfiz4VafdePNCtRBpOuMoLwqOmDR47/AGEv2ZPiv+0L4c/aq+Ivwn0y+8e+F4mT
SdbeHLxLk45P4UfF/wDYa/Zh+Onxo8P/ALQvxR+Fen6p4w8KMreH9UuVBe3dDuQg
9ucVz/7TP/BMv9iP9sTxWnjT9ov4CaTr2spbC3kv5oSGZTg7CRyw4H5V6V8BP2cP
gj+y78O7f4WfAP4Z6X4b0O1YeXp2lwCNM8fMfU8V3W5SSoYZHUZ6UFlHVh+dAZSx
UMCR1GelBdFIVmALHgE9aCyggFgM9Mmh3VF3N/Kq7onngq4Mm0+TgcLXzf8AtE/8
Enf2BP2sfH0HxS+NX7OOi6nr0Klmu0g8tp2B6yMOG/HtXpkH7In7N8XwDf8AZkX4
NaJH4HuLM28vhsWq+QVIwTjucd64n9lz/gmZ+xF+xX4juvEv7OnwF0jw5ql1HsGo
xQbnVeMqD/COOlU/id/wSf8A2APi98Uda+L3xF/Zr8P6jrfiKza31e5ktf8Aj73A
hnfHViD+laPgv/gm5+xd4H/Zpn/ZD0D4EaMvw9lmmmuNAkssoZZGLFx7jJ/OqfwC
/wCCYf7Dn7K39rx/Az9m3Q9KuNc06Sz1O7tbba8lrICjx7mz1DNwPWudn/4Iv/8A
BNmX4QWvwNm/Zn0hvDVvrp1mGx8ngXhYsZPrkmu/+IH/AAT8/ZI+J/xy8G/tF+Mv
hJZ3fi/wBpq2XhbVmj+eygUEKg47BjXH/Hr/AIJDf8E9v2l/iZcfF74xfs46Fq/i
G8/5CFz5Oz7YvpKP4s8/nXvXgH4deD/hd4U0/wADfD7wzb6No+mQrDZafp4CRIij
AUL9K2hBEWWWO1DBsBs8bcdODRhVeRZG2uxzvjQgn05714l+0V/wT0/Y1/av8daF
8UP2jPgTo/ifxD4ZlVdI1LULbdJGVIKn6A8103x+/ZG/Zz/ag+G6fCL49fCbSvEW
g2sSLaWV7a7ltti7U8vuCBxXGfCX/gmR+xT8Cfhprvwj+F/wB0PTNH8R2LWmt5tw
7XkDgq6N3xtJ/Oq0n/BLX9hEfss2/wCxxP8AAPS2+HVtqRvbfw/5OY1nLMd/ucse
a9r+Fnw58CfB7wDpnwy+HGkQ6doujWwt9Ps4eFijHQD2roAyklQRkdRS0gdCQA45
6c9aUkDqaMjpmgkAZJ4pBJGTtDjOcYz3paQMp6MOnrS5BGQaCQOSenWkDKQCGBBH
BBoEiFd4cEeuaGdF+8wHOOTS5GcZ5rA+J3w+8H/FfwNqnw3+IWi2+paFrenzWeq2
Fwm4TwyIVZfyJrwq2/4JM/8ABPyH4HaN+zWf2ctAm8IaHfNfadpM1qCI5S7OXH/A
mNdHP/wT7/ZNuf2htA/alh+Cel2/jrwrpP8AZugeIBEN0VttZdmO3DsPxNcl8Wf+
CQ3/AATp+NHxIb4x/Ez9mPQb/WXuBcXswtdqXMoOSzoPvEnmun/aL/4J7fscftV+
HNF8I/Gr4HaJq+neGgsejJJZYNnGv3FiI6AH0rjPBn/BGz/gnD4B8Qa54p8Mfs16
Pb3/AIl8Py6LrFwybjNZsFVlJ9SFFb7f8Euf2Frj9ly2/Y3m+AumH4e2d79pt9Ca
IFDNu3eaRjrnj6CvW9N+CPwy0b4OQ/AHT/CVrH4Sg0caUmjBP3f2QJs2Y9MV8t2X
/BAD/gk1p2onV7H9k7RY9shlmgjjYLLJv3b2Xv6V7L8bv+CfX7IX7RHwy8MfCj4r
/BPR7/QPCNxFL4YsGtwqacyFdmwdj8o/Ko/ht/wT4/Y2+EPxx1T9o74dfBfTNM8Y
61pK6Tqmr2sGJJrdUVAje21FH4Vofs7/ALDX7LX7J8/ib/hQ3wg03w+/jC8e58Rt
b2+RfMxO7fjrnJ4PrXmOsf8ABFz/AIJnax8TLr4wat+yZ4Y/te41Bb6eQW20PcL9
2QjOM16bqP7Cf7K+p/tO6T+2Hf8Awb0ub4haJo40zSNeMI8yzttrrtXt92Rh9Caf
+1F+xf8Asz/tqeEYfBf7SXwu07xNZ2txnT31CzPnW0nPKN1A61yngP8A4Ja/sI/D
/wCCuvfADwT+zjoemeGPEqeV4g06K3/4+FGCFLfxDIz9af4s/wCCYX7Dvjf9mTSf
2PfFnwE0q4+HOgXa3WleHJYw0MMwziUAdGGTz7mtH9or/gnn+yH+1To+i+Gfjp8G
NK1W38NW6W2gyNBzb2yptEWRztxkY963/gt+x3+zL+zn8Mbr4N/B74N6Ponhe+ga
PUNHgswYr1CMYkz14J6+tee/CD/gkT/wTt+BXxF/4W78Pv2ZPDdn4gDM8V9La72t
9z7z5QzhfmNfSEsTzkBY3dGkDlmcfLjsBVvI6UZGcZ59KKKKKKKKKKKKKKKKKKKK
KKKKKKQOrLuQg56YPWo4mlKl5lCtu6A9u1eHaT/wTi/Yx0r4v+Mvjpa/A7R5PE3j
qzNl4n1CWAM13AQMxn2OBWBqP/BI/wD4J3at8CZP2aLj9l/wzH4MfVV1OTQ0tAIz
cg7hIefWtj9or/gm7+xj+0z8PtB+H/xr+C+kazpfhe2S30OO7ttxtIlXaqIRg4Aq
58PP+CfP7IXwx+AGpfsteEfgDodn4I1eMjUtFjth5d8xHzNJnufevLNN/wCCEv8A
wS80k6Ulj+ytoMZ0W+F1pZSHm1kyWyMnpknpXpvw4/4J8/sa/Cb4seKfjX8Ovgfp
mm+IfGsMlp4m1CCDDXUbKVKn2IYjHvWz+y9+xN+zd+xjouu6D+zV8NrTw5b+I9UO
oatFYgIZpyWJcnvyx/OvM/j9/wAEbf8AgnZ+0n8W7/46fGP9nTTtT8V6m6tf623E
zkdBuHr0+hru/gx/wT0/ZA/Z9+FPiD4KfCb4I6Xo3hzxVA8fiG0hhGb1HBDK57jk
1w1p/wAEbv8AgnHB4R8LeDE/Zk0Qad4M1k6noFr9nBW2u85Eg98816D4q/YN/ZU8
bftHaR+1j4h+EOnXPxB8P2SW+ma40f7yGNQAig+20YrK/an/AOCbH7G37ZesWfiD
9or4IaTreo2g+TUvK2TOOnlsw5K4ql4+/wCCX37DHj34A6X+zfrv7NugS+DNFuo7
nTfDkcISFLhMbWOfvHI617HefCv4fah8Mv8AhUOq+DLKfwydKSxk0SaIPA0CqFER
XuAAPyrwb4Ef8EoP2Af2W/iOnxg+D37M3h3RPEKykwXwg3yROT8vlHOI8mur+F3/
AATy/ZC+Dnijxt4y8DfBjTtN1D4hiRPFl1FGN18JeZA5HqetUvhr/wAE0P2HvhX8
BNa/Zh8D/AHQrHwVrt893qeieQGinkfH7wj1+UY+lUf2aP8Aglr+w9+x94ym8e/A
D9nrQtG1lwVXVPs+65X/AGY5CcIPbFZ/xw/4JE/8E8f2jPiZcfGX4x/sxaBqviC7
cT6hPNb5E8q8hpAuPMOQK+gfhx4L8OfDrwjZeDvCOiWemaVYW6Q6fY2EPlQwxgYC
qnVcDtW6GUsVDDI6jNLRRRRRRRRRRRRRRRRRRRRRRRRRRRUN3BHcRtFKg2smCc4P
0r5h/b0/4Kf/ALOP7As2geHviwNR1jxT4jnC6V4W8PAPeTsSAoCFlB3HgZPJrif2
cv8Agut+yd8ePji37OniXwl4r+HPi2OxNyLDx/pq2YdBjIVlZwTyK9f/AGUf+ChH
7Nf7bOveN/DvwC8Ui/l8B6w2na7JO4RBMoUlkwx3J8wwxxzXtM2paasS3Ul/EkK4
IvWmURN/s7s06e5tJPMlvJvKhACqHkCh+h3qc8j/AAr5n/ZF/wCCsv7M/wC2Z+0v
8R/2W/htBqlvr3wz1JrTVri+RI7ed1d0by2D5bBQ9q+m7q+s1KfaJ44l83avnTBN
3H8PPzUshkUuUkdA/JZ8bVH1zTIr6wuZPMsbyKdgQCYJFcgdD34psms2SSul1qFk
gLhIP9KALE8YPvXKfHb48/Cr9mT4Uap8ZPjB4lTSvD+jRNJezz88jsMnrXxHq3/B
yh+x74b8N6b8SvEPwM+Ktp4D1W5WLT/Hs/huI6ZchmCrLG4mLFCT1IB9q+7vht8V
PA3xk8C6N8R/AXiG3vdI1+wS60u6EgVpEcBgNvrzWF+0v+0b4G/Zd+CPib4+ePhe
3eieFNNe51Oz0qNJbkhRnAUsOfxFcx+wx+2/8Hf2/P2ctE/aU+Dz3ljoeuO8draa
0ES4V1OCpUM3PtmvZHuraEBJZkjfBCpMygv+ZqJdZtgNrXkB2Aee4nT90T680tvq
FrPMY7bU0dvLL/Z1dWbGcZ4PSkSe1uJ0RLlS6DJVZlJB9CAeafDdW08rwpcx+epy
0RcF0+q54pG1PSRbyySazbbVco8hmXEZPG0nPBpY9RtZLgWlvfW8jeWCE84bmHrg
dqljluGj83yMNvwU9vWp6KSQBkIIBBHfpXwJ+05/wcRfsT/spftnN+w58RvC/jCT
xSmpW9jPf2emxGzWSbbsO4yA4+cc4rof+Ck3/BdP9j//AIJe+IPD/hX416P4i1S9
8RWYubZdCs4pNkZAIZtzqeQc19Pfs+fHzwT+0T8EfDfx28KSS2+jeKLAXWnpqAVH
CEkc89eD3rsYr2GcrNbTxzxPnZNEVYR/iKE1PTd6w/2pCJWbAUzLlj6AZpf7Q0/7
Q0ElzEHTjYzqCv4ZzUbNYXPmXgmjeJl2u6z5XPpxxV2BnaJWkChiOdpyKdRUDPD5
77JF8xBl9zH5V9a+Efit/wAF8v2X/h58Rte+F3wy+E3xI+JV74cDNr174H0WK8gs
dpwzTFpVKIOmQDz2qTW/+Dg79g/Rv2OL79tGGXxBd6NpOrxaXrHh6208DULOdyV2
tGzBeCpH3u1c/wDD3/g4z/ZE8UeKvCOn+Pvgn8S/Auk+N5Fh8OeJvFWhxQWcxbOA
ziU4Bx71+gujX9lqNst5Y3UE0U0ayQSW77keI8qw7c+1XK+V/wDgoX/wVJ+HH/BO
aOy134qfAr4h+I9EmtzLda14P0WK6gshjkys8qYrmv8Agnx/wWZ+EP8AwUd8Vpp3
wd+AXxJ03RZ7KWaz8W+INGiisJWRwuwMsrfNye3Y19fRXcP2qS2+3K5bG2IyoCx7
kYOfzrxLx5/wUR/ZT+Hv7V+gfsceJPH0X/Cc67F5lrYxyLiPJXasnPU7h617PJc2
8MZhvpYY2mbLrNchS5/2eenFfOX/AAUg/wCCoPwF/wCCY/gHQ/iL8dtN1q6s/EGq
x2Omppduj+XJnG52DD5R1PWvonwX4j0rxl4U03xvpwk+y6tZw3tqJh8ypJGGH04N
aLy4m8hTGDkY3H5ue9fBv7Y3/Bwx+xh+xX+1qv7HXxa8N+Km8Rm6t4ft1rZxm0jM
wXazOZAQMMO1dL/wUY/4Lgfsg/8ABM1PCy/GaHXNUk8X2H23S49EtUkKwbQyFsuP
Wvov9mH9pTwF+1d8BvD37Rfw/Fzb6F4ktftFgmohYpEXJU7wGI6g9CeMV38VzbSs
rw3EbB92CJAQ2B2I6Cq8WoaeZGittXtJpC2Gha5U7f1qZLnT7aZg13EoK7nElx8y
/gTwKfaXFneSrdWlwJwynEsUoZB7cHrVqio7lUeMhywA5ypxjHNZXirxX4c8G+G7
vxt4o1WCw0qytGub++uG2rHGoyST2GK+A77/AIOR/wBj2e31bxX4M+DPxP8AFPhD
Q9Re0vPGeg6BFLYQuhKsS3mg4BB5xXQ/tG/8HCP7Df7Pvwc+G/xlV/EXiqy+Js8t
v4c0/wAM2Cy3azxiMskyOyhSfMUDBOTmtD9nv/gur+y38dv2hrH9mjxR4C8Z/Drx
lq9ssug2fj3TY7SO9DAEBCsjZPPpX2+wScCSNsn19aR2mVlXKqucEk8k+gr4b/bz
/wCC8PwH/wCCdnj+48L/AB//AGfPiWdKhOxPEWlaJFJayMeAAzSr1/rXqf7A/wDw
UQ0D9vzwzd+NvA3wJ+IHg7SYfKuNPu/F2kxwpqdu6lgY8SNgEY5GOtfQa6lp6rPH
bvbu6kM0KXCs6DIySM8AdfwrxP4Of8FGf2ZPj/8AtQ+Lf2Rvhp45jv8AxR4OijfV
mhZTG+d25FIOcjGDXuc+o6ZFdrDLq9vHIvSFp1Bb8Cc18xftS/8ABV39nv8AZO/a
2+Hf7GnjzQNbm8UfEq9jg0a4srZWtlMjKq/MWBzlh0FfUUs6JF5kkbBVwGDfepZ4
TICJGJAOcJ1x6V86fAz/AIKU/s9fHn4bfEX4oeG728trH4V6tc2nieKVVL5hLqdo
LdDt9q8y/wCCb/8AwXS/ZL/4KhfE/W/hL8CdL8QadqmiWYuJ21iyjjSQZYMUIck8
L1xXZfspf8FX/wBnT9rr9qnx5+yH8JbbV5Na+HxkGr6rNCv2XcjhWAbcc8nHSvpw
6nYz2sl5YXQuDFCW3Wro5kA5woBwSenNeSfsxfteaf8AtPeJPF+k2fwd8XeFx4R1
M6e934itYoo7o5YF02SMMfJ1PrXrF1qGlgRMviK2iG/AYzqfMP8Ad5NfNH7Jv/BW
H9nP9sb9pz4m/ss/DSw1mx8QfC6/e01m71G3RLaRo3dH2NvPAKHtXaftqf8ABQb9
mj9gHwPY+Ov2hPGcVjbazqcVlpcEJVnmkcgDAz93Jzn2r1zQPFGjeLfCGn+LNAvz
NZ6rbxXFndIoYMsgyrenQ1rq4Di3Z8ybM7sdR0zXx/8A8FL/APgtH+zD/wAEt/Fv
hXwf8f8Awv4m1SbxeZE05fDVjHO6Fdud4d0xneoGM5rtv+Cdf/BSr9nb/gpp8Lr7
4pfAOTULZNNvnsr/AEvWY1iurcqxALKrHHT1rm4f+CuP7Luo/t/J/wAE5dFh13Vf
G0du0uoX1nbK1pbsoJKswfj7vpX094i1i28PaJdeJdSuJFtdOhknnREGSqAk4/Kv
zh+H/wDwc3/sy/FPSvEGr/DH9lX4weJrHw1qM1nqd5oHh6GaJDHyz5Mw4xz9K+sP
2DP+CiH7OX/BRb4WXvxT/Z61ud49Km+y6tpGqIsVxp8xz8kwBO0/Ke/Y17lDqthN
G00U8NxMEw8VpOHPXoBmo01Wzt3Hl31qkKjDtNdDer/3Dk8f/WqdbkC3Be9VFC7m
ugVKEZ6ZJr5i+P3/AAVn/Zn/AGff22/B37CnjfTdcn8XeNIIp9LnsrVHtNshxFl9
4OT349OtfTt1e2dru8y5hglbBZnlUYPbOTnpT7i/s7edYbrUoYjMMQo8qgv6kZPN
V5NQsLhXghuILgxsN6tOuIjj+LBzz1qaK6i1CNLizvUmhIw/2Zwyk+xBp7XVlp9h
JeXV0FggVmkmlbhVHUk+1fn38S/+Dkf9gX4efFnWPhkmleNtb03w7q403XfF2j6T
HJptlcZUYMvmAlcsOSK9U/bS/wCCx37Jf7EX7PHhL9pXxw2teJNB8cTJD4dXw1bR
zT3LPjau0uo7gdayv2e/+Cx/w/8A2gL7UTq37LPxW8CaPpeiNqlxrnjPQIba1kiA
JGHWZjzgdq6f9l3/AIKrfs1/tT/Drx18UvDC6pp9t8P7Y3etxX0Kr51mVdo7iIbv
mV1QkHjtXuPwP+NPhf8AaB+FOj/GLwPbXH9la7bNNYJeRBX2K7ISQM91Jrzj9uv/
AIKA/s5/sE/DeDx38dtfnB1CXy9B0bTvmu7+cYxGiZGckgde9eM/su/8F1P2U/2j
fiyP2edc8FeOPh54zk0x7+20rxno6wC7gVC+Y3DtnK8jpXpP/BOP/gqB+z7/AMFI
9M8W3HwL0bXrP/hC9afTNUXWrdUDyKSNyMHYsDg9cV9NUUUUUUUUUUUUUUUUUUUU
UUUU2TaPnYkBec14t+3r+238K/8Agnv+zbrP7Tnxhsr2fQ9CmhSaHTYg0rGSRUAU
EgEktwPWvnz9gD/gv5+xp/wUW+MSfBD4V+HvFmhapPYi6sE8T2EUH2lcA/LtkbPU
fnXo3/BRH/gqx+zp/wAE2JvBmnfHPT9XvNR8dasmn6XpuhQrJJlmwJCCwOMjGa+k
fCmtQeJfD9n4i02GWODULaOeGK8TbKqMM4Yc4NfEX7Tn/BfP9m79nH9r/U/2Jovg
1478YeN9KWNp7Hwvpcc+AyK4I3SL2YV1n7E3/BaH9l39tz436p+zbo3hvxX4L8f6
dE8zeFvGdilrdTRICS6KsjArgHmvrf8AtvTIpzbTahaJKHCxxNdLvBx0YZpz6rZR
uLRbm3WeTbIITMu5lJ6gE89KdDqMMkjC22zpvwr27qxHru545rwL/goZ/wAFHfgX
/wAE2PgZF8cvjlFqNxplxqcVnHDoiJPMJHdVB2swGAWBPPAFes/Db4oeH/iz8LNB
+LPhi7NtY+JdHtr7T5b9lTdHNGrr8uSM4IropdQtLa0a7v8AU4oYHYbJXlUKp4GM
5x19+9OGp2JZPMuY8k4QidPnH97ryKIr21uHltotTgeVDnbHKGZR7rmpJ5na0eWB
VYLGShI7jpXyH+3D/wAFn/2X/wBhX4j2/wAG/F+l+IfFXix7UTXGheE7Nbi5tlxu
3yKXXCY7+4rY+Dv/AAVx/ZC+PH7JPiX9tHwh4lvYvCng21ll8SabqNpGl3ZyRqW2
su44PBxz1FeK/AX/AIOIfgp+08dNv/gx+yF8Y9X0nVL02tp4jPh6IWJIcqxZvOzg
EHt2r3Hwn/wVb/Zq8Z/tgy/sW6Rpuup4jSd7Manc2Ma2cl0i7ngRg53MgIJGBgEV
6h8Df2svhZ+0R408YeAfh3Nez3fgPUxYazNJAvlm454U55+6a6n4pfFzwH8D/h7q
XxU+K3iO30bQtKt3uL+/v3CbAozgDoScYA75r4f0L/g45/Y31PxTo1lqvwn+I+le
FvEWqtY6J461DQUGl3Mu/buEglJC56HFeu6T/wAFa/2YPEH/AAUAtv8Agm/ZWuuz
eMbzTPt9rqy2yrYzRCMyACQNuJwv92vrCiiiiiiiiiiiiiiiiiiiiiiiiiiiorkS
4/dAdPvMeB+Ffjt/wcWf8ErP2yPjf8fvCv8AwUC/Yim/tTxH4G0qP7V4djuF88+S
zOs0MZOXPPIAJOK8b/ZB/wCCsGg/tueJLj9gT/grn+zQfDfxK1LQprLQPGB0lrO+
EhjyhBcbg2ADnpXz/wD8EbPgrpXg3/gn7+2D+0H4a8Q6vb+ItAjudI0y6W88tDEj
8Stnq/znn2Fdp8Qvjb8bIP8Ag028GePU+Iusx+JLz4ueS+r/ANo7bmWATTgLvPLJ
jGQPQV2EfxR/aO/bt/4KL/s6fsD6t8bNf8NeGIvhi+o3E9he/wClT3EcFw++ZgCC
PkXsK/P+9+A/x98AfG79p34g/DX4naomo/CLxfPc6nf2l3s+3JDPP80uOWBCc/U1
95/G/wDb7+IH/BV39oX9jr9k74M/EzVLCC602HVfHN54bnaORZoTKCGPPykRqCD6
19z/APBy7+1v8XP2K/8AgnrZaL8HNWazvvEeoWuizas+S8UR+V2QqQQ+DnP04r4y
bVfjl/wR6/b+/Z08I+Afjbr/AIv0j46/D37b4os/E96ZjHI8RY7MBQCCBitf/ggP
8GLr9rX9vr9orxp8Wvi74qubbwH4yhuNK0JNRYQlzPKwDKwPHyAYGP1r9Sv+Cs37
EviD9vj9hrxX+zb4J8Rto2p6hbrNpcqvsVpFGBG7HgA5r8OfgZ+3p/wUg/4IjaVb
fsZf8FBP2YR4t+DVjeRWaLqWjtLb2yBxgxXH+rIwQQM/QmvoL4sftPWPxJ/4Lx/s
k6t+zZ4j1DRvAHiSytbhPDmnysluyNGhaNk6EZP6V5T+1f8AFD4har/wUs/bp+Ht
78Rr/UPD+n+HJpLTSLi6LWtqxTG1V6Aj+ZrxHwv8L/i5+yp/wQu+FX/BSb4T/tD+
I7C/sfimtlH4YtrrbY7GmmyZExluYuxHX3r61+Pnxn/aV/4KWf8ABXX4UfslS/GH
V/B2gD4eDU7WTSbgxedcC2lcvJ14JGK+NtN+Kn7SHwu+Bn7Z/gS6+OOualfeEfGt
nYw6mNUJWMLNeozRnPfYOnpX6UfAqTX/APgm1/wb7a/+3p8OviN4g8Q+O9c8Dxyy
3euXnm28Est0sWYkIDDAOc5PINfHl7qP7QP7CH7LH7Nn/BUjwb+0F4h13xp8UPEt
vJ4n0XWrh2sb2CV4Skarx93e/fvX0p+wH8c/ip8T/wDg4w+NSeIPHOqppk/wqXUT
oNzdl7e0lewtHIVR8q4ZyR3+bvivz38Y/tGfHm3/AGDf2mdVg+M2vfarL4t6dFaT
/bXVlie9IIjPVVxX1D8VfEPx7/4J0fFj9jj48/D79ojxF4jX4q6Dap4m0jU7oyWr
htgyigAhgOMknnNf0O2N3c3ttBK8DReZCj5LAjJAJHFXaKbNJHFE0kv3QMt9K/ln
/wCCz3wO8RfHH/gut8Wo/CVzOt54XsoNb8yEfd+zwxy4PthK8O/4KHfF7Vf+Cmfh
W7/a90+WWOz+Gvgzw7o2oAqxEl5LC6yZB6fNFwf519YftKfteeL9W8TfsvfsFeOv
EfivR/hTH4FS+1qD4fxST6xqTP5u1AsSuXAfacBM4Gegr6C/4Je/tJftM/DPwR+0
d8HPjj4u8eeFfgv4W0+a68HeNfGmlXCXtvbss37tiyKd7Kqj7o57V8aftc/Hf4h/
D7wl8Nf20v2QZ/iRpXhu78bxQJ438QakfL14h3VisZVSFyCBkdBX0x8ONP8AjD+2
l/wXz1/4XeLPj34h0zTZ/hvPfTpZ3pXy2EErDy16Agj0r6D/AODWT9oL4x+P9b/a
E+BfxK+IWo+I9O8FePJ7TRbzVpTJII1mlT5mPf5Qe1fsPESYwWZScdV6U6iqepWf
9p2lxZTxBY5YmRwDy4Ix17V/OF8cf2Xf+CtP/BBn9rPxX+0n+yt4Yn8Z/Drxhqkt
3qLWVob5J7cuZHt7hI9zLjBOTgYxW5/wUp/4KXfs9f8ABR3/AIIaeMfFXwp+Fth4
F8Wad4/0Y+NNBsIAm64kklydo5AJDda99/4K56H4W1f/AINpPBHiXxFptquq6XpG
lyaLdzKElil3qMxEYIO3P5V+kn/BI3WPEuv/APBND4Jav4wkuZNSn+HWmtdzXbZk
dvKHJPX86+jDwK+R/wDguI3mf8EsvjATBG7HwtcbVwDj923P86+VP+CKHxi134Af
8G2lv8ZfCFih1TwxoOtXtkZkG0yC6fHPHrnrX516dqv7R2hf8EwH/wCC6lr+0z4q
PxJtPiTHazaQ10/9lvbvPCvk7Mdw7A/N3rV+F3wW8G/tE/8ABfv4Q+KvEuua7FL4
48IaP4s1do74edHdz2sMzRodp2xhpCAMEgAV9Mf8FLvF3wy/aK/ap+I3wS+EfjLx
v8RPiN4f0Ke4itfDl21vZeGLeKJtvmbk++GUsTnuK/PX4xftI/G79oH/AII1eGtA
+PXjW41nUfB3xgg021vb+TzJRH5soKFu4XYPyr+qH4DXRufgv4REhDMfCentwuF/
494/WuqUXLSRtIVZTlnx2PbBr+YT/gu/8BfEv7QX/Bd3xn4a8MK4m0nRLXVC0bjc
PJtYpOnXHy185/tx/GnXP+CmPwzPxz06W4aP4PfDvQtO1RNjCPz281JTz/uDFfUv
x9/bM8XSfDn9kL9hbWtR8TaV8L77ws194qt/A6O+qX5MkgURLGrtnkcbTnrX0R/w
Sn/aL/aK+D+vfH/4HeM9f+IHhD4FaXpFxqHhLxl8QNJuUvtKi2SHbIzxr8zBQoAU
c18c/tsfF7xb4V+DPg79t/8AY2j+I1v4bXx2tkfifrupEQa1dB5NyJEVVhHlGAyO
gHNfSfwpl+OH7a3/AAXy074V+K/jV4k0nR9e+H8upalZ2mo/L5otZTkYGM5UGvob
/g2P+Nfxm1X9pD9pf9nTxz8SdR8SaH4J8c3Fro0+qTGSWJEuZ4wAemMJX7IUUybH
ygk8kjaD14rzL9rf4FR/tKfs0+OfgA+vtpi+LfC9zp0V+oI+y742XzM9iM5/Cv53
/h34j/4K5/8ABu3rWrfCv4jfAMeO/gpd3rzarpzad9s0+aAsR5hkjyEYrg8nqecV
2H/BVv8Aau/Zr/bI8P8A7Efxd/Zi8IQ+F/D0/wAS5objw/HYsosJxNY+YMgbWByO
B02171/wdMaRonhG/wD2X/iR4KtYLPxqfFenW8GqWSbblrfacj5eSMgV+2fh+Wf+
wLG6lH72a1hMgPQEouat3bQoytcZKk4Axxn1r8qf+DvswR/8ExIfMKrK3im0Ky+Q
SRiaLuBxW5+3X+2L8TP2JP8Ag3n8D/GP4TGMa7eeBdB0q31EYU2vn2Y/egDByNtf
n/8AEWw+OX/BNXTP2Yf2kfCP7RHi7xJd/tASrZ/ELSNTvS8Mxui8bvBwNrKjjGSc
FRW//wAEJf2Zfh9pv/BZH9oK40rxTrVoPAFxqU+jahcXW9oy0jkPdkD96V29Fx1N
ebft5/Etfjd8Pviz8Z/2UtZ8f+NNV8Aa/v1v4oQ6kbXTdPkWVMxKjqCcZ6A96bqf
x0+KH7Rv7YH/AAT3+LXxa1iTUdamv9Pjmvnba0iI9ttxnknk896/ppmLAGMHLHlM
iiPc0mTwNq89ya/lP+Nf7Zniv9inxV+2X+ydrUuoJr3xG8UTnRLeJW2Iss24MBjn
IPasj9n3wv4l/wCCHn7Tnwn+P/xA1a/g0X4k/COe/wBSfYQYrq4gnVYgAM8NtODy
M1r/AAl+O3xj/ZH/AOCYPxL/AG5PhFqE1nrfxm+K02iw6xMpEq2Mr3LuU6MJP3a4
PQehr6E/Yi+MP7SHwL/bY+HWr/slaN8aPEPg7xX4XlX4rv8AEHR7r7IbxopC0sMj
QxrxlCGBI4FeY/Cz9vz9o79nv9j79tnxZ4K+Jd817P8AF+HR9NN9dZNlbTyX24xN
wA4CoABzx061o/tefCL49fsY6z+yL440n9qfxZrNh8RdS0+7v4tTvmWdZZZ/mVsg
ApjjGK3v2E/2eNT+O/8AwUE/bg1X/hZGr+HrHw42tXdwulXHlzXE4knKtnB4ypP4
18ffGhNe/aE/Ya8C/Fz4p/EzxJruv2/xrPhRHvL8NEtjhmG1SP8AW5I59O1f1efs
dfCDw38EP2ZvBPw98L3l9cWul+HLeOKfU5xLcuPLXlmAAJ/CvT4wVcySDsAh7kdf
51+IH/BzP4esfE3/AAUt/ZG0DVLa3lt7/wAa28M8cxADIbq2DBsnoQTXI/sffE/R
/wDgi9/wWV+P37PfxDW20rwj4r8Ntr2iz3FwEUu0cbhYznb958Y616L/AMGu3wo1
/wDaB+Mnxx/4Kp/EDRo428Z+I5bDQIJZATb7G3OVLdFKyAen1r9f/iyxm+FviKGC
wSWb/hH7n9wzY3ZjJ+8eK/m2/wCCOf7YH7c/7Gv7FPx78cfs6/sn6d498GL4nvhq
mrTXKefYyFFRiY9wZ0VMNgAjrXun/BNm0+FH7Nn/AAR0+JP7afi79qNvCy/FXxo1
54utNGnHnxtum22cSgEo7B2HT+GvAdc+PXx1/ZH/AG5fgx8Yv2erPxz4M8IePb2I
WUXizWBL/bCTM0TTOmFPIzjgdBXov7F3gD4rftTfHz9uu88YftE+K9PsfAs+pXdm
lhqZDeest1sVcghV+TGAO1eV3f8AwUg/bCt/+COPgX4P23xU1KKfxf8AGb/hHZfE
q3R+2pZjccB88NlcZxXqvxr/AGbtb/Yv/wCC6/7PfhlfiNq/jWW18LWOpQ3es3Ie
5JAUlWcgAjjtWf4d179oj/got8Kv2tP+CnXjb9ofxN4X134KeKGj8HaN4e1Dy7WN
omRVEiENkFMg4x1rL/ar/bQ/aX/bbk/Yi8TeIfiNqfhu/wDGmo22m6zLot40cE48
y3Vn25J3EOwOSRz7V6jefAz4waV/wcE65/wTr8M/tI+MofAF/oNpea3HNqoaQo9n
HI5hIXCnc3cHqa91/wCDbD42/FjTf2wP2j/2R9a+J+reJvCHgXVl/wCEck1258ye
3UylSWfAGMD09a/Xrx7o0vizwFqvhy0mV5NR06a3jaM4Us6EAg/1r+aUaL8ff+Cc
n/BPn9qn9hn9oT9lvXnvvE3iI6pp/jyDT2uLFIvMixunVSqk7M/eHJr1n4ff8Ewv
23/+CmP/AATm/ZQv/gB4jstJ0Lwq1zLrM+o3yBo3EkXl3CIzAuAFbgAnmvoX4A/t
b/tifFX9qH4v/wDBDT9rzxJpetaqPC3k+E/F+kweSWVYkKpKCSQDgg9OM15T4l+A
37Wn7FGm6p8OPjf4f0uO413w3YQ32m+Hb+PEugaJGySPgO20yJKPvdcV+iP/AASc
/wCChEn7UN5qf7P+sfBZfA1z4c8Pw3+gWtqwKS6aHSIPxnkuck+5r4p/4Kvq3jT/
AIOR/wBm74b+Plabw3BFaXllZ3ALQTXZkXOF6HlVr9dfil8IPhTqSXnxC1L4daRP
r+n6JdrYam1kvnQp5LjAbsMcV+Tn/BoLP/xJ/j/ZzQZnXx67S3IU7Xy7/KG6HGP1
r9paKKKKKKKKKKKKKKKKKKKKKKKZOQoGe/GCcCvzu/4Oj0Ef/BGr4lhZvlkvNNYj
bnkXsPA9OlflZ41+H7/sEeGP2Gv+Cnngi3t7bS7vTtO0/wAVMXCCTKQbi3I/uscn
ivddV8T2P/BaD/g4p8NtpV6ZvBHwd8PwXcKI3nQykjzOSuVzvl/Sv3lLRsT5TiME
iM+Tyy+nTgCv5+fj548/aR+Gf/B0z468X/svfBuz8Z+JodLts6Fd6hFCk0IsIvm+
dlO76HNaP/BMO78Tftu/8FhPjH+3Z+0Rdaf8KvGXw38K3dld+EnIQp+7lV7gKTl1
QDdkEg4rwH9ur4r3vjj4X+O/2nf2PdW+ImqXfgXxERr/AMUX1XbZC5LllFupUfKF
O0jnvXT3/wC0B+0t+2D+3p+x7oGq/G3XNJXxp8ONJuNdSwujHHKWkkEhUf3to75r
uPh1+1x+0H/wT8/b9/bC+Fnw1+KureIdJ8EfD681nQYPEdz5ojug0IyemV/escDB
zivnL9qH4DfE3xV/wQy8IftsePPj94h1298a/EBptT0DVLkvbAO8QCwgjIAPua+r
9X8YfE3/AIKJft7fBb/gldrXxG1zwR8P/C/wJ0TWGHhu+CXVxMdPtmYs4BGMtxx0
rxHXP22/2oNF/wCCYf7Tn7JGofFHVp/+FU+K7X/hHPEaXZF2LQ3tvF5Uj9eQW9Ot
V/21PD/7RPwE/YD/AGUv2pfB37THiyHxh4+hjtrxZtT/ANHmgkEOzKYyQQfm5/Kv
oS6tfjL+wV/wXj/Z8+Efgb42eJ9Z074n+Ere88WabqV/5kXmPBK7GIYG0ZQdc96/
emSZQn2iC4Qpn5+cggdce9fin+2P8Ifj7+xB/wAF2Nd/4KC+I/2f9c+IHw98beFp
LKzi0Kza7e3kFuFIZFViijYWyQB+dfKH/BLv4EftDft7fstftm/CH9mexWy1Txh4
ks5rTTtRuBbwRI88xkt/nKhX28da9u8B/EX/AIKH/wDBurqnwK+B/wAbfH+ieMPh
34zlGn6j4StLYCTTZpHOTFKSVJBznrnNehftPfsKftW/sv8A7QetftLW66WfBF38
QL3X/C2sQahH9vF/rUUVqsAj372WMojHC9Ca9B/4Jv8A/BRCT9nf4x6X+yp4s+Cy
pD4i8YjT/Evj2C7QS3ms3JkliV4ySxUKJO2eOtbH/B3R4k8X6P8A8E5dI0vQL2WK
y1TxdbQawYZNitD5kRAb2PQ/jX2j+xf8CPgbr37BPwl8CXngDRtR0KLwVpN3DZva
iSFblraNi6n13E5Oa/MXTStr/wAHfFlp+nRqYo/DNysixqFWBRZS7VA/LpX7h0UU
UUUUUUUUUUUUUUUUUUUUUUUUxriBCwedBtGWyw4HqaZNPld0PluCM8v1r48/4KIf
8E6/j9+078VPC/7QH7Mv7ZHiP4Z+KvDIXybW0kMlhchTkCaLzArg9CCCCK8h+FH/
AAQ18XeK/wBtGw/bs/bt/aAh+IXizR7f/QbbTdEis4hJt25AQ4HHtVr9k7/ghDB+
zLb/ABy+EyfHFtT+Gvxjjn8zQZtPTzbKWTPzhy2eDjp6V4L4l/4Ni/jN4i/Yff8A
Yivv22Zp/Dej+LDqvhW1fS0CWyF3bax3ZJww617B8Zv+CAuteIfiR8J/2hPgF+0l
c+BfiF4E0IaRreuWtqJP7Qt9jqcDcNpO814Lq/8AwTE+Hv8AwST8CfHv4jftHfEn
xB8TYvjppF5Z2+n6ToKSy/an8whnJkzktL+lYn/Bq/8A8Ekfin8D/HniP9tj4++A
7jREuYZLDwLp2sJsuYrdn3+bsPCggsOvev1I/wCCkP8AwT++En/BSL9nO++A/wAU
3aAbhc6PfxEF7S6UZR8ZHQ4718jfsrf8EDfG/hz48+Gvj1+2x+0/dfFC88BaRJp3
gSzurYKumQlWVBuLHOAa9W/4JQf8El9c/wCCcfxh+M3xX1j4sw+JJPipriX0UC2i
xfY1WSRwpIPP38fhX0n+11+zt/w1N8CNd+C9v8R9a8KS6vD+613QNReC4tpB0Ksj
KcfjX56fFz/ghb+3X+0Z8GNO/ZB/aL/4KIyeMfhbYXcLp/auhRvqojjcMqtcsxkk
bj77Nmuu/aY/4N7tA8ZfEr4LfFz9mH493XgPXPg7Yw2WnXS2azfaY0VVLMCwwTtH
r1rjdG/4NwvFVj8bfjX8Y/EH7Vsur3Xxe8OPaXjT6NGGW6YEFz8/3R8p/OuH0j/g
1/8Aizd/s8+A/wBkzx3+23eXngDQPEI1XWtAh09UhuXD7gqjf3y3OK4v/grT+zpc
fCb/AIKKeE/i/wCDfCfjPwFonhrwkuj2/jbwxaG7Orqsbr9lILp5R53bgScHFeQf
8EyP+CIv7QX7X3wV/aNt/iVqGqeDNK+IfiKCfwtrWsWwea+VZLlvOkjZuRiRSeT1
Nfsr4J/4JzfDsf8ABN7TP+Cdfxa1VfEGhW3hb+yry9KhDK28yBwuezHP4V8Z/Cf/
AINwfGVt418DeFv2gv2wdQ8W/Cf4Zai174O8CvYKFhYMhjQuX6DYo6V6Z8Tf+CF1
2/8AwUN1T9uz4A/tFXfhCTxToQ0jxHokNirKbcQJCNrbgekaflX57f8ABSH/AIIU
/FD9gf8A4Js/ErQvh54u1b4l6r418e6dcW0NrZbpo4FuQzFlBPODya+o/wBjH/gg
748+KF/8DP2gP2pfj/qOr6J4A8NW0nh/wVdQ4NlIyq7I3zcENmv12h8tYhDtVEUK
EG8E4Hr6VP50X/PVf++qPOi/56r/AN9UjSQMpVnUgjkEjmvzv8Sf8ERrjxR/wU2+
I37dutfGBTpPjzwxNpUugw2KM8ZlhMJOSRkAHP4V4l4J/wCDXzTPhz+wT8Uf2PfD
fx0hbUfH3im01GDxE+nLuht7ZpfKhZd3YSEZBr1P4r/8EEbrV/C3we+I3wH+Pf8A
whXxj+EOkLYaf40GmJdJdL8+5mjdgOQ5HPT8K6rwN/wRk8a+LP2d/iv8Kv2tP2vP
E/jrV/iwGa+u5ZmjttOYB9ojgEhTGXPAwOK+ZPiD/wAG0H7T3xE/Z08A/sr+LP28
WvvBPw61s32i6UNEjTK+a7BSA4GQHIyfSvpX9nD/AIIr6x8C/wDgprqP7fV/8bo9
Shu/B82iR6QunJGV8yJ49+Qe27PvW9/wSR/4JFXv/BNbx98YPGWpfFFdfX4m+J5d
TigSMJ9lV3d8E9z89fc8UsQjAyqcfd3DinedF/z1X/vqjzov+eq/99VWnja4t5bM
yqiyqyiRZPmXPevzt8bf8EoP2+/BHxL8Ya1+y/8A8FHNUsvC3jaGSPVvDPi3S01K
GJZPvCATSMIuP4lwccV5jr//AAbDeA3/AGBfFX7MXhf4wpa+M/Gviiy1nxF4t/s9
AJnt3kYIqBuB+8bjIq5N/wAEHf2v/jr4M8Bfs9/ti/tzQeJPhb4DnieDw7pvhqC2
a8WMfKHKMM9hk+lfqB8OfBnh74Z+DtM+HfhLT4rPRtE0+Kz0y3WQfJFGu0DHbgCt
0yxEf61fzrxz9u79mi4/bB/ZQ8afs2WPildIm8VaRLaJqghVhCWUgcZ5615j/wAE
+P8Agml4f/ZI/wCCcdl/wT/+Jvir/hLNLW2vINTnCCITJcStIyrg9Bu/Svj20/4N
ktZQH9n+8/bF1h/gF/wlY1s/DkWw2u6ujrGX39NyKM17X8WP+CIdr/w3z8Mv24P2
afi9H4Nm8DWFrpt3oc2lx3KXFnBGkaoHZs/dQdq4r4g/8EFvi1pP7bfxM/a0/Zj/
AGv5/BSfFnR57XxZpyaRHKZJJI2VirFhsU56CvF7P/g1b8WxfsaR/s0Xv7UkVxdr
48h125u30xAtxGruzLu3ZVju61+wvw48LL4D+H2i+CpLv7S2j6TBYmYkDzRHGq56
+1bIAEEYilEe3BKhgePSvgHx3/wRSfx5/wAFXda/4KL6p8YcWOraBJp03hv7BGwd
WtfIHzFu3B/CvCfAn/BsDp/w4/Y4+Lv7Nvhv48xrqXxL1i3uE1Y6cgFvBFI7CPr6
ORXo3xJ/4N+LbX/hD8F7z4afHZ/C/wAXfgpYmDQ/HVvpySx3yFmbZLGWA4Lcdfu1
3Hwz/wCCOPxL8R/CT4teEf2xf2yPEXxB1v4saaba+uXzDZ6fw2zy7cSFDtLZ6Cvl
Xxb/AMGxH7S3i79k3Q/2LNV/b7un8DeGPEn9paFpn9kIYo/mc/Om8Dd85Oeea+lv
2bf+CI+r/s//APBS/Sf2+IPjmbyDTvCT6PJohskG8tDJGWBzwPnzXT/8Etv+CQ+o
f8E8/wBpb40/Hm9+Lo1uH4p+JJ9Tg01bVUFqJJ5ZcMQeSDIRX3V50X/PVf8Avqjz
ov8Anqv/AH1Uc/lSAMsqh1OUJI4Nc18Vvh3YfFf4c658OdR1m9sE13TJLaS906+a
KWAspG5GUggjOeOtfm3qP/BFv/go2Pg/4i/ZVb/gp3e698M/Elw/2u18T6DHeX8U
DPnyknldnAAwOD2rD/aM/wCDZPQfEXwB+C3wg/Zo+P8AL4Xu/hLrN3qv9o6jYLc/
brqUQEOUZ8Lhoff7xrvfBv8AwRF+NPxi/aa8I/tD/wDBRP8Aalj+JkHgKKP/AIRr
w9Z6PHZwRugAUkI2Djr0r9KIUtoYUt0kXbGoVRkdB0pZZUJXDIw3cgkce9fI3/BZ
X/gm1q//AAVG/ZY/4Z50j4kR+HnXVobsXMkIcNsdGx1/2a6z4n/8E6/hh8c/+Cem
lfsEfFq6jvtO0/wjZ6UNTSMBo7i3gESzqueuQT1718dfs+/8G7XjKy+Kvw+8Qfte
ftcap8QPC3wnn3+BPDL2qxRW2GYpuIc5I3dcdq9U+CP/AARYuvgD/wAFC/iT+1t8
O/je1r4U+Kun3UHijwm2noHDS5yY5Q2R95ueDXz8P+Daz42eCvgn8U/2W/g9+29c
6T8M/idq7ajfeG5tGjd1l3qw3S79zD5AK6Twb/wbf6p4O8efs2eNY/2lpLz/AIUV
fw3E1tPpcY+17GhbarbuFHlcD36V+rIfH+skDkHKnIGP1pZJwu8rtbCZUbhyfSvy
d/4KRf8ABtNZ/tz/ALdyftf+H/jpH4btbia0mv8ARV05H3tFs3DduGd209u9exf8
FqP+CI+gf8FTvhJ4E8CeE/HNl4R1DwPLL9ivVsEYPC0SIsRAI+UFSf8AgVN1P/gg
z8F/HP8AwSs0T/gnT8RvES3F3oX+mWHiezjETRaiM7ZtqnBHzN371X/Zc/4JMftm
eB/ix4c8U/tJ/wDBQvW/E/hjwdoj6Z4e8K6RbfYbcxFHVTcCNwJ2G7q4OcCvl/8A
aB/4IbeJ/wBkr9if9pWzjsP+FtT/ABe8cxaxYabY2Yhm0Mbrlxdoqk73j87GOM5r
44tv2T/2lv2p/wBo39nP4Y+AtS+IHxAsvAF9avr154o0gW8GjpHKXKA+Y/C/hX6y
/sj/APBEfVf2Zvj5+0P8bJ/jeNRf43JfRR2YslC2STtIRkk/NjzP0rwjSf8Ag1tt
l/Yfu/2ZtU/aPddft/iafGWh6zDpqGOGfaEERBbgbcnPrX6o/s/eBvFfw0+Cvhz4
eeP/ABUms6tpGjw2l5qkcax/aCiBcgA8dK7JxExjYTj5DnG4c8V8Kf8ABTn/AIJA
6h/wUG/aq+C/7Q9p8VY9Ag+GGvxaheWLWqyteKssT7QSRtI8vrz19hXC/wDBaj/g
gdpX/BU/xx4W+KHgn4pR+DPEGjW/2TUtRktBM13bjgLjcOwH5Vu/Gn/gm54u/Zd/
4Ipaj+xL+yd8RdR0nxXYaXCbTxDop8m6urtHV3IKsDlwu3r3r6A/YP8Ahz8a9O/4
J7+Evhf8d9du7nxfJ4U+yapqGqTF597JtzIWJO4Z6Z7V5B/wSI/4I/N/wTW+E3xH
+D/iv4oQ+MdM8fa5cXsqXFkqJFHLGqFCmSG4HU9zXzH4p/4NbZdX8G/FD4K6N+1R
LaeA/GfiI6/oWhNo8brpl9ukZQoLcKDIRx6VZ8X/APBun+1D8ZvG/wAIfF/x1/bi
h1pPhU0MWnWA0CIRrBE5ZQvze/pXtX7Hv/BEPVP2X/Gf7TviW/8AjcNVh/aAiuYo
o49ORG04zNO3mfe5IMx49q8m8N/8Gx/h2L/gnbqP7Hnij43tP4ltfG58SeFfF0do
oNnN2XZu44zz61peA/8Ag3u+M0P7aHwu/bD+Mn7Ytz4uvvBOn2tpqNhe2CqZ4ogA
UVwx4IFQfF3/AINw/GB+IXj/AEP9mX9rK68E/C74r6l9r8eeDIrBXW6JdXcA7hjJ
HWu2+Pn/AAb9eE/GvxT/AGddV+D/AMSIvDnhj4FXNvMdPa1V31J43jYv1+Unyx69
a9Cvf+CQmoXH/BZa+/4KmW/xhENvd+HYdPHhsWittdII4i24nodhP418sfHH/gh5
8cP2YPh1+1D8dfgX+0jrNt4m+K15azaBB4cg8q4hKXPmiMMjgjeW2nB6Gv0X/wCC
engf4ueF/wBhjwD4K+P2qXlx4ri8NRw61c3FyRcCRkGSzZzvH1zXx14u/wCCH/7Y
njV/F/wQ8W/8FGta1r4N+NtdF9q/hnVtPE13FCHVxbJO8hbblcdR1PFevftVf8Em
fF3i34UfD7wV+xX+01rfwhu/hjbRW2gR6Qxe1u4lVQxnh3qjMdi8kHvzUH/BOz/g
j6f2Vv2gvFH7ZX7Q/wAXn+I/xZ8SgRz+JrmAQBYtgXaEBIU8dq9L1b/gndoXjX4v
/FL4m/E3x3NrI+IPhUaBpUdxCsj6FbSRuk4iLHvleRjO2uM/4Jm/8EtNf/YO8eeJ
/iF40+OVz4yvtUsDpWjtNarGbPThKJVjJ3EnDKKvf8FNP+CVPhX9vmDwt8RfDnjq
Xwf8SvAt4tx4Z8XWKgyKVKkKxyD1UVxn7OH/AATB/bBsfjs/x+/a9/b18QeLr2HQ
JdNsdC0mVrPTjuTYHlgjcI528kkEk59a2f8AgjX/AMEpdZ/4Jgab8R7fXvilF4gb
xx4ok1OCKGARpaxkkhcDvzz9K+3POi/56r/31R50X/PVf++qPOi/56r/AN9UedF/
z1X/AL6o86L/AJ6r/wB9UedF/wA9V/76o86L/nqv/fVHnRf89V/76o86L/nqv/fV
HnRf89V/76o86L/nqv8A31R58O7b5y5xnG4UjTwL96ZB9WFL5sf/AD0X86BPCwys
ykeoYUedF/z1X/vqjzov+eq/99UedF/z1X/vqjzov+eq/wDfVHnRf89V/wC+qPOi
/wCeq/8AfVHnRf8APVf++qPOi/56r/31R50X/PVf++qjmaJ5FLBGA55cda+bf+Cr
37DF7/wUX/Yt8Rfsq6P4zTQZNbe3cXzqGVTHKsgyM+q15J8Zf+CLng741/8ABJ3w
9/wTn8YeMLa71HwvoMFro/iaWzQm3uY4wolVc8cjNYP/AARw/wCCJOj/APBJ74bf
EGbWfiofE/irxbbyRHxCtqsL2luIQFRDuJOGXOcg9ql/4IafBb9rn4S6l8aLv9pL
4h+JvEOjal4z3+C5vEdwzN9nEkpJjLO3yYKe2K2NA/4I+6voX/BZHVf+CpH/AAuG
Oe31PT1t38OtYorJiFY+HByRhe9cn+2N/wAEJ5/j7+3dc/tp/B345HwNPr/hebQP
FWlWtkkkd9bSxtHJI3Iy5V2/TmvD5f8Ag2h+P3h39lfxr+xL4E/bla3+Hev6yup2
NgdDjR3mPLrMQ2WXLN3Pau/+D/8Awbv618Kf2k/2fPjjH+0OLu2+C3haHS5rF9PT
deNHuwQd3Ay1dro3/BBfw1qn/BQX4x/td/FD4r/2xoPxZ8KXGj3PhtbJI/swl8r5
twb5seXnoOTXzx46/wCDXn44+K/2X7X9kyT9vG9n8H6D4he/8MaRLpaiO1RmU7Cd
/OAOte5/tN/8EGdb8Z+JPhr8b/2Wf2g5/h58TPBHgiz8N6v4jt7ZZf7WgigiiJOW
GP8AV/rXOap/wbheGD+wB8Qf2WtJ+N7v8QfiVqsGqeKvHFzahjdNHNFJsKbuFzEO
h71t/tef8EEtb/ai/Y8/Z7/Zmh+PMVpN8E7e3hfVPsa/6WIxECAAeP8AV11X7Wv/
AARs1f4//wDBQH4Xft3wfHyXQ4fhd4IbSJbG3sVaWeVLaeNZEbcOpl6eoGKf/wAE
Mfgj+2F8H7X4wf8ADTXxC8Qa5Y6r4wkl8G/8JTcMzx22+TDIjM2xSCvA44re/bW/
4J0ftp/F/wDaO/4aF/ZL/bs1jwEl/ojabrHhvUIzeWWxjhjHE77I2IB+YAHmm/A7
/giV4C+Av7D3jD9mH4d/GzXdF8WeObg6jrfxA0iY292L/wC8HXY4IXdzjNeZ+CP+
CEvxj+Lfxm8CeOv+CiH7Xlz8U9C+Gmx/CeiGwW2IlT7rzSK2ZSeSd2ck19k/tH/s
jJ+0P8TPhv4s1bxuLbQ/AurzX1x4d+yKY78lEESsc8eWybga+eLP/gizpdj+3+/7
VifF6RvCI8TW/iSHwW1ihCajCjIrebu3AfvH7d6+l/2zf2QPhJ+3H+z5rP7PHxg0
dZ9J1WyK21yxDTWk/wDDIMnqpwevavhnwL/wRV/b10Dw/wCDPgFqn/BSnXIPhh4M
1ASWllotv9kvZ7dWGyFpo3DkBRjk16d4Z/4I1X3hb/grXpP/AAUjg+Nst3Z6XoDa
f/YFzbKZp2MTx+Y8+Szn5s89cV98edF/z1X/AL6o86L/AJ6r/wB9UedF/wA9V/76
o86L/nqv/fVHnRf89V/76o86L/nqv/fVHnRf89V/76o86L/nqv8A31R50X/PVf8A
vqjzov8Anqv/AH1R50X/AD1X/vqjzov+eq/99UedF/z1X/vqjzov+eq/99UedF/z
1X/vqjzov+eq/wDfVHnRf89V/wC+qPOi/wCeq/8AfVHnRf8APVf++qPOi/56r/31
R50X/PVf++qPOi/56r/31R50X/PVf++qPOi/56r/AN9UedF/z1X/AL6pPtVsN2bi
P5D83zjj608EEZBr5M/ag/4JXaP+0z8Wrr4u3X7WXxV8JST24VtG8JatbRW46/wy
QuT19a4Ef8ENtFkleRP2/vjimQvyf21aZHHf/R6d/wAONNH/AOkgXxy/8Hlp/wDI
9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB
5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9I3/AAQ30IKRd/t8fGu4jH3Y7vUrCVFP
qA1scGhv+CHOkyspk/4KDfHUj/lkg1qxRF+ii2FL/wAONNH/AOkgXxy/8Hlp/wDI
9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB
5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6S
BfHL/wAHlp/8j1Cf+CGukyygQ/8ABRD48K0bZx/bdngf+S1Je/8ABC/w7rMxlvP2
+vjfK2NribUrBwwHs9qR+VSS/wDBDPRZ0SzX/goH8c4oIR/x6xaxYon5LbCnj/gh
no4GB/wUC+OQHb/ieWn/AMj0f8ONNH/6SBfHL/weWn/yPR/w410cc/8ADwL45f8A
g8s//keoJP8Aghb4bkikhvf2/fjnd280nmMl9rVjIgb6G2FSr/wQ20SSR5o/+Cg/
xzKtgKg1yy2IAMAKBbDAp3/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8
j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgX
xy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAO
NNH/AOkgXxy/8Hlp/wDI9B/4IZ6G8bwzft//ABxZJFKsp1uzwQe3Nuag07/ghf4W
05mfR/29PjbbIAUkW11HT42b/gX2Spl/4IZ6MqhV/wCCgPx0AA4Da7Zk/j/o9L/w
400f/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/AMHlp/8AI9H/AA400f8A6SBfHL/w
eWn/AMj0f8ONNH/6SBfHL/weWn/yPR/w400f/pIF8cv/AAeWn/yPUbf8EMtIlt2g
uP8AgoT8e7iB23eW+vWJx/5K0sH/AAQz0LBkg/4KDfHco2Aqya9ZnZjjAxbCn/8A
DjTR/wDpIF8cv/B5af8AyPR/w400f/pIF8cv/B5af/I9H/DjTR/+kgXxy/8AB5af
/I9H/DjTR/8ApIF8cv8AweWn/wAj0f8ADjTR/wDpIF8cv/B5af8AyPR/w400f/pI
F8cv/B5af/I9H/DjTR/+kgXxy/8AB5af/I9H/DjTR/8ApIF8cv8AweWn/wAj0f8A
DjTR/wDpIF8cv/B5af8AyPTZf+CF2g3C+XP+398cXXIO063ZnkdOtvSTf8EM9KvZ
F83/AIKJfH3EfSNNfsQP/SWpD/wQ10cnI/4KBfHT/geu2ZP4n7PSf8ONNH/6SBfH
L/weWn/yPR/w400f/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/AMHlp/8AI9H/AA40
0f8A6SBfHL/weWn/AMj0f8ONNH/6SBfHL/weWn/yPR/w400f/pIF8cv/AAeWn/yP
R/w400f/AKSBfHL/AMHlp/8AI9H/AA400f8A6SBfHL/weWn/AMj0f8ONNH/6SBfH
L/weWn/yPR/w400f/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/AMHlp/8AI9H/AA40
0f8A6SBfHL/weWn/AMj0f8ONNH/6SBfHL/weWn/yPR/w400f/pIF8cv/AAeWn/yP
R/w400f/AKSBfHL/AMHlp/8AI9H/AA400f8A6SBfHL/weWn/AMj0f8ONNH/6SBfH
L/weWn/yPR/w400f/pIF8cv/AAeWn/yPVLWv+CKHgvw/aPfeIP8Agox8b7KFv3az
T+I7FE5+tvWav/BHT4RWkjtL/wAFQ/i0QqAbZPGGnZX0P+pqzp//AARq+G2oahDY
6X/wUx+MtzcSqWEVt4q09y49QBAa1v8Ahxtoz/Mv/BQD45gHoDrtmT+lvR/w400f
/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/AMHlp/8AI9H/AA400f8A6SBfHL/weWn/
AMj0f8ONNH/6SBfHL/weWn/yPR/w400f/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/
AMHlp/8AI9H/AA400f8A6SBfHL/weWn/AMj0f8ONNH/6SBfHL/weWn/yPR/w400f
/pIF8cv/AAeWn/yPR/w400f/AKSBfHL/AMHlp/8AI9H/AA400f8A6SBfHL/weWn/
AMj0f8ONNH/6SBfHL/weWn/yPTf+HGWkCXzU/wCChXx4Q7cME12y2svoQbY01f8A
ghfoJiWKD/goN8eI4FbKwx67ZBd3qcWtSf8ADjTR/wDpIF8cv/B5af8AyPR/w400
f/pIF8cv/B5af/I9H/DjTR/+kgXxy/8AB5af/I9H/DjTR/8ApIF8cv8AweWn/wAj
0f8ADjTR/wDpIF8cv/B5af8AyPR/w400f/pIF8cv/B5af/I9H/DjTR/+kgXxy/8A
B5af/I9eD/8ABQv/AIJpeIP2RvgNH8Tvhx+3l8bpL268TaZYXbza1ZsBFPdxRHH7
gY+/Xtln/wAEQNDvLWHU7z/goL8dUuJYxIzRa3aAAtywx9mPerEX/BDvS7aB1f8A
4KF/HaSKcYKPrNmf/bamwf8ABDbQ7NRaad/wUD+OkCkYbZrFnz/5LU6L/ghroqzG
H/h4T8d2IGSr65Z4+v8Ax7VJ/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8
Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/
AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8
ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8
Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/
AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8
ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8
Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/
AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8
ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8
Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j0f8ONNH/wCkgXxy/wDB5af/ACPR/wAONNH/
AOkgXxy/8Hlp/wDI9H/DjTR/+kgXxy/8Hlp/8j0f8ONNH/6SBfHL/wAHlp/8j02X
/ghno7RMD/wUD+OWNpznW7Q/+29Oh/4Id6DHqEGoH9vX45v9knjlEEuu2fkzFcHD
D7Pkg/UV9t+GtIfwt4fs/DkD3F2llbJCtzcyKZJQoxuY+prSMS7SOQSMFgefzo2k
HA6BeprxL9tH9sfRP2VPCmk2tjow1fxb4uvHsPBmhJJg311gY7E7QWUnjpXzvpH7
V/8AwUw/ZW1yw+JX7c/hDwzrPw51W9W3v7nwdEDP4cDnO+42oMiP7hzjJPrXvd3+
0zeXH7ZfhP4PaL8TfDjaF4i8Hf2rBo0hQX91nzds8fcodgHp8prT079v39k/Vv2k
p/2R7H406K3j2G2Mx0VbpS+0YDDr97JHFeCXv/BW/wANfCT9t74w/Bf9pPXtN8Pe
Cvh9oVpdaXfbAZZ5ZZkTk8Z4ccV9S6F+0Z8GvEnwgX9oHRvH1hN4UOl/b5tR+0L5
cUO0MSeeGAPSvMfgJ/wVK/Yf/aP13VfDXwt+OOm317ollLe3a3DqhMMYO9kyecAH
gdhmu0tP20/2cJ/2cn/atT4nWcvgWKFpZNeXaItgGSeuP1q58UP2rvgZ8Jvh/onx
E8b/ABK03TNM8WTR2/hq/uZVEVzNLA00Sg55ygLfhXG/s1/tW6drP7OviD4z/Gn4
seH7618O67fW2o6zpgSO3hjgVWMZAONyg8+uah0v/gp/+xbrX7POo/tU6b8aNOn8
E6Tcm3vtSt3V9kgJGMZ9jWB8Df8AgsV/wT9/aM+Klp8D/hJ8e7DVPE9+rm20+NV8
wBVyWK54GO/euv8A25f2zNJ/Y6+Fj+KE8PXmveItQheDwxoFhbF3vroKSM45VODz
g9a53/gmv+2X49/a3/4J/wDhv9rH4reE4NM1vUtHub7UdItjjyvKaT5OgwcJ6d6+
YLn/AIKUf8FBviJ8OvE37f8A8KtF8J2vwE8HXt4NU0GSIT61NFp0rQ3igFAQXZSV
wcgDpzXqX7Sv/BSX4reJp/hR8Dv2NtB06L4ifGTQW1jwzqXiN/8AiXWcMaSSSpIS
py+yFwFx1Iqf9nL/AIKG/Gfwd4j+LHwB/bQ0GyuPHnwl8Iw+JtbvNBiEdte2U8Ty
xx24UAOVVCCeDyK8lX/go/8A8FGPCHwtsv8AgoL450LwXP8AAW9uozb6Pbuqao0E
119kQu2zMZEhz36YPWv0k8IeIoPF3huy8S2sO2G9tkmjB9GGfxHvWltX0FMNrAys
joGVjyrcj8qWOCGHIiQKD2A4FPwPQUYHoKMD0FGB6CjA9BXF/tA/F7T/AIB/BfxX
8atYsGuLPwpoVxqVzbg7fOWJC5AbBx09K/PyH/gpT/wUE8A/DrSf+CgfxT0zwhdf
AfX72BLTw3pir/a0EU1x9mQhtuZD5hyR6V+kUt7q2o+GXv8AQiiXlzaeZZR3SbfL
ZlyoYexr80/2r/2nP+C2n7K+mf2vqni34W6te6nrItfC3he3tYhfalG04+bYFyu2
PIyM5IzX0n+1Frf/AAU/vdA8MeKf2ZNW8AeH4F0VZfG0XitkItLrblwjMvQfhXMf
8EqP2qf23f2ldS+Ium/tNafoEukeHdVhsvC3i7QLdVg1RymZSigYYI4Zcg9q+00w
yBipGR0IwaSUuu3y41OW+Yk4wPWvmL/go1+2d4+/Zd0zwR8LPhNpdrd+PPibrMul
eFru/QfZoJ44/NZnUghvl7Vxn7IP7Yv7WPh/9rEfsNftxW2hX/jHUvD0ut6Rq3hq
FY4BbRBN6sqjB/1i85r3D9sP4r/Hv4Y/DiCD9nb4YT+JvE2rXwsrS4igLwaaxGfP
uBghY8cZPevB/wBnX9rf9tP4S/tY+G/2Q/2+4vDOo6x8RdLv9U8Jap4UjVIbGCxC
GaKYBRlm81ME/wB01j/Gj9of/grRPq/iL42fC74c+HvC/wAOvCssrXXh7xRaj+07
+0g5kuYyy5wwBwPfivqz9kf9onw/+1r+zj4Q/aM8K6bLaad4u0WHUbSCcYZFkXOD
Xo+B6CjA9BRgegpGGFJVQTjgV4B+2p8Vv2vvDX9i/Db9kL4Ux6hrfiAssnizUo9+
n6MQcZlG0g568kdK87/Yn/bK/aTvP2idb/Yh/bK0jRL74g6T4bh8SrrfhAh7L+zZ
pzbxpIFUBJPMRyR6EVyX7an/AAV11z9n7/goV8HP2C/APgy1vr3x94ntbfWtZkl3
QwWbMBIqnGBLhhheuQea+6pGmVJWLKuGGwsOMcVJCZHUmaEKdxAAOePWllaOKMu5
AA74rI8Y+Ib/AMN+FtQ1rR9HfVLuxtWkSwh4adgCQo4OCcV8BfFP9tP/AIKjfs6+
GtQ/bT+PvgfwppHwa0i6V9U8JhAdYt7RpxAsjMUBBLMpA9GB7199ad4wtb7wTB46
uontbWXTFvJlkTmKMpuJP0HNfFPwT/4K2eMf2hP+Cpdt+xx4H+GU1n4C/wCEMv8A
VI/E99AVbUp7e4iiby8jhQXYcE9K7H/gqT+3H8W/2cNM8L/Bv9lvUPDdx8VPGesx
R6XYa5Muy2tAymWVlIORs389sZrsP2DNT/4KA6xNrt9+2h4t8BarZvIo0BvA8iSL
HjIcSuoHzZxx9a+kcD0FQNNJFcFJY8xnG1gOn1r43/bJ/bM/afuf2nrD9gn9iuDQ
bL4iSeGv+Ejvdc8UqptF0/zWiCohUhn3j8q6b/gnb+2r8Tf2iPEXjz9n3456Rp0H
j34VXdvZ+Kb/AEhwbe9lkMgLIgACDMTdCetO/wCCpP8AwUYf9gP4L3HiDwd8OL7x
V4wvLMy6JotrCShUNtLyMAcAc9q9T/Yz+Mviz9oP9lD4ffHDxZp8NvrHinwnZ6lq
NiihVillTcyj0AOR+FfMHx4/4K9aj4H/AOCrXwu/4Ju+APC8F2niS+J8S+IpgPLV
PLdvIj4I3jg5zn5TX3gT9PypUweoH5U7A9BRgegpkreWMhCenCjJ618rfthfFP8A
4KJ638TG+Dv7EXgXRNLa0tVurrxf4ri3WkgxkxKrKRn3zXB/Dv8A4Ky69oX7Hnxa
+Knxt8CpN41+CeuQeH/FNvo53Wd9qE5hEUkLgYMX+kR7iBxg1S/Z8/aS/wCCpWnf
E/w3qXx40XwX4t8LeKXiJ0TwUUfUNIt5yNtzKEXLRxjJJONw9K+7oZJZArqu4Mfm
DrtKDHpU+B6Co2dFmEZcDcPlUjqa+KP+CkP7cv7Rnw8+Ovgv9lP9iLWPCB8caksu
oeKP+EsuES3sdNC/LIWYHaRskPvjFbMf7WH7UP7IP7Enjj9qT9uDUfC3iqfw5Abj
R18Csht72IthcugwMEqDwe9eV6Z+3x+35+zN4z8BeMf20bfwfqPgX4o6xBp3hqHw
+qx3VrJMVKeZheSA68e1fav7T/x10L9mb9n7xh8f/ElhLe2Xg3RptUurW3GGkSNc
7R/j7V8JD/gon/wUF+Cfh/wt+1p+0lp3hC8+D3jbW7S00rStDwNRtUu5lihLsFy2
GcZGfrXoH7af/BQ39pPQf2jvEP7PP7Jmh6Lb3vww8KReLPiBceKQqJd6Y8fmiOAs
Dh9qt05yav8A7Ov/AAVG8V/ttfHP4f8Aw4/Zx8Jpa6XJ4XfxL8QdS1OHKR2gmktP
s8LY+/54Vs9dtfbJkUklJk27Qc/3f/11KApAPB98UuB6CkwvcCoJEkkcGCcIMDYR
yD6jH0r4P/aM/wCCwWq+EP2+PhP+x/8ABD4fS6npniPxzHo3jnxDcQ/u7Avv2xLw
RlgpO7PavvJiUjy864K4DlR1J4NfIH7Q/wAVP+CpvxB+MOq+Bf2N/hz4f8O6N4T8
tL/WfG0YCa80o3Brbch2qu0g4zywya4m8/4LPW1r/wAE/tN/aYg8DSy+J9Q8UL4T
S2mi8u2/tR5VgWcHH+oEjqc4xwas/Bb9tH9ur9n79qPwP+zR/wAFEdN8K6hc/FZb
weDtR8FAGGzNoYhIZyEX7/noQD0wa9f/AOCrv7VfxU/Y3/Yq8TfG34KaTY3Piezu
LS20hdSAMAea5iiywIIIw5r0z9mrXvjJr/wN8Na78eJ9PTxVf6dDPqg02IfZ0dlB
KAjAGea+UP23f+CvevfBn9qb4cfs0/AzwBNqSa743i0bxt4jurYm30pXgeUIvBDM
QFPJHBr7yXc25dwB6g47V8Jft8/t2/tX6Z+1don7Jn7B2teB11ey083Xj2/8ZXKR
Q6WG2mIEsDyyMG7da9U8NfFL9vL4W/sb3Hi/4ueB9I+IHxPm1FbfS7TwIu+1eOUo
iTHYuNkZLOxxyoryT4Y/toft5fs8ftL/AA/+Cv7fVv4Vv7D4samdP8KXnhWJVks7
oniKYKo6DPOexr70DqzlA68HHqajmuQu7yGRivBUnHPbJ7V8H/8ABRf/AIK+eLP2
Y/jh4L+AvwK+Fk3iK+1Txfa6Z4o1Qx7oLCGRlBwcEFvmHpX3mZojJ5azJkNgjOT9
K+VP2sfiX/wUo8S/FX/hU/7FngLQtEt9PgF5feLPF0W61vIidghiDKQZNxB69Aa3
P+Cd/wC2l4h/al8G+LPDvxO0y3sfGPww8UXXhnxy9uAttJf2zbZpIzwAuQTXjfwH
/wCCu3iT9pD/AIK1+Pv+Cf3gbwla2nhrwT4Lkuv+EmkO83WoGSLY6jH+rAkKkZxk
V2f/AATO/bH/AGmPj/8AGn41fAz9p3TdAi1P4a+KPsWmz6CwKT2rMwR2wBhjtPFf
YuB6CjA9BRgegowPQUYHoKMD0FGB6CjA9BRgegpGA2nGB74r56+KP/BUf9if4LfE
K9+FvxN+MVjpes2A/f205APfpz7V87ft1/8ABQv9k79pj4Lv4D+DXxZF5rUWqRHy
bXhipRjjg9+K+QYZ7mYvDLd3cLTQhh9pBYuw54zXpf7K/wAdvAXwA/aB0b4k/Frx
qmnaJDbbZhLcbsHjnb+Ffazf8FoP+Cd8CYT4420n90RRAluccDNfRfwx+JnhH4v+
DLD4g+AtQF5pOoxeZbXGMEj6V0OB6CjA9BRgegowPQUYHoKMD0FGB6CjA9BRgego
wPQUYHoKMDGMUiqqjaqgD0ApcD0FGB6CjA9BRgegowPQUYHoKMD0FfHX/Bb2FZP2
Obcl3H/FcaDwGwP+QnbV9c6LFG+l2c5XBFsoGOnIFWhGAoQMePenY5zk/nRgHqKM
D0FGB6CjA9BRgegowPQUYHoKMD0FGB6CjA9BRgegowPQUYHoKMD0FGB6CjA9BRge
gowPQUYHoKMD0FGB6CjA9BRgegowPQUYHoKMD0FGB6CjA9BRgegowPQUYHoKMD0F
GB6Cm+UuWzyG6g8ikaFWJYs3Po1PqK5DlQEBOOSoI+b2r4P/AOCwvh/UdK/aE/Zh
+Nlzo0yeG/CHju+bxV4gVS8WlwzRQpCZFXLHc+5QQDjGTgV73+0n+3B+zl8Gfhuv
ifV72w8Xzawyw6B4W0R47u41Z3IIQINyrn72XwBjB5r5W+NOqQ6j/wAF1vhhfxaQ
1k13+z/fPBbvgPEDDfMEKr025x8vcVzn/BNXRf2Tde/Ywiuv2yLvS5tWj+POunRH
vVddVF0NRnFtHmICcx4zjd8uAM9q0P2fPgn8H/jH/wAF6fjz4l+IfgiDV9Q8MeCb
H+ykvSJLfy2kQDMedrHk/eBr5j8Sax4xsv8Agln+0nD8P7yc6lb/ALUGoxaNYROx
gtiL+4AhYL923HAKjgAV65pfwm/bF+L37Rv7O0v7RU/7P3hDwzpmoEXWlfDlbl77
xAsumSRvDcFGYKNjlju2jcK888e+D/jn4e+L3iL/AIJaeDvDl1b+EL/4mPe6V4Dt
TGzS+F/Pz56s2cJ5XO0tu9q6H9kKP4x/tZfGX4e/s7/tLae+v+H/AIP6Jrj+JdAu
AoGh6rHcXK6cZduMn7C0RGCfvCuB0e9un/4JH+H7jR7yWK0uP2zbQaqbYO8VxE2o
2Yk8wjOI9v3t2FxnPFfpZe6h/wAE+vhBqnxA+JnhvTfCd1rmheGo7vxPp1qU+xeS
sUZHB/0YsRt+783P1rx//gmf8MPhh+0D8dNQ/wCCpMj+DNNuviV4ZhsfAnhrRzar
c2OkxvIY5nQf8tiXfdjsozX2t8VdBsLzwFq9xeW9rcyWukTNFdX0Cu0TrERvQkfK
f6mvkn/ghbBpWr/8EivB1hOXjsZ9L1GG4uN26Uq0s6vIfopJx7V8c/tI/BX45eDP
+Cd3xj+CfwB/aT8I/wDCj9Li1rWrfV9PmaPxDqV405e508wS4yvmMy52c4GCc17t
8QPhpqH9i/sz/H34KfEzw9pXxi8L+BhB4T8KeMY3h0vUraWKaOR5HAXy5FV5G5dQ
dvT187/Yx+Evi66/by/at8FftV/F7+3m8UfCbS/+Eq8TeHf31rpcdzbTl4bN9rbh
FyMHceleX/tt/CX9pjTv+CbEXw90X9ojwi3wg8Bazpz+BrHwpMX1bxLE2rRZW8hk
yw2tI7EKq/cz35/a34WIrfD/AES6Y7pH0i3DvtK5wn93t19K6GiiiiiiivEP+Ck4
mk/YD+MkMFq08j/DvVEhhjjLM7tbuAMDryRX5zftDeIPDeof8G8Hw58MWerWdzq0
dzpCLplrcq9yp/tlC37lTvyMc8cda/Wzw9eaIdPtdHXUYGvWs43e1FwvmhdvUqTk
Cvhz4G3Q/bG/4LBeNfj/AOE5rc+F/gt4d/4Q3WtL1Ms7yavO0d3HcwJ0UrFlcn1N
dt/wWb+KNl4P/ZFn+DH2u8bWvizew+EvCl5BIIja39ywgW4dhjgGVD+FfQH7LXwc
k+BH7PXhH4PiG1t7jw74as7G8e2HE10kKLNOx/iZ5AzZ/wBqvSFGFAzn3ps4cp8i
g4PINfn/AP8ABZK+isv2qf2Rb68t18i0+JuoyzTXClYbcNp+3LycKo+pFVr7WtG8
R/8ABwZ4evfDV3bXtsnwT1cNqWnzefGhLWmQzqSqHI4BIJr7O+Kvxy+Cfwy8NWur
/EP4jWOl2GsXosLS/wB7SRvckcKXjBCkHBySB6mvgnwx4N1H4M/8FdfAWk+O/jPe
/GZ/Gmm69e+Hda1GSGQeC40MJNtCbUKAr7gB5u7IjFejf8FL/wBomP40apF/wT1/
Zo+KOnW/jLWLiJvGN0+qwRw6dpW8NKkrOwOXHG1eRur6++BHwz+H3wc+FGg/DD4V
abb2vh7RNKhtdKjspd8PlKuBsOTkfjXYUUUEEggHHvXmn7R/7TPwg/ZW+G1x8VPi
74xt9L021LJDBNOqSXdwc7Y0B7nB9hXy5/wT/wDhz44nX4n/ALffxSuNJ134meK4
bq48FabHqcU01hoaRb7XTpBA+MGcO2eo8zrX5f8AjX48fFb4aftIfCn4h/GL9jHx
3pnxA8TfH+21/Uo9QntntXVbl2S0tG3l1EgkOATj5Rmv6GPDmqL4l8O2msy6dNZt
f2yTtZXX34WIBKtjuPatVM45xnviknwImym7jpVeS/trTZ5rqEZCzzEgKABySe34
1+fn7V3xK8Lf8FHf2pfDH7K3wx+KOk3vww8Fa+l58Z5p9Wt0tNTRQdmmrlg7t5jR
vleB5fWvuuzGh2Zg8H6fLbWuy1V303z1cyRsNu0KSSRgdelfDHj/AEzTdA/4OCfh
doul6db20CfA7W3trSwVY0RTf2pdmAxk7j+tdZ+3j+wx+wP+1/8AtYfDnXP2uPFk
j6ppWlXR0bwffXktnb38Rik3ZuIihVgMnBkGcDFcp/wTf0jSvgR/wUh+M/7JXwJ1
a5g+Efh3w/o194a0Vb5ry2huLi2Ek3lzszsdrkjBcmv0IqGWXbxOuEwd2ew9a/P7
x3q+maJ/wcHaTqviO4t7GxT4Dqgv72UQRb/7RkIUSOQrHp8oJPtUX/BLvW9GX/go
d+2L4hS7t/7MPifTZF1bcBbsEe834lPyMBkcg4r6C/4KUQaHdfsP/E7xZ/ZNpc+X
4TkEeoKEkdoyynMTcgDmuc/YO1/xZ4P/AOCQ3w38YfDnR/7a17TPg/b3WiWUrc3s
y2xaOEnIG5iAvPGTX5GeEvj98RPgz+1v+z14t+Jv7GfxHtfGeufF251XW21RrSS5
uXY3UYt7cq3EYDhvmPROtf0No29FfaRlQcHtT4+9Ooqvf+W6eVNHlDjkng89OOa8
P/ai8T/D/wCK+n6v+y14X/all+HHjObTvtEV/ZNHHcQJjh0adDG2M5xk/SvzM8QP
eJ/wSd/bC+HTT3mq63oPxG0zTdT8f2sIe58Vzs9htvmCjyyYw6jKKF/dc966jxD8
E/Cf7C1n+zN8V/g78Y77xF8T/E/jDQtG8deJF1f7XPf6ZJJEs8LwRMUjG1mGdigc
5PFfrzbNc+YWlhLAvhH6HaRnJHt0q1VW7MMTs8z/ACgb2BBzxxxXwj+0l/wTn/4J
x/tS/wDBQzVfiz+094vj1DxUPBdlYv4Mu9WnsIlto5ZisplR495JY4Cv25GK+UPH
ev69N/wSz/bP+B1pqd/f+E/AOtQWHgC3lzOllbuxYpHIuTKoIHOW+teuf8FOvEuh
eJvgt+yTpXhrxLaajqEPxB0mSe206dLiVVAgLsypkqAAc5Axivrj/gq7f2Wo/wDB
N/46adp1wl5dwfD7UBNaWriSZdycAouSMj1Ga+LP229X0jUv+CNnwT8L6VrtpqGr
W3iLw0ZNNs7uOW441OAn92pLDavJ44xzX05+3/8AsU/DnxRf337YyfGXXvAclhoB
j8ftogty/iXS4U/485PPVgAU3L8uDzX5o/8ABPXwT8X/AAx4/wDiF8Gvg18b7j4N
eApNJuPiV4S1K3EYvtWgjc239lyvdKymJpEabZHg5Oelfrb/AMEyv2lfGP7W37Hf
hT42fETRpbPXNQheG9MsexpWiA+cjp82e3FfRSklQSO1LSSb9jeXjdg7d3TNfL/g
fxD/AMFVrv8AakuNM8f+CPhfD8KI76Rbe8snu/7SaHHynBfZ+leL/wDBWbRdI0z9
sf8AZHtNO0+OFrz40WpufskccbzZWU5YgAtj1P8AWvve+1fSNMnS21XVLaBJ3ENt
DPKELuADgbsZOCOlfPP7VuqeFP2o/DPiH4F/CP8AbRuPht4q8KXlu+r3li8UEluX
Rykb/aU/eKwByUzjHOCRX516j8XvDSf8EatF09fghZ2czfF2HRJL6SGUyW1011Gg
1XOSpbcwfI+QY6da9U0r4X+MP2Yv+ClXwH0L4qftJ3/7Qt94ni1SC013xK9u58Jm
NrfaIVslQLv38GQEfuzmve/+DgKI3P8AwTa8Vx3HlC0/trRWdpS2d41W1AHy84rp
/h/4h/4Kmf8AC89GsW8IfC9/g8Y44/tNv9rGrLEcAP8AM/l4A5HGa8q/4LdaRpFn
4k/ZqubBLe0e++Pts9wbaJI3vJlsLlQZDgEqFH54r791LXNC0RIbjWNWt7QSyrDE
biYJvdsAKM9TkjpXwP8AFr/gmx/wTJ/aA/bj+LXxV+OPjFdb8Yatp1lDrfhy/wBZ
n05NNMdrGIZInDxCTKKrHDMATzWz/wAEbfjRfWv7KvxG1f4sfELHhbwF8RNT07w/
quqylI7fSIIYmUiQ4LgAvg5JPvWL+zpc6T/wUB/b+P7ZWp+INLu/hb4RtTafCvS9
Q1a3aWTU0KiS/hjjfeo3K5AcZ+fpX3nZ6hpupzOLbUBcGKcpNCkit5D4+6wXkduv
rXzb4n1b/gqa37TsWjeHfBfwyb4TzX6LfXkr3Y1IwZO7b8+3OPavH/8AgvBp+jaX
8IPhXcppi2v2j4taUJpLKNFd/wB9Hje33iMj19K+9tQ1fRNIV21u/htI3mVFlupl
jVnbooJIyT6da8J/b4/bP8Ffsy/DdvDGj+I7W48e+JlfTfBfhuPUIYp7q7kjYK5M
jAIiAmTcSAdmMknFfPWk/Bv4v/sTf8EovEl98JvBWn/ET4v63p8tx4zn0DUBLJqu
p3Sn7VcF1fbuzzxXxh/wS++NCfC7/grP4A+HUH7KXxA0e/vfhPdWWrz6ybbzzJPf
pPJdzkH5o0kJjUD5sba+5f8AgmGs1t/wUV/a4tLiWMu3jiOXZHzgM8nfr26V960U
UUUUUUUy5gW5gaBiQG64NYep/DD4d6zqb6xq3gLRrq5lTZJPc6VBI7DnqzKSetfM
3/BUjwH4N8Nfs5xyeDvBGlWl2upoT9h0dFcptYE5jTPpX52xWepC3FhBpM7RrCCR
9jmBZvTJFe0f8E99Ai1T9qbSNF13wxLdWckObm31HTQ8SHj++uK/T2X4QfCyXK/8
Kx8OFdm0K2iwYx/3xW1pek6folrDpuk6bDa28Me2OC1jCRoPQAVboooooooooooo
ooooooor49/4Lc/8mcQf9jxoX/pytq+uNC/5Atp/17J/6CKtUUUUUUUUUUUUUUUU
UUUUUUUUUUUUUUUUUUUUUUx96yhxGCMctnkVifED4feEvib4R1DwP420eHUNM1K1
khmtpVByrKQdpPQ4PB7V4B+zZ/wSZ/Y2/ZU+JU/xT+F/hHVZNXnG+FdZ1U3UNsf+
masuFNep6n+y78Ide/aC0n9qTxB4YEvjfRtHbTrPV1kwIbYlyUAx33tnnvXCWH/B
M39kOH9pv/hrSz8E3B8T7HAT7Xmy3uQxlEOMb8j72e5ruvBP7NPwe8C/GrxD+0V4
X8Iiy8V+MLJLPXbs9Z442DDjHsKyPBP7Ef7OngXwP4w+G/hvwBEdG8e6zdap4ltZ
mBElzcOzvIoxwcsSDXB/sz/8Eqf2Rv2RviHefFb4WeG9YutYuZSYm1jUWuY7dj/F
GpHy4HHFepv+zJ8HZP2g4f2qpNBQeOINGbSf7YxwYSu3GP8A69N+H/7LvwW+GHxF
8b/Fjwp4WSz1z4hSpN4tu1AxdlIVhXaMfL8qr681i+Dv2H/2afAnwE1j9m7wx4Ei
g8J+Ibu6vr7TJMb/AD5gN8qnHyuNoIOMgiuFtP8Agkp+xfF+zlq37KkHgjUz4V1x
zNqckupk3UrE52mQrkjnpWR+zf8A8EW/2FP2UfiNpXxP+Cnh3xDpmoaQhXTrOXxA
7WyKRjaIiuAK+qdT0+x1vTLjQ9S08ywXUDpcRkcMrcEfjmuP+Af7Pvwu/Zn+Gtn8
G/hPoKafoVlCywafxt+ZmZu3Odxrwrxv/wAEd/2IPG3xz/4aB8ReDtVh1h71LqTT
oNVIsJdh5VoAu07yckd69K/ag/Yf+AH7Wvw/tfhj8WvCcz2ViiCxuNLuPss1rEpH
ypIASOhGPepf2XP2HfgF+yP8Pr34b/CTw3IbHUnYX9zqc3n3FzC2cRvIRlwoJAB9
a8y8O/8ABH39hv4ffGr/AIaC0rwRq02sRzmc6bd6oZrHLN2gK7RhiG+or6rtLZbY
+Wo4WNVGFwMD0qeiiiiiiiqWs6dp2r2c2j6tZR3NvdwNFNayrlJkIwysO4xXzL4G
/wCCQH7Enw6+PSftEeHfAV+2vRTGe30y51UyafExzyICu3gnI969ktvgH4Ftfjnd
fH+1N2viK40wWLRG4PkqmCNwT8etV/g5+zH8IfgV4x8X+P8A4Y+HBbar481SLUPE
V1nInnjiEQbOP7oxVj4/fsz/AAk/aSg0GD4seHv7QTwvrcGsaSP+edzC6ujdOeUW
u6kljZIo5V2FnAEa+nvVhOVGVx7Uy5L7VVDyzAfc3fnXnv7Q37Nvw0/ag+Hd78Mv
i3ov9oaXdyB49jeXPbNkbjG+CUJAxketcV+yb/wT7/Zk/Yn0zVtI+BHhW9jl1jaL
261fUDPcEAEBFkZcqpycj2FaVx+xD+zxcfASb9mfXfDV3qPhuaWWTyLm7Ms8byOW
aRXIypBYgHtiuc/Y8/4Jxfsr/sR6lqGufATQtUlvLpvJmude1U3ktuoJD+UWAKhs
jIHXAry/xr/wQQ/4J3eOPiT4h+LGteD/ABWmveJ2L6pqtv4kkRwS4bCfL8oyBx6V
9ZfBz4YaF8F/AOl/Crwkt42k6Fp8Vrp8t9eGaRkUYG5iOT711VFFDEAEk4wOteB/
tnf8E5v2ZP8AgoLpVho37SfhzUb+z0ubzLOLT9WMKsfVgAc1n/skf8Eyf2Y/2I/F
9940+BNv4igub+zFtNbanrj3MKIDkAKQAv0r0f4v/s1fCH49+J/CXjD4leGE1K98
E63Fq3h65DAeRdxnKsRg5APau8w6sLiYB3PCKo6VPECEwUC+wNK+7Ydqgn0JrK8T
eG9L8WeHb7wjqsLLY31q8FzHCdrOjDDAHtxXxX4X/wCDfL/gmv4T1e68TeE/C3i/
TrmfWP7SuktfE8kebjduyVC9CTnFfVNr+z58P7H4z2vxvRtSbXrTRV0228y8ZrdI
QGGCuMFiG61W1T9mb4P6r+0bp37UGo+GP+Kw0rRZNIsdQB4EErpI69P7yCsP9rj9
i74FftmeDYfBPx+8PXVza28pni1DSrs2tzAAMlRIoJwcYI96s/sifsc/Ab9jvwS/
gz4I6FcRwXD+dNqGpS+fdTqeUVpSAWCg4Ar12oHWWaQBwBEQyup7+leL/tdfsIfs
8fttaPp2m/HXwfdzvpUpa01HTL42tygII2+YASV5zt6Z5qT4f/sKfs/fC/8AZ81P
9mTwZ4burbw1rdi1tqd19u3XdzuUgl5cZY8nn3rstS+CXw5134Lt8BNU0SW58NT6
cunXVnM2WaBVAAJI/wBkHNXvhN8MPB/wd+GeifCf4e6Y1pofhuzjsNOtd23y4oxg
D3GKyfiB+zn8Kfip8TPCnxh8aaFHd674JvGuPD98GA8hiGB45/vGu9p0fenUVDOr
vJsCjaV+ZieleC/tc/8ABPP9mD9tk2Vz8b/C+oRXGmyDyNT0i+NrM6/3WkUEkcV1
Xwx/ZQ+CPwW+Bn/DOvgv4e28nhd7drea0vAs0l8rZzJNIV+Zxk4YjIwK8z/Z4/4J
Nfsdfsr/ABSb4v8Awl8KalJq6pJsk1vVTdxQSfwmNWXCEHoR0r6YgaaFY45XZmLY
dhHkEkZ69hVqoLhEcmOR2Cn5mJPH0rwX9r7/AIJ9fs2/tspEnxz8E3ZutPUbdT0b
UTaXEkRPQyqpOBydvvXXfCH9kn4CfBX4JR/s8eB/BFvL4VltXS6s9RiE7Xqt3mcj
5zz1Iryz9nn/AIJK/sX/ALNnxYl+L3w/8JaneayVD20us6mZ4bNdxYeUrLhTnPTt
ivYtB/Z4+GGg+OfGXjq10aS7uvHcUCeI7a+n823mWNGVVCEYAIY5rxn4Xf8ABH79
iD4P/GZfjt4O8EapPrMNw08dhqOsGazic5+ZYGXaMZyPoK9r+PXwG+H/AO0j4APw
s+JEFxLpdzcpcTRQts3quf3ZPoc9K8/+Pn/BN/8AZQ/aV0nwxofxH+GzQW/hGdTo
R0aYWzCNUI8uQqvzIecqepOa9g8HeD/Dnw98KWfg3wloVvpum6dbCK10+1hBCxKM
YwMckVvRkFFKqQCBgEYxS0UV5z8Zf2X/AIP/ABy8ceD/AIifETw99q1TwLqy6l4f
uxJt+zzrnnp71Z+LfwN8B/GiDQbj4gLek6BqKX1j9kuymJlYFS2B8wyo4ryT9rH/
AIJffsm/tjeN7X4hfGbw3q9nq9sFiivtB1drT7Ux+6ZQq/ORjue5r0nVf2TPgZef
Akfs7XfgO0k8JRWf2eOw2hWXjBl34++Ou7GcivPP2Rv+CYX7In7GviW+8a/Bnwlq
cuq30KoNS1vVDfSRJzgxMwGzI649Ko/8Fe/2a/jB+1d+wr4t+D/wH0+yuPFl29lN
pKahcCONmhu4ZjkkHHCGvW/2X4fjHF+z/wCF7P4+6PZaf4qtdNhj1aLT7oTRF1UD
cGAHX07VH8fP2X/gv+0pe+GLz4t+EzqEng3W11jQZFOPJuQjIG6ejnirvxi+B3gj
432uk2Hjk3H/ABJtWjv9ONnKU2sjKwDY6j5a8w/a6/4Jn/slftm+JtM8T/G3w3qn
9oWSrBDd6NqLWkk+BlTIyjL4Axz2rY8V/sE/s2eO/wBlt/2OtX8LXNr4HvGUXFlp
9+UlnKEEM0oGcnAzxzjFeZfs8/8ABE79g/8AZb8caP4/+DXhzxDpV1o7P9gtX192
h8wnO4pt5PB/Otr9gT9m39oP4GfGf47eO/jP4jkvdP8AHXxHl1TwpZyaiZhaWZgg
QIoP3RlGNfTf2nzJmWGU7VzvAjx0964b4/fs2fCj9pbSdK8PfFnw2L630XVYtS0r
58bLiNgyt09QKu/Gj4HeC/2gPDdr4V+I9pcta2WpwX8EVneGM+dESVJIHIrw39q3
/gj3+xZ+2T8VtL+NPxv8Ia3e+IdI00WNjd2eutAIYRxwAp+b3r0f9kb9jn4M/sT+
Brn4ffA/+2jpd3dGVzrerNdush9CwGBWjrf7N3w3Hxyf9qO18Mmbx7b6C+lafcz3
m2KSIkOE6cfMor56/wCCWn7L37VPwl+PPx5+PH7UHhTRtIufiL4ya70mDS75Zi0C
sxDNhRj73Ffa1FFFFFFFFFFUNe0HQ/EkH9na7o8F5EPmEdwgZc/jWQ3wo+Gt8oa7
+H+mK2cDFovb6Crek+BPB2i341TSfB9ha3CLtWaCBVbH1AraVQowKWiiiiiiiiii
iiiiiiiiiivj3/gtz/yZxB/2PGhf+nK2r640L/kC2n/Xsn/oIq1RRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRUF2pLKVkdT6qPve1c58Uvij4E+EPgnUviJ4/8UQa
ZpGkQtJcXMh+YbRlkAx8xI4AHPNfNn7M/wDwV6/Zi/aW+KL/AAp0zTfE3hbU72bb
oz+KtONvbai38Ahf/bX5hkj+le8a38ePDFj8edO/Z/bS79tUvdJa/tr2KPNsqgPl
Hb1whPHrXbRXCtAIXnjkmaJm8qFsMR/sg9vc15b4M/a3+DXxG/aW8Xfs0+F9bebx
T4D0qK81yKcFIbdZHCA7jjJ5HtXqsbxzW8Tx3SSCWIsp3fKyEA8Edvemx3ttPIv2
aZJX2FXWOZSIxz8x5z7UWssE1uClzEyKMTuG4GOwPTHvUV9d2tvC2qXBAWGF3RQ3
zSBQTgDoenFcn8Cfjd4Y+PXg+fx3oOg6hpYGoT2TQatEEkLRYy3BICnd1rr5NXZr
U3UD20cccgDzTzrsK45wVJ5+tKmp6bdEQm8hZpPuqJkLA+nB5xXnf7Uf7Vnwt/ZJ
+Hsvj/4pajMERhHpemWSF7nU5sHEMS45Y4PHtXBfsb/8FJ/gF+25HfW/gGPVdD1b
R5G8/RfFVr9kvJIMczohxuTrz/smuJ8ef8Fk/wBkXwV8d4/gXIniPUY4rwQXfi+x
04vpVpIDtkaSY/8APNuG7V6l+1T/AMFAPgD+yj8MLL4peLNauNYXVY1OhaRocJmu
tTBPJiQDJwuW5wMA1H+yn+3Z8C/2tfA2o+N/BE97or6KhfVNL8Rp9nuLaJgSJHTO
QrBSR9K8s8N/8Fsf2SfFHxri+EMmk+JLGB7021v4rvdMKaXIwJQEzHjBf5R719ha
Xcefbhjcxy5AYPCcoQemD3FWaKKKKKKKY1vC7MzJksME57VFJaxwWZhto14GAHY9
M569a8o/ax/bS/Z+/Yp+GqfFL4/eKU0axe6S0to2YNNK7nChVBJPPevSPCOv2fir
w3Y+J9L+ex1Oxhu7MkYdo5UDqT26MK8c/bK/4KCfAP8AYl0OJviTLqepanduiWfh
/Q7N7i8nVzgsiqOQOp9K0v2Qf2yfg7+2T4Ifxr8MLy/sryOTZqXh7V4RHfaftJVf
NQ/dDABh7EV7JasGt0YFTkdVzj9aZqKh7ba7YQkeYMnLL6DFeZftQ/tUfC39kb4d
yfEX4o31wY2n8qx06wTfc30gAJWNT1IHOPSuM/Y9/wCCjHwP/bbS70zwLpGraJq0
CO50bxLbC3uZIlODIq5yR05969m8d+OvCXw38K3/AI+8c+IINO0nTIGmu76ZtohR
Rk9ev69a4r9lL9q/4R/tmfCWb40/AXXIdT0V9Zu9Nt7yNSEeWB9rE5Ge4rxP4zf8
Fmv2VPg18aH+EV3pfiPXJbaRYL7XdC08z6dbSZG4PKOF285+lfVPgLxf4d8f+FLL
xt4N1621PR9VgW502/tXLJNEwyrA1s0UUkgYxsEIDYOCema4T46fH34cfs4/CnVf
jB8XfEEOk6Holo815NI4DPt67B3qP4F/tB/DL9ob4HaH+0j8PdZMnhjXtJOoWN5M
NpMAZlLEdOqGvndP+C2P7JafG0/B+XSPElrCNSFjJ4tuNMZdKickruaUdFBHJxX1
xpmoW+p2UN/b38MkU0Ilt5Lc5R0bowJ9c1Z0+FIYW2EHfIzEqxOSe/P/AOqpzjHN
VneGJyzsY1i5aVyAoH1PavH/AIbftx/s9/FL9p/xJ+yR4A8YwX3i3wrpf23WrKE7
liVmTB3d+HHevXLy9isLA3c4BjiBaaRmAEYHJY+w618heI/+C037JGifG1vhRG/i
K7sLbUBZXXjK104nRoZDne5mIz8jAoe2a9R/aq/b8/Z9/ZF+Htl4x8XX91qramsb
6NouixG4ur+FzzLEgzuUDJ59DVv9jT9uT4MftqeG59e+Gy3um32nO0d/oGtxeTfW
yk/I7R9lYDI+te3VGWDkPGQ2Hwfb1rwP9sr/AIKGfBL9iKx09fiTa6tresagWaHQ
vDVp9pu1h5/elB0TIxn1rov2VP2vPg9+2L4G/wCE3+FepXURtlC6jo2ow+Xc2rP9
0Sr1U5B/Wtj9o39pb4RfskfCrU/jV8a/EsWk6DpsAkvLuVxnO4KAF6nqOgrS+Gfx
s+H/AMVfgtpH7QPh/XIx4Y1jQU1eDUJTtj+ysm/zD3A281806F/wWm/ZH1v41J8M
pLLxDYWDXRtIvGd/YbNIc7sDbKM5ywwMjvX2FFMtz5M8D5jlTcvuCMg1JbbjF85y
cnn8akoqG4E28G3CZIwxkJxj8K8g/bA/bc/Z6/Yj+HkXxE/aD8cW2jWVzepY2VnO
26S6lc4UKq5POOM12fiv4q+DfBHwxuPix4s186foFvpsd5JfzlVHlsqupHfJ3BMe
pr51/Z6/4LFfszftEfFmL4S2Oh+JvDV1dziLSdQ8S6b9nttQlY4SKJ+QxY8CvrG2
MjXY3pIrLGQd5GCM9sVbqvdAMGjeRl3MAh49O1fPf7c3/BSL9n7/AIJ+eHfDmr/H
f+1ppvF2ozW2habpFi1xcXDRKrEbEBwMMOvFT/s6/t/fBT4/fBzxB8fG0nXPCHh3
w38+ov4rtfsxKkFg4GSQBjGPccVxP7P/APwWP/Ze+P3xcPwistE8SeHria4aDS9T
8R6YYLS+k7LC/wDFnjH1r6j8UeKNB8G+F73xN40vYrHTbC1kn1C9lfbHDGnVietf
KXwu/wCC0f7KPxZ+MS/B+DQ/EelQ3FyLez8S6tpxh0+5k3bUCS/xZbAH1ru/2s/+
Cj/wA/Y78Q2HhP4ly6jqGoX7j+0ItBt/ObS7fjbcTrnKJg5yARwa3te/bj+BOj+N
/A3w/sPEX9tap4+i+16NDox80xWm1v8ASZf7q7lKfWvYEhtplJibKO3mRAE53DnP
P8qtrnaM9cc0tHSomZnyUc4YYUgcj3r5O/aM/wCCwH7Mv7OfxTtvhZqekeJ/Elz9
p+yalfeHNN+0W+nSZwRcMPuHg/ka+kfhx8T/AAT8X/BGnfEHwBrtvqmkarEJrK5t
2ypX39CCDxXgH7bv/BUz9nL9gvxxoHwu+JWieIdb17xXp91f6Ro3h6wN1PKkDIrn
A+7zIOpFdR4L/wCCgPwK1n9l/wD4ar8Rzan4f0Bo2WO08Q23lXckwHEOwDlzwAB6
iuZ/ZF/4Kr/s6/te+M38AeFtL1zw1rCxE2Nj4osfspvgPv8Ak5+/t4/MV6V+2B+1
d8Lf2Iv2f9Z/aK+Mr366JoDR/aPsMQkmlMkixqFXvy4Fb/wG+Mfh79oP4W6T8YvC
GnX1rYa/ZLNZ22qReW6IRkFl7ZzXhX7TH/BWX9nD9lnx+nww1Ww17xXqsCBdVHhi
yM6aczMMLMf4TtIPfivoH4SfFfwF8a/ANh8RPhtrsN5pd/D+6ZWztOASjHswzyK+
cv2qv+CunwT/AGS/jPd/BXxl8KPHusalYwxyGfQ9E863k3xhxtc8cA88jpXQ/s5f
8FQf2ZP2jv2U9b/a/wDB+sT6f4S0G8nsrqLV4DFcJdxIrGAr03MWVVxnJOKyP2S/
+CuH7NX7W3xFb4X+HNF8ReGdYlAfTIfFOnfZl1Fu6wE/f619SokDyxuSzNFkIxJ7
1Psjt0JVeCSSB3Jr5c/a2/4Kq/s4fsheOYvhx4usPEfiLVt2NQt/DWnG4a0yMjzQ
Pu8Yr2/4FfGz4eftC/Dmx+K3wx137fpl/arsiIxJbSY+aKQdnBOCD0IqT42fGT4Z
/s+fC3WPix8XvFsOk+H9JtWub28un2rGij7oPqT+prl/Af7YfwE8f/sz6Z+17pvi
pLfwXrWirqFnqF18gMJXco/3iOleR/s2/wDBXz9mP9oz4nP8KdI0PxF4fv5Y5ZNM
k8R6a8MWplMjbbvjDMwBYZI4ruv2Kv8AgoP8Ev229b8aeFvhdp+r2Op+ANXOleId
P1eAI8Mykjjk5HB5r36iiiiiiiiiik2jduxzjrSCNBjA6dOaEijR2kUcvjcc9adR
RRRRRRRUEUhC7ZZXBZ/lLAc/lUTavp+5ozqtsrLkMPPXI5+tfEP7d/7bvxy+Dfxw
j8E/DTxbb2elGyEj3EkEcq7+flztPXgV4x/w8x/a9/6HS1/8A4v/AIivrr/gnJ+0
h8Sfjz8Ptf174teIrSe4sdaEFsx2RkR+UrdABnknmvok6zZTXAgttUtGDKcbZ1LZ
9hmrcO8R5d9x9aWJzIu4rjnoadRRRRXx7/wW5/5M4g/7HjQv/TlbV9caF/yBbT/r
2T/0EVaoooooooooooooooooooooooooooooooooooooqOcO+UWXblew5+tfAH/B
YW9uNT/aV/ZV+HN/eyx+GvFfxC1BNd005EV75UMDxiXtyxwAevSvp39rH4Afs9/G
34QzeFPjRc2uhaJorxGw8QRXSWb6U6DCtHO3EW37tfMvxF+JHjfwt/wWX+Gfw08I
/Eq+l8KxfBG4u7bT5r/zrW/kjjvNszAYDuQikuDyAK4v9gr4XftG/thyXH7e/h/9
qHxJpvjW1+JOsaDqGh3+pNdaH/Y9rePEYorMFRG5VEwdx6HiuBv/ANmbx1+1l/wW
p+Ovw0sfjBrHg7wofB1i3i5vCt41tqs+Jk2GGZclELhcjaeM1DP/AMFCP2h/hL/w
S4+MPiKLxPNcn4WfFS88C6brVzm51CXR4Z5bcPuBBa5CRr82Mk84rhf2bPj74Q0n
9pX4Z/Db9gj4q/tAeJ7n4nm5sPibN8TdLvbi00iCWwldLi2mkRFgK3GzA54HXmuh
8R/tq/GPwZ+yR4g/4J4z/FDWLrx5pvxFfwPF8TxfGNmfzhCXYnJXn+LdXY6X+3D8
S/2/LH4C/s7/AA78a6j8P9UGm6jrmu+J4dQ8xtYt9Je502S2G3acyzRCUnJ6dK5L
wd+2l+0Xof8AwSpl8VQ/Em8fV/Gn7SP/AAiV5qMspF1ZaXdXVtA8ULZzHIEdtrdi
elfXPgb/AIJr+IfCXwi8V/BL4g/ta+NZ/hXqlkl5ZXj+IWg16ymKq0jPqJziMEvg
bBxjnivnz/gm9+x1rus/8FFPEnxd+FX7TnxT8VfBPwXpUVjot14m8WPNHqOrhpBN
sVlHnwhTERKPlY5A6V+lXjX4Y/DbxjfaZ4i8eeD9K1Ofw7f/AG/RrvUrNZDp9yMk
TIx+4QC3zds18EeApLf9tD/go98V/wBr3SLF7PQfhL4NvfBOkXSwG4g8RL5c0huo
ZVwqgNckEjdjZXl3wAghj/4Nvvjlb3V3Nn7R448u9nl3vH/xMHG4P6gn5fXaK2vC
cAX9v39hgXCTLMvw0vGfFxtjf/Q7wBmTHJ9D616h8EfD2meL/wDgud+0R4V8V6bY
3WmyfDTwsLzTZoQ0MqtbT5bZ0Bb+KsL/AILMah4s0f4GR/shWHwCg8LfBm8v9ObV
fibY6ikiaSVvYpVUWSoHIaQKhO8ffr9B/hdZafY+BNIt9M1WO7hj0qBIZIIvLjdA
vDrHk7M+mTXQ0UUUUUUUUy4ERhYTKCvcN0r83/8Ag4L/AGWPhNrf7K/iX9p7xfp1
7quv6W+nx6RZXd+GtIGDtyI8cH3z2r7v+ANylx8CfBBlmEbS+ENMdY0bGP8ARY+B
6isr40eFbDw/b3n7QHgT4Kaf4q8feHtJuRoETSLb3MxeMgwiZgdgYDHSvkL/AIJU
alqvxA/bN+P/AMavifoy+FPiBql1pMfif4dhPP8A7IC2SCN0uRhZQ6hWICjBbFfo
FaArbIGdGO37yLgH6Cku2ZIS6MoI5BccD/CvgP8A4LB2E+oftVfsi3FhqC2ry/FT
Ukbc26G6jGnZw46degPcUzxNp1gn/Bwp4YMjhyvwY1WZLWA7F3qbQAsn8R5ODX1N
+1x+zp4D/ad+F0nhT4k318dPsIJ717SxuPKS6xCw2SjB3r3x6ivnL/g310LRvC37
EOveG/DmnWlnpth8YPE1tY2dqoVI41ulC/U4FfI/wS+LPxl+AXwC+OfwM/Zl/Z+j
+J/w6vvFOqHX/ilHrCWcekmbcZkNiyO8pjBbkOM7c96/R7/glL4X8G+D/wDgnt8K
dA+H3jf/AISLRoPCFoNP1b7OYTPHsGCUJJU+oJr6FoopGGQRjPHSvlz/AIKh/stf
CT9oL9nTxJ4p+LltqN1F4a8L3s1ppdvf+XDI4wQzpg7ulZn/AARn03Ttd/4JOfB3
TNQ0yB7C48Iy29xYKQ0YiNzONvHXivOv+CtEHgS3+B/h3/gmr8HvBix3Xxi1uLQ/
J0JgsugxXDYbUZY1BJiTOWPH1Ffa3w08GnwB8PtF8EPcpeyaJottpzXCDAlMcaru
284zjNdFbLsiEec7fl4XHSntu2/L1rK8ZeGLfxl4Z1DwtqDyrBf2jQu0EuxuQQcH
tX5y/sdfs3fDT9mb/guh4z8C/DPTpY4pvgrLd3moXj+ZPczPf2pwz4GSAxx7Cv0I
+KNppup/DHxFY6hdmztrjRryO4uAc+UjRMGlI7lRzj2r8ZdO+Jvxh8Of8EsvHv7K
fgX4HNr/AMDbi71mK6/aCOtov2eGTU2e5k+w7C5aKU+X/rOcD0r6B+LGmWH7LXx4
/Zo/bf1Cz8QeJ/hR4E+G82kapr/h3SJb24mlnt5ordvskYL/AOtlXLZ+UcnpU/8A
wS0+MHjH9oX/AIK4ftCfF3xv8I5vBrXugaINGsbt8yXVibYeVcEbQUZ02synJBbB
Nfp1VRp47aZrdISV2s7HHevgjxGzW/8AwcUaEtvBNCJP2eibmNJsoXOpygMVx6Y5
pf8Agl5Ko/4KOfthQ27v5cHijSUVN+5ELPebgq/w9BXb/wDBYf8AZS+FPxu/Zp8Z
fFL4oQ6lqUXhbwnK1toIvNtpPL5gKs8eCGxnr7Ufsz+CvFvxV/4Ia+HPht4F0mEa
54h/Z+Nho1nHKEVbmeweOJAf4QGZfm9vavzi/a3/AGl9Z8K/8Ek9H/YK0b4J+J7n
xJ4JvbOD4h6hqVhJZQ2jC8U77aZ1xdZLDJT+lfub4Flkm8G6PNN94adCGz6+WtbE
eAzKOxp1FQX3mMvlq6oBgl2XIPPSvzb/AODhL9lH4Za1+zVrv7Svii1vNY1my1LT
odHs7uXdBp8o34niUjhwcHivaP8Agpr4c8G+Kv8Agk9rth8QvG//AAjunyeG9Ff+
2HhMjxyLLatGgAIKl5AqE+jGvj/x58Vvjz8eb/8AZv8Aht+1b8DB8KfCnh/x3os/
hDxjDrKX6+IruGWL7PEYURDEkhVcksQN1frzBBElz53kiIgbEI4DjqeO3NWqpXMU
xvMbiQWDxswyEYDGMeh55r88P2uv2Kf+ClPxo/4Kf23x1/Zy+Lfh3w34J0DwVbjR
b7xdpX9qR2uqO0yz+TB5iEZTywGB/lXmH7W37XPxB/aE/wCCQv7Uvw3+NX2A+Mfh
Z5WleItf0xRbwajJJIHWVY8kxcLjaWPWuu/4KnPer8C/2RUe9FnKfiHpAeW0/cIi
gW52EdgRxjvX1h/wVjMKf8E4/ja1xdbU/wCFf3ru3m7TEFUcj09c+1fFv7bUckP/
AARQ+B7yJMqr4j8NMsjSbGhU6pAOW75Bx2zmvSf21v2VP2jPAf7V/jX9pb4GfDm2
8daT8ZfAdr4N8QW1xqSWUvhq2SFoTdrI4bKAMWKgDoOa+K/+CWHx68efst/Fjx54
U8NfA+f4sfFzwBbPo891Z34s7Gy8ICUXcl9G7K4uHSdnjO0j7pFftL+zR+0Z8P8A
9qr4LaN8cPhZfvc6RrNurxvOhVkbALrz1xmvRRjAweMUUjsEQuc4AycV81eDf+Co
/wCzd8Qf2q1/ZI0DQfH6eKYb6e1ea68C3cWml0XLH7Ww8vGOhzzXzZ/wSljiubj9
sqB5mnZ/iPcxuzndwI7oD8AK9L/4N7Xt7j/glt4Cu4llLzNdPPJNPvLt9pkGc9un
SvHPEP7DH/BWHX/+CgfxM/aQ+EPxn8JeEtFCQ2vg278X6F/bNyLQqxuUgIljNtuZ
Ux1z+FY/7SfxS+Mf/BT/AP4JneG/jJ4M+G1ydd8BfE21ufE1rpbYaeGxuY2ubiOI
DLZjR8R8knAzzWL8TP2ytJ/ba/4K7/sxeLPAHwh1rTPAllZ6yukeIPEenSWNxqFy
WtRJA9tKoeIIQACx53HgV9Lf8F8zcXP/AATT8WT2twbZ49c0domZcEL/AGnbKQU7
9TXVfDb/AIKe/sxWXxn8N/sbQ6R40j8WSWkFnbTS+BrpdOd1AXAu8eWoz0PSvGf+
CcmlW9v+1t+25pqOit/wmFsipdJvEedHjJRc9Vz8xxXV/wDBvvDE3/BP2aHUrp5A
PiLqwEkrffx5JAHt6Cup/wCCyH7QfxU+DvwA0PwP8D/EHkeJPHfiu20aSC0TdeRW
MgcyzQqPmXGwKW/2q9m+H37G/wCz54B+B9p8CV+GOman4aN1BfXtlqdks4ur5WRx
dSgj5pN6qckcFQa+VPjm1t+2B/wVh+Hvwq+HVrDp+n/s+mPxBf8AiaNRcWk7FUP2
HKYETANtwSfuGv0EhkilVWYBZGGdmea+b/E3/BUn9mTw3+07Z/sk6ppfjl/Ft1qU
Vpbi38EXT2RlckLm5A2BffPFeJfsVsZv+Cof7X6i6HmwywCEvMJPLBtLc8L/AA8k
8Vt/8EFTLF+zF8Qo7p5Z5R8dPFZa5kfcWUXnA9sdhXiv/BdL41/DH9o/xKP+CcWt
/FjQ9H0WHQrrW/iPLq2sx2EkMEcUjW4hMh/fuZhCNi84JNcD4p8XeC9W/wCDYDwl
D4A1Kx1j/hH9B0i3e3028U7rmP7qOVzsJIGVPNekeAvjR+1t8LvGv7O3in9tbwp4
P1Xwz8TNX03R/A3gWy0dRe+Er1dOZkuBc7iJleOJ3OEXaZNvavUP+CX0UMf/AAUW
/a8a0giWNvHiFniHDSb5M59+lffFFFFFFFFFFFFFFFFFFFFFFFVLiznkjNlG2yGV
GWRoTtZMjqp9a+NvHP8AwRf+GnjTxnrPj3U/2rfjnZy6tPJI9ppXxDeGCAMxOFQR
nivkv9qn9mPSP2UPii3wl8O/EfxJ4ltJ7JZ2vvGGrG9nX5jgAkD0rzX7M5/5eo/+
/dfQ37F//BPDwT+2J4X1jxh4q+PHxK8LTabffYI7TwN4pbTraZdgfzJECtukycbs
9ABX0H8JP+CNXwv+EnxM0T4laV+1Z8b9Tm0LUIruKw1fx+81rcPGwIjmjMY3xnGC
ueRX2NFGY1OTkk5pyliPmXH40tFFFFfHv/Bbn/kziD/seNC/9OVtX1xoX/IFtP8A
r2T/ANBFWqKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKjlKGRVIO4crj+VeO/
tkfsl+Ef2sfAFroWtSLZ+INFma88K6wrENYXeAd6kdPurn6V84+Ff2Cv28vjn4it
PCX/AAUA+PvhjX/h/oNzDcaPo3hR5Yn1B4xhY7wmKMsGGS3LcivTPHP7COpeKf8A
gob4P/bGsPFFlaeGPDvw9uPC114edGEzo6XChoiF4AEwHUHivL/hb/wTI/af+Enx
Gj+FHgj9oK10j4DW3iqbxRZ6TpgK6tLeyytLJDLIUBaJmduN56DivW/gd+xD4v8A
hL/wUC+Kf7Z1540g1Cy8f+HbTTbDTUQCS18qVWyx2jPQ9zXlHhb/AII7yal+zZ8X
vgH8VviFHfH4g/E/UfGGj31mu2Oxme4klhSRcANjzMHg9O9an7Ln7G37eth8V9H8
Xftb/GrwX/YHg+dX8K2/gTSkgluVWPyVS6Igjz8pzwW5FdPqP/BNPQLz/goL/wAN
WPHpJ8HzWTzXnhKWDIuNaJyL48fe3YbOevaov2av+CZ+l/s+/tOfEv43Xd7YXOl+
JJGg+HulQwDHhi2mhBuUT5RgSXBkkOM8yVwHgz/gjne2P7D2ofsweMfHsN1run/F
eXx34U1GMYjF9FLFPaCXAB2CSIbhg5HY1qX37Ev/AAUb8U/s8fEBfGf7TGhz/Ffx
tY/YY5Yw40i0tQAgCp5Yw+1VyQnXPNZ3/BOr9jz/AIKvfskab4E+CvxJ+N/w51X4
beEtL+xSW2mWrrfToNxUuxgXc+T13H617D/wVC/Z9/bN/af/AGb7j4T/ALGXxq0f
wLrWp3HlapqurB9otcncEKRuwY8dgOtcR+wZ+yz+398CNEk+E/7TvxE+Hd/4BbR2
sYbHwhayR3Qd1ZWd3aBCxfOCSSa8q1T/AIJXftu+GfD/AIi/ZC+DPxh8HWX7Pviu
9vJdZ0jUUkfU447yUyzojGJhySf469U/aS/4JqeMru4+GfxU/ZL8b6fpHxE+EulN
pnhi78Ts7Wk0TRurbwquTxI3G01b/ZN/4J9/F/w14t8eftBftb/E3T9W+KvxE0G3
0bVNV8JBo7WyghjdI/LDLGSQHPVa8v8AGX/BOf8A4KJ/G/RH/ZT/AGgP2i/C+p/A
6S+i+3C1RzrVzFFcrdRguYgB86Kp+fPBr9BfC+k6V4e0W18OaPB5VvY2scMERJLJ
GowoJPfitGiiiiiiiimzKjRlZFyp6ivAv+CkP7KniD9tb9lrWv2efB/iODS7+9u7
WcXl0mU2xsTt6HrXZa34S+K/hz9naz8A/B/XtOi8V6XoFnZWF5exZiR4Y443bG09
drdu9eP/ALUf7OX7b/jK58OfFr9l39oHRtE+IuhaWlnqena8jnRr7fkSuypG53Yy
V+Tr6VN+wh+xb8SvgV418ZfH/wDaK8badrPxR+IM8Emv3ugFvsgjgiESKiuq8YC9
geK+pLcMIFDZzjncAD+lNvHKxBRA7722nYAcD1Oe1fOP/BQP9im//aw0zwl40+Hv
iy30jxx8PNVl1TwVeXrN9ljuJI/KPmKARjHsa8//AGSP2Df2n9G/aOn/AG0v23vi
X4Y8Q/Ey18PT6L4ebwwkkVnDBIFzvHlpknYv8J719FfCPwx8bV+EF34f+OuvaVde
I7qK5hW704Hy0RywQHKjkAjtXBf8E6f2Rtd/Yr+B2rfCbxH4ht9Rn1DxxquuwTRr
xi6lD4PAr5t1f/gmB+2z8H9b8T/B/wDZB+MvhDTfhF421e41DxVpGvxP9vla5UrN
HG6xNgHcT94dBX2l+yb+z54O/ZV/Z88K/s9/D9j/AGT4S0eHToNzsxLRrhmJbk5r
0aiikcgKSRxjmuD/AGh/h3e/Gn4G+KfhVpWpRaffeItDnsLS6mXIi3jG48HiuH/Y
s/Z38V/sifsT+Ev2bU8RWV/r3hPQZbGG9YEQySmSSRWOB0Bcdu1fGXwz/wCCd3/B
Z/4Z/tB+Kfj+/wC0v8MPEOp+IdQc2N/q0Ez3GlWDMT9mhU2xTO0gA/7PWv0u8PRa
zFodnF4iuoXv47aMalLbjCPNtG4jgd6v2sqTIzxzbxvIzjGPapaK+a9E/Yx8S6H/
AMFMNb/bauvGFtJpGr/D7+wLTSBkSw3XnQuJDgdNsTd+9eheLfBnxz8WfFW6s77x
Ro4+G9/4ZlsNR0hIz9sa7kR1aRW2fdG5f4u3Svitv+CV/wC2tofw+1X9ib4Z/GTw
VF+zhrV5ci80eWBzq/2e7na5u1DmHAJnZiPn6E9M17d+0j+xJ+0Hovw78Fw/sP8A
xd07Rda8C6WNM0zTfGKmXSrqEqV3yoEk3MNxI+U8gVofsJfsSfF34OfFLxT+07+1
R470zxF8TvGWn2dlqlz4djaPTreC2jEaJGhRMZAH8I6V9UVXJSVZreBeQOSfU18k
ftifsV/Hnxd+0VYftm/sSfEXw/ovxJtNAHh7VP8AhLFkazbT/MaUBQsb/P5jemMd
6b+y3+w58dv2dPCPxQ+KEvj3QLr43/E+IT3urweYdOW6iEhRtrIOA0h/gr2T45fB
j4g/Hf8AZI1r4G+IfE1nD4k17w2LO/1GOP8AdG4+UswG37uQccd6p/s9/s2Xfwq/
Yt8KfsueJvEUrX+jeDI9Dm1XTpCjowiKeYhGORnI+lfJPi7/AIJZ/t3fHC1n/Zk/
aE+PvhPU/glJeK7HT7Ux69KiSiVN8ohUnlQD+8NfotpOnrpelW+mp0ghSMfRQAP5
VYAwxPrS0VFNF5rFJWHllRhe+Qc14J/wUs/ZL8Q/tt/ssaj8BfDOuQabc3+o284u
bliEVU3Z3EAkDntWx+0n+yT4W/ai/ZC1D9lfx9eYstQ0Wyt5rqFjtWe2aJ0YHrjf
Ev4V8yeCf+Ccv7cfxM8e+DtB/bI+MXg/V/h98NvEVlqfgnTdBhdbpRaOph81jEhJ
wqg/MelffaBpJgQjpzuO4AjjjHt61YqteJ9rSS2ErRdAWA5Pfivln9rv9nn9t7Wf
ifF8ZP2KP2hNL0PWJtPWzvvD/i5CdLhC7isg2RuxcliMbccCuV+G3/BJXS7r9lD4
nfBj4/8Ai2HVfE3xlmW/+IGpaapFrLeJnYY8hW2jPoPpXG+Hf+CbP7bnxj8X+EdC
/bp+N/hPVPAHw71OC/8ACOmeGIG+2SywMDH57PEnOEUHDGvpX4l/An4hfH/TPih8
G/jzrWly/D3x1oi2Om2+nM4vbSBoysobKheSR3PSvlrQP+CYX7cnxGs/Dn7O/wC1
Z8cfBmo/BLwjfW9zpVhoMco1Of7NMJrVZC0Krw6R5+Y8A9a+w/2ufhl8Yfi9+z7r
3wq+DPie10fVtbtvsTajfEp5drIrLMVKAkPgjB/Wvk/xN/wSN+LPwSi0fxR+wB8V
NH0TxBceDT4P8Zz+K7cyR32kyTtcTOjCN2M/ms2CcYGOeK+qP2Nv2WfCf7Gn7P3h
79n7wFmWz0aPBmMjMC7Aeafm7cDFewDpxRQenNZEHhLwnY6gdctPDdhFOztI92lq
ol3MMFtwGefrXwl41/4JzftvfBz4peMZ/wBhH4seDdI8H/FDUDe+O4vFAl+2+aQy
5tdkTgDa75yy8kV7f8Cf2RPiN+x7+z78P/gD+zF4r0tLDw9qO7xLLrG7/SYmIaRY
8KfmJLY6DpXG/tB/s3/8FENH+M+r/Eb9iH4/6Ba2HiZ45tZ0rxoZHSzaIFdluFjc
DIY9cDgUvgr/AIJk6x8Lf2Jov2cPht8Yb7RvFf8AbDa7ca5bSERXGoM29kZf+eJI
wVx3PFc18Dv2B/2sfGfx/wDB/wAfP+ChXxG8JatdfDma6Pgaz8D2xt4zJcsjHzVW
KMFgY17Edea0P+C/89y3/BMTxpd2ltd3UVtqOl3F4lhbeZOIo9Qt5GCqByflr6G/
Zc8W/Cz44/BLwj8afBWg2s8OoaRDNb3V5paR3ULbAdpyoIYHrXy/8Wf+Cev7bXwu
+Ovjf4n/ALAXxo8K6DpfxP1KO+8c2fiyJppmdbcW5EJ8qTB2DIyRzXp3wK/Yt+KH
7G/7Nvhf4E/sv+OtKtby38RR6p4vv9cLul55joblYQUbbuCkDp26VZ+PH7E/jP4v
ft2/CX9rDR/G9rHo/wAPtHu7HVfDlyCwupZ5lkEwyp5XBAPvXpP7X3g/9oj4j/s7
eI/BH7LHjvSPDvjW/tjaWGtayjGC2DjbI/yIx3BTleOoHSvk7/gnh+xH/wAFS/2S
fEWj+Hfij8Yvhp4i8LSzSTeMtQs4Jf7Q1Vy2VJd7cHIBI64r2L9hH9qj42/tA/HD
47eB/ih4dhs9L8A+P5NH8J3KwFGurRYYXEhJAB+aRhkZ6V9HS+EvCk2ppr0/hTT5
L6NlZL5rKMzbh3D4zn8a+Mvjj+wX+2P4M/aL8XfHX9gX4p+EPD0/xFZZfGUXiqN5
XlYIqZQiKTHCD0xXafAf9iX4r/slfs02nwx/Z18f2aeKdX8ajXvGupXu57d7i4k8
y+EIKk7C5O0YHHp0rZ/as/4Jlfst/tdaTrPiH4o/BvRtR8bal4ck08eIneSMhyny
nKkZAfB6V5r8Hv8Agj98Nvh5/wAEvLL/AIJ/3csNtd3NnHc6zqGnzO0c2oxgEupb
kLu9hXM/D/8A4J7/ALZ3jr4i+CfEf7f3xZ8Gat4O+Ed+mq+Cbbwu08d5btBC0MbS
nykDHyic8tz61R/4I5fETw78Yv22f2rPil4IS/Oial45UWk11ZNCkrK8m5l3AZ7c
1+ilFFFFFFFFFFFFFFFFFFFFFFFMm+VDJgnCnj1rwL4//sC/CD9on4ij4jeLtcvY
br7MIfLt+nU/41xv/DoL9n3/AKGTWPzX/GvZP2aP2XvBH7LPhy/8MeB7+5uINSv/
ALVM11jcH2BMDHbAr0tTtkKjvzT6KKKKKK+Pf+C3P/JnEH/Y8aF/6cravrjQv+QL
af8AXsn/AKCKtUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUEA9R06U0wxFxI
YxuUkqcdM9aQ21uYzEYl2tnK465pxjRmVigJX7p9KQwxEAGMcNuHHQ+tBhiLbzGM
7cZ9qPJiwB5Y+XG3jpigQxqzOqAFvvH1pPs8PP7ocrtPHb0pRFGH3hBnbjPtSLbW
6zNcLEA7KFZsckDoKcFUAgDr1pI4o4l2RoAB2FOpFjRM7VAz1oeNJFKuoIPUGklh
imj8qWMMvHBpdoIAx06UixRo5kVAGb7xHelCqudoxk5NLRRRRRRRRQRkYNIEUAKF
4HSlwOmKaYYiQTGPlORx0pPs0HlGDyhsOcrjj1p9FMitoIIxDFEqqowFA6UqxRoS
yIASckgUi20ChgsSgOctx1NO2qMcdOlNaCFmDtGCQ24HHQ9M05VVBhVA57UtFFFI
yK/3lB+tDokilHUEHqDTfs0G9ZPKG5V2qcdB6U4qrdQDilooowM5xTWjjY7mQE07
A9KYttAqqixDCjCjHSlSGKNi6RgFgNxHfHSnUUnlpz8g5OTx1pBFGFKhBhiSR65p
JIIZQFljDBTlcjpSrFGoIVANxJPHUmhoYn5ZAeMfhTsD0ooopGRGYMygleh9KR4o
3BDoCD1zQsUaklUA3HLcdaUKAcgdaFjRWLKoBY5J9aWmmKNn8woCduM+1J9ng2qv
lDCghRjoDQtvAhVliAKjCnHQU5o0Zg7KCV+6fSmi3gVi4iALHJOOpoW2gR3kSJQ0
n3zjrSfZbfzFm8ldyDCtjoKdJFHKMSICAe9AhiUsRGPn+9x1pwAAwKKKb5UYcvsG
WGCfWlKqV2kcYxikSGKOMRRxgKOgApVRUGEUDnPFNktoJRiSIN82eR3pEtLaOXz0
gUOc/MBzz1qO80rTNQsn02/sIZ7eQYeCWMMrDOeQevNOt9OsLS2jsrWzjihix5cU
aBVXHTAFPEEKsXEYyxyTjqacsaInlqoA9KRoo3KsyAlT8p9KBFGG3BBnJOfemvaW
zhg8KkOctkdajttK0yyEwtLCKL7TIZLjy4wPMYgAscdTgDn2qaOGKFBHEgVV6Adq
SG2t7eMRQxKqgYAA7UvkxAqQg+UYX2FDQQuArRggZwMdKbHa28UKW8cKhI8bFA4G
OlOEMSgqIxg5yMdar6Zouj6KkkekaXb2qyyGSUW8ITex6scdTVqiiiiiiiiiiiii
iiiiiiiiiiijAznHWk8tP7oo2Ljbt4o2ru3Y59aWiiiiiivj3/gtz/yZxB/2PGhf
+nK2r640L/kC2n/Xsn/oIq1RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRXx7/AMFuf+TOIP8AseNC/wDTlbV9caF/yBbT/r2T/wBBFWqKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK+Pf+C3P/ACZxB/2P
Ghf+nK2r640L/kC2n/Xsn/oIq1RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRT
JW2DcX2gcsSOMeled/FD9qn9nj4I69a+Fvi78a/D/hnUriHzYNP1bUFjeZDkAjd2
yDTPhb+1j+zt8b9dvPDfwd+NOheKNSsoTLPp+j3gkaNRgEkj3NegPJhkVkkUlcqx
JwD6Gs+bxl4dt/EMXhG78QWSaxPCXTTBcjzWTj5wvXHI/OtIvH5aK5IBOEIfvXK/
En40/Cf4QNp9v8UPiJpmiSapcGPSl1C88s3MoIyqg9cEj866iO4aSwS+8xXDx7t6
N8pU8gj8Oa521+MHwuu9N1LV7L4g6ZLaaA7Ra1cG8AW0YZzvPY8H8qyfhV+038BP
jVqEujfCn41eHvEtxbK32mHS9QR5VIOPuj06VmfEr9sr9ln4QeIrjwV8S/2g/C+h
alDEDJYalqixzRDnLFTz/wDqq7Y/tZfs5X/gKy+Jll8bvDz+Hb+f7PZa0L8eVPKC
QVUnqcg/lXT3fxA8I6YLGS98TWUP9rSFNL8y44u5MAkR/wB4YI6etarTLBEYxvZw
RuUNnDHnr6VwvxX/AGmv2ePgNf2+h/F/406D4cnu1321vquphJJPwPIHFWdc/aC+
DuifD+D4p698WtBtfC10REuu/wBoL5DSP/qwr9MkA1q+Hfix8OPFOsJ4c8O+O9Mv
tRe0E4trW7DOYj0fb/dPrW+FnMkjtkF0wq56Yqwudoz6UtFFFFFFFFFFFFFFFFFF
FFFFFFFBzjiuK+K/x6+DXwQ0+LVPi/8AFTR/DMLsSkur3qxB/pk81Y+GPxZ+Gvxk
8Mjx18MfH+ma9prAxtqGk3oliGOTn+6cHrXOWX7XH7NGo/EX/hUll8e/C03iSOVR
/YSauv2gfh1J9q9FDRW8EpVJdquOSxO7OOh9OatJ90cEcd+tLRRRRRRRRRRRRRRR
RRVe9kZCoNyIlbjcRzmvPfih+1d+zp8C9Zj8N/Gn45eHPDmpNGZYbXVNRWJ5Iv72
01tfCr43/CX44aBL4i+DfxE0zxLYRP5bXOlXQlQMf9ofWm6F8cfhFrnj+6+Enh/4
k6Ve+JrGJmvNEivA1xEF6ll6gV1dtL5mC42SEHdGTmp6wvG3jTw54B0O98UeNPFF
lpOk2kW+71G+nWOO2HA5Jqi3xf8AhuPAUHxTi+IGlN4ekt/OXW3u1W1ki7sH6dM1
l/CX9pD4FfGy7ubD4PfGfQfE0tqS1xBpt8sjRA+uOazvGH7Vv7NPw58Rp4C8efHn
w5pGqXM2ILK81ZVmc56YP3T7V6JYalaX8UN3a3cUsM0QktXhk3CVCAQwPfjH51w3
xH/aj/Zx+EXiODwr8VPjhoGiarMf9HsdQ1FYpGz/ALOf51q+Jfjd8KfBfhm08eeK
/iJpNlot8UWw1Ke8CxTlu6noc9qv3fxB8J2ltY6nd+NNOgtdXlC6RK0y7br5c4Qn
qcZ6VtSZlZUhYgFg+7PBHpU9FB6VjeKPFvhnwV4dn8T+NvEVvplhaAG5vr2YRRoA
e5PArA+F/wC0T8DvjdNd2Pwm+K+ieI5bQZuotJvlkaFT0yBzXReIfEWleEdLfX/F
OsW9jp9hCZb2+u5gkaLjqSa5H4aftPfAL4y6pNo3wi+MXh7xDf26lmtNP1QSNg9y
BUPxN/a0/Zs+EXiOHwp8Uvjz4a8P6hLgrYahqSJJIG+UDB6c13GhaxZa5psOraTf
w3NjcRLJY3FtN5gmTGQwPfIxXD6P+1J+zjqnxSPwh0f42aHeeKopDbz6DHfg3CNg
vynrjvXoU5ZAzs5AJ5x1PoAK5zxZ8Z/hZ4F8Q6V4U8bePdP0jU9ZO3S9MvrhUmui
CR8q5yela/ibxFpPhPSJ/EfiTWYLHTLOJ5L67uW2rEgGck9gOea8jtf+Cjf7C9/I
0dl+1l4MIQ7WDaqgwQcYye+a7vxZ8cfg34D8HR/Evxh8StJ0zQL5Ea21e91EJbzK
x4KMfX2qb4ZfGf4X/GXQZPEnwp+JOk+INPjlMRvtKu1mWNv7rY78H8q62MAIApJG
OpptxIYo9/y7Qf3jM2Aq9zXmlr+2N+yzfeNG+Hdl8fvDEuueb5A0lNVQzGT+7jrm
vRo3EeIXuACseXi3Zx75615rf/tnfspaP4wX4b6n+0H4Wh1ppvJGmNq6mXzM/dPo
a9FuL1FtGupL5I4oYzJKUYMGjxnO4+wrkrD9o74H6t4M1n4i6P8AFLR7vRfD7GHW
tQtr0PDZuCAQ7DoR3qz8IPjt8G/jjp9xqnwc+KGkeJbS1YJNLpV2swjPuRXZUUUU
UVG3nlsBRjvzRLKqrgSKD6k1GZoZXDCcHjna1ShExuBJ/GmybgMm52f72KYbkQxb
nuoio6yO4Arl/EXx4+DnhScweJvinoVg6ffSfUEB/U1x+t/t+fsXeH45Dq/7TfhC
Ax53btWQkfgK8Y+JH/BeD/gmP8KJbi38R/tHafdS2rbZf7NZZQT7fMM14x4q/wCD
r3/gkt4ejdNP8deJdRnVsCODR49p98+bXinxP/4PKP2RvDsrL8Nvgxr2tqD8rXB8
rP5Zrxvxj/wev3HkSxeDv2QUgck+VNeauxz6HG3FeIePP+DyP9t/WfMPgv4baFo+
5j5btEs3Hphk/WvLbz/g7R/4K4/bTdwfELwysLH5bdfD1u20fXZXoHwz/wCDxn/g
oDoEyD4keDvDutxjG9YrOOAt+KpxXvnhX/g9n1FLWKDxT+x1bSOoAlnttcfn3xsr
2T4bf8Hlv7I+vQK/xA+C+vaVKcb1tT5oHr1Ir3HwR/wdc/8ABJrxdPHZ3fjnxFps
r4AN7pKKufr5te4fDr/guZ/wTS+JdysOmftM6NY+ZjyhqMyxls/ia9d0T9vj9jDx
KAmi/tN+ELrfjb5eroCa7bw58avhH4rcR+GviXo98xPC29+jZ/WulWeKYho7pCCO
NrA596UyI4KK2cDqDRtd02OBt9Q3NRllaLbA8mAeSBmhpFVcASpj/low4H1p8Llx
kXAf6DFSjJHIoor49/4Lc/8AJnEH/Y8aF/6cravrjQv+QLaf9eyf+girVFFFFFFF
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFVr5I0P2qZiVVMNGeh5/nX5yf8ABy9+zf8A
A/xN/wAE1/iH8ePE3w00y58Y6NYWsWj+IZGlE1spmAwpVxjhj145riv+CN8n7N37
CH/BD/S/287j4aWVprOk+Dr6+8Q6usj/AGi9KzHCszsQc/L+VeC+Fv8Agu//AMFN
Ph58IPBn/BQv4z+D/C0/wX8deJJNK0vRIYJBfQxsQscrvv2ZDOCcDoK8v/Zy+I/7
bvxl/wCDliyu4vjxo8k134Zg1lo5Y7j7CNCmihl+zRx7s+cFeMbuhIPavq7/AIKN
/wDBTz9uj4AeKvGWo6R8Zfh34HHh+1Mmi+BdRs59U1LUAp/1oazdliUjPEmMY5r4
A/4KFf8ABRrxv/wU4/ZQ/ZU/aB+I+kLout2XxLvNM1c6dcMq3TpcQKJAA3A4PBr9
0/8AgoT+0zd/sd/8EvvGP7Q+lKzXOheAoFsSoLESSxxxK31BfP4V+Lfxs0v4++Cf
+Db/AMOfFrwRq+ualqfxM8ZjUPHuqWIle4W1dlYgkfdTDNk9hVfxf42/Za/Zf/4K
T/smav8A8E3/AB9HaHxB4atoviGthftJ9ovDES6yKxI3Z4Ix1qt43v8Ax34d/wCC
qf7QX7av7Rv/AATn8U/FrwN4UlnivItRmNslpD+83Tp5jIJBjkbc4xX0b+27rX7P
P7T37MvwP+OP7GPwr1E/Be/tLlNQ8P8Ah61uGfT9VLsRHIoycqwcE9OK3f2ff2u/
AlnqnwSt/wBsnx7faD4Z+DHg+OC5nRJC17r53rJbsuC2+JfJZi3ZhX69eHPjB4Q+
IXwgf4z/AAz1OLU9LvNIe90+7ThZQsZYZB5Hoa/GH/ghp8DPht/wWC+KXx+/ay/b
f0U+L7qXxHc6FpGm31zJ5Wm24A5jCsMNhzSf8HCP7Avwh/4Jy/8ABGWX4afATxh4
lOk33xT024S21jUjMbdWM5EcZUKRGoOADnoOaofH34t3X7CH7ff7G/x/8AXN5HY/
EvwNY6P4q06O6O2cO0iowDHGQ5Un2Ffu3KZFlRwuR0OO2alooooooooooooooooo
ooooooooopHLBCUXJA4HrXxB/wAFO/8AgnT8JPjPrK/tleKvg34k+LXiXwfpbrov
w0i1qK30+7kwDlgxTkbf73evx4/YQ+N3jz9mr9mT9tL486D45ufA3iSyiGnyfCa1
uGb+wvOljiEsZYsvHmYyCfu1W/ZN8b/scWfwU+BHif8AbX/ZR8ceFNT1bxPDNaft
AWWsqDqt4XUqJFJY+XknI2iv6V/B9xZXHg3TZfDV6buzayh+x3M2cyRbFIY+uRWt
AioGCsTlyTn1p9FFFFFFFFFFFFFFFFFQzusc8WdvzEgluvTPFfzgftiaf8cfF3/B
bP4lftKfEX9h7xb8Wvh78P7KQzaVeF7e2FvFn51ZyiuuF6KSa/TX9jT/AIKC/sK/
8O1dQ/aS/Y7+FcHhMXU502TwbaSlZ4dVkcR+VukJDFQ3mHHZfWvz6/4IX+HPjP4d
/wCDhn4k6f8AH/WXvdcn0LUbsvLO+HikDGIqrHoADxX9Bkcyve4MeDsIztPrVmvx
K/4Os/hb+3j4p+GPiH4k6Z8S4NI+DHh3ToQ2i2rOs+pTtsLFyDjaGLDB9K8a/wCC
i/xR8U+HP+CDH7EHw50DxFeWmk/EK6srXxILeV1+0QBojhm+9/Ee9WvG3wl8Lf8A
BNL/AILVfs4+AP2UtY1Lw/oXjzwhBNr9sL0vHcSNbIxdg2e/868g/ZD+AngH9tL9
lb9sP9r/APaAlu9c8eeF9avJfDGrvqDqbV1KhWT5gBiv1z/4Nsvi944+N/8AwSU8
CeLPiJ4guNR1O2mvbBbu4k3yhIX2L830HFfl9+zN8EvAX/BRP4//ALa/xe/ahn1X
xJqXw70W+m8GT3V+Q2myICFKlSFOPT3rnv2cfGnxq/aM/wCCUnwX8YfFvTfEPi3w
z4a8T61o0sWmxyzTPKJYVtAfLycKFbJPrX1L8FP2rfBtynwb0b9sjxdqGgeDfg9p
st4ZLaGUve6vJcyolsygFspbSq5DdkNfsj8L/ih4J+Lfw+074kfDXXrfVdD1SFZN
MvoMqrxEDDfNg9Pxrp1OVBznjqKGYqOBk9hmmNcZYxxxszAcgDH69K/ID/g7J+Kf
jbw98OvgN8F9I8T3tlo/j34jpp3iSO2kKM8AaDILDg5DkV4dZfCnwn/wTd/4L+fs
5fBz9lm7v9H8NeP9DsYvE9i140i32+GMl3XJwf8AGvrL/g608TfF/QP+Cd+n3Hwu
1XUrbTbjxTAnigabFIZJbMvGCp2DKpySxP8ADnmvz3g8Tfsw/szf8FGP2Lb3/gnL
44gS68aaVaWXxMhttQd4Gupvs4IIZuMZk656V598ZNd+BvwT/aK/ax+Hf/BRTQ9S
8Z+M44nHgLV7GaW5j0yR9jxkSREogBboTmv2F/4NoNA+L+kf8EuPB+ofGLxwuuXO
ozSz6ZIbnzXt7VsFImJJ5UYBr4s/4IZ/DrwR4+/4L3/tO+J/Guky32seHUafSJbi
R2FuxmiTcMHA4JHPrX7h6++ux6Ddz6BFHJfmzka1WTp5u35QT0Az61/OX+1x8M/2
5fhF/wAF3f2eNU/bH+MFt4j1LxRrk9/oljYTOsOn2azTIkTAnBOMHNf0XeKfCeie
PvD154P8YafDfabqNj5OoWM6nZIrKQRkY4P1r8Gf+CtP7KP7L37T3/BTv4a/8Er/
ANi34O6L4auLN01P4ja7pLzboIyysE4c4O1xye5rO/4KwfFrV/hz/wAFbPg7+wNo
3wo1b4i/Dr4c+CovsPw5iuiDrEzJMqFyCOVZA2ScV9ff8G8PjD9hHWvGXxUs/wBn
fwp4v+H/AI7/ALZmbxv8KfEl+txHpTJIy7oSg24JPZj1r9UYpCyDJBIHO3/Cvnv/
AIKtfE/xR8If+Cc3xg+JHhOdrTUtJ8FXs1pMH5VgnUEdDX89fiv9n7wF4K/4IQ+B
/wDgo54bmurf4s3fxCL3/iX7dJ5zp5wGB839K/ox/Zcnm+OP7BngO98Wa7eef4q+
GunDUNTtpB9oLTWi75A2DhssT06mvxe/4Ln/ALIP/BO7/gmz+zY3wF+A0et618e/
iD4oj1DRNUm1F7jU4t0gJJ2YCpwQBjOSK+yP2h/g/wD8FQPiB/wRy+FXww+D3j5f
DfidPAscnxL1m9lxdCBIEZgjZ+ViN/X8a8D/AODVbwTp/jz/AIJ9/tG/C34sRHX7
C48aXNtqEN5M7ibZaybiTnOSy7uD1rX/AODPe1t9O8LfHXSbKB4ILPxn5MFr5rMk
KK7gKNxJr9qaKKKKa7Mp4XjH3vSvEv2lP2uZf2e7OW9j+HGt+IDHEzrFpdsSWIHT
kc/hXwJ8c/8Ag5p8efCTVZdOsP8Agm38S9UWPOJobB9v/oOa+Zfi9/wd5ftPRXcq
+C/2F9e0GMQjbHrNhLuVucseBxXzX47/AODvH/gprc38sOg+HvDOkoc7Y7nT5S6/
+PivGfix/wAHKf8AwVL+Kyst98YLfTQ4xjSoGTH5sa8M8W/8FX/+CiHjO6luNY/a
u8UKs+A6Q3oVemMcCvMvFH7Sf7QHjGd77xR8Ydf1F2++099Jz9cEVyUniPxFfStN
e6xeTFjktLdSHn86guby4nUGY5+srH+ZqBPkBcopX0JpwERUyOSvP3VpJPOIDc7f
4cnPFL9plMflSu20dAKWOQW2JYJGBPcY4pGSXzPNMcnJzkrRvlJIUtz0zQrNA+WY
nPpTm+VtsqIp/vf/AKqVLi4DqkV5Ivo288fTFX9O8V+JtFuPN0vxHqMDjo0dy6/1
rr/Cv7V37TfgiQXHhP42+IbFgflMOpNn9a9H8Jf8FXf+Cingy+jvNN/as8VuqDPk
y36sp+vFe2/Db/g5N/4KifDVk+yfFqHUBGQcajCz7seuGGa9l8I/8Hdn/BTmGaK1
1DQvDOohSN6w2Mu5h/32a+kPg/8A8HeX7VckUX/CY/sS6z4g5xI2jafKd30ODzX0
t8Hf+Dn7x/8AFadLKX/gml8TLB3baJJbJtp9+U4H1r7W/ZX/AOCiGs/tESRJrXwB
8R+GRIRk6jaN8ufoK+nra4juoFnhJKsONykH8jT6K+Pf+C3P/JnEH/Y8aF/6crav
rjQv+QLaf9eyf+girVFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFMlRSwZ13D
GNuM818h/wDBcb4EfFj9pj/gmh8Svgp8FPDEmveJdVt4GstJgBMkwEoYqoAJJO3A
+teXfso/8E6viT8Rv+CCtl+wJ8dNIuPDXiLWfCFzY3treoUeydpCyK+eQelfn7p/
/BNv/gqn8bv2XPh9/wAEk/iL+zm+h+DPAPi9b67+Ik6sILqxWVWAQlcZ+U9+9fQP
gr/gmV+1f+yJ/wAF0PB/7WHg34Uv41+Gj+BrPwwdW08kHTdkEMXnyAKeF8vOSe9e
OQ/8E+/+CjH7Pv7Xf7SHirXf2PF+K0fxQ0O4tPCfiy6LXZ0kSE7QgZG2EZI4Irw7
wp/wRn/4KQ6P+xJ8EvAR/Zh1Ya74X+Kt/qXiCxuYG3Q2zXMbJJjb0KqTmv24/wCC
of7OHin9pn/glZ49+AHh0GDWrvwNCFgXlo5IFjlZMev7sivh3/gnb4//AGnviR/w
QL0bwH+x18NtA8U+NPDVzNo3ibwp4thUx3caBUdUV1b5iAccda4z9mz/AIJFfEn9
qv8Aby+HX7UXxB/Yjtf2e/Cvw0sRJqWhxxYk1nUMnMqny0ypdiR7V7X+238Xf+C2
k8vxj/ZeT9i7TPGvhTx7ZXOleCfFnh5Nv2G3nR4xJdBIyGKBgSSe1e1f8Evf2Avi
1/wTa/4Jax/AjTZ7HXfHYtJ75LSZvMt1vpmZyig55BcjHtXzd+1D/wAEzP2jbX9l
X4a+O/CXwgi8YfEI3+r6l8QvDN1Dv82+1G2W3E+Cp+4VVunG2vvv/gnh8BvFfwT/
AGH/AAt8HfizCtvqdvpcyatZg4EHnEsYvbbux+Ffnt+z5+y1+3z/AMERPjt8TtH/
AGXv2btQ+L3w++Ieoy6poyaWj7tMuX6eZtVum0cGqn/BVD9mv/grn/wUI/4JMHwd
8Wfg1plx8QLv4h2d/a+F9DTM9rp4aUqJFCAhlVlB46151+3r8EfF/wC0f/wUV/Y2
/Y28O6MsWt/DvwzZ33iu3Y/vLMQmR23ccDK96/dMCN5jNFc7gzhSoOQCvUVZoooo
ooooooooooooooooooooooor4q/b2+Pf/BU74C/GrTPE37LHwA0b4j/Daa1aLUNF
tX26h9p4HBWNmxndXw5+zv8A8EHP2jv2gPhv+0t8Zv2i7FfBXjD4624GkeG3BxYh
JFlRZMgc7lx0715P4n/4Jpf8FUv2sPgD8Hv+CYHxH/Zwfw74W+FviRJLz4jXEzi3
urRWALINgBOBxzX77eBfDw8IeCdI8IQXQlXS9Mt7JJFGA3lRqmfx2/rWyhJHJBOe
cdqWiiiiiiiiiiiiiiiiiql4iGfzZn3iNQViVMlTn72fSvzn/a8+On/BYr4b/Fj4
ifC/wx+yBp3xJ8AeK9AntvCmseHwVls5pUKobgJGdwGecmvLP2G/+DdIQ/8ABP3T
fgl+058TvEvhrxZqfjuTxdOfDGpywCxuGUqISEZc4XH415h+wh/wRa/a2+Cn/Bcr
xJ8cfFvirxvN4A0SOd9I8aarcTSHVVbOLcyM3KqAABkj5q/cBJGLgGTAx8qsOT71
LXxR/wAF/v2cPjH+1d/wTW8afB/4D+EZ9c8R3jwm1022yXlAYE4AHWvlD9qv/gk/
+0/+0H/wRc/Z4+EuneEfsnxO+DUFlfyeGplIWSSJ0Z4iMdSEx0rnfgn+wp+33+3t
/wAFKfhz+13+1p8BR8M9D+FfhiPT7W1vFJN66RJGGXcq9cE/jXkMf/BPX/gqD+w9
pHx//Y1+BX7Kr+N/Cfxl1Rn0/wAUWgYppsMrqCzYQ9ACetfVf7OvwM/4Kc/8Esvg
/wDs4/shfstfCiy8WeFLq7nn+Luu/ZvN/swyyIzrnadpGX5z/DivA/GP7AX/AAUo
/YC+Pf7Qnhf9mP8AZ5/4WP4L+PenPFHq9luRtImmA3CTajYAOe/evuD/AII+fsCf
GD/gm5/wSuX4NaposOpeP2jvNZ/sq4PnQR6hIAyRqCOCG9u1fPn7Tn/BOH9peL9l
T4efGDwl8Fn8T+Px4x1DXfiB4RuCxE8txa3FlGoTafkRXjkxjqtfdX/BMb9njx7+
zF+wt4I+EPxMbOuWNgs+o2jHd9nlZVJthn0IxX0dGSY1JTblR8vp7Uy5VWAyxU4O
GHQV5p+098ANX/aX+E138NtO+K3iDwVczn91rnhm/eKZR9UZSfzr87P+Cq3/AARU
+NnxM/Y88BaZ8G/ij4l+JHjX4TeLxrtjJ4t1CWWbU9piYp87PnPl479a8z/Zy/Ym
/wCCjv7Z/wDwU78H/t8/tPfAf/hWS/DDwvDDodjeRsFv7yKJFjC5UcHae1e5aV8U
v+C23x7/AGF/iNqnxh/Y/wDCcnjOx8RtbaL4H8Q2SBNa0rcgk2K0ZyWQyAHHoa+f
f2Uf+CUHxX/aj/b4+Fn7TPjX9hCw/Z/8K/C+2afVdBiPOqXrbCvl/u04QqwzjjNc
NrH/AATh/wCCiX7IfxG/aG8D2P7Gcfxt034zI66P4puHMx0rfIuHLGNsMigdx0Ff
pH/wQb/YY+Lv/BPn9gTRPgj8c9be+8QvqNzfzRee0v2KOYhlgBPTb0x7V8F/8EML
7Trj/gtz+2H4T1HxLDY3OtaI0FmY7jZOjG4h+ZehyOvBr9M/2Sv2A/EP7LnxJ1v4
ha5+1Z4/8bR63HhdF8RapNNZ2Z5yyI8jAdfQdK+K/wDgrB+wT+1N+0P/AMFnP2bv
2h/hb8MbnV/BHhCJote1izhIis18x3JkYDGMnv6ivq3wF8c/+CkGrf8ABTPVfhP4
v+BlpZ/s/QaJLLY+LzFhmuQjFED7eckLxnvXyp/wRg/YB/ap8Df8FLfj/wDtlfte
/CybTL7XNVuLbwfqlyh23Fn5uIWQkcjylSpP+Cln7BP7V/wu/wCCqngv/grZ+yN8
OG+IdxoWnNput+ELYEzN8ki/LgMRxKe1eUfs0/szf8FC/wBiLwF+0z/wVsuPhXZ6
B8Q/Gi3N5oXgjVIN8ljF5hb96rLnk7TyK/TH/gnF8d/iv+2D+wR4H+N/xw0hdE8T
+LfDJm1q305TC1tOXkQlcYK4Cg15N4r/AOCRGs638NPiv4b1T9rXx54tPxG8NX+m
WekeJ9ennsLI3A4ZY3kZQy9AcAivy0u/+Can/BXDxz+xz4e/4JEa/wDsu/Y/Cfh7
xuLyL4jhD5L2vmhixOzB4z3r9IPAPi3/AIKsfs3/ALS2h/sseBPgPY6z8EPBnwpt
rWy8TwWeGvdUhtlUKH2nqw+7718KfsrfBf8Abf8Ahz+1b4q/bV/bd/4Je+P/AIs/
EWTU5l8IPcCaW1060807WRWRlGBkjiv2kmvPFfxp/ZZ1DULzwLdaJrfibwZIG8PX
oJa2nkgYeQQR1BOOlfn5/wAG+P7I/wC0F+wt+yh+0Dov7TfgaTwnPq/i6+1HThej
Zuh+zygOMgccgivM/wDg0GvrXUNE+P13a3CzLN48eRJk6Mpd8Gv2koooopsiM4wr
lfpVe7tYbyRFmjV9rZBaENj8e1Vbjwv4emJN5oFjNuPJlgUk/mK5Hxn+yx+zv8Rp
nuvG3wa8PX8jxhGebTY2yo6D7vvXk/i7/gj5/wAE0vHPmr4j/ZJ8GztMMO39jwhv
wO3Irxf4m/8ABtJ/wSr+IIk+z/BFNG8zodLPl7fptArxDxV/wZ4f8E4ddmmm0TxR
4r0935RRduVU/wDfVeK/E/8A4Mwfh81tOPhV8d75WJHkRXxOMZ5zlq8N8Xf8GYX7
VtiJZvBX7QXhy5UZKW9yCrfTPSvFPiD/AMGnn/BTXwk840TRdI1lImIjazmJ8weo
wteP+Kv+DdT/AIK4eFreWe4/ZW1W4gi5M1rC7Z/8drxfxt/wTL/bj+G4lbxl+zh4
igEJw+bJ+P0ry7Vvg78VdFeSHUvhjrdqYmKuJLOT5SPwrCudA1i1JW+065gI/wCe
8LKPpzVMgo+1+3Wrtvpuv6jiOxsryb0CRMf5Vs6L8Ivihrkpi0z4bazePxxFZyHG
fwr1DwH/AME2P22fibEs/hD9nXxDcI33SbN/8K9k8F/8G83/AAVr8aQrNY/sla5b
ROQPPvLZ1GP++a9t+HX/AAac/wDBSjxc8A1/SLHRGkxva7Jwn14Fe3+GP+DLr9p6
5kjl8X/tF6BHkgyQ26EkDuM5r3L4c/8ABl/8IIljX4nfHa+fBy5sgR/7MK9j8If8
Gev/AATh0C8ivr7xj4q1Fohh1ku2CMfcbzXt/wANf+Da/wD4JdfD+VHvPgpa6yEI
O3U4VffjsSQa9e8K/wDBGX/gmf4IlW48Pfsk+FIHByMaZGf/AGWvWfh/+yf+zV8M
4PsHgn4L+HdOUMXWKLTIhgnv92uztvCXh7Th/oPh+whUfwQWCj+VXrW1tYRiG0WM
+qRhasAYGMn8TRRXx7/wW5/5M4g/7HfQv/TlbV9caF/yBbT/AK9k/wDQRVqiiiii
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiik2rndgZ9aUgHgijr1oACjCgAegooqO4
gingkhlhR1kUrIrDhgeCD+FcR8LPgJ8IvglcazJ8KfBFpoUuv3bXOoLbKVSWQkkt
tBwvU9MV3EXzQgMO3OTmn0m1f7o4PHFLgZ3Y59aQqpzlRz14pahVT5xlfKvyFB6E
Vxem/s8fCLTPitd/G+y8E2sHiq+tRb3etBd0skQbcEDHJAzzxiu1UM37wAKBzjHW
pQcjNFFFFFFFFFFFFFFFFFFFFFFFFFFFAAUYUAfSiigADoKKKKKKKKKKKKKKKKKK
KKMDOcUdOlBAPUUUYBOSKKMD0owM5xQQCMEUUAAdBRgDoKKKMD0ooIB4IoAA4Aoo
IB6iiiimT7hC5TAO04LZx+lfPfg//gmD+wv4I/aQuP2vPB/7P1hpXj66mMl54ht7
udXuGK4JZPM2nt1XtX0JCyOpZckFj1FPACjCgAegoIBG0gY9KKZLEzIVhfyyWBLK
KwfiN8NvCXxX8OXHg3xzowvNOuMF42cgMR2IBGfp0rU8P+H9F8LaJbeHfD2lw2Vj
aRCO2tYECpGo7ACrgVQMACloAA4AoowPSuW+Knwq8CfGzwDqXwt+JWhHUNC1e2aD
UNPaZ0Mqk8jcjAj864X9kD9gf9kz9hHw7qHhb9lf4PWPhO01SYS6glpNI5nYZwWL
s3TJ/OvYzyMVWKlF2QRc7Su8t+X61JaxsiZY8lRuHocc1LRRRgelBAPUUUYHoKKK
KMDriikf7uPXrVC68PeH73P23QrKbPXzbVGz+YrJ1L4SfCfWreS11T4a6BdLJkOs
ukQH/wBlry7xt/wTY/YW8fs58X/s0+Fr1ZifOjkstucjtsI5zXmK/wDBBT/gkc2t
nW7j9ibww13KAXLS3G33483FekeCv+CXf7Anw7ljuPCH7L3hm1aIARj7IXwB0+8T
XqWh/BT4P+HYvs2gfCzw/ZoAB+50eEZA6D7tbVr4T8OWIxZaFYwj0iso1/kK0QAB
gDAHQUUYGc4oIB6igADoKKKMDOcDPrRRRRRXxx/wW+S4m/Y1txAcMvj3QMZ7/wDE
ytq+vdG83+zYBMAD9nTp9KtUUUUUUUUUUUUUUUyeNJYWjkGVI5FRIkkrJJNDskRc
g54DHgipbcIseIxgZOfrnmn0UUUUUUUUUUUUUVFJHEZhK8WWVflbP6VHE0yk7JA2
9wwU9lNWaKKgurv7K4D7AGHy7nwWb0A+leR/tBftrfC/9nD4p/Df4U+O7S+N78Tt
XutP0CS2gLqJYI0clvbDjJ7da1v2r/2ofBP7H/7P3ib9on4nW8zaP4XsvtF9HZ/P
IwLKqgDHfdmu18KeONF8YeDtO8b6Y7RWeq2cdxafbB5TFXGVDA9DyK5746fHvwh8
A/gh4m+PPitJbjR/CukzX+oiwXzXKRffVQOrZ4A70vwT+PXgz47/AAl0n4yeD5wu
kavYrc28t04TZuOAjZ6HOPzrrv7TVLUXc8e1DjLqcqPUk/3femDWIJLhrclVAtzK
cv8AMVz94L/d9/WmxX8F5YpNps0bGWLchJBbZ647/SnjVLSB1sN6JOw/dQyEIZO5
Kg9e9PTUof3jzERom7LM3TaMnPpimxa5ptxC1xZ3cc6KMk27h8flSyavZwMI7qeO
IlguXcBSx/hB9fb3pH1i2hmeO6dIFRSxMz7SVHBbB7Zxz71Fda59nsLq7S382S1j
kLQRtlndU3bFHckY/Ovn/wAYf8FHfhT8MPhX4U+J/wAUPBviXw+njP4hDwlpul6p
p7rci5aV4xKUbBERKZDdCCK9+g1q0bT5LyZXWOILuJGV+YAgg9xgj9anh1GG4kMF
rcQyYiDhUkBJBHBx6Hsa+X/22P8AgqHp/wCxd45Xwlq37LfxM8V2a6a15c654W8M
TXVpCq5JDOoI4AzXBfss/wDBcLwd+1d4u8M6L4J/Y/8Ai9Z6P4puVhsfFWoeD549
OiLEBTJMV2opz1zX27PrFnbyLA8i+aW2+Tu+cn2Xv6/TmnNqlvFKYJwUcKWw3G4A
ZO31xXm/7VH7TMP7MXwhuPiqfhd4m8XGGZYl0fwppj3dySwJBZEBKrgdfcV5P+wn
/wAFVfhz+3J8U/FfwX0v4N+NvBniPwhYRXOp2PjHRJLPeHZlxGXA3gbetfUa3YaM
yCJjtAzgZB+nrQLicqJFt8qW/vc7fXFeBftp/wDBQ/4a/sZLp2haj4J8ReM/Feq7
5bDwb4K05r/UpbdCA0ohT5v4lwMc5rX/AGPf24/hr+2L4YvL3wro+o6Fr+lS7Nb8
I+IYDbajp5IBHmwt8y9R1Heo/wBsj9ur4cfsc6Bp8viDw9q3iLxDrTEaD4P8O2pu
NS1HbjeIoVyzEZXgDnNZ/wCxj/wUL+GX7Y+m6paWHhDXvBPifRR5mqeCfHVg2nar
aQZA86SCT5kTJ6kY6etL8Lf+Ckn7NHxm/bB8RfsV/DvxK+peKvDWkRX+oTWyBrba
+/KiQHBI2GveXvrZLoWTSr5pi8wRg/MVzjOPTNYnxC+Jnhf4W+D9S8e+OdTt9O0r
SYZJr26upggCKM/Ln7zHHA718n/Cf/gtX8HPiB8UYvBfi74HfELwd4fv7gxaL498
S+HZLbRtQOcLsuWAQ59ia9z+J/7ZPw4+FH7RngH9mfxFp9/Lr3xCW7bSGsoDJGi2
8JlZnI6DAPNei694yt9C0C98SJp1zf29jC0jppcZnklC/eWNV+8+eNtfJPxt/wCC
xGm/BPQtC8R6j+xz8XNVs9X0OTVLq50nwlPMlhEjSArKQvDYjzg+or3n9jz9rfwH
+2l8CNF+Pvw30bU9P03WvMEVjrtqba6iZCAQ0bcjrXqD3ZTkRFtpxIEOSv4d6bFd
zsW322AT+72tnI9T6V8efGH/AILPfB/4efFm4+HfgH4JeP8Ax/pGnNs1rxz4N8Py
Xui6a4fbIk91GCiFOcgntXqn7Qv/AAUG+CX7Pn7JT/tk3xvfEHhWaGF9IXw7Abq4
1Bp+IUjReSzHgjt71zH7F/8AwUnX9sbxrceFbX9ln4meC7aHR0vo9W8Z+GZrKCXd
sIRWcAE4bOfavWf2pv2lPBf7JvwP1346+PrK8udO0K2aV7PT4TJcXBA4SNByzHsB
Xh37GH/BVzSv2y/G0Hh3R/2TPix4R0q50g6hB4l8Y+EJ7GyaMBc5kcYH3sjnkDNZ
PxF/4LR/Bjwf8WpvA3hD4NePPF/hvT7ryNb+IPhjQJLrRtPIOHaS4QFAqD5mJIwO
a+s/Bnjzwt8RPClj438Ea3a6lpWqWqXGmXttOGjuI2AIZSO2CK1XldDxCThSWx29
h6mvJP2hf2zPht+zr4x+HvgjxTY31zefEjxbb+HtFNpDuWK7lbaolI+5z6+hrjfi
T/wUp+Gng39pjTv2ZvBfgHxF4zv3cR+ItW8Kae13aaBMScRXciAiJsbTg4+8K+jF
ukZUYYUv0Vzg/THrTTeZcKsRHzEESfKSMdQO9cB+0f8AtR/Cb9lH4Pat8cfjX4jg
0nQtJ097l5JJR5kpVSxRFOMnj9al/Zj/AGi/BX7VvwJ0D9oH4ZiR9E8R2rXGnGb5
WZA5TJHb7pra+K3xb8G/BX4fav8AFL4iapFp+h6Jp73d7eSuAFVQSQM9Tx+tfIHx
T/4Lm/Cn4b3/AIP8Lab+zb8TfE3iHxno1zrOmaR4Z8My3bHTY5VRbkFByGDocY43
da9H/ZC/4Kh/DX9qbxrL8NNe+Fni/wCHPiOQF9J0Tx9o76fcalEBkvCkgBYAA9PS
vpiO/WSKWX7PKgiJBEkeM47j1FK19ao8cT3EYeYfukMgy564HrXNfF740fD74E/D
/Uvid8UNfh03R9LhMlxcSOOSATtUHq3HAr5n/Zy/4LEfC744/Fa3+F/jD4JeOfh+
mpzND4e1/wAaaJJZafrMoyRFazOAs0hQb9q87ea+qPHvxD8I/C/wdf8AxB+IOvWu
k6Npdm9zqOoXkwSOCNRkkk+2a+TPhP8A8FovhL8Q/ipb+CfFXwM+IHg3w/qN0bbR
PHHirw/JaaXqUhYhBDM4CuHHIIPINdn+2T/wU6+HX7JvjGD4ZaJ8K/F3xJ8VfZBd
ar4b+HukPqN3pMDD93NcpGCYkfDbWIwdp9K6jwJ/wUL/AGbfGP7M9z+1FqHjO30f
Q9NQprUOqSiKbTrnn/RplJ+SQsNoU8knFec/s1/8Fc/ht8efidZ/DDxj8DvHvw3u
tYVh4fuPH+gSadHqUgySkRkA3HGCMZzuFH7Tn/BXT4afAL4qSfCjwN8E/HPxMu9N
UDxRefD7Q5NRttAkOCsd48YIhJXLDdjhSa9s8CftefAT4g/AQftLaL8QdOHhBNPk
urvVHulC2vlqWkjk5+V1A+6ea439m7/goj8Gf2tP2XNZ/av+A9jqOueHtKv9QtoU
gtyZb37LK0bNEBnfnGRj1rvf2bv2lvhl+1L8KbX4s/C/VlnspXaK8t5WCy2Myn5o
pl/gcDBwexHrXeG8VrcXELRsrAFHMmFYHkEGvkfxz/wWB+F+hWPjCf4f/Av4g+Mr
rwT42HhrWNM8N+HJbi6Sf7Kk/meWoJCfOBn8a6j9gL/gpj8N/wBv238VWfhP4a+K
fCmseDNSjs9d0jxdpb2ckbszD5N4+fBQ549K+k/PQgBfvEZCngmoUvZXlO22Plhe
Tn58+m2vmz9sX/gp58Ov2TvGNj8NNL+E/jH4ieJ5lE2qeHvh/oz6jdaXbkZE08cY
JjByp5xwwNdJ8Pv+ChPwH8a/s1aj+01qurjQtL0Rjaa7p2sOIbqw1IAf6DIjcrKS
yKFPJLgYrzn9m3/gr78N/jp8V7b4U+OPgR4/+G02pyFNB1Lx7oEmn2ursT8gtpJA
BKXHzDHUVt/tC/8ABV34Cfs+/HKH4M3nhrxF4jSyuEg8Y654Y0xry28MySELGLxk
4iyxXO4jAbNdtoP7eHwb8aftEWH7N/w8uJfEWqz6P/aOpalow8+y0yNwrQJPKvCP
KjFlU9Qp64r2ZL6NtwkwpRtr5bgHHrUyNuUNxyOxpaKKKKKKKKKCMjFRPaiRjukb
aUxtz3znNPiiEIKh2bLE/M2adRRTZE8xdu4jnOVNN+zgKqrI3D7uTnPtUlFFFFFQ
Q2QiXb9olb5y2XfP4fSnwQmFQu/dhQMkcn8akPTmvkX/AILK/Hv4pfs8/sn6X45+
EmvPpt9cfEPw9YyXEcRYiCbUoI5ASCMAqxFfUfhfXrXUNCs72fVYZJZbKF5T5gA3
FASfzrQ/tGwHJvoP+/opv9r6V/0EYf8Av4Kcuqac/KX8J/7aig6lYAZN9Bj/AK6i
m/2vpX/QRh/7+CnLqenOMpfwkf8AXUUHUtPUbmvoQB/01FJ/a+lf9BGD/v6KVdT0
9huW+gI/66il/tGx/wCf2D/v6KP7Rsf+f2D/AL+ij+0bH/n9g/7+ikbULFhj7dB/
39FJ9tsf+f8Ag/7+im/2lpCEgX8AbufMFVdR1TTY4i1vfQG4aOTyCpHDBCcnn2r5
I/4JDftI/E748+Bfive/Gvx3b6hf6H8atf0jSvmCNHZxPGIlC5ORycV9gi7sdoDa
jHkdf3wFKl5YxnI1GI5/vTg07+0bL/n+g/7+il/tGx/5/YP+/oo/tGx/5/YP+/oo
/tGx/wCf2D/v6KP7Rsf+f2D/AL+imtqumocPqEI/7aij+19K/wCgjB/39FH9r6V/
0EYP+/opV1PTnGUv4SP+uopf7Rsf+f2D/v6KP7Rsf+f2D/v6KadW0xTtbUIQf+uo
oGraYx2rqEJP/XUU7+0bH/n9g/7+ivh3/gvl4intf2JLa+0S8iZrf4ieH0mXzQM5
1O1z+ABz+FfafhnVrO70K1uhqltKPsyB3inBXOODn3q//aNj/wA/sH/f0U06vpYO
DqMOR1/eihdV01zhNQhP/bUU7+0bH/n9g/7+ij+0bH/n9g/7+ij+0bH/AJ/YP+/o
o/tGx/5/YP8Av6KP7Rsf+f2D/v6KP7Rsf+f2D/v6KP7Rsf8An9g/7+ij+0bH/n9g
/wC/oprarpqHD6hCP+2ooGr6WTgajDk9P3op39o2P/P7B/39FH9o2P8Az+wf9/RU
OoaxYW1hPc/2jbr5cTNuaYADAr5H/wCCUX7RXxK+ONh8Y5vi342j1CTRPjHqel6I
Jx5eyzjigMewkncMs3SvruHU7No8vdwg5IIMgFP/ALRsf+f2D/v6KP7Rsf8An9g/
7+ij+0bH/n9g/wC/oo/tGx/5/YP+/oo/tGx/5/YP+/oo/tGx/wCf2D/v6KP7Rsf+
f2D/AL+ij+0bH/n9g/7+im/2vpY4Oow/9/RR/a+lf9BGD/v6KP7X0r/oIwf9/RR/
a+lf9BGD/v6KVdU05/uX8Jx1/eij+0bDvfQ/9/RTf7X0r/oIw/8AfwV8efts/tI/
FL4e/wDBRf8AZs+EPgnxza2nhvxfrF3H4js2kGZVW2uWU9ecsirj15r7ESOTzBM0
AEhOCc/dWrFFFRToxO9cMQvyoQMZ9a/Nf/gvZr3xi8KfG79lHVfgN4OsPEPjC2+I
Gqf2Xp1+5SOYNbwB0JBGAV445FeR/wDBWH9pD/grn4r/AGBviJ4c+Pv7E3gbw94S
urAR6trVhq88r20QnQBtpkOeO+Kj/wCCmvx78Jj9oX4HfsiftCaZ4t1r4T+IfhPD
q+p6R4DuZob4XyxSnzleJlfb+7Qbc44PHNcR4Q0q7/aa/wCCf37Vnwku/DfxB074
K+AvDdnf/CoeKbp4b43ItpGnSRg3mSKXxw5IOKo+OvE/gv8AZb/ZP/ZM/Zc8UWXj
XUvhJ4/0O6uPF2m+GbyRtSmuFjuHXYyt5mAUToccV6P+wh8UtR0rTv2iPhP+z14D
+JWhfArQfhe19pEPji6Z9Rh1SS3kaZkkmdn2swyvzYAHasf4B6V8dP2bf+CLOq/8
FCbr9orW/EPxJ12zi03Tby/uC0Om6fNrSwNbhSNrP5bMd2CRkYPp6J4o/Z88L/8A
BOD4y/s9fFr9mzxf4m/tL4w+N7DSvGP9s67cXUE8NxJCJNkczssf+tYYUCtbUPg1
r/8AwUA/br/aT074g/FXxDoEvwO1KGy+GmraJqTQ/wBm+bp8dw+9MhJP3kjn5weD
Xz74b/aj+Pn7Pv8AwQ4PjjxD8WNe1nXdS+Pv/COeKdZgkE17qenS3NvFMqZyFYo7
AbMcniuu/wCCffxC8LeCP2/Ph74A/YX8AfFzQPBHiawnb4mt4+kea2uX5OYzcO7J
yAflxij9nX9lDxb+1NoH7U3xo+L/AMevEt7oXw4+JniK7+Hnhqx1eaKLT761tI5o
5GdWDsNyp8jErx060ftN/t8fFO8/4J6fs03/AMZfFGtalo3xG8YHQviVD4Zj/wCJ
hf2StIvlxMoDBsIOUI5HWui/4JtfEa08O/tTeKfg3+yZ4E+I+gfBn/hWl7dar/ws
O4mmnGriGcl0kmd3AwsXQ9q+ePiH+zz4U/ah/wCCefwQ+JnxI8U+IL/xJf8A7VF1
4ajvhq02XtJL+4QFBv2qYxGoDcHrXsVj8e/HP/BPz9n/AOLX/BNHw74j1rxLdaRr
tnpHh3xZrF5JLepDqcttbu27JLeULhmBGcba/Sf9kb9iXw3+y7oujs/jzW/Emt6b
4S07QrnUdUvXZJvscPl+dtz95+pzXdftHIq/s9+Ny9vG7L4N1MjKgqD9mlxyeetf
Nv8AwRWjvW/4JM/Dlre8i0+7TwqNmoFVZUlEYxId4I4PPPFfnR+2h8Yf2WvgLN4u
+OXhTx38XPHPxq0a9EujfFjTbyVdCjuDcohQxblhZUVmiOEPI/Gvsrwx8XviJ8Rf
+CnH7LF74m8Z3CT+Ivg3qeqeItJtpm+yXM7WJKvt74IzzXL+IfAPx/8A2nv+Cj37
Wf7OXwv/AGhNT8GG68P6NFb31pMs8lpG9hb71t0cNGm5jliQGBr23/gk7/wSx+Jn
/BOeXxXH8Rf2lr34kQ6+sP2S41WBPPttjljulCB2znpkivHv2mPid8YdL+O3ieLS
v+C4eieBrOOdha+F5dDglOnDP3TutWzj6mvp7/gmd4j8a+JfhJqeqeNP23LH45zj
VWVPEWn6fFbC2XauINscUQOPvZxn5uteS/E2C4H/AAcBfDX5Npk+DGvuXgAYsVez
C7lbO3qeQB9azf8Agn4S3/BYb9rYJCABcWSoiNyf3Vtk4PTJzzX2p8SvD8MWlN4r
0DwVo+r+K9I0+ebwzBqKqZGmAB2q5+ZQSFyQeOK+Cv2BLTxN8Xv+Cj3xj1X9rTQo
vDfxT1n4eLZ6j4I0iUtb22kG5iCXCy5JLEhOdx+9VL9l34DfDb9mv/gvJ4m+GPws
8Piy08fB7TrmWSVzJNdSss+5mc57r696+85/gJ4LufjpB+0A19qD6tDpD6etqLuQ
QNucNv2Z27gBjpXyX/wXJa4tPBnwO8Lvq7RabqPxn0K01G3kkcRXcb31upWQr2AJ
4b5Tk54r6o/aG+FnwG8ZfBTVvA3xt0uys/B8dmEllnVYorJBgAxlcFD7jmvzv/4K
DfA2z+If7YX7IfwL/Zw+JN/pWk3Wn6zBH4htLppZb3SxYtvjEspLZK7xuBB5HNbf
wd0jX/2TP2sPjx+wZ8LvHWr3Hw+0n4TNr1oNUv5J57DUJIIndxK5Ljc0jkAHFeY/
Dj/gmj+0p/wVT/4Ju/AXU9J/ba8T+DfD2maFNN9ktinm3U4u51DyPtLSLwo2uSMD
pX6BaX8IvHv7Nf7Bv/Cp9d/aSi0LV9A0Awv8SItMhVbUIoAlaMRbS3GT8hr4at/i
h8efMgkP/Bwzo0jJcoEhHh61xcRlwMH/AEPOT0r9S/hTJeX3w80F9T8YDxHK+mRt
NryIEW+YqMyAKAAD1xgda/Gf9gLS/wBvLWvgV8a9c+BHxJ0zwL4E8H/EXVtVa4Np
Hct4iERkaWydZUfapXOeF5A5r3z48/BH9p7/AIKq/s0/sm/Hf9krXIfhfprJ/b3i
SzEMLJaRyJbtCVgYNHJtZHIG04z0r2D9jb46/tOfCf8Abe1X/gnV+018XR8Rr3/h
BpPE9l41bT4bWdIluI4hAY4URMfvB/DnitD/AILKfseftN/tjfDP4f8AgH9mn4gw
eGbnTPG8NxrF9NICotBJF1VwQ/Ctxg1y/wAA/id+1R+yz+2lo37B/wC058cIviVD
468BXus6PrkemxWraDb2jJbm2RIo41cOGDksGIK4zivkn4ReMP2ivAv7GPxl+EH7
JHwd0nxt8BNQ1HXV8S/EXV714tQs0e3AvWRFdVJhi+dflPP1r9O/+CbGhfDrw7+w
r8LdC+E/iq91vw5F4Lsl0rU7+MLJLEIEwWwBya4v/gsb8ZfHvwA/4J8eLvHfw51W
ew1RL7SrFru3cBo4rq/ht3OT0BWQjI5Ga+Dv2jv2FbX9nX9ov9j3V/Anxc1yfwt4
x+I2lT+JPCOp6m1x5+oTlHN1DJKWlTDM54YKM16v/wAEjv2QPhd8J/8Agph+1X4h
8Bapqf2jw744TT7S0u9RlmjMMlrbzM029jukDSNgjjAWuu/ba8efFzw/+0bfabof
/BYnTPhnYR28Jj8G3ekW8kttnP75mNs5O7rjccY6V6t/wTB8UeOvEk3iE+Of+CiF
h8dAFH2drKwjg+wcr1CQx/5NdZ/wU0/Zr+FXx2/Zs8X+LPih4YfV38J+CdauNL0z
7QywzO1qxVnUEA4KDr61l/8ABF2UP/wTT+GKW1skQGmXapHEMLEBdygJ+A4/CvO/
+C2niq+u4vgj+zpe3DN4a+JXxDTTfFFtG2DPbI0B28dvnavDf24NX+P/AMBv+CzP
wl0z9iX4O6H4q1jRfgZf6ZaeHtUuZIo47Bbi1XqrKMjanOc17V+zh8A/20v2kP22
PDP7af7Znwn0j4cXXw/0u50/R9D0K7NwmopNHIm5yzNgjzD0I6CvpH9tvxz8fPhr
+zZrvjL9nbwgupeJLdWK27NuaCIhi06KThnXAwpyDnpXwb/wTS+Kd1+0f+07bT/t
X/tXeO/EviHw8JJPBui+J9GTS7eaVgyuo+zwxiXaC33s8Cvef+DgGe4X/glh4+zA
kdwDEkKSuVXfh8MCvPPUV55/wU6iaDTf2K51ggcx/ESyZFOURT/YrA4xgk8nGfWv
of8A4LHQh/8AgmH8c1MSSmT4c6lsSViFVhA+DkcivkP/AIKN+Vcf8En/ANnGWe1R
W/t/w2Yow5UIRCoO0jn1PPqa9n/Zfy3/AAXR/aFDwiRo/hj4WVZDjzI18y8xnsQe
1fC3xMs42/4JXftQwqYR5nx7iG63Y7WH2onDBun4V9if8FVxBF8df2KpptMdkX4h
NvjeTayAw2mMlSN2PTmrX/BL+zgj/ar/AG2mctdGTx5ZedIgHKGwnwmD7Vxn/BHH
9nH4Z/tL/wDBKnSPDvxe0szWVh4rv9SNpa3kiQzuH+VZQpBYZUZXpjtzXp//AAQH
trez/Y38WaVZ6RDZ6fbfGTxZa2FnBEqwpENTmBWNR/DwMZrnf2M/DemeCv8Agox+
0H+wl4ShW0+HU/hqPxDc6XBM4mF/dyi3klV87l+VRwpA+UcV9x/CL4VeG/gv4D03
4ZeDlun0/TbcRpcXl000hKgAZLkkmvy1+Cv7JHx0/bX0j9rf4CfCj9oe4+HA1b44
xyeIdZ0qEG4ulGm2u1FcoWj+6mdpXpX2L/wTA/YF+Kf/AAT3+COqfCr4gfHdvG7X
FwZbHWbmzjW5hLZy00mxTJt4OSW718peN/ih8c7Hxvr1hH/wX60bSIvtc4i06bw/
as1gRIcQ5NmegGOp6V91/wDBP/W/FHiL9nXTtR8W/tNwfFu7llYP4utrVIUlGBxt
SNP5d6+UfjPr3jr9hP8A4Kn+OP2pNW+EOteJdE+JXhW30jw6mhRidlvEjh5mBOUU
tC3PHBr5m+C1z/wsH/gmJ+1Vr37VqS+CNavv2kPtmpWmmES7L8T2jW0BDbgokkCo
23oD2r0nxH41/an+KHxl/Zj0j9vD4P6Z8OfCmieNdMn+H+s+F7s3EmtajHbutrbT
iRmKq8RdmAA5H0rr/wBtP9iD9pH4c+NfjlJ8LLLS77wN8fnOq+LvGOq3HlS+FzGq
kJEAQCAYgQWB5avnL/glp+2l8VP2d/hl4y8Y+CfgND4y1bwLcx2vx48dazN5EsGg
2SvHpVxborKH8yzVpMhTnGa/Z74L/FvwV8afhT4e+LHgKR5dH8Saet1pgZfmZTnO
c+4P5V2MZLRqxQrkfdPanUUUUUUUUUUUUUUUUUUUUUUUUUUV8E/8HE/hzTfGn/BP
628FaxDNLbar8SvDdvP9nZ1ljVtTtwWQx8ggHOe1VvDv/Bvl+xBqmg2V5feIPiDL
LLaRyPN/wm9+gcsobgLNgYq4f+DeL9hRPmbXPH4+vjzUf/j9Sf8AEPP+wx/0F/H/
AP4XWof/AB+mt/wbxfsLOcnWfH4+njvUf/j9IP8Ag3g/YWByNa+IHH/U96j/APH6
f/xDz/sMf9Bfx/8A+F1qH/x+mt/wbxfsLOcnWfiAPp471H/4/SD/AIN4f2FlO4a1
8QDj/qe9R/8Aj9P/AOIef9hj/oL+P/8AwutQ/wDj9Nb/AIN4f2FmO4618QB9PHeo
/wDx+k/4h4P2Ff8AoN/ED/wu9R/+P0f8Q8H7Cv8A0G/iB/4Xeo//AB+j/iHg/YV/
6DfxA/8AC71H/wCP0f8AEPB+wr/0G/iB/wCF3qP/AMfo/wCIeD9hX/oN/ED/AMLv
Uf8A4/Th/wAG837C4GP7Y8f8f9T1qH/x+o77/g3u/YYtbGedNT8fGRYHMUn/AAnW
oZjYKef9f+FfKX/BJn/gj1+yh+0N4A+KN/4+n8Z2jaD8ZNe0i2tLXxNeW/mxQPGB
KSkoLE5+8Tk19Xj/AIN4f2FGG5da+IAB5A/4TzUeP/I9H/EPB+wr/wBBv4gf+F3q
P/x+j/iHg/YV/wCg38QP/C71H/4/R/xDwfsK/wDQb+IH/hd6j/8AH6P+IeD9hX/o
N/ED/wALvUf/AI/R/wAQ8H7Cv/Qb+IH/AIXeo/8Ax+j/AIh4P2Ff+g38QP8Awu9R
/wDj9Kv/AAbyfsLoMDWPH5+vjvUf/j9O/wCIef8AYY/6C/j/AP8AC61D/wCP0f8A
EPP+wx/0F/H/AP4XWof/AB+mt/wbxfsLOcnWfiAPp471H/4/Sf8AEPB+wr/0G/iB
/wCF3qP/AMfo/wCIeD9hX/oN/ED/AMLvUf8A4/Tl/wCDeX9hdBtGsePz9fHeof8A
x+hv+DeX9hdxtOsePx9PHeof/H6b/wAQ8H7Cv/Qb+IH/AIXeo/8Ax+vlL/gsH/wR
j/ZB/Zp/ZctviB4Cm8b3N7ceLtFsZra58V3t0rrNqEEbSbJJiNyh85A4xntX1Fof
/Bvd+w3qGlW91deKPH9xLJApaRfG9+gPHPyrMBVv/iHg/YV/6DfxA/8AC71H/wCP
04f8G837C4GP7Y8f8f8AU9ah/wDH6Rv+DeT9hdxg6x4/H08d6j/8fpP+IeD9hX/o
N/ED/wALvUf/AI/R/wAQ8H7Cv/Qb+IH/AIXeo/8Ax+j/AIh4P2Ff+g38QP8Awu9R
/wDj9H/EPB+wr/0G/iB/4Xeo/wDx+j/iHg/YV/6DfxA/8LvUf/j9H/EPB+wr/wBB
v4gf+F3qP/x+j/iHg/YV/wCg38QP/C71H/4/R/xDwfsK/wDQb+IH/hd6j/8AH6Vf
+DeT9hdBgax4/P18d6j/APH6U/8ABvN+wuRg6v4/5/6nrUP/AI/Tf+IeD9hX/oN/
ED/wu9R/+P0f8Q8H7Cv/AEG/iB/4Xeo//H6Zc/8ABvR+wxZ20t1Hr3j9THExDHxz
qDY4PODNg/SvlH/glR/wRm/ZL/aB8LfFxfH9340jl8NfGPU9JsUtvFN7blo4o4GD
nZKN2d33j1x1r6ut/wDg3i/YVePd/b/xBbJOSfHeo/l/r6f/AMQ8H7Cv/Qb+IH/h
d6j/APH6P+IeD9hX/oN/ED/wu9R/+P0f8Q8H7Cv/AEG/iB/4Xeo//H6P+IeD9hX/
AKDfxA/8LvUf/j9H/EPB+wr/ANBv4gf+F3qP/wAfo/4h4P2Ff+g38QP/AAu9R/8A
j9H/ABDwfsK/9Bv4gf8Ahd6j/wDH6P8AiHg/YV/6DfxA/wDC71H/AOP04f8ABvN+
wuBj+1/H/wD4XWof/H6X/iHn/YY/6C/j/wD8LrUP/j9H/EPP+wx/0F/H/wD4XWof
/H6P+Ief9hj/AKC/j/8A8LrUP/j9Nb/g3j/YWfrrPj8Y9PHeo/8Ax+k/4h4P2FRy
db+IH/hd6j/8fpw/4N6P2FyMjWPHx/7nrUP/AI/Xyp+1H/wSY/Zf/Z//AOCm/wCz
B4O+H+peLwdf8RXDzTXviG7ughit7iT70kjbAfLxxjJPvX7I2sMVlEllbwtFFGcL
lt3H45NWqKKguXlWZdsIZQM5MuOfTFfPP7Yv7EN5+1N8c/gv8V7fxt/Zi/CnxNea
oIRblvP86KNCmcjGQmM+9b//AAUH/ZRl/bY/ZM8Yfs12PiU6S3imzWF79RnaFZTj
g+1eUftLf8E5/iR4n1/wb8cv2W/jJY+Eviz4H8MReHbPxL4h0g39lLYqrAn7PvT5
/wB4/wA27044q34b/wCCffxg1X9mP4lfDL43ftO6n4s8cfFHw5Lpmp660bJYWjbC
iyQ25Y7MZ6bunFeb+Hf+CSPx78L/ALP3w9tdC/agsn+MXwq8208DeP5vD7fYrKyk
Dq6SWZkzMdssgzvHWvTvg3+wv+0TF8OvHg/as/albxt428c6BLoc2oabprWmlwW5
QpHIlmXfY2Dlju5q14M/4JneCof+CbNh/wAE7/in4pl1TTbKzeMajZH7OwkF413C
wBzwspXI74Irzj4Zf8EyP2pfFvxO8HeJv23f2qNE8c+Gfhrfx6j4I0jw34YbTrmy
uYirR+dKZZPOIKLngZxXzv8A8FBPGvws+Cv7Y/xG0v4XfFD4n+GR8QEik+LljoHw
tvdQg1WT7KkMD2t5EyorBRErEBsYavQf2Dv+CWur+Kv+CUtl+zf8YLjU9D1W3+IE
vizwHfSyGS6t3R4pdPubpMAhhJHlkODxjNe8fs3/ALGn7Z+j/FPT/it+2x+1uvjK
XQLV4PD2m+FdIbTrfexwHnj8x/OIXPpzWx+zb/wT6vPgH8KPjb8Kb74ipqTfGHxN
rWprPb2BjSw+22qw7SNx6Y9RmuCj/wCCS19pn7H/AMPPgj4M+MttafED4TavNq3g
PxmNJMkNjeNIzKXiD/MBuIxuFdt+zf8AsZ/tTaFqmr/ET9rb9rb/AITzxBqPh+XT
LG30jSm03ToQ6Ohd7YyPvOH9R0rx3xd/wRo+J9z+wl4c/ZN+Gv7Q1noniPwt8X5f
G+neJ/7EZoV8y5mnEIjEg6eZj73aovG/7PniL42f8FVfhrqMHw/h1DSfAugM/wAW
PETaC1jaareiGRIGXcSJWEnkttBJGM19peE/B3xpsfjX4g8V674/sZfBl1YW6aF4
dttOKSWs4VvNdn3HOTt7Ctz4peDj8Q/h14g+H4vDE+u6TcWHnKP9SJImXP615h+x
7+yDY/swfsZ6H+yhr3iY6tZaXpBsb25dcboSgV1znjjPPavkn4jf8EPfij8R/g74
g/ZB0z9r290P4LpO914X8J6dpTm6tppbn7U5nug+LhC7PhdowGHpXsXxg/4JseON
R0D4a+Ov2e/jTb+GPid8NvDDaBp3i6700yw/YXi8t1a33qd5XPO7gmn/APBPj/gl
/qv7Fn7QnxD+PfiD4033jHVviDFay61d32QTcpCisVUklUJBIGeBivsGNYirW8Vv
sHl4+ZePpXivi3/gnd+wj4/8WXXjHxz+yJ4F1bV74lr/AFS/8ORO8p9SWBzXb/Bz
9n34G/s+aRL4X+Avwp0DwrplzOZ7qz0HT0tleQgDzCEHJ4Az7V4V+2t+wj8SfjR8
VtB/aW/Ze+L0Pw++KWg2U2lJ4hvrE3UMmnylC6yRh08wfu0+XIzVP9lr9gL4pfAj
wn49+K/ij4u2mp/G/wCI1uBrXjGPTzDbl0KhAsO44GEXjdW1+0P+yL+0l8V/hz4O
8WeAv2mLrwj8U/CulpB/wkC27S6bcSOq+cZrUOu4EqMnfzVH9h79hj4kfAT4oeIP
2mv2kvi5aeOfir4o01NJ1TXNLsDYWS2CyLKqx25d+d6Kc7vWuj039iK7sP8AgpHr
H7dx8YH7Nf8Agm10L+xVXIPlLICx5/26ztX+OX7Q8H/BU3Tvgfb6NOnwvX4Vz6jd
339mOUbVBeRoi+bnH+rY/lXq37SX7Pvw1/aV+Gd38M/idpcd1DOM2F1FHmWzux9y
4j7qyNtYHtivlXw3/wAE0P2xPiHeaf8ADH9qv9uCHxj8IdKuMWvhfTtEeDUb1UJ2
JdXvmsJUA4KlB2r2D4n/ALBek+Lf2pvg18ffCmt2+iaL8ILPULay8MWlhtiKXFs0
OEAIAAB9KxvEf/BPPVfEH7X/AMU/2o4/iR5EfxI+HkfhuLTVgINqywxxrLnPJwnT
HevRP2Df2Z2/Y7/ZX8Gfsyy602pS+FNNeNr9hxKXmkf/ANnr0vxv4C8J/ETw9e+D
fHWgWmraRqUPlXenX0QeKRcYwVPUV4zD/wAEuf8AgnRDNF9n/Yn+HaG3fekv/CMw
q6MDncGxnrXt+jaHoXhjR7XQvDVlBZ2VnEIrKytQEjRQMBQBxivhHxV/wSZ/aS8B
ar4i+H37JP7WGleEPhP4zvZbvxP4P1Lwy1zqNzPO37/y70SqEBUtgbDXq/xV/wCC
dup6f+zb4C+D37KXxu1jwNq/wt09YPBepGdpbbbhQ/2yFSv2hcINoyuOfWs39jv9
gD4vfDT4xav+1N+1P8c7Dxr8W7vw7Jolnr2k6UbK0ismKuM25dzw6ofvdq3/AIsf
so/tAfFr9nXS/BXjP9pOSD4haHqrXei+MvD+nPb2u9SpX7TAHPmL8vOWFcp+yj+w
D8cdE+PcP7Vv7cv7Rek/ETx5pOkT6F4Q1DQNEOm2tpp05DzRPGZJPOkZ0U7gRjB4
rzjXf+CRX7Sng+41/wCC37Nf7WOkeGPgj41vJ5vFHgjVfCrXN7cLcjZdLFcecojL
RcBthweecV3nxE1v4t/seftEfs1/sc/s36DeSfDGaybSvEEtzZtceTbwGOOPfKMB
TtB5Ir3f9r/9mTwZ+2D8B9Z+BPxBvTbadrDQzRSLKD5V1BKs0DkfxoJUQlOM4PNf
JGmf8EbPjf40+P3wr/aK/aM/bGl8R678IPEtte6Zp+naQ9tp81hE2VgEBkba+1VG
/PUdK+i/2V/2MtR/Z6/aN+Nfx5fxdHqH/C1vFMerpEUx9lC20MQTr/0yrpfiR+wT
+xf8YvFcvxH+Kn7LPgfxJr1xGom1XVdBhnnkA6AuykkDPFa/wW/ZW/Z1/Z0kupf2
f/gh4d8HvqH/ACEF0PS1t/PHoSuB2B/Ctj42/DJvjF8GvFnwtjvhYv4l8PXelPcH
59iyxNHu7dmNcp+w/wDs1zfsf/sxeF/2d38QjVj4fSaJ7/y9nmB5XkHGTjG4D8K8
y/4Kr/sxeMfjd8ArLx/8INChvfiB8NdTXXPBscpGGkjZHdfckRjA9a5j4C/A/Uf2
nv2n/hl/wUqvfEN1pF7pPw0uvDWveFtQ0poy+qPNC0zqSRgB4ZAOO9fZ8BUwqVVQ
COinIpLlo0j3yOq4OQXHQ1zniD4Z/D3xprekeLfF3hqw1DUdBlaXSNQuYFLwMylS
VPbg1yP7XX7MXgT9r34Ea78BfilITpmuQeXFKg4imwdj474Jr5m+F3/BMX9p7xj8
UPCmt/ty/tQ6Z498I/DrURqHgTQNH0NrG40+8SIwo885kcTJ5Jxs2ryc5r3jxr+z
T4u+OegfEr4UftF+PYNY8D/ECwaw0/T9NtTbzWcDB1K+ZubnDDnHavm7wt/wSa/a
d8Xa7oPw+/ak/ay0XxZ8I/Bt7FeeFfB9h4Ta0u7YwfLCJJjM3mbU6naMnnvXoH7T
H/BPz48a/wDH+8/ar/YT/aLsfh94p8U6RBpvjSfWNHbUYr+1ttxtUhUSR+QUaSQs
ctu3Dpim+HP+CSHwpuf2NfFH7LPxQ8YvrF74x1b+1/EHiDTYfsol1QEusu3LcBzn
BPI9K5/4Vf8ABNn9qnxX8W/Cvjz9vH9qbRviPp/w3vRf+DLXRfCrWHlXXA3HM0nQ
Rx/XFT/GD/gnB+074V+MXiv4pfsG/tRaX8PrT4h3aX3j/S9b0I309/dqpRGhlEqe
QAjONpDZJB7V71+x/wDsh+Af2Pf2frX4A/D27kltYROdTumG0TXUi/vJAP4ckj16
Vxf7H37PMX/BOT9mzxdpWu+JZ9fsl8S654me5hsGMyfarp7hIETJMpAfGRjOK8a/
ZE+Hvx20z4d/G/8A4KP+PPB72vxR8YaHfR+ErUWxR/7Jt4zNbJJb/eSQzKxwT0x6
19J/sAfE34vfGL9jb4f/ABR+Omkm28V6zoNvdazam3NuVleNSwKHJ6k/Wsf9jT9i
yT9lDx18WPF9x4zfVE+JnjQa15DKQLUi2jix1/6Z173NZJc24W6ZZo3jKSo4ysik
civDtc/4Jk/8E+PEGp3Oqaz+xj8Pr+8vpzNeXN34ahdpXPVizAnNepfDL4PfCn4J
+EY/Afwi8FaZ4a0W3Pyado9usMaH2A6V8+ftXfseftZ+KvilN8Yf2Nv2u1+Hms63
AltrNv4n0h9ZsJFVQqi3gEkYhYqnJyeeazvCf/BKP4bH9kbxn+z/APEbxPeavq/x
D18eJfE2twxmFJdbVkeOdYznYgkjRimeQMZHWuS+D3/BM39qDxF8W/Bvi/8AbZ/a
w0nx5oHw21WHUvAGkeHfDTaYbK4gUxx+cxlk87CsQTgV7z+21+zT49/at+FS/BfR
/iNY6FoWqXqf8JYtxpxnkvbFWUtFGwceTkAjPPWvnX4xf8EedZ1XXbvQ/wBmL42Q
eEfB3jLw/YeHvidoeq6eb6TV9LtIRBbJHIHQIfJBA4PWvs34TfDXwt8FvAmjfCTw
bCttpmh6clpplu8wJ2LzuC9uSa65AyqAzZIHJ9aWiiiiiiiiiiiiiiiiiiiiiiii
ig9K57xr8OvAnxC0mHRPH/huy1WyhnSe3t76EPtkRgwYA9wQK1bKCWyhFu6oYoyB
AkMW0RoOi474GKnkhSdSkkSyIxDYb1FS0UUUUUUUUUUUUVFdoHiwUL9cpnhuOh9q
53wF8N/Afw6s7yH4eeFLHRodRvnvtRj0+AL51w5y7HHUnHNdODkA+tFFFFFFFFFF
FFFFFc545+Gfgr4j2K6P458MWWsW6XSXMEWqWwmSKVSCCoPTGMj3rbt4UtZlgtbZ
FjWMBivG3HQAelWKKKKKKKKKKKKKKKbKgkiaNlDBhgqehHpXPeDvh14E+H8moxeC
vBlnpY1a6N5qBsbcJ58zYDO2OpwBzW/aqywhWlV8EgFRjj0qSiiiiiiiiiiiikYB
lKkZBHI9ahVTCQzKERBhEXmuf8SfDD4f+LfEWneMfEvgzTb2/wBHy2nXd3ZB57cn
P3GPKjk8e9blvDNsWR523yOGdiOgH8PtVuiiq2oLbDZNdEBUbK8nJb0rmvF/xq+E
vw+1yDw344+I2i6Rf3EXmJa6hqCQs6juNxHpVOx/aD+BviTUo/DOg/Fnw1e6jdTC
K0srbV42aRyMhcKc5xnpXWCaV4EZbcvG5wigZIHvmnIJkleFLhVZo/8AR4yPu46m
qkus2UNuuq3txFBBbqzS3Mz7UKAElh7deTjpU+la3o+vWMGt6NqcNzZTRh4bi3YN
HKD0KkdR/jWRrHxM+H2jeKbLwL4j8Z6daa3qS77DSZLlRcSgf3V6ngE1vRH96QkR
2l33txisu58K+G7zVHln0PT5fNTdJ51mjlgCPmyynnI6dO9aVoUVd8MARJD8jKOF
Xt9PpSeZcBhJMWXzJNiqwHye4+tLEkFlGHRSFChU2sTn8+p+tNeeKO5EEeEZhtwF
6se/HpTTdbnZBxKVDRxqvzBM9OePWnhvtKq0ZclWwEwBsPYn6VA39k6Naz67cyW8
Q8oveXjkIm1eS7H2A6+1UoPGfhG7Gm/2d4msXk1mFp9KAuhm7iwCzxjPzcMp/Gth
GCzYaLG4bd7Hlj+FRA2sIFkiiPzTkrLkhx3rF1b4jeC9D8R2fhDXvGen6XqGpow0
7TLq5RJ5CuclFJ5G1TUfhT4g+BfF7XcPg/xbY3y2Eii5ktLlJfKBOArAEkHg9a3F
eC1xHHGcF9yYOfMz6H/Gj7at0hiErK3mLuBHKc/dOKg03xVouuR3K6Lq9ldfYpzF
e+RPvER5yp25IYY6Grd3LGsD3AniSJIy0jE4ATHJJ7YGTXCRftMfs4tdDTU+Ovhk
SiTykjk1eIFWTgqcn19a6jwz4n8L+MNOj8U+Edbs7+wuwfJvLa481WcHHGMjHFa2
yQhUuIzJuADgfdHr9aYdzZkVFBibad+BlfT2rk/E/wAYPhP4I8UQaJ4z+Imi6Rqs
6mSDT9Q1FYpHjbqdpPJxXTrPp0zJqkKxTJNGBbzhASynkAHqVPWk1rW9F8MaRd+I
NfvIba1sYHnubiRwqoApLHJ9hVWXxPoUfhuPxWmqW1tpj2gum1NpFWJIWAYNnpyC
OayPAPxk+GnxGuLvTvh5460rWmslBkbTL1ZvJQnC7sHrnNdNK0ctt9pkAlCDAKEg
k9/1rndR+NHwr8NW9zceIviFolillcm2vJLjUUQRTABjGSx6hSDj3qLwd8cvhN8Q
tQbSfAPxS0TWLoIZGhsr5JHWMfeOFPuK6xH8xiN+50O07hgHv/KkKgAL5RRY23bm
A4FR3ZmaQ7J9u/CxbEBwepY59siuWt/jl8INR8Zj4eaX8TdBk1xJGj/spdRQzts+
+u3PWuli8i4hd5gXkUEMGG1gN3A47Vzl58Z/hFb+Lf8AhB7r4haINYEnkrpC6ign
MvdShP0rf1fVdK0TTJdR1nULewtbPDy3E+1UiHuTwOvUVSn8XeCtIsRqUviWxhtb
mWPyLqW7G13kYKoDMccnAABrRktotRuiZLZBLCP3M8kKsYye6E561bSGKTPmxKxX
jlePwoW2KPuWU453KQDn059qILfyYBCJM+rEDmnrFtbhvlAAVQOBSNEHQxyMWB/C
lSGOMERjGepzQ0YZduevekkh3glXKtjAbHT8Kq2mhWdikcNmiRRRlnEUUSqpkJyX
wB15P51cRdihc9PbFJJGkoAkUEA5GahhsNqBbiYykLjJUDvnoKPsCiVZFlYAA5U8
gk9+emKkW1jWQyLxuOXH944xTjFGcAoMDkDHQ0z7Gm0ruOM/LnqPb3ogtIoMlRyQ
AcDA49hxSLZRISqYEZ5Me0YJ9aVrWNs5z97cMcYND2kUgHm/MwOd2O/rTZbGOfiV
iR1wOOfXjrSz2UN0nk3SLLEVw0UiBlb8DSGxiNp9kAUKV2n92MFe4x0xjimw6Xa2
8KQQRqiRcQJGoVYx2AA4wKkisraIMFTO85bJJzThEQww/wAoGAmOKEjdQRJKW5yM
jGKUwoVZcD5uvHemS2qyR7Q21gQVfGdpHGRmneUfMaTzDyuMenvSJAUl3CT5cfc2
jGfWo5dPEk5lWdlV12yRgAhhQNPAgNuJSF2lRhQCB2/IU5rOMkOmA46PtBI/E1NR
RRRRRRRRRRRRRRRRRRRRRRRRTZZPKG8/d702SZ40LiIvn7qp1/WvOf2ofFvxp8If
CC91L4A+BU8QeK7gx22n2M8gXy/MYI0+c4/dBt5HcL36V8deAvj5/wAFBP2OP2qf
hn8H/wBtP4u6H48sfi3rY07RhpFkIX0dmPKSbY0389G+boea/QTz08zyEZMl9qqS
c7hyR+XNW6KKKKKKKKKKKKiF0huDbBTkDJPaq+qXk0VhLcI/lCNCzMwyQF5OB06A
1+fGmf8ABVX46fE7/gq94F/ZY8GfDC40P4aanY6x9p1vUYAs1/cWsSMNq8jyyWHP
XBr9FBnHP6UUUUUUUUUUUUUUUV+fvxp/aK/bu/ak/a2+IP7PH7FHxQ0b4eQ/CNoz
4guNdsEuG1suqOfL3RybBtcAH5eVr3P/AIJk/teeJ/2wvgVf+JvHOjra694V8U6j
4c1mWMYS7ls5TF56+m/aSRgAZ4r6PoooooooooooooqGW4lWYQRwE9DvY8Y7/jXl
37XP7Sb/ALNnwhvfGuk+FrnXdan3QeH9GsoizXVzsZgrdNowpOfavG/+CNH7YHxw
/be/Zc1n4z/tBaGulayPH2oafa6WiBRbW8SQsi8deXbrX1zGGVcMFByfu9KdRRRR
RRRRRRRRSMMqQD1FVoZo5YQynf5TkEKeSR6Zr4E+O/iT/grqsPir9pLRPH/h3wN4
K8JSTXB8HXdoss+sWsPzGQSNGxj3KNuAy19Z/sc/tFD9rT9l/wAC/tH2OgHTE8Y+
H7bUzYTH/VeYoYhepI9M16lRRUU4MjiPyicDcrA4wfSvmH/goR/wT0/Y4/aV+G3i
34vfHj4CaP4h8QaP4K1KTTb6/iMj2siWsjJIhBGGVgCD618u/wDBEf8A4Jy/sO2f
7Efgf9qe/wD2dNEfxrouo6nfw695Ra5d4LmZUJOeoVQKyG/4K9/tg+JPh3fft1+C
vGXwv034K6feSG88G6zOkniBokfY2xhMuzOOEMZI5Ne6ftT/APBRf4rHTfhD4N/Z
Ys9B8O6/8YvCX/CS6T4p8bANpVhbbYm8mVyyL5hEykJuBO04HFcR8ZvjD/wUX+If
7Bvxf8G+I7XwTceMNJ8JXMh+ImgQ50bVNPKHzI4MSsFlA38bz9K9J/4Imaf+0ev/
AASt+HQ+KGs+Hpdal8JRP4TvLG0Kqtm0Km384FyWcLjccjJ7Cvh79kv4gfFrwL44
/aH/AOClv7fPgvwz471/4P8AipND8KXltBtu9PmuGhiiMJLsI8C4XcMZ2k9M19Ue
Av23v+CgHwC+Jvw7sf254vA+s+EvjBrUOjeEoPBunNaXWnyTsixtcO8sgf8A1i5w
F6HpT/CP/BQP9uL41f8ABSj4ofsR/C74aaWvhf4ca7ZrceK5YSENo9rFI8TNuwJN
z8DqQM4r6D/4KIftjTfsZfAmx8aaT4b+26r4o12y8OaJAEJSG+vpVghlk/6Zq7gt
04HUV856b+3F/wAFGf2bvitpX7P/AO11oPg3xN4m+IemzN8OYfBWnNbIkyAlRcFp
JN33Tn7vWtQf8FVvilrX7Fvg7VvCWi6JJ+0Brvia20LWPA0abootSjmj+3wj5uPL
gdXOTxmuQ8T/APBR39tL41+NPF1p+zT4u+FXgzSPh48dl4w07xzeRJcvdbC1w0Je
ZOA6OFbBHI61P+0j/wAFq/iZon7GHwS/ao/Zs+EsPiK9+KHihtJPhy4lGbnGEYxd
MjdluM4HNepfF/4//wDBSbwx8LfDHh3wt4U8CeH/ABt4giur7U/FHiUrHomjQq6+
RZSkyKGuAj4xvBYoxAHNeRSftvfFX4//ALKH7RX7NPx91XwzqHjTwJ4GuLi/8V+A
ZQum3MLqFTylDyYYOTk7zXA/DWa6j8S/8E1Q+rXLPJ8NLtZE844u3+z6dgyevOTz
/eNff/7f37WFh+xP+y74j/aDudES5/sjyY7GOT7vnzTpCpYegL7ifQV8lfD/AP4K
T/te/CH40eB/CX7WfxC+FvirR/i7qSab4GtPASL9q025lZVja7VZpDJGDIuSAoGD
k18D/tW+Dv8Agpb8TfHv7UPx0+KPiHwDq2tfBHWYLLS9furJpbzw9BOIXj/s4LNm
IskgDHDfeb1r6g/Z5+InxC/Y6+EXwz+B3wI0X4beFfj58bvC48S69498RRiPTrpI
o/NEcoeVd7H5gAHBO7ivov8AZi/4Ki+LW0b4u/Dv9pK98OeIfGXwY0iLUfE2peBc
f2VepJEkgjiw8gDfvFz8x6Gp/wBkP9rT/gox8WrfTPiRr3wx8P6p4J+KmkXN78Np
9NiMf/CO7YmaEagdx3qSBwNmeQOa+fP+CMOn/wDBRSVv2lotP8V+C21M/E6YQ3M2
muY1vPNn89UTzflTfuxz6V+rlpY/adA/sXXre3ne4tfKvVWEpHOxTEgCk9Dk1+Vf
/BST/gm/+wRr/j/Qf2W/2cf2SfDOoeNviP4qibxxqdjAXudA0uRibi6R1P7lxuBB
PSvv/wCFHwb8DfsEfsmw/D79nv4a3OrWHhPSSbDRLSXFxfSqOQGIOWJ9q+Zz/wAF
gf2zzD5j/wDBHH4lxIFUmc68jkZ7mMW24V9o/DPxbqnxQ+GGmeMPEvw/m0C91a2W
a60LUZAZrfnoxwMEEZ6elfHv7bv/AAT6/Ya8JeB/iN+1h+16snjLV3juJPD+t+MJ
zcNoL4YwQ2pG3y/mIA69BXr/APwSkPxwtv2BvAcn7SF1ez+JVt7qQPqUu+drNrqQ
2ZJ7j7MYgPbFfHf/AAcd/Hj4rfEL4Sar+xh+zn4gvtM1aDQpvEPifX7B2EVrZ2yN
K8E0i8IZFRlwSM5xW9+3rr3jbw1/wSU/Z/0zwrcXdnYeIrvw1p/jFYHKQ3GnTaeX
l871RiqHOcc1zWhzfshfst/8FePgl+zx+wI2keH7bxHpuqzeO9J8LKWtNRKWTPGr
yKxXerDcR1Ga+3/+Ck/7VVv+x5+yR4h+Ml/p1w9wyLYWJtn+aCeYMEfOOgwTX5jf
8FEP2aPgJ+y98Af2VPCv7Z95Drdp4g+IF7qfxL1iW3e4m1SaS03or7Tkp/q1544r
rdEh/YZ1f9p34Sy/8Eb/AASuga2nxEsh8RxpOhz26DRA589WZuBkfhxX6Wfti/tC
/Ef9mX4VR/EH4Zfs9a78TdQF2lu+h6DdiOZVOP3h+RsjPHSvnfwN/wAFXP2vvFvj
mw8Iav8A8EkfiJpFte6hFbPqlz4gjaKBXbBkfFuMAdTk19L/ALWXiHxL4X/Zc8b+
M/D1zPY6lZeEbqe28iYfupRGT+Y6Zr8pfEH7OXwR8Ff8EePh1/wUU8L/AA907Svj
PrCaFd6j49hjY3jTTSjzSGB53V+tWl6/q15+zlD4mbUi19/wgkdy9w43MZjZCTzG
XqDu5r8iPDHwP+Ffi3/gjNrX/BSXxJ4Qgu/jlZQXN7H8SGY/2h56kEMJM9Oa+if+
CmHgn9qH43/8EodG8U6d8a5tJ8OWvwa07XPFd9YBk1LUNQaK2dVEobmMq7kjbycc
17V4A/Zv0r9rD/gk94S+E2pW0Fze3XgKGbw5fXzHNrqahjb3ROR88cgSQH1Wtn/g
k1+0p4g+Pf7NEXh7xxql3qPif4b6pN4S8T6rdIR9uurR2ge4BP3gTETnnrX1PZpL
HbiKeUyOvDORjNS0UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU
UUUUUUUUUU2VnUfIuTg4XOM/jXlv7U+l/tVar8ILy2/ZE8SeHtJ8aZ/0SfxVp7Xd
uB6YV09u9cp8FvGHxr+B/wCy5qHxA/4KNfF3wnHrOjPLfa5rfh22/s2wt4Y1DiCN
ZZHyflPRjvLYHNfM/wCyP418Aft9ft7/APDamqfEbw3N4IsNPW2+E/hG88QQTXy3
a7BLfR24YPFuZS2Cv8Y5r9C1dvM8tt2532t5fAyOc+3FXKKKKKKKKKKKKKztUt9T
mgulsVCTmJhZyznfGsmOCVGDjOO9fNf7OXg3/gqbonx91TUf2nPi14B1X4cPv/sr
S9A8OSQ3seW+XfKZmDDbxt2jnmvHP2s4rTTP+C5n7MltE0cFt/wifidFs0ZVVy1t
CNxX1FfoQAAMAUUUUUUUUUUUUUUUV+dH7K3jLwV8Ov8AgqN+1dqHxW8Q6X4bhvZI
Bpd94h1GK2S5TyIc+UZSoYA56Zrr/wDggnZXlv8As6fEa8uIJhFe/G/xTcWU0n3b
i3a+YxzRn+KNlOVYcEdK+6KKKKKKKKKKKKKKrXNqstwJpIVym3ynxyDnn8Kpa/aW
0ml3kssAk2QyODIoxE3lsNy5/L8a+JP+CAF291+yr45kku/tbr8Y9ZIczBti+Xb4
6dO9fd0BVo8qCASetPoooooooooooopHICEknp2qpMscphjUu0m0vC7jgEY61+fX
/BTH9rXwV+0t41g/4J+/Az42eG9O1RdRt5/HOs3nia3t7W1tVceZaPuYZZl7Z79K
+4fhT4e+G3gvwHoHgf4T2dinhyws1g0IaUQYI7eNRtCspIYY7jg12FFFFch+0JpG
r+IfgH440Dw/ZPc3994Q1O3sbeP70sz2siog9yxA/Gvm/wD4JKfCH4h/Cj/gm5oP
wm8ceG7nRvEMb6tC9hqY2lZZ55WUtjJC/NX5vfCH9gn4efAjwy37IPxI/wCCa/j7
x98TJdXkVfG9rrVyvhb7Q828NcYmG2NQQTiJs196f8FBPhz4i8O/AD4f+EPiB+xh
H8UvBui6Fa2XiTw58P7uRNY0+6SJVAsMeXm3G1gWLqeF49PK/wBiz4D/AB2n/Z8+
PVz8Pvhf4v8AB/wq8TeAr2y+GPw18YzNLqlpfNC4LMHkk4JJH3zX0J/wRP8AEvxB
uP8Agnj4B+HXxP8Agh4h8FeIfBegRaHqVj4hgVZLm4to1jeeMBm/duwyvTjsK+a9
G/YS+PXxo/ZR/a/+Dlz4Vn0XVfGPxXtNb8PDUF8tL2O2SylYKRk/MLcge+BUn/CQ
/Hz/AIKJ/FT4HfDfTv2TvGnw8Hwc8U2WtaxrvjfT44bPUEtnibbbMjuW3eWcZAzm
vev2EfhH8V/B/wDwUU/al+InjPwTe2Hh7xb4m0240G9mTEd0I9Pt42IwefmVufat
j/gsJ+zl8Sv2jv2btFl+GdjHf3PgrxxpHimbSY3ImvYLC5S4lijwOWKpgDIBJrw/
4ea18af+CkH7e3wk/aFtv2ZvGvwz8P8AwihmbUj48sI7dtQLAri38t33D5uM44FV
PhL/AME1fE/hn/gqheXV74d1y18AeFdfufiNovi2VAFvda1RRbXFmWDZKqltEf8A
gfSvCfjD+xL8Pv2ev2rvitq/7R//AAT3+JnxkuviV4kGp+G9b8CalNFZQRtv/c3K
JPGoQF13Hax+XpXtn7Rf7I/xr0H9n/8AZQ8BeEP2fbfSm8IfERL3V9G8MTPcJpFs
QhBZ5ArLx97Hoetd5/wV5+GPxQ1n4o+C/id4v+HXiX4kfBXSra4tPEvwv8EXLx6p
e6xMyGzusK8YMSKsu5t+fnHBr5s/Y0/YW/af+FWi/tfwT/sv3Xhiz8aeEW/4QbRD
eyXLTFkTEO+QltwHJXOM5r1z4c/s1/H23179gOW7+FN+IvAnw5ubfxs5TB0qdoLA
BW54O6N/yr6X/wCCuX7NHi/9tD9g7x38APAax3F7erbNLbbyskqw3MU7JGwGQ7Ro
VHI618S/sUfs2fCHxx+0l4B1f4N/8ExvGngy88FXsE2teLviVrt0YWCsv7yxTzpV
YjaSQQo5XrXT/Ef9mv8AaM1v4Xft82mnfCjVrmT4heItLm8Hwm2RX1LyobRH8tgc
sBsb8qyv22P2KNQutF/Z8/aM+On7MviT4g+F/hx8PZNI8T+A/B9zJFrsc9xbiKEq
EeMYV8n/AFg6Gu7/AGN/2Nh49/Zy+McnwX/ZAufg7o/xM0Eaf4ftfFWpTT61JIiK
pe7WRpAq5QjIdjyK7X/gmb8Vf2sNDs/h9+xhc/s6ar4e0r4VaK2meO/E/idfIg1W
RQwVtPEZYSrkg/OFrh/+CenxG+M/7IfxE/ad0jx/+y943vIH+I76t4fvNP0+N4b2
CZ5nBDNID/Gvavu746/FXWfhT8CdV+MGi/DTVfEOo2Gmrd23hnTxm7nnIBSJRuHO
7AIz0zX5bfsQftu/HX9nv4g/Ef8AaF+N3/BL/wCPmqeOfiRrST3MWm6FbTppFopk
8qGEyXIIUqw3Yxyg61+knwo+JnjH9sf9mWbX7Lwp4r+Eesa5bSW9vDrthEuoacTn
94Iw7Ln8a+Y5/wDgj9+2W9mYI/8Agsv8VGb7QGVJ/DVknmBT90sr52mvt34aeE/E
HgX4f6b4L8ReK7nxDqGnWaxXGt6hEI2uyOrNt6Gvy+/4KK/tQ/tB/GH9qg/BTx7+
wP8AFnxH8EPBt6ss6eHNKhkXxHcI2QxLTKSmV4/3jX3T4X/as1O2+DXw08XaL+y3
46sbfxReLp//AAjsmnxNd6Fboron2oGTCDCKRgngivjP/gqL/wAEZvif480f41ft
J/AD9prxt/b3jTTJFk8A6fpFvcQ3ZRXZYA8jblQlyDjsa9g8Ifs+ftEfA3/glH4P
+DOpeFofiv4mtPDlrP4k8K68Sk8lqYh5lvblQdssW5UXBXoeRXhH7Fv7Pem/GX9s
D4VfFz9nv9ivxb8FvC/wlk1Q+IG+IOXu9TFxamEGKVpJXkG7PLEHFfWv/BYn4A+M
f2lf2EPEfg/wJq1tBd2M8ero9ypKTRQ7iYhwfmYMMcdutfPn7QE2of8ABRnw3+xx
8c/gf8J5da8N6Z4xu5fFWmaxZRyppsCWJh/0lG3YG9DtyDyRX6GeFfhT8KvAt9Lq
XgH4aeHdGvJ1xJc6Vo0Fu7r7tGgJrgP2wv2dviF+0l8MF8B/C/8AaF134bX0d4JX
13w5bJPM3HKMshAC985r528Bf8Er/wBrHwX430vxlcf8Fa/iX4gs9NukkvNIn8O2
ardbTypIfoa+q/2iPh1rvxU+APij4V6DfRrf614cm0+K5unKZkeIjOADyf61+Wsd
l+0T8T/2LPBv/BHC3/ZF8faVrfhafTdPuPiBqtjGujMtlIC0okWQtg9fu9K/R3Sv
FPiGPVF/ZHk+H2tm4t/hv5Nx4tS1UaU9wsCQBRLu3k855Wvza0zw/wDtJeCP2Ibz
/gi1N+yL44v/ABBfrPp3/CyLeyj/AOEfG7H7zzt4fHT+CvuT9rX4E/EqD/gkb4h/
Zz0mxfXfElj8KbLRItO01eZ7iGKCI7G4J+4a3vgR4x/4Y9/4JqeG/Gfxc0ebT28E
/D03Oq6NcsBPugjeRolJzmQhcAepFcB/wRM+EfiTwL+zFq3xU8S3W20+Kvi+/wDG
eh6fIpE1nZX1xJcxRy+4SZRjJ6V9nW5JDBs7g3zHsfpUlFFFFFFFFFFFFFFFFFFF
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFB6Vw3x5/Z7+E/wC1B8L774Rf
G3woNX8P6lj7bprTNGJMHIBKEGvHfgR/wSN/YL/Zu8baX8Rvgv8ABGTRtW0c406Y
a1dMIB3wrSEY4HFfSSufMQYyd53CPnHHerNFFFFFFFFFFFFFNl8zgRgc9Se3FcR4
h+A/wv8AFfxa8OfHDxH4VguvFHhazuLfSNTeMFokuFCyAfgoruRnHNFFFFFFFFFF
FFFFFeG/tO/8E+P2SP2utfsfEXx2+FH9r3mnHEU9reS2u7qf3hhZTJ1/izxXp/ww
+HXgz4V+EbLwN8PNAtdL0jTYRDa2doMqqgYGSeSeK6OiiiiiiiiiiiiiimzQx3EL
28yhkdSrKe4PBrivhF8C/hr8A9CufCvwn8LwaPpd1qU2oX0ECACWaQDc3v8AdFdt
GyvGrr0IyPpS0UUUUUUUUUUUUjAFSD0xzVZ9kabHMjK67VQdQPqK+VPGv/BFD/gm
3418e6t8TfEnwB3634gufO1O/g1q6jaWTg5IWQDsK+kfhn8OfCvwk8G6Z8OfAtj9
n0nR7dbezhedpGRAMAEtk9q6SiiiimNbQvkFBgjDDsaa1nbsMGMdMfdFNOm2hlWY
x/OiFEb+6p6gflUohjVDGFG1uoxxTVtLdQirEAI/uADAFNlsbefi4XeM52t0z60g
sIQpQk7SeAABgenA6VKsaJ9xAM9cDrQ8aupRxkHqD3HpSJbxopRVG0/whQAPypGt
YJBiRA3IPPqO9JJaROhRflznBUDIJ78imSadbvD5KFkG7IK9R6jn1p5tULKQx2qp
ATjH1/ChbK2QgxxBSowCByBSvaxugjBKjdkhe/t9Ka9lFJGEZmyv3WzyP8jigWFr
5BtvKXyzHsKYABH4UGwtNqKsIXy/uED7tLJZxySiUMVIGGAAww7ZyO1N/s2y+cfZ
1xIQXAGAxHepBbRKRtQADsAKZJYW0srSPGCHQrIm0Yf68c0ptIWKkjJUkgn1xikO
n22Q4jUSBSvmbBu5/Cl+yglczPhRgrkYb68UsVtHCNseQoACp2H0pJLRJYTBJI7K
Tk5PWkawtXkEpiXcgwh2D5fXHFK1lA/DqGQDiMgYB9frTRYRG6+1yuzsAQgc5CZ6
4+tLFYxwuWjkcKWDBM8Lx0HsetA0+0WY3CwKJGABcKASAcgfSo7rSLG9tHsb2LzY
ZQwljkAIdT1U+1cP8Dv2Xvg9+zrNr83wq8Of2ePEeqNfX8avlFdlUbUH8K/LnHqT
Xem24QCeQbTng/e+tONvESflxlssB3PvSmJeikqPRaa9usj7mduBwPQ+v1pPskO4
sVGGHzDaOfU9KaNNsBE0ItU2uMMMdacbSFmzIobgYDAce9DWkbIsakqqtkqOjex9
q4n47/s5/DL9o/whD4G+Kumy32nQ6pBfJCJduXidXCHjlCVAI7gmus0bwx4f8O6f
FpOhaRBaWsMSxRW9um1ERRgKAOgA7VdSPZn5ycnIBPT2FOoooooooooooooooooo
oooooooooooooooooooooooooooooooooooooooooophgzGY/Ofk5znmlWNFxgcg
YBpQuBjcevWlooooooppdizIowR0J6GmrKDIIsnI+98pxSPM8cuGA21IrBhuU8Gl
oopssYlTYWIHsaJIt7BvMYYBGFPrTgMADOcdzRRUJnuEiMj2xJ34ChudvrR9ocyN
CF+YD5Wxwc0Nc7ZtgkU5GAo6k96mooopp80OTwVx8oxzmhmYD7vQcmoIri4lJ2le
u5coR8nb8allkkCfusFyvyqxxk0nmSjKl0znIAHKr7/rUm9du7nH0pEU7vMLk5HT
tQY/3gcOwwD8o6GnVHLKUBUON3UcZ4prTsskZLfI5wB5Zzn+goM0+1tkQZg+Mbsc
VMMkZIx7UUUUUUUUjMEUsx4A5qKOS5EWZIw7eqnAP51JGzOMsm056ZpXwEJLY461
V+0h4ftDMXUqFaNR0yeTU9ssiRBZWU4+7tGOO36VJRRRRRTJTKNrRsoAPzgjqMdq
ihnuLhVmRVVHVWXcOfcVYoooopGUMpVhkEYIqOGzgtlK26lAR0U9KSSzRwNsjqwb
JZTyac9ursHV2Q5BJU9fY1JRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
RRRRRRRRRRRRRRRRXzj+2r/wUt+Bv7EXjrwt8L/iL4Z8U694g8aK7aFofhTTVubq
eNDtd1UuucEjPPeqX7O//BTj4cftF/Fm0+D/AIY+A3xT0K5uopHh1PxT4YS2s1CK
WIeQTMQTjA4OTX0otzazRBnlTOduM8g+lSrsjTG4YUc0gnhIUiQfMMrz1FILq3LB
VnUkttGDnnGcUG6twQpnXLNgDPU08OjZKsDjrg02W6toIXuJ50SOMEyOzYCgdST2
qvYa/omq2X9o6Xq1vc25OPOgmDrnOMZFEXiDQZ79tKg1q0e6Q4e2W4UyD6rnNSX2
qaZpkXn6lqMFun9+eYIPzJrxP9nX9tn4e/tK/Gz4nfAzwZZXcGo/CvxD/ZeqXUuD
FcNhCSpzz96vYrLX9E1W/m0/TtftJriAESQQzqzx/VQc1w3gn413fin40+I/hbef
DbUdOtPDtqlxZeIbsKLbUAx2t5bZ5xznOOhruYvGHhSfUItKg8S2ElzOhaGBLtC7
gdSADz1FTXuu6JpkCXWpatbW8cj7Y5J5lQMfQEmp7a6tbyIT2dzHKhPDxuGB/EUk
99ZWsTTXV1HGirlnkcAAZxkk+9HnRzjbDcKd6gqVOePUV8Z/t1f8FW/iH+xT411H
TbX9hP4neM/CmkaabvUfGnh/SRLZQAYzucuOhPp2ri/2Zv8Agt94i/aT0SD4iT/s
A/FzRPAE/hm81+LxzdaGq6e1rbwtKG8wS8hthGcV9a/sjftLeDv2wvgFov7QfgWx
urbS9a81rSO8TEihJGQk8ngkEj2rkvgD+3b8H/j/APEL4seDrG0vdLn+EGvz6Z4g
u70BInSKJJDJnPTDnj2rxrwL/wAFtvhl8RfHusL4F+AHjrU/htoNxJDqvxXtNKDa
NbNG21y0u/IAIOcDtX2D8Mvip4A+Mfgiy+I3w28TW2raNqEW+1vrV9yOK3zNEJFi
Mg3MCVHqBTqilWVlzGQjbsBtueK+T/2hf+CvX7OP7PP7RN9+zPqHw/8AH/ifxZp2
mLeapZeEtDW6+zQkrh2BlXAO5efeuw/ZJ/4KCeAf2ufE9/4Z8K/Bb4ieF5LGIstz
4x0BbSOYDP3SJGyeK+gY7m3chEuEZtueGHQdTTo5opcGOQNkZGD2pEuYJCwSZTsO
G56UefDuKeYMhdxGe3rSrLE/3ZFPGetJFcQTgNDKrgjIKnNQ6nrGk6LaPf6xqUFr
BH9+W4lCKv4mpYLy0urZby2uo5IWXcsqOCpHrkcYqtpniTw9rk89po+t2l3JbEC4
jt51cxk/3gDxWb4x8WaN4I0O81/XdYjU2NpNeC285VeRI42YqqkjPArz39ib9sbw
H+2t+zpYftF+DbOXT9LvZpYiL3C4MeNzZz93nrXqkWv6RfWktxpeoW94I1OVtplf
JxkDg9TXDfBD42TfFLwldeMPE/gq88Jta6vJYfZdYKxmcjaFYHOOS3FdvpviDQL+
eaw0/WrWeeAnz4YrhWaM+hAPFP1DxBoWk3ENpqms2ttLcHEEc86o0h9gTzVsMrAM
rAgjIINRy31nBKIJ7qNHIyFdwCR+NPSWN0EiOCG6H1qK21PTbyB7m0v4ZI4yQ7pI
CFI65PaoJ/Evh22t4bu5120iiuB+4kkuFVZPoSea8u/ba/a28A/sYfs4ax+0l43t
5r3TdDMJ8uzO7zGklSIcg9PnrvPAnxE8H+OtIsdT0PVYt+pafHeR2LzqZURxkZUE
4+ldGBgACiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
iiiiiiiiiiivy/8A+CvmsfGjw7/wVh/Zj1v9nnwVpPiPxbFoupLY6TrMgSFkM6bm
3Flx25yK+jvhH8VP2/pPDfjDW/2qPhX4D+HOmad4buJtL160uQy28wjf53ImbAXA
PavzH+Nn7YXjH4DeDtH/AGlfg3+218YvHnxIj8bQWuvXl3oskPha7sJXc+Qkj2yq
YgAoDeZ0A5r7ln/bH+KP7Ln/AAU28S+D/j545kufhz46+E7eL/Ba3MyrFpt7BDLJ
cWaMeGPl27MAM53ivnzwx+1X+2f8Vvhp8MPh5N8c9Z0TVv2pfiVfXmia1tVLjRPC
sdyBHFDuXCu8NxHjIP3a9gufHHx4/wCCen7c9v8Asqan+0V4j8feDPiN8NtTv9Df
xNKkuoaPqFtbXEnmq8SIoU+R1ZSPmrxL9kCD/gqV41/4JweL/wBvzS/2pPE3jj4j
zWN/Z+FfCDXNvHbQWcYxE6llAa4AIPBOT2rvP+CZn7Tdn42/an8J+CfCv7bXxGbV
5NCJ+Ivwp+L2jS20smoHLO1hK1vCkgBPAUv8oJr6H/4Li/FXxP8AD39knTfCvhjV
pNMPjr4i6D4XvtRt5drra312IJQpH3TtbrWZ8Ff2E/DX/BLv4IfE3xt8Cviz4ivt
Om8Lm/s/D2o6gJmtrlYV3SgsMgM+5v8AgVfEep/s5+Dfhn/wTf8AAn/BZfTfFOvN
8ZtYvtH1HUdROrOYZRd3qxS27RZwflJxjoTX0Z+0B4as/wDgpF/wUM8IfsZ/HjUd
Wi8GR/BiHxkLXSLtrZ3vWFr95v4uZ249q+ef2StS8X/8E/Php+33d+A/Fd3qer+B
fGLpZa1fP5zyDbCPLyoyX2nH4iuJ/Zt+Lup2Xj/4Q/Gr9kL9i/4ueHfiL411bS3+
IXinXZnOk3tncx+ZcSgOuOWIK4PQ19C+KfGHiiD9tP8Ab4tZvF2oraad8IlktLeK
4P8Aob+WDviH8JLZ6V876t+w34T/AGb/APgkn8DP+Chvw78eeL7f4oSX+gXT6rJr
DSLcx3Sb3R0IPB2ivYv+Cov7UPhbx1+3jpn7IH7RfwF8bfEjwVL8JbDWDo3gSZ0u
YL13XM7FQfXFfSn/AAQh8cfGfXvg7468G+PPhd4j8JeC/DviVoPh5b+J5N98bHc+
A7YyWAVO3eqn/BwD46/b78Ofsf8AinS/2XfAOhX3hS60OM+Itdu52W8s/wDSI8eW
FkU9dvIU9a77/gjB4u/bc8VfsneGV/a+8GaFpNnbeGNPXwteaVKxkvoQpxJNukYh
yAuQcfSvVv8AgpFNMP2FfiwsGN6eEp9nyeu2vB/2GgG/4N6fDmxkYH9njU/mcY+b
7Fc9fxr5X/4JWfFr/guZpH7B/giz/Z//AGd/hZrHhWKO6TSbzWr10upY/PblwLlB
1zj5RkeuK85+EWufH9v2Rv2+/EnxR0+20f4kS/Etf7d07QZd0MKk2vmbSGb5due9
fq7+wn4a+FP/AAwn8OLDw7pelL4cvPAFi+rW8AT7LLI9sjXLynpu37icnqTXVfsk
2v7POnfCqLS/2Z760uvDcdzKIHspN0QO87th7jdnpXp8AVPk3MxycFh09qlqKaSR
JBlR5eeWzX5OeNfE/wC134Q/4LzfFvUf2U/hJoPii8l+F9qmpprcqoIIN9qRImXX
Lb9q4GeCeK+jfiD8Zf229A/Yn8eeKP2mb3wf8EPFFu6Q6T4l0XM8UMcpKrIu15CZ
OOB1yOlfE/wg/at8QfBH9uL4EeDfgj+0h8ZPG/h74j+IE0r4i/8ACx9ONrZXbvBK
zz2Ze3i+UyIGHLcGvbNB/wCCg3xt/ZM8PftbfBD9o/4i3GteKfAd3LqPwtvLkgTP
aakDbaZBEMDeUuEJ4B61n/DrXv2v/wBpf4wfC3/gnl4//aS8S6RNB8KW8Z/EfxPp
jxxX91eXJt5orMh0OFjW4ZPu/wAA5rE+I/7VX7W37Jvgj9p/9lCX49at4g1b4Y+F
7DxD8PvHetSxyXsEU1z5Qhl8tQMjY3G3vUHxB0L/AIKK/Ab/AIJ1eCv2h7b9p3x3
8RtY+KMmh6n8RLjS/KbUNI0ie2Msw06IR7jgSKCNrnIH4+y/8Eivj5pPxR+K3i7Q
vh1+2N4j8d+Exp0VxYeEfiNYPaa9pV5uVZVZHiiJQKCeE61X/wCCt+kzftJ/twfA
L/gn/wCNfEF9beCPHNjqmq64NIuzDczmza3CoW9xKeMVQ/bS+H3iT/glL/wSl134
Z/Bz4u6rq6yeKLHTbHUtXu/MubS1ur2GJrcMMHIWVjmuS1T9m7Qf+CUv7d/7Pyfs
7eJtae3+MGp3Gl+ObbWdRNwlx5fkfvUHYt5zEfhWdH+zdpX/AAU6+MH7TfxE+M3i
jU4PEnwh1abw94JvbDUjDbWcLWH2nfImeeu3PvXg/wAKP2lfEf7Mv/BBj4J+HLXw
5qniWy8T/EBdB8RWOgZ+06hA0sCSiJhnBKucGvYP+CXnifWfAH7ckvwt/Zd/ZH+I
nw9+EureDL+98UDx3ctI8l8rhVePcARwTXiHxE1Hxt43/wCCJXjLSZviDqr6hqP7
XVlo0esJfFJoLV7+xUoremHb86+g7j9k/wAI/wDBO/8A4Ki/s3D4EfEPXY1+KOnv
Y+N7XWtVM8WpeWsYGxeMMfx6V8+/Hz9pnwX+09+0H8bb345/sq/F34g+Lfh/4uvN
L8B6/wCA5njsdP8AIgSW3gcbTysrbmJ/hav1m/4JgePfjl8Rf2H/AAL41/aM0OTT
fFc1hi+s7v8A1sMIwEVvVtoGa/P/AP4L/wDxE/4Kl6L8Y/hlpHwn+HPhtfA9v8S4
W8I6ot8y3WoXXkgiC5VZhiMnd1VfrxX6cfsu+JP2lPEHwcste/a18I6D4f8AFrl/
7V0vQ5TJDEo6bW3vnPPc1+Wfxa/aA8WfsWeIPj3+wnD4n1HUNT8ReKLO58IXE9w3
nyW949usixd/lEsnT+7WD+3D4x8D+E/2y7X/AIJ0ftE/A74kfFHwf4N+E2iHTF8B
TutzDMY5Q0kjAHLfIMn2qv8AFDxX8a/Hf/BAH49eFPir8Ntb8IaPpPiOx03wFZ+J
Jd94umtcwYMjf3gxx2rtviv+yZ4X/wCCbXxF/ZU+M/wO8Ua2mv8AjrxbY6F4za91
Uyw3kUzW6kqnbHmt61+xtFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
FFFFFFFFFFFFFFFFFFFFFFFfO/x9/YatfjX+278LP2un8bPZT/DXTrqCHSVtQwvR
LIrnMmcpjHoa9N/aL+BugftJfA/xT8C/GVzLHYeKtFuNPuJIWw0SyRsm4epG7Pv0
r4C8Vf8ABE39rL4m/snW/wCxn8Tv23be28BeE0j/AOENstC8Hw27kQfLAt2UkH2g
beCGzmvZf+Cg/wDwSes/+CgHwC+HPgb4mfF6bw74l8B38E0viXQtLUPex7Vhmt9o
ZdkbxZUgEgbjxXX/ALU3/BNbwh8b/g18P/Cnw68VyeCvFHwhmtJvh74osrYStZG2
QKsbx5UPG+xCyk4O3vXMfCH/AIJr/FDVvjNq37T/AO2B+0Onjzx/ceDrrwz4dnsf
D0en2mlW00citIsMblWfEj84HWk8Gf8ABKk+AP8AgnTbfsA+Hv2hvEGm39rdyX+l
eNNILW1xDcKQyZCOMpk8ruwRWR8N/wDglp8afF/7VPw5/ah/bG/aXtPGerfCaIjw
pFpPhSLT5JpfKaIS3M0blpvkduG7819Dfts/smeA/wBsr4Aaj8GfHV49jvnivtL1
eCANJp99Cd0Nyi5GSj4bGRnHWvJ/2Iv+CcHjr9nfw34ptv2jf2otf+LupeLbL+zp
7zV0a3hhstgVUSHzHVSFVeR6V5Z4O/4IpeNtO8daX4L8T/tbX2q/A7w/rRvdJ+E0
mgIkasjB4g9x5hLhWAIBWvYP2yf+Ce2rfHfxV4e+Mf7PHxsuPhf438O6a2kW+v2W
lLdedYErm3dC65HyLjJ42iuQ/Y5/4I4+Ef2bvB3xf8HfEj4p3/jy3+MWrSajr39p
RFGjmZFBO7cxc5QEE1S+Ff8AwS5/aW8PfGrw7qXxa/4KC+J9f+Hfg1lk8JfDvStP
OmxxLFhYY554piZkRPlwy4NdVqn/AAS80K/+N3x9+K3/AAtK5ST44+DzpF5aCwH/
ABLVK7d6tuzJ0zg4qL4pf8Es9E+I/wDwTi8B/wDBP6X4v39raeEBo8cHiSKz/fTi
yjKLlN3G7vzVv9q//gnr8Q/iZ4hsvil+yx+0Cfhb8SovDkPh+78ZR6Cl+91YRgHa
UZ12tkdcmvRP2Hf2Utb/AGS/hevgjx58atf8f+I9Qna61jX9buXZZpjyTHEzMIRk
nhTXsOv+F/D3irS59C8TaNbahYXUXl3NheQrJDKuQ2GRgVbkA8iptN0bSdG02DR9
J02C2s7aNY7a1t4gkcSr0VVHCgegrkf2kPg5D+0D8CvFPwWl1h9OXxLpL2LX0abm
hDY+YDIzjFcH8HP2M9L+D/7A9h+wpD4zlvLa08A3PhZdee0AZllhkiM/lZxkeZnb
nnb1rS/Yb/ZVtP2K/wBmLw3+zfZ+KZNci8PpLFHqk0AieYPIz52gnb16Zrgv2cv+
Ccvw7+DnxD+O/iPWfEreJbP41eJJ9Q1nSbzT1jS1SWJIzCDlvMwFyGIByfavnO//
AOCG37TWh6Rq/wAEPg7/AMFI/EnhP4P6peSyN4Kg0bzriOCRi0kCXhmDopzgYHAF
fdn7NH7Nvwu/ZR+D2j/BP4R6L9j0jR7URQh33O56szMeSSxJ/Gu8MYMgkycgEYzx
TqiuYDKAQN2DnZuwCa+fvhx+w1b+Bv8AgoR40/bnPjua5n8VeEotDbQmgxHbhJIX
EobPJxFtxjvVv/goX+xJo37d/wCzhd/BHU/F9xo9xHqcGpabqKR+ZHFdQOJI2kiJ
CzIGAyjHBGR3r5k8U/8ABKD9sn42eJ/hf8T/AI3ftj2F74m+DmuW8/hvTNM8Iw2u
nPBHGyAvGj7S5Ujtx0r0X9tD/gjx8Pf2yP2xvh5+1zrfxAutMm8ImBPEfh63t/3H
iBbd/NtvNYMP9VKS4yD+FdN+13+wF4v+Kfx68O/tc/sr/F4fD34meGdMk0qbUW0t
bq21SwkZWME8TMFfBRApOcBcCvOrT/gjY/jL4N/F6z+M/wC0Bc678SvjXDbjxP41
h0ZII7WCCVZY7eC2VyqpuU5wR948V6F8bv8Agn9418d/Aj4VfDf4MftJa14H8YfC
G309tE8QafAWgv8A7NCsfk3MAdVkifaMqxI46Vl/sif8E0fEnwq/az139uv9oz4q
6f4p+I3iHRU0pBonhqLTLW1gV9+4rExEshJOXIzg47V0X/BRv/gnyf2xLXw149+G
/wAWrj4d/EbwjcOvhnxvY6ctzJZxSlTKnlll3A7F79qg8If8EyfCs37FN1+yL8cP
iZrHjy81Cf7ff+LddmaWeS/DB47hEdm8sKyrhAccVxX7MH/BKn4n+BPj1pvxs/a6
/a6v/i7deExnwNZXmgJZR6Nu7jbI/mMNq/MQD8tV/wBpz/gk34r8cfGLxF45/Z8/
ap1P4aaR8TGaHx94e03RlnTVJTAU88SGRTG21QOAc+tbHwK/4JF+E/gv+wR4b/Yz
g+Js97f+Db4aj4Y8XSaeoktbtSrRS+VuwcMikjPOK0/2Of8Agn3+0d8Hfi7r3xu/
aj/bm8Q/FbW73T5LHSrSTTv7OsbGBwMgwJK6yEYHJArh77/giR4SH7IFz+yg3xyv
ha3PxptviAdWGkqHEsdzbzfZNm/lT5AG/Ofm6cV7J+0J+wb4e+OH7TfwZ/aE1Txq
9jN8JrlpLDTlsFkF6xx/GWBi4HUA9a8q/aH/AOCYXx58b+M9a1v9kH9tLUvg74Z8
cap/aXjnRdH0FZ5dQuH2xyvHN5qNCzIirkDIxX1f8DPg/YfBL4W6L8LbPWdR1SLR
bFYF1LV797m4uWwAzu75JJIzyTitnxJ8OvA3jT7GfGnhPT9X/s+YTWI1O0ScW8o6
SJvB2P8A7Q5rVa1iMZjZA+fveYM5+ua+Tv2mf+CVPwe/aL/b3+F/7bPiXxPcWl/4
DSRZNAitA0OrOVk2tK+4Y27hgYP3BVj9sn9gr4qfGTxzP8bP2UP2lZfhH46vrGPT
db8R23h+O+a7toshECs6bThm+YHvXOeJv+CUsnxA/wCCeHiD9in4iftIeItb1LxT
PFea14z1bdcyNNHcJKSkLuQikpjaGwM+1dr+0x/wTt0r9pWL4JtefESfS2+D/iO3
1i0xZiYag0RhPlNlhsz5Q+bnGelfTgyRyMH0oooooooooor/2Q==">
<p style="top:144.0pt;left:28.8pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Figure 3</span></p>
<p style="top:144.0pt;left:69.3pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">Forrest plot for meta-analysis examining the opioid-sparing effect of delta-9-THC when co-administered with codeine. Note: all mean difference</span></p>
<p style="top:153.4pt;left:28.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">and SD values are of log</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.0pt">10</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">ED</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:6.0pt">50</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">. THC, tetrahydrocannabinol.</span></p>
<img style="position:absolute;transform:matrix(.43636365,0,-0,.43594606,206.46265,115.04138)" src="data:image/jpeg;base64,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">
<p style="top:359.0pt;left:294.8pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Figure 4</span></p>
<p style="top:359.0pt;left:336.0pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">Funnel plot showing data from the six studies included in the</span></p>
<p style="top:368.4pt;left:294.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">meta-analysis. MD, mean difference, SE, standard error.</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1759</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:727.7pt;left:55.4pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Table 2</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.5pt"> Summary of Evidence of Opioid-sparing Effects from Clinical Studies</span></p>
<p style="top:729.3pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">(a) Study</span></p>
<p style="top:729.3pt;left:82.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">reference</span></p>
<p style="top:683.3pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Study design</span></p>
<p style="top:593.6pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Population</span></p>
<p style="top:530.7pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Follow-up</span></p>
<p style="top:530.7pt;left:82.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">period</span></p>
<p style="top:472.9pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Opioid used</span></p>
<p style="top:399.6pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Cannabinoid used</span></p>
<p style="top:320.6pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Effect of cannabinoid on</span></p>
<p style="top:320.6pt;left:82.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">opioid dose</span></p>
<p style="top:227.3pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Outcome on analgesia</span></p>
<p style="top:227.3pt;left:82.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">observed</span></p>
<p style="top:133.4pt;left:74.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">GRADE evidence rating</span></p>
<p style="top:133.4pt;left:82.9pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">and other notes</span></p>
<p style="top:729.3pt;left:101.3pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">Laboratory studies</span></p>
<p style="top:721.8pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Abrams</span></p>
<p style="top:721.8pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2011</span></p>
<p style="top:683.3pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Clinical laboratory study of</span></p>
<p style="top:683.3pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">self-reported pain under</span></p>
<p style="top:683.3pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">observed conditions (also</span></p>
<p style="top:683.3pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">measured pharmacokinetic</span></p>
<p style="top:683.3pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">effects of concurrent</span></p>
<p style="top:683.3pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">administration)</span></p>
<p style="top:593.6pt;left:111.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">People (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 24)</span></p>
<p style="top:593.6pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">receiving chronic</span></p>
<p style="top:593.6pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">opioid treatment</span></p>
<p style="top:593.6pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(mixed pain</span></p>
<p style="top:593.6pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">conditions)</span></p>
<p style="top:530.7pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">5 days</span></p>
<p style="top:472.9pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Morphine sulfate</span></p>
<p style="top:472.9pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(mean daily dose</span></p>
<p style="top:472.9pt;left:127.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">62 mg,</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt"> n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 13) or</span></p>
<p style="top:472.9pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">oxycodone</span></p>
<p style="top:472.9pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">hydrochloride (mean</span></p>
<p style="top:472.9pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">daily dose 53 mg,</span></p>
<p style="top:472.9pt;left:159.6pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 11)</span></p>
<p style="top:399.6pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Vaporized cannabis dose</span></p>
<p style="top:399.6pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">of 0.9 g of 3.56% delta-</span></p>
<p style="top:399.6pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">9-THC or as much as</span></p>
<p style="top:399.6pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">they could tolerate,</span></p>
<p style="top:399.6pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">administered three times</span></p>
<p style="top:399.6pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">per day.</span></p>
<p style="top:320.6pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Opioid dose held constant to</span></p>
<p style="top:320.6pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">examine effect of delta-9-</span></p>
<p style="top:320.6pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">THC on opioid</span></p>
<p style="top:320.6pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pharmacokinetics (ie, no</span></p>
<p style="top:320.6pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">reduction from baseline</span></p>
<p style="top:320.6pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">opioid dose possible).</span></p>
<p style="top:227.3pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Mean pain score reduction,</span></p>
<p style="top:227.3pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">from 34.8 (95% CI 29.4, 40.1)</span></p>
<p style="top:227.3pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">at baseline to 24.1 (95% CI</span></p>
<p style="top:227.3pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">18.8, 29.4) on day 5 with</span></p>
<p style="top:227.3pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">morphine, and from 43.8</span></p>
<p style="top:227.3pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(95% CI 38.6, 49.1) at baseline</span></p>
<p style="top:227.3pt;left:160.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">to 33.6 (95% CI 28.5, 38.6) on</span></p>
<p style="top:227.3pt;left:168.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">day 5 with oxycodone.</span></p>
<p style="top:227.3pt;left:176.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Significant reduction overall.</span></p>
<p style="top:133.4pt;left:112.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Cannabis inhalation</span></p>
<p style="top:133.4pt;left:120.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">produced a subjective</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">high</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:133.4pt;left:128.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">low</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> quality.</span></p>
<p style="top:133.4pt;left:136.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Downgraded as study did</span></p>
<p style="top:133.4pt;left:144.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">not have a placebo</span></p>
<p style="top:133.4pt;left:152.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">condition, so placebo effects</span></p>
<p style="top:133.4pt;left:160.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">cannot be excluded</span></p>
<p style="top:133.4pt;left:168.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Note: no pharmacokinetic</span></p>
<p style="top:133.4pt;left:176.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">interaction observed.</span></p>
<p style="top:721.8pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Naef</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt"> et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">,</span></p>
<p style="top:721.8pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">2003</span></p>
<p style="top:683.3pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Experimental heat, cold,</span></p>
<p style="top:683.3pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pressure, single and repeated</span></p>
<p style="top:683.3pt;left:202.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">transcutaneous electrical</span></p>
<p style="top:683.3pt;left:210.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">stimulation pain,</span></p>
<p style="top:683.3pt;left:218.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized, placebo-</span></p>
<p style="top:683.3pt;left:226.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">controlled, double-blinded,</span></p>
<p style="top:683.3pt;left:234.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">crossover study.</span></p>
<p style="top:593.6pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Healthy cannabis</span></p>
<p style="top:593.6pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">naive volunteers</span></p>
<p style="top:593.6pt;left:202.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 12)</span></p>
<p style="top:530.7pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Four study</span></p>
<p style="top:530.7pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">sessions with at</span></p>
<p style="top:530.7pt;left:202.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">least 7 days</span></p>
<p style="top:530.7pt;left:210.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">washout</span></p>
<p style="top:530.7pt;left:218.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">between sessions</span></p>
<p style="top:472.9pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Morphine (30 mg)</span></p>
<p style="top:472.9pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">daily</span></p>
<p style="top:399.6pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Dronabinol (20 mg)</span></p>
<p style="top:320.6pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">No significant analgesic effect</span></p>
<p style="top:320.6pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">of dronabinol or morphine</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span></p>
<p style="top:320.6pt;left:202.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dronabinol combination on</span></p>
<p style="top:320.6pt;left:210.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">heat, pressure, or cold tests.</span></p>
<p style="top:320.6pt;left:218.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Additive effect of morphine</span></p>
<p style="top:320.6pt;left:226.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">on transcutaneous electrical</span></p>
<p style="top:320.6pt;left:234.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">stimulation test.</span></p>
<p style="top:227.3pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Potentiation of analgesia not</span></p>
<p style="top:227.3pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">observed in this experimental</span></p>
<p style="top:227.3pt;left:202.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pain study.</span></p>
<p style="top:133.4pt;left:187.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">moderate</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:133.4pt;left:194.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo-controlled, blinded</span></p>
<p style="top:133.4pt;left:202.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">study. Downgraded due to</span></p>
<p style="top:133.4pt;left:210.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">indirect evidence as use of</span></p>
<p style="top:133.4pt;left:218.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">experimental pain measures.</span></p>
<p style="top:721.8pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Roberts</span></p>
<p style="top:721.8pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2006</span></p>
<p style="top:683.3pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Experimental thermal pain.</span></p>
<p style="top:683.3pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Double-blinded, four</span></p>
<p style="top:683.3pt;left:261.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">treatment crossover design.</span></p>
<p style="top:593.5pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Healthy volunteers</span></p>
<p style="top:593.5pt;left:253.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 13) with no</span></p>
<p style="top:593.5pt;left:261.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">recent opioid or</span></p>
<p style="top:593.5pt;left:269.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">cannabinoid use</span></p>
<p style="top:530.7pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Four lab sessions</span></p>
<p style="top:472.9pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Morphine (0.02 mg/kg</span></p>
<p style="top:472.9pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">IV, 1.4 mg dose for</span></p>
<p style="top:472.9pt;left:261.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">70 mg adult, ie, sub-</span></p>
<p style="top:472.9pt;left:269.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">analgesic)</span></p>
<p style="top:399.6pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Dronabinol (5 mg)</span></p>
<p style="top:320.6pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">NA (opioid dose held</span></p>
<p style="top:320.6pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">constant)</span></p>
<p style="top:227.3pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Combination of delta-9-THC</span></p>
<p style="top:227.3pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and morphine did not have an</span></p>
<p style="top:227.3pt;left:261.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">effect on pain intensity. The</span></p>
<p style="top:227.3pt;left:269.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">combination resulted in lower</span></p>
<p style="top:227.3pt;left:277.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">ratings of unpleasantness of</span></p>
<p style="top:227.3pt;left:285.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pain compared with either</span></p>
<p style="top:227.3pt;left:293.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">drug alone.</span></p>
<p style="top:133.4pt;left:245.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">moderate</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:133.4pt;left:253.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo-controlled, blinded</span></p>
<p style="top:133.4pt;left:261.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">study. Downgraded due to</span></p>
<p style="top:133.4pt;left:269.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">indirect evidence as use of</span></p>
<p style="top:133.4pt;left:277.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">experimental pain measures.</span></p>
<p style="top:729.3pt;left:315.6pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">Case series</span></p>
<p style="top:721.8pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Lynch and</span></p>
<p style="top:721.8pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Clark,</span></p>
<p style="top:721.8pt;left:342.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">2003</span></p>
<p style="top:683.3pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Observational case series</span></p>
<p style="top:593.6pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Mixed pain</span></p>
<p style="top:593.5pt;left:333.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">conditions (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 3)</span></p>
<p style="top:593.5pt;left:342.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(peripheral</span></p>
<p style="top:593.5pt;left:350.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">neuropathy,</span></p>
<p style="top:593.5pt;left:358.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">multiple sclerosis,</span></p>
<p style="top:593.5pt;left:366.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">lower back pain)</span></p>
<p style="top:530.7pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">9-month</span></p>
<p style="top:530.7pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">observation</span></p>
<p style="top:530.7pt;left:342.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">period</span></p>
<p style="top:472.9pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Morphine (75</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">360 mg</span></p>
<p style="top:472.9pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">daily)</span></p>
<p style="top:399.6pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Smoked cannabis plant,</span></p>
<p style="top:399.6pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">unknown content</span></p>
<p style="top:320.6pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Mean baseline morphine dose</span></p>
<p style="top:320.6pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">of 195 mg (SD 147 mg)</span></p>
<p style="top:320.6pt;left:342.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">compared with 35 mg (SD</span></p>
<p style="top:320.6pt;left:350.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">31 mg) after commencing</span></p>
<p style="top:320.6pt;left:358.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">smoked cannabis. Opioid</span></p>
<p style="top:320.6pt;left:366.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dose reduction or cessation in</span></p>
<p style="top:320.6pt;left:374.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">each case.</span></p>
<p style="top:227.3pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Improved pain control</span></p>
<p style="top:227.3pt;left:334.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">described, with patients either</span></p>
<p style="top:227.3pt;left:342.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">reducing or ceasing morphine</span></p>
<p style="top:227.3pt;left:350.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dose.</span></p>
<p style="top:133.4pt;left:326.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">very low</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:729.3pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">(b) Study</span></p>
<p style="top:729.3pt;left:403.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">reference</span></p>
<p style="top:683.1pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Study design</span></p>
<p style="top:608.3pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Population</span></p>
<p style="top:525.2pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Follow-up</span></p>
<p style="top:525.2pt;left:403.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">period</span></p>
<p style="top:464.0pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Opioid used</span></p>
<p style="top:378.7pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Cannabinoid used</span></p>
<p style="top:301.3pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Effect of cannabinoid</span></p>
<p style="top:301.2pt;left:403.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">on opioid dose</span></p>
<p style="top:215.9pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Outcome on analgesia</span></p>
<p style="top:215.9pt;left:403.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">observed</span></p>
<p style="top:128.8pt;left:395.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">GRADE evidence</span></p>
<p style="top:128.8pt;left:403.1pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">rating and other notes</span></p>
<p style="top:729.3pt;left:421.6pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">Controlled trials</span></p>
<p style="top:721.8pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Johnson</span></p>
<p style="top:721.8pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2010</span></p>
<p style="top:683.1pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Multicenter, double-</span></p>
<p style="top:683.1pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">blind, randomized,</span></p>
<p style="top:683.1pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo-controlled,</span></p>
<p style="top:683.1pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">parallel-group trial.</span></p>
<p style="top:608.3pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients with cancer pain</span></p>
<p style="top:608.3pt;left:440.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 177), with inadequate</span></p>
<p style="top:608.3pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">analgesia despite chronic</span></p>
<p style="top:608.3pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">opioid dosing.</span></p>
<p style="top:525.2pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">2 weeks</span></p>
<p style="top:464.0pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Varied opioids reported as</span></p>
<p style="top:464.0pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">OME (IQR)</span></p>
<p style="top:464.0pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">120 mg (50</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">213)</span></p>
<p style="top:464.0pt;left:488.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">80 mg (30</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">180)</span></p>
<p style="top:464.0pt;left:520.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">120 mg (40</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">240)</span></p>
<p style="top:378.7pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients randomized to</span></p>
<p style="top:378.7pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">delta-9-THC : CBD,</span></p>
<p style="top:378.7pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">delta-9-THC, or</span></p>
<p style="top:378.7pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo</span></p>
<p style="top:378.7pt;left:464.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Delta-9-THC (mean 9</span></p>
<p style="top:378.7pt;left:472.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">sprays per day)</span></p>
<p style="top:378.7pt;left:488.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Delta-9-THC : CBD</span></p>
<p style="top:378.7pt;left:496.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(mean 10 sprays</span></p>
<p style="top:378.7pt;left:504.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">per day)</span></p>
<p style="top:378.7pt;left:520.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo</span></p>
<p style="top:378.7pt;left:528.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(mean 11 sprays/day)</span></p>
<p style="top:301.2pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">No change in median</span></p>
<p style="top:301.2pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">amount of breakthrough</span></p>
<p style="top:301.2pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">opioid medication in any</span></p>
<p style="top:301.2pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">group.</span></p>
<p style="top:215.9pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Change in pain NRS (out of</span></p>
<p style="top:215.9pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">10) from baseline was</span></p>
<p style="top:215.9pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">statistically significantly in</span></p>
<p style="top:215.9pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">favor of delta-9-</span></p>
<p style="top:215.9pt;left:464.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">THC : CBD compared with</span></p>
<p style="top:215.9pt;left:472.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">the placebo</span></p>
<p style="top:215.9pt;left:479.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">1.01 (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 0.245)</span></p>
<p style="top:215.9pt;left:487.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">1.37 (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 0.014)</span></p>
<p style="top:215.9pt;left:520.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.69 (reference group)</span></p>
<p style="top:128.8pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">high</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:128.8pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo-controlled and</span></p>
<p style="top:128.8pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized.</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1760</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:727.2pt;left:31.5pt;line-height:9.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:9.5pt">Table 2</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.5pt"> Continued</span></p>
<p style="top:728.8pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">(b) Study</span></p>
<p style="top:728.8pt;left:59.4pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">reference</span></p>
<p style="top:682.6pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Study design</span></p>
<p style="top:607.7pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Population</span></p>
<p style="top:524.7pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Follow-up</span></p>
<p style="top:524.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">period</span></p>
<p style="top:463.4pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Opioid used</span></p>
<p style="top:378.1pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Cannabinoid used</span></p>
<p style="top:300.7pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Effect of cannabinoid</span></p>
<p style="top:300.7pt;left:59.4pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">on opioid dose</span></p>
<p style="top:215.3pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">Outcome on analgesia</span></p>
<p style="top:215.3pt;left:59.4pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">observed</span></p>
<p style="top:128.2pt;left:51.5pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">GRADE evidence</span></p>
<p style="top:128.2pt;left:59.4pt;line-height:7.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:7.5pt">rating and other notes</span></p>
<p style="top:721.3pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Lissoni</span></p>
<p style="top:721.3pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2014</span></p>
<p style="top:682.6pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Two groups (not</span></p>
<p style="top:682.6pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized):</span></p>
<p style="top:682.6pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">cannabinoid tincture or</span></p>
<p style="top:682.6pt;left:101.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">melatonin</span></p>
<p style="top:607.7pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients with untreatable</span></p>
<p style="top:607.7pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">metastatic solid tumor</span></p>
<p style="top:607.7pt;left:93.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 26)</span></p>
<p style="top:524.7pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Not stated</span></p>
<p style="top:463.4pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Oxycodone, median dose</span></p>
<p style="top:463.4pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">of 30 mg (10</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">60 mg),</span></p>
<p style="top:463.4pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">twice per day</span></p>
<p style="top:378.1pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Cannabis flos (19%</span></p>
<p style="top:378.1pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">delta-9-THC) was given</span></p>
<p style="top:378.1pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">as an infusion. 100 ml</span></p>
<p style="top:378.1pt;left:101.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(500 mg/l water) three</span></p>
<p style="top:378.1pt;left:109.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">times per day</span></p>
<p style="top:300.7pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">5/12 patients (42%)</span></p>
<p style="top:300.7pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">achieved control of pain</span></p>
<p style="top:300.7pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">without opioid dose</span></p>
<p style="top:300.7pt;left:101.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">increase compared to the</span></p>
<p style="top:300.7pt;left:109.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">control group, where 2/14</span></p>
<p style="top:300.7pt;left:117.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(14%) achieved pain</span></p>
<p style="top:300.7pt;left:125.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">control</span></p>
<p style="top:215.3pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">The number that achieved</span></p>
<p style="top:215.3pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pain control was not</span></p>
<p style="top:215.3pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">significantly different</span></p>
<p style="top:215.3pt;left:101.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">between groups</span></p>
<p style="top:128.2pt;left:77.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">low</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">. Non-</span></p>
<p style="top:128.2pt;left:85.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized design, no</span></p>
<p style="top:128.2pt;left:93.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">allocation concealment</span></p>
<p style="top:128.2pt;left:101.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">described. Control group</span></p>
<p style="top:128.2pt;left:109.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">received melatonin (20</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span></p>
<p style="top:128.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">100 mg). Greater disease</span></p>
<p style="top:128.2pt;left:125.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">progression documented</span></p>
<p style="top:128.2pt;left:133.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">in the cannabis group</span></p>
<p style="top:721.3pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Narang</span></p>
<p style="top:721.3pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2008</span></p>
<p style="top:682.6pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 1: randomized,</span></p>
<p style="top:682.6pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">single-dose, double-</span></p>
<p style="top:682.6pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">blinded, placebo-</span></p>
<p style="top:682.6pt;left:168.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">controlled, crossover</span></p>
<p style="top:682.6pt;left:176.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">trial. Primary outcome</span></p>
<p style="top:682.6pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">measures TOTPAR</span></p>
<p style="top:682.6pt;left:192.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">score</span></p>
<p style="top:607.7pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients on opioids for</span></p>
<p style="top:607.7pt;left:152.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">chronic pain; BPI</span><span style="font-family:AdvOT8608a8d1+2a,serif;font-size:7.5pt"> &#x2a7e;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 4</span></p>
<p style="top:607.7pt;left:160.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 30). Pain diagnosis:</span></p>
<p style="top:607.7pt;left:168.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">neuropathic (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 7),</span></p>
<p style="top:607.7pt;left:176.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">nociceptive (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 7), mixed</span></p>
<p style="top:607.7pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">neuropathic and</span></p>
<p style="top:607.7pt;left:191.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">nociceptive (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 11), and</span></p>
<p style="top:607.7pt;left:199.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">uncategorized (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 5)</span></p>
<p style="top:524.7pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 1: three 8-h</span></p>
<p style="top:524.7pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">lab sessions with</span></p>
<p style="top:524.7pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">3 days washout</span></p>
<p style="top:463.4pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">OME mean 68.1 mg (SD</span></p>
<p style="top:463.4pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">57.2, range 7.5</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">228).</span></p>
<p style="top:463.4pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Participants were taking</span></p>
<p style="top:463.4pt;left:168.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">oxycodone, morphine,</span></p>
<p style="top:463.4pt;left:176.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">methadone hydrocodone,</span></p>
<p style="top:463.4pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and hydromorphone</span></p>
<p style="top:378.1pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 1: single-dose</span></p>
<p style="top:378.1pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo, dronabinol 10</span></p>
<p style="top:378.1pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and 20 mg</span></p>
<p style="top:300.7pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">One subject took rescue</span></p>
<p style="top:300.7pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">pain medication in all</span></p>
<p style="top:300.7pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">conditions, one subject</span></p>
<p style="top:300.7pt;left:168.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">took rescue medication</span></p>
<p style="top:300.7pt;left:176.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">during the placebo and</span></p>
<p style="top:300.7pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">10 mg dronabinol</span></p>
<p style="top:300.7pt;left:192.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">condition, and six subjects</span></p>
<p style="top:300.7pt;left:200.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">took rescue medication</span></p>
<p style="top:300.7pt;left:208.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">only with placebo.</span></p>
<p style="top:215.3pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">In single-dose studies, 10</span></p>
<p style="top:215.3pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and 20 mg dronabinol</span></p>
<p style="top:215.3pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">significantly increased the</span></p>
<p style="top:215.3pt;left:168.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">amount of analgesic relief</span></p>
<p style="top:215.3pt;left:176.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">reported compared to</span></p>
<p style="top:215.3pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo</span></p>
<p style="top:128.2pt;left:144.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">moderate</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:128.2pt;left:152.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Randomized and placebo-</span></p>
<p style="top:128.2pt;left:160.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">controlled. Downgraded as</span></p>
<p style="top:128.2pt;left:168.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">only a single dose was</span></p>
<p style="top:128.2pt;left:176.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">examined. TOTPAR 31.1</span></p>
<p style="top:128.2pt;left:184.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">in placebo group,</span></p>
<p style="top:128.2pt;left:192.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">compared with 39.7 with</span></p>
<p style="top:128.2pt;left:200.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dronabinol 10 mg and 41.7</span></p>
<p style="top:128.2pt;left:208.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">with dronabinol 20 mg</span></p>
<p style="top:682.6pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 2: open-label (no</span></p>
<p style="top:682.6pt;left:227.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo) extension.</span></p>
<p style="top:682.6pt;left:235.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Primary outcome</span></p>
<p style="top:682.6pt;left:243.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">measure change in pain</span></p>
<p style="top:682.6pt;left:251.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">intensity</span></p>
<p style="top:524.7pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 2: open</span></p>
<p style="top:524.7pt;left:227.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">label for 4 weeks</span></p>
<p style="top:378.1pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Phase 2: flexible dose</span></p>
<p style="top:378.1pt;left:227.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">schedule, dronabinol</span></p>
<p style="top:378.1pt;left:235.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">5 mg daily</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 20 mg</span></p>
<p style="top:378.1pt;left:243.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">three times per day.</span></p>
<p style="top:300.7pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Opioid dose not reported</span></p>
<p style="top:215.3pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Mean baseline NRS of 6.9</span></p>
<p style="top:215.3pt;left:227.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">compared with 5.2 after</span></p>
<p style="top:215.3pt;left:235.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">4 weeks of dronabinol. This</span></p>
<p style="top:215.3pt;left:243.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">represents a statistically</span></p>
<p style="top:215.3pt;left:251.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">significant reduction</span></p>
<p style="top:128.2pt;left:219.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">low</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">. Open-</span></p>
<p style="top:128.2pt;left:227.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">label study. Significant</span></p>
<p style="top:128.2pt;left:232.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">improvements (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">p</span><span style="font-family:AdvEls,serif;font-size:7.5pt">o</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.05) in</span></p>
<p style="top:128.2pt;left:243.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">sleep, energy, pain relief,</span></p>
<p style="top:128.2pt;left:251.2pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and social functioning. Lack</span></p>
<p style="top:128.2pt;left:259.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">of placebo control means</span></p>
<p style="top:128.2pt;left:267.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">effects may be non-specific</span></p>
<p style="top:128.2pt;left:275.1pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">or placebo</span></p>
<p style="top:721.3pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Portenoy</span></p>
<p style="top:721.3pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2012</span></p>
<p style="top:682.6pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Randomized, 4-arm</span></p>
<p style="top:682.6pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">placebo-controlled,</span></p>
<p style="top:682.6pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">graded-dose study</span></p>
<p style="top:607.7pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients with active cancer</span></p>
<p style="top:607.7pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">and chronic pain on a</span></p>
<p style="top:607.7pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">stable oral morphine</span></p>
<p style="top:607.7pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">regimen, plus fentanyl</span></p>
<p style="top:607.7pt;left:317.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 360)</span></p>
<p style="top:524.7pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">5 weeks of</span></p>
<p style="top:524.7pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">medication</span></p>
<p style="top:524.7pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">administration</span></p>
<p style="top:463.4pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Morphine and fentanyl</span></p>
<p style="top:463.4pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Median 120 mg OME</span></p>
<p style="top:463.4pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Median 120 mg OME</span></p>
<p style="top:463.4pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Median 180 mg OME</span></p>
<p style="top:463.4pt;left:317.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Median 120 mg OME</span></p>
<p style="top:378.1pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Nabiximols 1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">4 sprays</span></p>
<p style="top:378.1pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Nabiximols 6</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">10 sprays</span></p>
<p style="top:378.1pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Nabiximols 11</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">16</span></p>
<p style="top:378.1pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">sprays</span></p>
<p style="top:378.1pt;left:317.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo</span></p>
<p style="top:300.7pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">No change in median</span></p>
<p style="top:300.7pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">amount of breakthrough</span></p>
<p style="top:300.7pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">opioid medication in any</span></p>
<p style="top:300.7pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">group. Note that patients</span></p>
<p style="top:300.7pt;left:317.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">were discouraged from</span></p>
<p style="top:300.7pt;left:325.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">reducing their opioid dose,</span></p>
<p style="top:300.7pt;left:333.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">so the opioid-sparing effect</span></p>
<p style="top:300.7pt;left:341.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">could not be observed</span></p>
<p style="top:215.3pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Treatment difference</span></p>
<p style="top:215.3pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(change from baseline pain</span></p>
<p style="top:215.3pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">score):</span></p>
<p style="top:215.3pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.75 points (95% CI</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">1.28,</span></p>
<p style="top:215.3pt;left:317.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.22,</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt"> p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 0.06 compared</span></p>
<p style="top:215.3pt;left:325.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">to placebo)</span></p>
<p style="top:215.3pt;left:333.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.36 points (95% CI</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.089,</span></p>
<p style="top:215.3pt;left:341.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.18 points,</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt"> p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 0.19</span></p>
<p style="top:215.3pt;left:349.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">compared to placebo).</span></p>
<p style="top:215.3pt;left:357.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.09 points (95% CI:</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2013;</span></p>
<p style="top:215.3pt;left:365.3pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">0.62, 0.44 points,</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt"> p</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 0.75</span></p>
<p style="top:215.3pt;left:373.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">compared to placebo)</span></p>
<p style="top:215.3pt;left:381.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Not reported</span></p>
<p style="top:215.3pt;left:389.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(reference group)</span></p>
<p style="top:128.2pt;left:286.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">high</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:128.2pt;left:294.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo-controlled,</span></p>
<p style="top:128.2pt;left:302.0pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized controlled trial</span></p>
<p style="top:128.2pt;left:309.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Opioid composite</span></p>
<p style="top:128.2pt;left:317.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">measure showed better</span></p>
<p style="top:128.2pt;left:325.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">improvements in the low-</span></p>
<p style="top:128.2pt;left:333.9pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dose group. 1</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">4 spray</span></p>
<p style="top:128.2pt;left:341.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">group had significant</span></p>
<p style="top:128.2pt;left:349.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">improvements in analgesia.</span></p>
<p style="top:128.2pt;left:357.8pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Lower tolerability of delta-</span></p>
<p style="top:128.2pt;left:365.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">9-THC : CBD in higher</span></p>
<p style="top:128.2pt;left:373.7pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dose groups</span></p>
<p style="top:721.3pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Seeling</span></p>
<p style="top:721.3pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">et al</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">, 2006</span></p>
<p style="top:682.6pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Randomized,</span></p>
<p style="top:682.6pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">controlled trial (two</span></p>
<p style="top:682.6pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">groups)</span></p>
<p style="top:607.7pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Prostate cancer patients</span></p>
<p style="top:607.7pt;left:406.2pt;line-height:7.5pt"><span style="font-family:AdvEls,serif;font-size:7.5pt">o</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">70 y.o. (</span><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 105).</span></p>
<p style="top:607.7pt;left:416.1pt;line-height:7.5pt"><span style="font-family:AdvOT503af387.I,serif;font-size:7.5pt">N</span><span style="font-family:AdvOT8608a8d1,serif;font-size:7.5pt"> =</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt"> 53 in intervention and</span></p>
<p style="top:607.7pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">52 in control</span></p>
<p style="top:524.7pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">From the day prior</span></p>
<p style="top:524.7pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">to surgery to two</span></p>
<p style="top:524.7pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">days post</span></p>
<p style="top:524.7pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">operation</span></p>
<p style="top:463.4pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Piritramide 1.5 mg/ml,</span></p>
<p style="top:463.4pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">bolus 2 mg (no continuous</span></p>
<p style="top:463.4pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">infusion) via patient-</span></p>
<p style="top:463.4pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">controlled analgesia for</span></p>
<p style="top:463.4pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">48 h post operation</span></p>
<p style="top:378.1pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Dronabinol 5 mg &#xd7; 8</span></p>
<p style="top:378.1pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">doses over 48 h</span></p>
<p style="top:378.1pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(perioperatively)</span></p>
<p style="top:300.7pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Median dose of piritramide</span></p>
<p style="top:300.7pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">alone was 74 mg (IQR 44</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span></p>
<p style="top:300.7pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">90) compared with 54 mg</span></p>
<p style="top:300.7pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">(IQR 46</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2013;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">88) when</span></p>
<p style="top:300.7pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">administered with</span></p>
<p style="top:300.7pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">dronabinol</span></p>
<p style="top:215.3pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">The difference between the</span></p>
<p style="top:215.3pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">intervention (dronabinol)</span></p>
<p style="top:215.3pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">group and control group</span></p>
<p style="top:215.3pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">was not significant. No</span></p>
<p style="top:215.3pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">evidence was found of</span></p>
<p style="top:215.3pt;left:440.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">synergistic antinociceptive</span></p>
<p style="top:215.3pt;left:448.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">interaction between delta-</span></p>
<p style="top:215.3pt;left:456.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">9-THC and piritramide for</span></p>
<p style="top:215.3pt;left:464.4pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">acute postoperative pain</span></p>
<p style="top:128.2pt;left:400.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">GRADE rating</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt"> &#x2018;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">high</span><span style="font-family:AdvOT96bbbf1d+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">.</span></p>
<p style="top:128.2pt;left:408.6pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Placebo-controlled,</span></p>
<p style="top:128.2pt;left:416.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">randomized controlled trial</span></p>
<p style="top:128.2pt;left:424.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">Patients administered their</span></p>
<p style="top:128.2pt;left:432.5pt;line-height:7.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:7.5pt">own opioid doses</span></p>
<p style="top:728.4pt;left:479.0pt;line-height:8.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.0pt">Abbreviations: BPI, brief pain inventory; CBD, cannabidiol; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IQR, interquartile range; NRS, numerical rating scale; OME, oral morphine</span></p>
<p style="top:728.4pt;left:488.4pt;line-height:8.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.0pt">equivalents; TOTPAR, total pain relief.</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1761</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:58.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">trials provided high-quality evidence. None of the high-</span></p>
<p style="top:69.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">quality studies provided evidence of an opioid-sparing effect.</span></p>
<p style="top:80.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The only study that provided direct evidence of an opioid-</span></p>
<p style="top:91.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sparing effect was rated as providing very low-quality</span></p>
<p style="top:102.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">evidence (Lynch and Clark, 2003).</span></p>
<p style="top:139.6pt;left:52.3pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">DISCUSSION</span></p>
<p style="top:156.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Twenty-eight studies provided data relating to the potential</span></p>
<p style="top:167.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid-sparing effect of cannabinoids in the context of opioid</span></p>
<p style="top:178.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesia. Most of the pre-clinical studies examined reported</span></p>
<p style="top:189.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reduced opioid requirements when co-administered with</span></p>
<p style="top:200.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoids. Few controlled clinical studies measured</span></p>
<p style="top:211.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">opioid-sparing as an end point and findings relating to</span></p>
<p style="top:222.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesia were mixed. Two controlled studies found no effect</span></p>
<p style="top:233.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of cannabinoids on opioid dose requirements (Johnson</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:244.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2010; Seeling</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006). One case series provided very</span></p>
<p style="top:255.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">low-quality evidence of a reduction in opioid dose require-</span></p>
<p style="top:266.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ments with cannabinoid co-administration (Lynch and</span></p>
<p style="top:277.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Clark, 2003).</span></p>
<p style="top:288.4pt;left:61.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Most of the pre-clinical studies examined found synergistic</span></p>
<p style="top:299.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effects when opioids and cannabinoids were co-adminis-</span></p>
<p style="top:310.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tered, although two studies found that with specific opioids</span></p>
<p style="top:321.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and cannabinoids the analgesic effect was additive rather</span></p>
<p style="top:332.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">than synergistic. Through meta-analyses, it was found that</span></p>
<p style="top:343.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the doses of morphine and codeine required to produce the</span></p>
<p style="top:354.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">same</span></p>
<p style="top:354.2pt;left:81.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analgesic</span></p>
<p style="top:354.2pt;left:125.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect</span></p>
<p style="top:354.2pt;left:155.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">were</span></p>
<p style="top:354.2pt;left:182.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">3.6</span></p>
<p style="top:354.2pt;left:202.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and</span></p>
<p style="top:354.2pt;left:225.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">9.5 times</span></p>
<p style="top:354.2pt;left:275.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">lower,</span></p>
<p style="top:365.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">respectively, when co-administered with delta-9-THC. Re-</span></p>
<p style="top:376.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ductions in opioid requirements that are smaller than those</span></p>
<p style="top:387.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">seen in these pre-clinical studies may have relevance to pain</span></p>
<p style="top:398.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">treatment. Some confidence in these findings comes from the</span></p>
<p style="top:409.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">consistent observation of an opioid-sparing effect when</span></p>
<p style="top:420.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">using different nociceptive assays and in pain models of</span></p>
<p style="top:430.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">arthritis and diabetic neuropathy.</span></p>
<p style="top:441.8pt;left:61.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The relevance of the findings from these pre-clinical</span></p>
<p style="top:452.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies (with acute-dosing paradigms) to clinical chronic</span></p>
<p style="top:463.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">pain treatment must be considered. There are important</span></p>
<p style="top:474.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">limitations in translating findings from pre-clinical studies to</span></p>
<p style="top:485.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical practice, particularly when evaluating doses and</span></p>
<p style="top:496.7pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect sizes. Although the outcomes of pre-clinical studies are</span></p>
<p style="top:507.6pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">often consistent with clinical studies, pre-clinical studies may</span></p>
<p style="top:518.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">over-represent effects. The lesser effect sizes in human</span></p>
<p style="top:529.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies have been attributed to the heterogeneity of clinical</span></p>
<p style="top:540.5pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">populations or the response being limited to sub-popula-</span></p>
<p style="top:551.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tions, reducing the overall effect observed (Berge, 2011). This</span></p>
<p style="top:562.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">underscores the importance of clinical studies to examine the</span></p>
<p style="top:573.4pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effects found in pre-clinical work.</span></p>
<p style="top:584.3pt;left:61.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Controlled clinical studies demonstrated some beneficial</span></p>
<p style="top:595.3pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effects of opioid and cannabinoid co-administration on</span></p>
<p style="top:606.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">outcomes of pain, sleep, and functioning in chronic pain</span></p>
<p style="top:617.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">patients (Abrams</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2011; Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008). One case</span></p>
<p style="top:628.2pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">series (</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">n</span><span style="font-family:AdvOT8608a8d1,serif;font-size:10.0pt"> =</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> 3) provided very low-quality evidence of a</span></p>
<p style="top:639.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reduction in opioid requirements with delta-9-THC admin-</span></p>
<p style="top:650.1pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">istration. No randomized controlled studies were identified</span></p>
<p style="top:661.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that provided evidence of an opioid-sparing effect of</span></p>
<p style="top:672.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoids. Important limitations identified in these</span></p>
<p style="top:683.0pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical studies included a lack of placebo control (Abrams</span></p>
<p style="top:693.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2011; Lynch and Clark, 2003; Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008),</span></p>
<p style="top:704.9pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">difficulties</span></p>
<p style="top:704.9pt;left:103.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">extrapolating</span></p>
<p style="top:704.9pt;left:165.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">from</span></p>
<p style="top:704.9pt;left:193.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">experimental</span></p>
<p style="top:704.9pt;left:255.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to</span></p>
<p style="top:704.9pt;left:271.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical</span></p>
<p style="top:715.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">pain (Naef</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2003; Roberts</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006), use of single</span></p>
<p style="top:726.8pt;left:52.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">doses (Naef</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2003; Roberts</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2006), use of small</span></p>
<p style="top:58.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sample sizes (Lissoni</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2014; Lynch and Clark, 2003;</span></p>
<p style="top:69.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008), and the mixed quality of the study</span></p>
<p style="top:80.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">design in general. In particular, Roberts</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2006) used</span></p>
<p style="top:91.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sub-therapeutic doses of morphine, which may have limited</span></p>
<p style="top:102.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that study</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2019;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">s ability to test the effects of co-administration.</span></p>
<p style="top:113.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Portenoy</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> (2012) noted that the use of fixed dose ranges</span></p>
<p style="top:124.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of cannabinoids may have limited that study</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2019;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">s ability to test</span></p>
<p style="top:135.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the efficacy of cannabinoids for pain, as some patients may</span></p>
<p style="top:146.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">have</span></p>
<p style="top:146.0pt;left:345.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">dropped</span></p>
<p style="top:146.0pt;left:388.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">out</span></p>
<p style="top:146.0pt;left:410.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">due</span></p>
<p style="top:146.0pt;left:434.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to</span></p>
<p style="top:146.0pt;left:451.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">tolerability.</span></p>
<p style="top:146.0pt;left:505.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Moreover,</span></p>
<p style="top:146.0pt;left:556.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">by</span></p>
<p style="top:156.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">discouraging patients from reducing their opioid dose during</span></p>
<p style="top:167.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the study, no opioid-sparing effect could be observed</span></p>
<p style="top:178.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(Portenoy</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2012).</span></p>
<p style="top:189.8pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">This review highlights some important considerations for</span></p>
<p style="top:200.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">future studies of cannabinoids. A dose-ranging study with</span></p>
<p style="top:211.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">patients with advanced cancer found that only lower doses of</span></p>
<p style="top:222.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabinoids demonstrated analgesic effects (Portenoy</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">,</span></p>
<p style="top:233.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">2012). In the same study, one in four participants in the</span></p>
<p style="top:244.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">high-dose group discontinued treatment. Side effects such as</span></p>
<p style="top:255.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">nausea, drowsiness, and dizziness are more frequent with</span></p>
<p style="top:266.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">higher doses of cannabinoids (Narang</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2008; Portenoy</span></p>
<p style="top:277.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2012). This suggests that dose range and tolerability are</span></p>
<p style="top:288.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">important outcomes to examine and that careful dose</span></p>
<p style="top:299.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">titration is essential. Future studies should carefully docu-</span></p>
<p style="top:310.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ment adverse effects from concurrent opioid and cannabi-</span></p>
<p style="top:321.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">noid administration to provide a better understanding of</span></p>
<p style="top:332.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">potential harms. One hypothesis to explain why patients</span></p>
<p style="top:343.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reduce their opioid dose with cannabinoid administration is</span></p>
<p style="top:354.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">that they experience undesirable psychoactive effects from</span></p>
<p style="top:365.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">concurrent use of opioids and cannabinoids. This could be</span></p>
<p style="top:376.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">explored in future studies.</span></p>
<p style="top:387.1pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Recent observational studies provided further data on a</span></p>
<p style="top:398.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">possible opioid-sparing effect. Two studies found 44</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">64%</span></p>
<p style="top:409.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reductions in self-reported opioid consumption in cohorts of</span></p>
<p style="top:419.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">patients with chronic pain who were using cannabis</span></p>
<p style="top:430.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(Boehnke</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2016; Haroutounian</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2016). These</span></p>
<p style="top:441.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">observational studies provide further low-quality evidence</span></p>
<p style="top:452.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">supporting an opioid-sparing effect. A further observational</span></p>
<p style="top:463.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">study found that in patients with chronic pain who were</span></p>
<p style="top:474.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">prescribed opioids, greater pain relief was reported from</span></p>
<p style="top:485.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">cannabis than from their other medications (Degenhardt</span></p>
<p style="top:496.7pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015). A single case study also reported reduced</span></p>
<p style="top:507.6pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">requirements for breakthrough pain with oral delta-9-THC</span></p>
<p style="top:518.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">administration (Holdcroft</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 1997). Taken together, these</span></p>
<p style="top:529.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">reports support the need for high-quality studies to directly</span></p>
<p style="top:540.5pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">assess the opioid-sparing effect of cannabinoids under</span></p>
<p style="top:551.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">controlled conditions.</span></p>
<p style="top:562.4pt;left:327.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">This review identified some limitations in the literature.</span></p>
<p style="top:573.4pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The pre-clinical studies examined used a range of animal</span></p>
<p style="top:584.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">populations, antinociceptive assays, opioids, and cannabi-</span></p>
<p style="top:595.3pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">noids, and often had small numbers of animals per group.</span></p>
<p style="top:606.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">This resulted in statistical heterogeneity. Despite this, a large</span></p>
<p style="top:617.2pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and significant effect was observed in the meta-analysis. No</span></p>
<p style="top:628.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">studies examined the opioid-sparing effect of cannabidiol</span></p>
<p style="top:639.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">alone, in combination with delta-9-THC outside of a 1 : 1</span></p>
<p style="top:650.1pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">ratio, or with other cannabinoids. Further, the lack of high-</span></p>
<p style="top:661.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">quality studies in humans investigating the opioid-sparing</span></p>
<p style="top:672.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">effect means that the evidence for this is largely limited</span></p>
<p style="top:683.0pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to pre-clinical studies. A funnel plot was produced and did</span></p>
<p style="top:693.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">not provide evidence of publication or small study bias;</span></p>
<p style="top:704.9pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">however, due to the small number of studies in the meta-</span></p>
<p style="top:715.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">analysis (</span><span style="font-family:AdvEls,serif;font-size:10.0pt">o</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">10) the interpretation of the funnel plot is</span></p>
<p style="top:726.8pt;left:318.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">limited.</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1762</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:58.3pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">The potential for cannabinoids to reduce opioid dose</span></p>
<p style="top:69.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">requirements and extend the duration of effective analgesia</span></p>
<p style="top:80.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">should not be understated. The rapid increase in opioid use</span></p>
<p style="top:91.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and opioid-associated mortality is largely attributed use</span></p>
<p style="top:102.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of opioids in chronic pain treatment (Chou</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2015;</span></p>
<p style="top:113.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Zedler</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2014). Use of lower opioid doses has been</span></p>
<p style="top:124.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">recommended (Dowell</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">, 2016); however, clinical processes</span></p>
<p style="top:135.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">to achieve this reduction are not well defined. Opioid-sparing</span></p>
<p style="top:146.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">medications</span></p>
<p style="top:146.0pt;left:85.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">may</span></p>
<p style="top:146.0pt;left:110.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">have</span></p>
<p style="top:146.0pt;left:137.3pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">enormous</span></p>
<p style="top:146.0pt;left:185.7pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical relevance</span></p>
<p style="top:146.0pt;left:267.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">by</span></p>
<p style="top:156.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">enabling effective pain treatment with lower opioid doses</span></p>
<p style="top:167.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and a potential reduction in opioid-related mortality.</span></p>
<p style="top:178.8pt;left:37.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">In conclusion, pre-clinical studies support the opioid-</span></p>
<p style="top:189.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">sparing effect of delta-9-THC. However, the findings from</span></p>
<p style="top:200.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical trials are inconsistent, with some studies found to</span></p>
<p style="top:211.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">have important limitations such as a lack of placebo control.</span></p>
<p style="top:222.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">An opioid-sparing effect of cannabinoids in chronic pain</span></p>
<p style="top:233.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">patients was observed in only one very-low-quality clinical</span></p>
<p style="top:244.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">study. These findings provide an early signal that warrants</span></p>
<p style="top:255.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">exploration. It remains to be seen if these promising pre-</span></p>
<p style="top:266.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">clinical and observational findings can be replicated in large,</span></p>
<p style="top:277.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">well-designed clinical studies.</span></p>
<p style="top:309.5pt;left:28.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">FUNDING AND DISCLOSURE</span></p>
<p style="top:326.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">SN</span></p>
<p style="top:326.8pt;left:49.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">is</span></p>
<p style="top:326.8pt;left:63.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">supported</span></p>
<p style="top:326.8pt;left:113.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">by</span></p>
<p style="top:326.8pt;left:130.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a</span></p>
<p style="top:326.8pt;left:143.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">NHMRC</span></p>
<p style="top:326.8pt;left:188.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Research</span></p>
<p style="top:326.8pt;left:233.1pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Fellowship</span></p>
<p style="top:337.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">(#1013803). The National Drug and Alcohol Research Centre</span></p>
<p style="top:348.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">at the University of New South Wales is supported by</span></p>
<p style="top:359.7pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">funding</span></p>
<p style="top:359.7pt;left:69.6pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">from</span></p>
<p style="top:359.7pt;left:98.5pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the</span></p>
<p style="top:359.7pt;left:119.9pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Australian</span></p>
<p style="top:359.7pt;left:171.0pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Government</span></p>
<p style="top:359.7pt;left:231.4pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">under</span></p>
<p style="top:359.7pt;left:264.2pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the</span></p>
<p style="top:370.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Substance Misuse Prevention and Service Improvements</span></p>
<p style="top:381.6pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Grant Fund. The contents of the published material are solely</span></p>
<p style="top:392.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the responsibility of the authors and do not reflect the</span></p>
<p style="top:403.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">funding bodies. MAW has received a grant to his institution</span></p>
<p style="top:414.5pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">from CanniMed. BLF has received speaker fees or consulting</span></p>
<p style="top:425.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">fees from Allergan, Mettrum, CCIC, Mylan Pharmaceutical,</span></p>
<p style="top:436.4pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Pfizer, Ethypharm, Richter Pharmaceuticals, and Lundbeck.</span></p>
<p style="top:447.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">He also received salary/grant support from Pfizer and</span></p>
<p style="top:458.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Bioprojet, and in kind support from GW Pharma, Mylan</span></p>
<p style="top:469.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Pharmaceuticals, and Brainsway. SN and NL have been</span></p>
<p style="top:480.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">investigators on untied educational grants from Reckitt-</span></p>
<p style="top:491.2pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Benckiser. SN and MF have been investigators on an untied</span></p>
<p style="top:502.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">education grant from Indivior. KEK has previously received</span></p>
<p style="top:513.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">a speaker</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:10.0pt">&#x2019;</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">s honorarium from Pfizer and Mundipharma, in</span></p>
<p style="top:524.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">addition to fees from an advisory board and an educational</span></p>
<p style="top:535.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">grant from Seqirus. As Director of NDARC, MF notes that</span></p>
<p style="top:546.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the National Drug and Alcohol Research Centre has received</span></p>
<p style="top:556.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">untied educational grants from Mundipharma and Indivior.</span></p>
<p style="top:567.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">MF took part in a single research advisory board with</span></p>
<p style="top:578.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Indivior in 2014. The remaining authors declare no conflict</span></p>
<p style="top:589.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">of interest.</span></p>
<p style="top:621.8pt;left:28.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">ACKNOWLEDGMENTS</span></p>
<p style="top:639.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">SN, PS, JMT, MAW, BM, NL, KEK, MF, AS, and BLF were</span></p>
<p style="top:650.1pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">involved in the conceptualization of the work. SN and PS</span></p>
<p style="top:661.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">screened the abstracts. SN, PS, and JMT extracted the data</span></p>
<p style="top:672.0pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">and checked the extracted data. BBS transformed the data,</span></p>
<p style="top:682.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">prepared the data for meta-analysis, and provided advice on</span></p>
<p style="top:693.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">the meta-analysis. SN conducted the meta-analysis and</span></p>
<p style="top:704.9pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">drafted the manuscript with assistance from BM, PS, and</span></p>
<p style="top:715.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">JMT. All authors revised the manuscript and approved the</span></p>
<p style="top:726.8pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">final version.</span></p>
<p style="top:57.9pt;left:294.8pt;line-height:10.5pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:10.5pt">REFERENCES</span></p>
<p style="top:75.3pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011).</span></p>
<p style="top:85.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cannabinoid-opioid interaction in chronic pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Clin Pharmacol</span></p>
<p style="top:95.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 90</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 844</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">851.</span></p>
<p style="top:105.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Berge O-G (2011). Predictive validity of behavioural animal models</span></p>
<p style="top:115.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">for chronic pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Br J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 164</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1195</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1206.</span></p>
<p style="top:125.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Boehnke KF, Litinas E, Clauw DJ (2016). Medical cannabis use is</span></p>
<p style="top:135.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">associated with decreased opiate medication use in a retrospective</span></p>
<p style="top:145.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cross-sectional survey of patients with chronic pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 17</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:155.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">739</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">744.</span></p>
<p style="top:165.5pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G,</span></p>
<p style="top:175.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Battistini L</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2010). Anandamide suppresses proliferation and</span></p>
<p style="top:185.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cytokine release from primary human T-lymphocytes mainly via</span></p>
<p style="top:195.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">CB2 receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> PLoS ONE</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 5</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: e8688.</span></p>
<p style="top:205.7pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I</span></p>
<p style="top:215.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2015). The effectiveness and risks of long-term opioid</span></p>
<p style="top:225.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">therapy for chronic pain: a systematic review for a National</span></p>
<p style="top:235.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Institutes of Health Pathways to Prevention Workshop Effective-</span></p>
<p style="top:245.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ness and Risks of Long-Term Opioid Therapy for Chronic Pain.</span></p>
<p style="top:256.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Ann Intern Med</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 162</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 276</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">286.</span></p>
<p style="top:265.9pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz DL (2004). Synergistic interactions between cannabinoid</span></p>
<p style="top:276.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and opioid analgesics.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Life Sci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 74</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1317</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1324.</span></p>
<p style="top:286.0pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz DL, Martin ZL, Smith FL, Welch SP (1999). Enhance-</span></p>
<p style="top:296.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ment mu opioid antinociception by oral delta9-tetrahydrocanna-</span></p>
<p style="top:306.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">binol:</span></p>
<p style="top:306.1pt;left:332.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">dose-response</span></p>
<p style="top:306.1pt;left:393.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">analysis</span></p>
<p style="top:306.1pt;left:430.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:306.1pt;left:453.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">receptor</span></p>
<p style="top:306.1pt;left:492.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">identification.</span></p>
<p style="top:316.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 289</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 859</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">867.</span></p>
<p style="top:326.1pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz DL, McCarthy EA (2003). Antinociceptive synergy</span></p>
<p style="top:336.2pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">between delta(9)-tetrahydrocannabinol and opioids after oral</span></p>
<p style="top:346.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">administration.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 304</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1010</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1015.</span></p>
<p style="top:356.2pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz DL, Welch SP (2003). Modulation of oral morphine</span></p>
<p style="top:366.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">antinociceptive tolerance and naloxone-precipitated withdrawal</span></p>
<p style="top:376.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">signs by oral Delta 9-tetrahydrocannabinol.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span></p>
<p style="top:386.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">305</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 812</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">817.</span></p>
<p style="top:396.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz DL, Welch SP, Smith FL (2005). Enhancement of</span></p>
<p style="top:406.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">transdermal fentanyl and buprenorphine antinociception by trans-</span></p>
<p style="top:416.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">dermal delta9-tetrahydrocannabinol.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 525</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 74</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">82.</span></p>
<p style="top:426.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cox ML, Haller VL, Welch SP (2007). Synergy between delta9-</span></p>
<p style="top:436.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">tetrahydrocannabinol and morphine in the arthritic rat.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J</span></p>
<p style="top:446.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 567</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 125</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">130.</span></p>
<p style="top:456.5pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca</span></p>
<p style="top:466.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Pacheco CM, de Francischi JN, Duarte ID (2008). The mu-opioid</span></p>
<p style="top:476.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">receptor agonist morphine, but not agonists at delta- or kappa-</span></p>
<p style="top:486.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">opioid receptors, induces peripheral antinociception mediated by</span></p>
<p style="top:496.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cannabinoid receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Br J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 154</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1143</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1149.</span></p>
<p style="top:506.7pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M,</span></p>
<p style="top:516.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Farrell M</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2015). Experience of adjunctive cannabis use for</span></p>
<p style="top:526.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">chronic non-cancer pain: findings from the Pain and Opioids IN</span></p>
<p style="top:536.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Treatment (POINT) study.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Drug Alcohol Depend</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 147</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 144</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">150.</span></p>
<p style="top:546.9pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Dowell D, Haegerich TM, Chou R (2016). CDC Guideline for</span></p>
<p style="top:556.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Prescribing Opioids for Chronic Pain - United States, 2016.</span></p>
<p style="top:567.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">MMWR Recomm Rep</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 65</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">49.</span></p>
<p style="top:576.9pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span></p>
<p style="top:587.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2004). Effects of coadministration of cannabinoids and mor-</span></p>
<p style="top:597.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">phine on nociceptive behaviour, brain monoamines and HPA</span></p>
<p style="top:607.2pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">axis activity in a rat model of persistent pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Neurosci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 19</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:617.2pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">678</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">686.</span></p>
<p style="top:627.2pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Gui H, Tong Q, Qu W, Mao CM, Dai SM (2015). The</span></p>
<p style="top:637.2pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">endocannabinoid system and its therapeutic implications in</span></p>
<p style="top:647.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">rheumatoid arthritis.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Int Immunopharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 26</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 86</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">91.</span></p>
<p style="top:657.3pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,</span></p>
<p style="top:667.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Alonso-Coello P</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2008). GRADE: an emerging consensus</span></p>
<p style="top:677.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">on rating quality of evidence and strength of recommendations.</span></p>
<p style="top:687.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Br Med J</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 336</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 924</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">926.</span></p>
<p style="top:697.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R</span></p>
<p style="top:707.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2016). The effect of medicinal cannabis on pain and quality</span></p>
<p style="top:717.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of life outcomes in chronic pain: a Prospective Open-label Study.</span></p>
<p style="top:727.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Clin J Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 32</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1036</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1043.</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1763</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:59.1pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR,</span></p>
<p style="top:69.1pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Rice KC (1991). Characterization and localization of cannabinoid</span></p>
<p style="top:79.1pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">receptors</span></p>
<p style="top:79.1pt;left:101.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">in</span></p>
<p style="top:79.1pt;left:115.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">rat brain:</span></p>
<p style="top:79.1pt;left:161.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">a quantitative</span></p>
<p style="top:79.1pt;left:223.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">in</span></p>
<p style="top:79.1pt;left:237.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">vitro</span></p>
<p style="top:79.1pt;left:262.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">autoradio-</span></p>
<p style="top:89.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">graphic study.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Neurosci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 11</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 563</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">583.</span></p>
<p style="top:99.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Hohmann AG, Briley EM, Herkenham M (1999). Pre- and</span></p>
<p style="top:109.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">postsynaptic distribution of cannabinoid and mu opioid receptors</span></p>
<p style="top:119.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">in rat spinal cord.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Brain Res</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 822</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 17</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">25.</span></p>
<p style="top:128.9pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M</span></p>
<p style="top:138.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (1997). Pain relief with oral cannabinoids in familial</span></p>
<p style="top:148.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Mediterranean fever.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Anaesthesia</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 52</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 483</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">486.</span></p>
<p style="top:158.8pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Houser SJ, Eads M, Embrey JP, Welch SP (2000). Dynorphin B and</span></p>
<p style="top:168.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">spinal analgesia: induction of antinociception by the cannabi-</span></p>
<p style="top:178.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">noids CP55,940, Delta(9)-THC and anandamide.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Brain Res</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 857</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:188.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">337</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">342.</span></p>
<p style="top:198.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA</span></p>
<p style="top:208.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2002). International Union of Pharmacology. XXVII. Classi-</span></p>
<p style="top:218.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">fication of cannabinoid receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pharmacol Rev</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 54</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 161</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">202.</span></p>
<p style="top:228.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ibrahim M, Rude M, Stagg N, Mata H, Lai J, Vanderah T</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span></p>
<p style="top:238.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2006). CB2 cannabinoid receptor mediation of antinociception.</span></p>
<p style="top:248.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 122</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 36</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">42.</span></p>
<p style="top:258.6pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A</span></p>
<p style="top:268.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2005). CB2 cannabinoid receptor activation produces</span></p>
<p style="top:278.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">antinociception by stimulating peripheral release of endogenous</span></p>
<p style="top:288.5pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">opioids.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Proc Natl Acad Sci USA</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 102</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 3093</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">3098.</span></p>
<p style="top:298.5pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Jensen B, Chen J, Furnish T, Wallace M (2015). Medical marijuana</span></p>
<p style="top:308.5pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and chronic pain: a review of basic science and clinical evidence.</span></p>
<p style="top:318.5pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Curr Pain Headache Rep</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 19</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 50.</span></p>
<p style="top:328.4pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED,</span></p>
<p style="top:338.4pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Potts R, Fallon MT (2010). Multicenter, double-blind, rando-</span></p>
<p style="top:348.4pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">mized, placebo-controlled, parallel-group study of the efficacy,</span></p>
<p style="top:358.4pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">safety, and tolerability of THC:CBD extract and THC extract in</span></p>
<p style="top:368.4pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">patients with intractable cancer-related pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pain Symptom</span></p>
<p style="top:378.3pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Manage</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 39</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 167</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">179.</span></p>
<p style="top:388.3pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Katsuyama S, Mizoguchi H, Kuwahata H, Komatsu T, Nagaoka K,</span></p>
<p style="top:398.3pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Nakamura H</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2013). Involvement of peripheral cannabinoid</span></p>
<p style="top:408.3pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and opioid receptors in beta-caryophyllene-induced antinocicep-</span></p>
<p style="top:418.2pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">tion.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 17</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 664</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">675.</span></p>
<p style="top:428.2pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Li JX, McMahon LR, Gerak LR, Becker GL, France CP (2008).</span></p>
<p style="top:438.2pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Interactions between Delta(9)-tetrahydrocannabinol and mu</span></p>
<p style="top:448.2pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">opioid receptor agonists in rhesus monkeys: discrimination and</span></p>
<p style="top:458.2pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">antinociception.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Psychopharmacology</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 199</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 199</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">208.</span></p>
<p style="top:468.1pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Lissoni P, Porro G, Messina G, Porta E, Rovelli F, Roselli MG</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span></p>
<p style="top:478.1pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2014). Morphine, melatonin, Marijuana, Magnolia and MYRRH</span></p>
<p style="top:488.1pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">as the &quot;five m&quot; schedule in the treatment of cancer pain</span></p>
<p style="top:498.1pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and the possible dose-dependency of the antitumor and analgesic</span></p>
<p style="top:508.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">effects of the pineal hormone melatonin.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Anticancer Res</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 34</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:518.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">6033</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">6034.</span></p>
<p style="top:528.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Litchfield JA, Wilcoxon F (1949). A simplified method of evaluating</span></p>
<p style="top:538.0pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">dose-effect experiments.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 96</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 99</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">113.</span></p>
<p style="top:548.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Lynch ME, Clark AJ (2003). Cannabis reduces opioid dose in the</span></p>
<p style="top:557.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">treatment of chronic non-cancer pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pain Symptom Manage</span></p>
<p style="top:567.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">25</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 496</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">498.</span></p>
<p style="top:577.9pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Maguire DR, Yang W, France CP (2013). Interactions between mu-</span></p>
<p style="top:587.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">opioid receptor agonists and cannabinoid receptor agonists in</span></p>
<p style="top:597.9pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">rhesus monkeys: antinociception, drug discrimination, and drug</span></p>
<p style="top:607.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">self-administration.(Erratum appears in J Pharmacol Exp Ther.</span></p>
<p style="top:617.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">2014 Mar; 348(3): 490-1 Note: Dosage error in article text).</span></p>
<p style="top:627.8pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 345</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 354</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">362.</span></p>
<p style="top:637.8pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA,</span></p>
<p style="top:647.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Fuentes JA (1999). Pharmacological and biochemical interactions</span></p>
<p style="top:657.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">between opioids and cannabinoids.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Trends Pharmacol Sci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 20</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:667.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">287</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">294.</span></p>
<p style="top:677.7pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Mason DJ Jr, Lowe J, Welch SP (1999). Cannabinoid modulation of</span></p>
<p style="top:687.7pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">dynorphin A: correlation to cannabinoid-induced antinocicep-</span></p>
<p style="top:697.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">tion.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 378</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 237</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">248.</span></p>
<p style="top:707.6pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred</span></p>
<p style="top:717.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">reporting items for systematic reviews and meta-analyses: the</span></p>
<p style="top:727.6pt;left:60.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">PRISMA statement.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> PLoS Med</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 6</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: e1000097.</span></p>
<p style="top:59.1pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Naef</span></p>
<p style="top:59.1pt;left:343.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">M,</span></p>
<p style="top:59.1pt;left:362.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Curatolo</span></p>
<p style="top:59.1pt;left:402.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">M,</span></p>
<p style="top:59.1pt;left:420.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Petersen-Felix</span></p>
<p style="top:59.1pt;left:480.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">S,</span></p>
<p style="top:59.1pt;left:494.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Arendt-Nielsen</span></p>
<p style="top:69.1pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Zbinden A, Brenneisen R (2003). The analgesic effect of</span><sup><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">L,</span></sup></p>
<p style="top:79.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">oral</span></p>
<p style="top:79.0pt;left:347.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">delta-9-tetrahydrocannabinol</span></p>
<p style="top:79.0pt;left:462.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(THC), morphine,</span></p>
<p style="top:79.0pt;left:541.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:89.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">THC-morphine combination in healthy subjects under experi-</span><sup><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">a</span></sup></p>
<p style="top:99.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">mental pain conditions.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 105</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 79</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">88.</span></p>
<p style="top:109.0pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Narang</span></p>
<p style="top:109.0pt;left:353.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">S,</span></p>
<p style="top:109.0pt;left:368.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Gibson</span></p>
<p style="top:109.0pt;left:403.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">D,</span></p>
<p style="top:109.0pt;left:420.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Wasan</span></p>
<p style="top:109.0pt;left:453.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">AD,</span></p>
<p style="top:109.0pt;left:477.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ross</span></p>
<p style="top:109.0pt;left:502.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">EL,</span></p>
<p style="top:109.0pt;left:522.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Michna</span></p>
<p style="top:109.0pt;left:559.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">E,</span></p>
<p style="top:119.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Nedeljkovic SS</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2008). Efficacy of dronabinol as an adjuvant</span></p>
<p style="top:128.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">treatment for chronic pain patients on opioid therapy.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 9</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:138.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">254</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">264.</span></p>
<p style="top:148.9pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Pertwee RG (2006). The pharmacology of cannabinoid receptors</span></p>
<p style="top:158.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and their ligands: an overview.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Int J Obes</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: S13</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">S18.</span></p>
<p style="top:168.8pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacol-</span></p>
<p style="top:178.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ogy of three plant cannabinoids: delta9-tetrahydrocannabinol,</span></p>
<p style="top:188.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cannabidiol and delta9-tetrahydrocannabivarin.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Br J Pharmacol</span></p>
<p style="top:198.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">153</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 199</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">215.</span></p>
<p style="top:208.7pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Portenoy</span></p>
<p style="top:208.7pt;left:359.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">RK,</span></p>
<p style="top:208.7pt;left:380.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ganae-Motan</span></p>
<p style="top:208.7pt;left:438.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ED,</span></p>
<p style="top:208.7pt;left:460.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Allende</span></p>
<p style="top:208.7pt;left:495.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">S,</span></p>
<p style="top:208.7pt;left:509.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Yanagihara</span></p>
<p style="top:208.7pt;left:558.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">R,</span></p>
<p style="top:218.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Shaiova L, Weinstein S</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2012). Nabiximols for opioid-</span></p>
<p style="top:228.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">treated cancer patients with poorly-controlled chronic pain: a</span></p>
<p style="top:238.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">randomized, placebo-controlled, graded-dose trial.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 13</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:248.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">438</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">449.</span></p>
<p style="top:258.6pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Pugh G Jr, Mason DJ Jr, Combs V, Welch SP (1997). Involvement</span></p>
<p style="top:268.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:268.6pt;left:342.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">dynorphin</span></p>
<p style="top:268.6pt;left:390.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">B</span></p>
<p style="top:268.6pt;left:405.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">in</span></p>
<p style="top:268.6pt;left:421.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the</span></p>
<p style="top:268.6pt;left:442.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">antinociceptive</span></p>
<p style="top:268.6pt;left:506.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">effects</span></p>
<p style="top:268.6pt;left:538.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:268.6pt;left:555.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the</span></p>
<p style="top:278.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cannabinoid CP55,940 in the spinal cord.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span></p>
<p style="top:288.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">281</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 730</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">737.</span></p>
<p style="top:298.5pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Pugh G Jr, Smith PB, Dombrowski DS, Welch SP (1996). The role of</span></p>
<p style="top:308.5pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">endogenous opioids in enhancing the antinociception produced</span></p>
<p style="top:318.5pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">by</span></p>
<p style="top:318.5pt;left:342.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the</span></p>
<p style="top:318.5pt;left:361.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">combination</span></p>
<p style="top:318.5pt;left:415.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:318.5pt;left:430.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">DELTA9-tetrahydrocannabinol</span></p>
<p style="top:318.5pt;left:552.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:328.5pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine in the spinal cord.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 279</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:338.5pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">608</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">616.</span></p>
<p style="top:348.4pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F,</span></p>
<p style="top:358.4pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Makriyannis</span></p>
<p style="top:358.4pt;left:380.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">A</span></p>
<p style="top:358.4pt;left:394.4pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et</span></p>
<p style="top:358.4pt;left:408.6pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">al</span></p>
<p style="top:358.4pt;left:423.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2003).</span></p>
<p style="top:358.4pt;left:456.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Inhibition</span></p>
<p style="top:358.4pt;left:501.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:358.4pt;left:516.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">inflammatory</span></p>
<p style="top:368.4pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">hyperalgesia</span></p>
<p style="top:368.4pt;left:378.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">by</span></p>
<p style="top:368.4pt;left:395.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">activation</span></p>
<p style="top:368.4pt;left:438.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:368.4pt;left:453.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">peripheral</span></p>
<p style="top:368.4pt;left:497.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">CB2</span></p>
<p style="top:368.4pt;left:520.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cannabinoid</span></p>
<p style="top:378.4pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Anesthesiology</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 99</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 955</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">960.</span></p>
<p style="top:388.3pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Reche I, Fuentes JA, Ruiz-Gayo M (1996). Potentiation of delta</span></p>
<p style="top:398.4pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">9-tetrahydrocannabinol-induced analgesia by morphine in mice:</span></p>
<p style="top:408.3pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">involvement of mu- and kappa-opioid receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span></p>
<p style="top:418.3pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">318</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 11</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">16.</span></p>
<p style="top:428.2pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Rice AS, Smith BH, Blyth FM (2015). Pain and the global burden of</span></p>
<p style="top:438.2pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">disease.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 157</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 791</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">796.</span></p>
<p style="top:448.2pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Roberts JD, Gennings C, Shih M (2006). Synergistic affective</span></p>
<p style="top:458.2pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">analgesic interaction between delta-9- tetrahydrocannabinol and</span></p>
<p style="top:468.1pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 530</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 54</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">58.</span></p>
<p style="top:478.1pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M</span></p>
<p style="top:488.1pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2001). CB1-cannabinoid and mu-opioid receptor co-localization</span></p>
<p style="top:498.1pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">on postsynaptic target in the rat dorsal horn.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> NeuroReport</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 12</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:508.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">3689</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">3692.</span></p>
<p style="top:518.0pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Seeling W, Kneer L, Buchele B, Gschwend J, Maier L, Nett C</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span></p>
<p style="top:528.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2006). DELTA9-tetrahydrocannabinol and the opioid receptor</span></p>
<p style="top:538.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">agonist piritramide do not act synergistically in postoperative</span></p>
<p style="top:548.0pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Anaesthesist</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 55</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 391</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">400.</span></p>
<p style="top:557.9pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Smith</span></p>
<p style="top:557.9pt;left:349.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">FL,</span></p>
<p style="top:557.9pt;left:369.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Cichewicz</span></p>
<p style="top:557.9pt;left:416.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">D,</span></p>
<p style="top:557.9pt;left:433.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Martin</span></p>
<p style="top:557.9pt;left:468.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ZL,</span></p>
<p style="top:557.9pt;left:489.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Welch</span></p>
<p style="top:557.9pt;left:522.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">SP</span></p>
<p style="top:557.9pt;left:540.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(1998).</span></p>
<p style="top:567.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">The enhancement of morphine antinociception in mice by</span></p>
<p style="top:577.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">delta9-tetrahydrocannabinol.</span></p>
<p style="top:577.9pt;left:440.1pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Pharmacol</span></p>
<p style="top:577.9pt;left:486.9pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Biochem</span></p>
<p style="top:577.9pt;left:525.5pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Behav</span></p>
<p style="top:577.9pt;left:555.5pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">60</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:587.9pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">559</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">566.</span></p>
<p style="top:597.8pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Smith PA, Selley DE, Sim-Selley LJ, Welch SP (2007). Low dose</span></p>
<p style="top:607.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">combination</span></p>
<p style="top:607.8pt;left:380.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:607.8pt;left:396.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine</span></p>
<p style="top:607.8pt;left:440.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:607.8pt;left:462.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">delta9-tetrahydrocannabinol</span></p>
<p style="top:617.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">circumvents antinociceptive tolerance and apparent desensitiza-</span></p>
<p style="top:627.8pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">tion of receptors.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 571</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 129</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">137.</span></p>
<p style="top:637.8pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Smith PB, Welch SP, Martin BR (1994). Interactions between delta</span></p>
<p style="top:647.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">9-tetrahydrocannabinol and kappa opioids in mice.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol</span></p>
<p style="top:657.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 268</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1381</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1387.</span></p>
<p style="top:667.7pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Tham SM, Angus JA, Tudor EM, Wright CE (2005). Synergistic and</span></p>
<p style="top:677.7pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">additive interactions of the cannabinoid agonist CP55,940 with</span></p>
<p style="top:687.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">mu opioid receptor and alpha2-adrenoceptor agonists in acute</span></p>
<p style="top:697.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">pain models in mice.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Br J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 144</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 875</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">884.</span></p>
<p style="top:707.6pt;left:318.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC,</span></p>
<p style="top:717.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Roques BP (2001). Delta9-tetrahydrocannabinol releases and</span></p>
<p style="top:727.6pt;left:326.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">facilitates the effects of endogenous enkephalins: reduction in</span></p>
<p style="top:24.1pt;left:154.6pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:251.8pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:22.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1764</span></p>
<p style="top:750.0pt;left:52.3pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>


<p style="top:59.1pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine withdrawal syndrome without change in rewarding</span></p>
<p style="top:69.0pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">effect.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Neurosci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 13</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1816</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1824.</span></p>
<p style="top:79.0pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Vigano D, Rubino T, Parolaro D (2005). Molecular and cellular</span></p>
<p style="top:89.0pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">basis of cannabinoid and opioid interactions.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pharmacol Biochem</span></p>
<p style="top:99.0pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Behav</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 81</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 360</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">368.</span></p>
<p style="top:108.9pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Volkow ND, McLellan AT (2016). Opioid abuse in chronic pain</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt"> &#x2014;</span></p>
<p style="top:118.9pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">misconceptions and mitigation strategies.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> N Engl J Med</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 374</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:128.8pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1253</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1263.</span></p>
<p style="top:138.8pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Wakley AA, Craft RM</span></p>
<p style="top:138.8pt;left:131.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2011). THC-methadone and THC-</span></p>
<p style="top:148.7pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">naltrexone interactions on discrimination, antinociception, and</span></p>
<p style="top:158.7pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">locomotion in rats.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Behav Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 22</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 489</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">497.</span></p>
<p style="top:168.7pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM,</span></p>
<p style="top:178.6pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Tsou K (1999). The neurobiology of cannabinoid analgesia.</span></p>
<p style="top:188.6pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Life Sci</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 65</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 665</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">673.</span></p>
<p style="top:198.6pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Walker JM, Huang SM (2002). Cannabinoid analgesia.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pharmacol</span></p>
<p style="top:208.5pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 95</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 127</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">135.</span></p>
<p style="top:218.5pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ware MA, Fitzcharles M-A, Joseph L, Shir Y (2010a). The effects of</span></p>
<p style="top:228.4pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">nabilone on sleep in fibromyalgia: results of a randomized</span></p>
<p style="top:238.4pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">controlled trial.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Anesth Analg</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 110</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 604</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">610.</span></p>
<p style="top:248.3pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T</span></p>
<p style="top:258.3pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2010b). Smoked cannabis for chronic neuropathic pain: a</span></p>
<p style="top:268.3pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">randomized controlled trial.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> CMAJ</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 182</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: E694</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">E701.</span></p>
<p style="top:278.3pt;left:28.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Welch</span></p>
<p style="top:278.3pt;left:60.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">SP,</span></p>
<p style="top:278.3pt;left:80.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Stevens</span></p>
<p style="top:278.3pt;left:115.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">DL</span></p>
<p style="top:278.3pt;left:135.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(1992).</span></p>
<p style="top:278.3pt;left:169.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Antinociceptive</span></p>
<p style="top:278.3pt;left:234.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">activity</span></p>
<p style="top:278.3pt;left:269.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:288.2pt;left:36.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">intrathecally</span></p>
<p style="top:288.2pt;left:93.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">administered</span></p>
<p style="top:288.2pt;left:152.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">cannabinoids</span></p>
<p style="top:288.2pt;left:212.0pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">alone,</span></p>
<p style="top:288.2pt;left:244.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:288.2pt;left:269.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">in</span></p>
<p style="top:59.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">combination with morphine, in mice.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> J Pharmacol Exp Ther</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 262</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:69.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">10</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">18.</span></p>
<p style="top:79.0pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, Welch SP</span></p>
<p style="top:89.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2006). Time course of</span></p>
<p style="top:89.0pt;left:407.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the enhancement and restoration</span></p>
<p style="top:99.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:99.0pt;left:318.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the</span></p>
<p style="top:99.0pt;left:338.2pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">analgesic</span></p>
<p style="top:99.0pt;left:379.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">efficacy</span></p>
<p style="top:99.0pt;left:415.3pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of</span></p>
<p style="top:99.0pt;left:430.9pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">codeine</span></p>
<p style="top:99.0pt;left:467.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">and</span></p>
<p style="top:99.0pt;left:489.5pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine</span></p>
<p style="top:99.0pt;left:534.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">by</span></p>
<p style="top:108.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT8608a8d1+03,serif;font-size:9.0pt">&#x3b4;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">9-tetrahydrocannabinol.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 539</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 57</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">63.</span></p>
<p style="top:118.8pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Williams J, Haller VL, Stevens DL, Welch SP (2008). Decreased</span></p>
<p style="top:128.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">basal endogenous opioid levels in diabetic rodents: effects on</span></p>
<p style="top:138.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">morphine and delta-9-tetrahydrocannabinoid-induced antinoci-</span></p>
<p style="top:148.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">ception.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Eur J Pharmacol</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 584</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 78</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">86.</span></p>
<p style="top:158.7pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Wilson AR, Maher L, Morgan MM (2008). Repeated cannabinoid</span></p>
<p style="top:168.7pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">injections</span></p>
<p style="top:168.7pt;left:349.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">into</span></p>
<p style="top:168.7pt;left:375.7pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">the</span></p>
<p style="top:168.7pt;left:398.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">rat</span></p>
<p style="top:168.7pt;left:420.1pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">periaqueductal</span></p>
<p style="top:168.7pt;left:485.4pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">gray</span></p>
<p style="top:168.7pt;left:512.6pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">enhance</span></p>
<p style="top:178.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">subsequent morphine antinociception.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Neuropharmacology</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 55</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">:</span></p>
<p style="top:188.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1219</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1225.</span></p>
<p style="top:198.6pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Woodhams SG, Sagar DR, Burston JJ, Chapman V (2015). The role</span></p>
<p style="top:208.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">of the endocannabinoid system in pain.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Handb Exp Pharmacol</span></p>
<p style="top:218.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt">227</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 119</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">143.</span></p>
<p style="top:228.4pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span></p>
<p style="top:238.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">(2003). Topical cannabinoid enhances topical morphine anti-</span></p>
<p style="top:248.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">nociception.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pain</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 105</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 303</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">308.</span></p>
<p style="top:258.3pt;left:294.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt"> (2014).</span></p>
<p style="top:268.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">Risk factors for serious prescription opioid-related toxicity or</span></p>
<p style="top:278.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">overdose among veterans health administration patients.</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt"> Pain</span></p>
<p style="top:288.2pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvOT7b9f888e.I,serif;font-size:9.0pt">Med</span><span style="font-family:AdvOT9be19100.B,serif;font-size:9.0pt"> 15</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">: 1911</span><span style="font-family:AdvOT852e08ef+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvOT852e08ef,serif;font-size:9.0pt">1929.</span></p>
<p style="top:309.3pt;left:28.8pt;line-height:10.0pt"><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt">Supplementary Information accompanies the paper on the</span><span style="font-family:AdvOT7b9f888e.I,serif;font-size:10.0pt"> Neuropsychopharmacology</span><span style="font-family:AdvOT852e08ef,serif;font-size:10.0pt"> website (http://www.nature.com/npp)</span></p>
<p style="top:24.1pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvTTdd0b0455.B,serif;font-size:8.5pt">Opioid-sparing effect of cannabinoids</span></p>
<p style="top:34.0pt;left:294.5pt;line-height:8.5pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:8.5pt">S Nielsen</span><span style="font-family:AdvOT503af387.I,serif;font-size:8.5pt"> et al</span></p>
<p style="top:47.6pt;left:554.5pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">1765</span></p>
<p style="top:750.0pt;left:446.6pt;line-height:9.0pt"><span style="font-family:AdvOT96bbbf1d,serif;font-size:9.0pt">Neuropsychopharmacology</span></p>

</div>
